{"@odata.context":"http://www.who.int/api/hubs/$metadata#factsheets(Id,LastModified,PublicationDate,DateCreated,IncludeInSitemap,SystemSourceKey,UrlName,ItemDefaultUrl,NewsNumberOfAdditionalItems,MedicalTreatmentBriefSummary,Content,ConditionName,OpenGraphTitle,DocumentNumberOfAdditionalItems,PreventionBriefSummary,SelfCareLongerSummary,EventNumberOfAdditionalItems,MultimediaNumberOfAdditionalItems,SymptomsLongerSummary,MetaTitle,ConditionLongerOverview,Title,PreventionLongerSummary,SourceKey,PhotoStoryNumberOfAdditionalItems,SelfCareBriefSummary,FactFileNumberOfAdditionalItems,SortTitle,LocalPublicationDate,Summary,FeatureStoryNumberOfAdditionalItems,OtherRelated,FactSheetNumberOfAdditionalItems,OpenGraphDescription,PublicationDateAndTime,ConditionBriefOverview,MetaDescription,MedicalTreatmentLongerSummary,CommentaryNumberOfAdditionalItems,SymptomsBriefSummary,Highlight,Provider,ThumbnailUrl,FormatedDate,TrimmedTitle)","value":[{"Id":"b22b958d-c5f5-4f66-9497-fd9fbdce83d0","LastModified":"2025-01-31T14:52:41Z","PublicationDate":"2018-06-02T02:27:00Z","DateCreated":"2018-06-02T02:26:58Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"dracunculiasis-(guinea-worm-disease)","ItemDefaultUrl":"/dracunculiasis-(guinea-worm-disease)","NewsNumberOfAdditionalItems":2,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul type=\"disc\"><li>Dracunculiasis is a crippling parasitic disease on the verge of eradication, with 13 human cases reported in 2024 (provisional) and 14 in 2023.</li><li>From the time infection occurs, it takes 10&ndash;14 months for the transmission cycle to complete, at which point a mature female worm emerges from the body.</li><li>Transmission mostly involves drinking stagnant water contaminated by parasite-infected water fleas.</li><li>Dracunculiasis was endemic in 20 countries <em>(1)</em> in the mid-1980s.</li></ul><hr /><br /><h2>Overview</h2><p>Dracunculiasis, also called Guinea-worm disease, is a parasitic disease transmitted through contaminated drinking water, causing a painful blister from which a worm slowly emerges. It results from ingesting the parasite <em>Dracunculus medinensis</em>. Although it rarely causes death, infected individuals are often incapacitated for weeks or months. This disease predominantly affects rural, underserved, and remote populations that rely on open, stagnant water sources (e.g., ponds) for drinking-water.</p><h2>Scope of the problem</h2><p>During the mid-1980s, approximately 3.5&nbsp;million cases of dracunculiasis occurred in 20 countries worldwide, 17 located in Africa and the remaining 3 in Asia. Subsequent interventions reduced reported cases to fewer than 10&nbsp;000 in 2007, then further down to 542 in 2012 and 126 in 2014. Since 2015, annual human cases have remained in double digits, declining from 22 in 2015 to 13 (provisional) in 2024. In that same year, 12 villages in Chad (7 cases) and South Sudan (6 cases) accounted for all known human infections. Five countries &ndash; Angola, Chad, Ethiopia, Mali, and South Sudan &ndash; remain endemic, while Sudan is currently in the pre-certification stage and Cameroon a certified country is experiencing a cross-border transmission at its extreme-northern border with Chad. Localized transmission of Guinea worm in animals mostly domestic dogs and cats, in the remaining few countries, added a challenge to the eradication programme.</p><h2>Transmission, life cycle and incubation period</h2><p>Roughly one year following infection, a blister develops on the lower leg in about 90% of cases, and one or more adult worms emerge alongside a burning sensation. Patients often immerse the affected region in water to relieve pain. This contact enables the worm to expel thousands of larvae into the water, where they are ingested by tiny crustaceans (copepods), commonly known as water fleas. People and certain animals, such as dogs or cats swallow these infected water fleas mostly by drinking contaminated water or by consuming raw or undercooked aquatic hosts harbouring the infective larvae. Although the water fleas die in the stomach, the released larvae penetrate the intestinal wall and migrate through the body until a fertilized female, measuring 60&ndash;100\u202fcm, settles beneath the skin. Ten to fourteen months later, it emerges at an exit site, typically the lower limb.</p><h2>The road to eradication</h2><p>Elimination and then eradication of dracunculiasis have been championed by the World Health Assembly (WHA) via several key resolutions: WHA39.21 (1986), WHA42.29 (1989), WHA44.5 (1991), WHA57.9 (2004), and WHA64.16 (2011). In May 1981, the Interagency Steering Committee for Cooperative Action for the International Drinking Water Supply and Sanitation Decade (1981&ndash;1990) identified dracunculiasis elimination as a benchmark of success for the Decade. That same year, the WHA adopted resolution WHA34.25, recognizing the opportunity to interrupt transmission of dracunculiasis during the Decade. This led WHO and the United States Centers for Disease Control and Prevention to develop a systematic strategy and technical guidance.</p><p>In 1986, The Carter Center joined the global campaign against the disease, in partnership with WHO and UNICEF. Later, the WHA, through resolution WHA64.16 (2011), urged all Member States where dracunculiasis was still endemic to expedite interrupting transmission and strengthen nationwide surveillance measures necessary for its eradication.</p><h2>Eradication strategy </h2><p>There is no vaccine or cure for dracunculiasis, but prevention and surveillance measures have brought the disease to the brink of eradication. Essential approaches include:</p><ul type=\"disc\"><li><strong>Surveillance and mapping</strong>: Locating endemic and at-risk communities; promptly detecting and reporting human or animal infections; and confirming infections in a laboratory.</li><li><strong>Safe water access</strong>: Drilling protected wells or boreholes, promoting the use of cloth or pipe filters in the absence of safe drinking water, and discouraging contact with contaminated sources when worms emerge.</li><li><strong>Vector control</strong>: Regularly applying temephos (Abate&reg;) to stagnant water to kill infected water fleas.</li><li><strong>Community education</strong>: Highlighting the importance of early case detection and reporting, alongside preventing animals from contaminating water, and proper management of aquatic animals&rsquo; waste.</li><li><strong>Case containment</strong>: Immediately isolating infected individuals or animals, providing wound care, and proactive tethering of domestic dogs and cats.</li><li><strong>Reporting and rewards</strong>: Maintaining high-level surveillance, incentivizing prompt case reporting, and consistently sharing data with national and global authorities.</li></ul><p>More detailed guidelines on eradication strategies can be found through this link. </p><h2>Country certification</h2><p>For a country to be declared free of dracunculiasis, it must maintain zero reported human cases and zero animal infections over a period of at least three consecutive years, during which active surveillance is rigorously upheld. Subsequently, an international certification team visits to evaluate the robustness of the surveillance system, examine investigatory records for rumoured cases or infected animals, and verify follow-up measures. The team also checks access to improved drinking-water in prior outbreak areas and assesses potential reintroduction risks. Their final report is sent to the International Commission for the Certification of Dracunculiasis Eradication (ICCDE) for review.<br />Since 1995, the ICCDE has convened 16 times and, upon its recommendations, WHO has certified 200 countries, territories, and areas (within 188 Member States) as free of dracunculiasis transmission. The Democratic Republic of the Congo, once endemic in 1950s, received certification in December 2022. WHO published the latest criteria for dracunculiasis certification in 2023.</p><h2>Ongoing surveillance</h2><p>WHO recommends that any country which has recently interrupted transmission of Guinea-worm disease maintain active surveillance for no fewer than three consecutive years. This requirement ensures no human case or infected animal is overlooked, thereby preventing disease recurrence. Because the incubation period ranges from 10 to 14 months, a single undetected worm can delay eradication progress by at least a year. Past instances of re-emergence in Ethiopia (2008) and Chad (2010), after both had reported zero cases for prolonged intervals, highlight why continuous vigilance is critical. If a country reports zero cases for 14\u202fmonths, it is considered to have interrupted transmission but remains in the pre-certification phase for a minimum of three additional years. Even once certification is achieved, surveillance must continue until global eradication is ultimately declared.</p><h2>Challenges</h2><p>Identifying and containing the final few clusters of cases and infected animals constitutes the most challenging &ndash; and costly &ndash; phase of eradication efforts, especially in remote or conflict-prone regions. Security issues frequently restrict access, slowing progress and complicating interventions. Infections in humans or animals have also been detected in certified nations sharing borders with remaining endemic areas, underscoring the risk of reintroducing transmission. This situation demands robust post-certification surveillance, including cross-border surveillance, until eradication is globally declared.<br />Infection of <em>Dracunculus medinensis</em> in dogs remains a serious obstacle, notably in Angola, Chad, Ethiopia and Mali. It was first detected in Chad in 2012, where many dogs carrying genetically identical worms to those in humans have been identified in the same region where human cases have been detected. From January to December 2024 (provisional), 661 infected animals were reported across Angola (36 dogs), Cameroon (312 animals), Chad (234 dogs and 47 cats), Ethiopia (2 baboons), Mali (23 dogs and 6 cats), and South Sudan (1 cat).</p><p>Interrupting transmission in animals requires enhanced surveillance, early containment of infected animals, proactive tethering, community education, and rigorous vector control.</p><h2>WHO response</h2><p>WHO, in collaboration with governments and key partners, continues to advocate for eradication, provide technical guidance, oversee eradication efforts, and support surveillance and response in cross-border areas of affected countries and in previously endemic countries. WHO is the sole organization mandated by the WHA to certify countries as free of Guinea-worm disease, following recommendations from the International Commission for the Certification of Dracunculiasis Eradication (ICCDE). The Commission meets as needed to evaluate country applications and determine certification status.</p><p>&nbsp;</p><p><strong>Notes</strong></p><ol type=\"1\"><li data-list=\"0\" data-level=\"1\">South Sudan gained independence from Sudan on 9\u202fJuly 2011. Before that date, its Guinea-worm disease cases were reported under Sudan, reflecting a total of 20 endemic countries in the 1980s through 2011.</li></ol>","ConditionName":"","OpenGraphTitle":"Dracunculiasis (Guinea-worm disease)","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Dracunculiasis (Guinea-worm disease)","ConditionLongerOverview":"","Title":"Dracunculiasis (Guinea-worm disease)","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs359","PhotoStoryNumberOfAdditionalItems":0,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":0,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":2,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"A crippling parasitic disease, transmitted exclusively when people drink stagnant water, dracunculiasis is poised for eradication, with 25 human cases reported in 2016. #BeatNTDs","PublicationDateAndTime":"2025-01-30T15:04:00Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on dracunculiasis (guinea-worm disease):  dracunculiasis is transmitted when people swallow water contaminated with parasite-infected water-fleas (cyclops). Includes key facts, scope of problem, transformation, prevention, eradication, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<div class=\"arrowed-link\"><a target=\"_blank\" href=\"https://www.who.int/teams/control-of-neglected-tropical-diseases/dracunculiasis/global-epidemiology\">Global epidemiology</a>\r\n</div><div class=\"arrowed-link\"><a href=\"https://www.who.int/data/gho/data/themes/topics/dracunculiasis-guinea-worm-disease\" target=\"_blank\">Dracunculiasis Eradication Portal</a>\r\n</div><div class=\"arrowed-link\"><a href=\"https://www.who.int/publications/i/item/9789240073333\">Criteria for the certification of dracunculiasis eradication, 2023 update</a></div><div class=\"arrowed-link\"><a target=\"_blank\" href=\"https://www.who.int/health-topics/dracunculiasis\">WHO's work on dracunculiasis</a></div><div class=\"arrowed-link\"><a target=\"_blank\" href=\"https://www.who.int/teams/control-of-neglected-tropical-diseases/overview\">More on <span style=\"background-color:initial;font-size:inherit;font-family:inherit;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\">control of neglected tropical diseases</span></a></div>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/dracunculiasis-guinea-worm-disease-jpg.tmb-768v.jpg?sfvrsn=dfc5d656_44","FormatedDate":"30 January 2025","TrimmedTitle":"Dracunculiasis (Guinea-worm disease)"},{"Id":"692a5f5a-96b2-4140-88c6-339f70fc6cde","LastModified":"2026-04-23T15:06:45Z","PublicationDate":"2018-06-02T02:27:02Z","DateCreated":"2018-06-02T02:27:00Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"chagas-disease-(american-trypanosomiasis)","ItemDefaultUrl":"/chagas-disease-(american-trypanosomiasis)","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<p><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Key facts</span><br /></p><ul><li>About 8 million people worldwide, mostly in Latin America, are estimated to be infected with <em>Trypanosoma cruzi</em>, the parasite that causes Chagas disease.</li><li><em>T. Cruzi</em> can be transmitted during pregnancy or birth (congenital) by triatomine bugs (vector-borne), orally (food-borne), as well as through blood/blood products (transfusional), organ transplantation and laboratory accidents.</li><li>Chagas disease is curable if antiparasitic treatment is done early, in the acute phase. In chronic infection, the treatment and follow up can potentially prevent or curb disease progression and prevent transmission during pregnancy and birth.</li><li>Without early diagnosis and treatment, up to a third of people with chronic infection develop cardiac alterations and 1 in 10 develop digestive, neurological or mixed alterations which may require specific treatment.</li><li>Key strategies to prevent Chagas disease include testing and treating girls, women of reproductive age, newborns and siblings with the infection; insect vector control (in Latin America); blood screening prior to transfusion and transplantation; earliest possible diagnosis and comprehensive follow-up and health care; and information, education and communication in communities and for health professionals.</li></ul><hr /><h2>Overview</h2><p>Chagas disease is caused by the infection of a protozoan parasite (<em>Trypanosoma cruzi</em>). However, this condition is the result of a complex health problem typical of neglected tropical diseases and socially- and environmentally-determined diseases. A missed or late diagnosis with absent or incomplete treatment and follow-up can transform this infection into a life-threatening condition.</p><p>Approximately 8 million people worldwide are estimated to be infected with <em>T. cruzi</em>, leading to more than 10&nbsp;000 deaths every year, and more than 100 million people are considered at risk of infection. Although a condition of increasing global presence, Chagas disease is found mainly in endemic areas of 21 continental Latin American countries <em>(1)</em>, where transmission has been largely related to the presence of the insect vector. In the last years, congenital transmission became the main route for transmission worldside, with over 10&nbsp;000 new cases annually.&nbsp;</p><p>Chagas disease is named after Carlos Chagas, a Brazilian physician and researcher who on 14 April 1909 diagnosed the disease in a person for the first time. Today, 14 April marks World Chagas Disease Day.</p><h2>Distribution</h2><p>Chagas disease was once entirely confined to continental rural areas of the Americas. Due to&nbsp;socioenvironmental changes and increased population mobility, most infected people now live in urban settings, and the infection has been detected in 44 countries (including Canada, the United States of America, and many European and some Western Pacific, African and Eastern Mediterranean countries).</p><h2>Transmission</h2><p>In Latin America, <em>T. cruzi</em> parasites have been mainly transmitted by contact with faeces/urine of infected blood-sucking triatomine bugs. These bugs typically live in the wall or roof cracks of homes and surrounding structures, such as chicken coops, pens and warehouses, in rural or suburban areas. Normally they hide during the day and become active at night when they feed on animal and human blood. They usually bite an exposed area of skin such as the face, and defecate or urinate close to the bite. The parasites enter the body when the person instinctively smears the bug&rsquo;s dejections into the itching bite, other skin breaks, the eyes or the mouth. Infection can also happen by consumption of food or beverages contaminated with <em>T. cruzi</em> through, for example, contact with dejections of infected triatomine bugs or common opossums; this kind of transmission typically causes outbreaks.&nbsp;<em>T. cruzi</em> can also infect a variety of mammals&nbsp;&ndash; wild reservoirs of infection, being opossums one of the most important ones.</p><p><em style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">T. cruzi</em><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\"> can also be transmitted all over the world:</span></p><ul><li><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">during pregnancy or childbirth;</span></li><li>through blood or blood product transfusion;</li><li>through transplants of some organs (such as heart or kidney); and</li><li>through laboratory accidents.<br /></li></ul><h2>Signs and symptoms&nbsp;</h2><p>Chagas disease presents in two phases. The initial acute phase lasts for about two months after infection. Although a high number of parasites can circulate in the blood, in most cases symptoms are absent or mild and non-specific (fever, headache, enlarged lymph glands, pallor, muscle pain, difficulty in breathing, swelling, and abdominal or chest pain). Much less frequently, people bitten by a triatomine bug show characteristic first visible signs, which can be either a skin lesion (chagoma) or a purplish swelling of the lids of one eye (Roma&ntilde;a&rsquo;s sign).</p><p>During the chronic phase, the parasites are hidden mainly in the heart and digestive muscles. One to three decades after infection, up to a third of patients suffer from cardiac disorders and up to 1 in 10 suffer from digestive (typically enlargement of the oesophagus or colon), neurological or mixed alterations. In later years these patients may experience the damage to the nervous system and muscles of the heart and digestive system, leading to cardiac arrhythmias, progressive heart failure, and sudden death, among other clinical manifestations and complications.</p><h2>Treatment<br /></h2><p>Chagas disease can be treated with benznidazole or nifurtimox. Both medicines kill the parasite and are fully effective in curing the disease if given early, in the acute phase, including in case of congenital transmission. Their efficacy diminishes, however, the longer a person has been infected; also, adverse reactions are more frequent and potentially severe in older age. Treatment is also indicated for patients in whom infection has been reactivated (for example, due to immunosuppression), and during the early chronic phase, including for girls and women of childbearing age (before or after pregnancy) to prevent congenital transmission.</p><p>Adults with infection, especially those with no symptoms, should be offered treatment because antiparasitic medicines can also prevent or curb disease progression. In other cases, the potential benefits in preventing or delaying the development of Chagas disease should be weighed against the duration of treatment (up to 2 months) and possible adverse reactions (occurring in up to 40% of adults). Benznidazole and nifurtimox should not be administered to pregnant women or people with kidney or liver failure. Nifurtimox is also contraindicated for people with a background of neurological or psychiatric disorders. Additionally, life-lasting follow up and specific treatment for cardiac, digestive or neurological manifestations are usually required.</p><h2>Control and prevention<br /></h2><p>The large number of triatomine bug species and wild animals (reservoirs) infected with <em>T. cruzi</em> throughout the Americas mean that the infection cannot be eradicated. Instead, the public health targets are elimination of the transmission to humans, early health-care access and life-long follow up of the infected people.</p><p>There is no vaccine to prevent Chagas disease. Vector control, reducing interaction between humans and vector insects, has been the most effective method of prevention in Latin America. Blood screening is necessary to prevent infection through congenital transmission, transfusion, and organ transplantation, and to increase detection and care of the affected population all over the world.</p><p>Depending on the geographical area, WHO recommends the following approaches to prevention and control:</p><ul><li>development of information, education and communication materials and activities, contextualized for the different scenarios and actors, and based on a One Health approach;</li><li>screening of newborns and other children of infected mothers; </li><li>screening of blood donors;</li><li>testing of organ, tissue or cell donors and receivers;</li><li>early access to diagnosis, treatment and follow; </li><li>spraying of dwellings and surrounding areas with residual insecticides;</li><li>house improvements and house cleanliness to prevent vector infestation; and</li><li>personal preventive measures such as bednets, good hygiene practices in food preparation, transportation, storage and consumption.</li></ul><p>The medical care cost of patients with chronic cardiac, digestive, neurologic or mixed forms of the disease has been calculated to be &gt;80% higher than the cost of spraying residual insecticide to control vectors and prevent infection.</p><p>All health professionals, beginning at the first level of care (primary health care), and appropriately trained and updated, have a crucial role in enhancing the detection, treatment, follow-up, and notification of cases. </p><p>Assessment of the available diagnostics (including rapid serologic or chemiluminescence tests, molecular biology tests) and the most cost-effective algorithms is fundamental to increase early case detection.&nbsp; </p><p>Innovation, research and development, and evaluation of new diagnostics and medicines can accelerate the path towards the elimination of the disease as a public health problem. </p><p>Promotion of biomedical, psychosocial and environmental studies focused on the determinants and risk factors of Chagas disease is essential to identify novel approaches for prevention and control.&nbsp;&nbsp; </p><p>National information systems are essential to monitor the number of acute and chronic cases and the active transmission routes. However, they are only in place in 6 out of the 44 countries that have reported cases so far.<br /></p><h2>WHO response<br /></h2><p>Since the 1990s there have been successful intergovernmental initiatives in Latin America and outside the Americas, leading to a substantial reduction in transmission and increased access to diagnosis and antiparasitic treatment for Chagas disease. The risk of <em>T. cruzi</em> transmission by transfusion has decreased sharply following the universal screening in all blood banks of continental Latin American countries, and progressively in other countries and continents.&nbsp; <br /></p><p>WHO recognized Chagas disease as a neglected tropical disease (NTD) in 2005. This facilitated its greater recognition as a global public health problem and was instrumental to strengthen prevention, early diagnosis and antiparasitic treatment, comprehensive care, psychosocial follow up, as well as information, education and communication activities. It also promoted the fight against misinformation, the lack of social demand and the weak political commitment to face the burden of disease. In May 2019, the 72nd World Health Assembly established World Chagas Disease Day, to be celebrated annually on 14 April.</p><p>WHO has worked to improve access to treatment: nifurtimox for all ages and benznidazole for paediatric age (&lt; 19 years) are donated through WHO and have been made available free of charge for treatment of people affected by Chagas disease since 2011 and 2020 respectively. Benznidazole can also be procured at a &ldquo;no-profit&rdquo; price through PAHO&rsquo;s Revolving Fund and through the Mundo Sano Foundation/Insud Pharma.&nbsp;</p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">The NTD road map 2021&ndash;2030 includes Chagas disease among the conditions targeted for elimination as a public health problem and proposes five targets:</span></p><ol><li>verification of interruption of domiciliary vectorial transmission</li><li>verification of interruption of transfusional transmission</li><li>verification of interruption of transmission by organ transplants</li><li>verification of interruption of congenital transmission </li><li>75% coverage of antiparasitic treatment of the eligible population.</li></ol><p>Currently, interruption of domiciliary vectorial transmission has been verified in the entire national territories of three countries in the Region of the Americas: Chile, Paraguay and Uruguay, and in a proportion of the national territories of five other countries: Argentina, Brazil, Colombia, Peru and the Plurinational State of Bolivia, for a total of eight countries. Universal screening of blood donors is fully implemented in all continental Latin American countries, while Canada and the United States of America have adopted national recommendations of testing all donors identified by a questionnaire as being at risk of infection. In the European Region, both screening of blood donors and screening of donors and receivers before organ transplantation are recommended in the European Union and implemented in several countries. In the Western Pacific Region, Japan has implemented universal screening of blood donors and screening before organ transplantation, while Australia recommends universal screening of blood donors and before organ transplantation targeted to people at risk of infection.</p><p>To attain the goal of elimination of Chagas disease transmission to humans and provide health care for affected people worldwide, WHO aims to strengthen networking at the global level and reinforcing regional and national capacities.<br /></p><p>&nbsp;</p><p><strong>Notes</strong><br /></p><ol><li>Argentina, Belize, Bolivia (Plurinational State of), Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, French Guiana, Guatemala, Guyana, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname, Uruguay, and Venezuela (Bolivarian Republic of).<br /></li></ol><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Chagas disease","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Chagas disease (also known as American trypanosomiasis)","ConditionLongerOverview":"","Title":"Chagas disease (also known as American trypanosomiasis)","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs340","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"Chagas disease is caused by the infection of a protozoan parasite (Trypanosoma cruzi). However, this condition is the result of a complex health problem typical of neglected tropical diseases and socially- and environmentally-determined diseases. A missed or late diagnosis with absent or incomplete treatment and follow-up can transform this infection into a life-threatening condition.\r\n\r\nKey strategies to prevent Chagas disease include testing and treating girls, women of reproductive age, newborns and siblings with the infection; insect vector control (in Latin America); blood screening prior to transfusion and transplantation; earliest possible diagnosis and comprehensive follow-up and health care; and information, education and communication in communities and for health professionals.\r\n\r\n","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on Chagas disease: Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite, <i>Trypanosoma cruzi</i> (T. cruzi). The fact sheet includes key facts, and information on signs and symptoms, transmission, treatment, control and prevention, and WHO's response.","PublicationDateAndTime":"2026-04-08T15:39:09Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on Chagas disease: Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite, <i>Trypanosoma cruzi</i> (T. cruzi). The fact sheet includes key facts, and information on signs and symptoms, transmission, treatment, control and prevention, and WHO's response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<div class=\"arrowed-link\"><a href=\"https://www.who.int/campaigns/world-chagas-disease-day\">World Chagas Disease Day</a></div><div class=\"arrowed-link\"><a href=\"https://cdn.who.int/media/docs/default-source/ntds/chagas-disease/chagas-vectors-20200408.pdf?sfvrsn=5f1c2005_2\">Number of triatominea species identified</a></div><div class=\"arrowed-link\"><a href=\"https://www.who.int/health-topics/chagas-disease\">WHO's work on Chagas disease</a></div><div class=\"arrowed-link\"><a href=\"https://www.who.int/teams/control-of-neglected-tropical-diseases/overview\">More on neglected tropical diseases</a></div><p>&nbsp;</p>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/ntd-library/chagas-disease/gettyimages-52965293-2048x2048.tmb-768v.jpg?Culture=en&sfvrsn=6e2a21a_12","FormatedDate":"8 April 2026","TrimmedTitle":"Chagas disease (also known as American trypanosomiasis)"},{"Id":"84455319-c5de-4844-9b6c-dca1f3180276","LastModified":"2026-07-15T12:59:34Z","PublicationDate":"2021-03-26T11:20:50Z","DateCreated":"2021-03-26T11:20:51Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"breast-cancer","ItemDefaultUrl":"/breast-cancer","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul type=\"disc\"><li>Breast cancer caused an estimated 694 000 deaths globally in 2024 and was the most common cancer in women in 164 countries out of 186 in the same year.&nbsp;</li><li>Approximately 80% of breast cancers occur in women with no specific risk factors other than sex and age.&nbsp;</li><li>Approximately 0.5&ndash;1% of breast cancers occur in men.</li><li data-list=\"0\" data-level=\"1\">Effective interventions for early and timely diagnosis linked to comprehensive treatment, rehabilitation and palliative care are essential to reduce the burden of breast cancer and to achieve and maintain optimal functioning and well-being.</li></ul><hr /><h2>Overview</h2><p>Breast cancer is a disease in which abnormal cells in the breast grow out of control and form tumours. If left unchecked, the tumours can spread throughout the body and become fatal.</p><p>Breast cancer cells begin inside the milk ducts and/or the milk-producing lobules of the breast. The earliest form (in situ) is not life-threatening and can be detected in early stages. Cancer cells can spread into nearby breast tissue (invasion). This creates tumours that cause lumps or thickening.&nbsp;</p><p>Invasive cancers can spread to nearby lymph nodes or other organs (metastasize). Metastasis can be life-threatening and fatal. Treatment is based on the person, the type of cancer and its spread. Treatment combines surgery, radiation therapy and medications.</p><h2>Scope of the problem</h2><p>In 2024, there were an estimated 2.4 million women diagnosed with breast cancer and 694 000 deaths globally <em>(1)</em>. Breast cancer occurs in every country of the world in women at any age after puberty but with increasing rates in later life. &nbsp;<br /><br />Global estimates reveal striking inequities in the&nbsp;breast cancer&nbsp;burden according to human development. For instance, in countries with a very high Human Development Index (HDI), 1 in 12 women will be diagnosed with breast&nbsp;cancer&nbsp;in their lifetime and 1 in 71 women die of it. </p><p>In contrast, in countries with a low HDI, 1 in 27 women will be diagnosed with breast&nbsp;cancer&nbsp;in their lifetime and 1 in 48 women die from it.</p><h2>Who is at risk?</h2><p>Female gender is the strongest breast cancer risk factor.&nbsp;Approximately 99% of breast cancers occur in women and 0.5&ndash;1% of breast cancers occur in men.&nbsp;</p><p>Certain factors increase the risk of breast cancer including increasing age, obesity, harmful use of alcohol, family history of breast cancer, history of radiation exposure, reproductive history (such as age that menstrual periods began and age at first pregnancy), tobacco use and postmenopausal hormone therapy. Approximately 80% of breast cancers develop in women who have no modifiable breast cancer risk factor other than gender (female) and age (over 40 years).&nbsp;</p><p>Family history of breast cancer increases the risk of breast cancer, but most women diagnosed with breast cancer do not have a known family history of the disease. However, absence of a known family history does not necessarily mean that a woman is at low risk.</p><p>Certain inherited high penetrance gene mutations greatly increase breast cancer risk, the most dominant being mutations in the genes BRCA1, BRCA2 and PALB-2.&nbsp;Women found to have mutations in these major genes or at high risk may consider risk reduction strategies such as chemoprevention and/or surgical removal of both breasts.</p><p><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;text-transform:inherit;\">Symptoms</span></p><p>Breast cancer can have combinations of symptoms, especially when it is more advanced. Symptoms of breast cancer can include:</p><ul><li>a breast lump or thickening, often without pain&nbsp;</li><li>change in size, shape or appearance of the breast</li><li>dimpling, redness, pitting or other changes in the skin</li><li>change in nipple appearance or the skin surrounding the nipple (areola)&nbsp;</li><li>abnormal or bloody fluid from the nipple.</li></ul><p>People with an abnormal breast lump should seek medical care, even if the lump does not hurt.&nbsp;</p><p>Most breast lumps are not cancer. Breast lumps that are cancerous are more likely to be successfully treated when they are small and have not spread to nearby lymph nodes.&nbsp;</p><p>Breast cancers may spread to other areas of the body and trigger other symptoms. Often, the most common first detectable site of spread is to the lymph nodes under the arm although it is possible to have cancer-bearing lymph nodes that cannot be felt.&nbsp;</p><p>Over time, cancerous cells may spread to other organs including the lungs, liver, brain and bones. Once they reach these sites, new cancer-related symptoms such as bone pain or headaches may appear.&nbsp;</p><h2>Management of breast cancer&nbsp;</h2><p>Mortality is reduced when breast cancer cases are detected and treated early. There are two components of early detection:</p><ul><li>early diagnosis: being aware of signs and symptoms of breast cancer and the importance of seeking medical advice for abnormal findings, timely clinical evaluation and diagnosis and referral for treatment services; and</li><li>screening: the application of mammography in an apparently healthy population, usually women 50-69 years of age, to identify pre-clinical lesions before recognizable signs or symptoms appear.</li></ul><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Treatment for breast cancer depends on the subtype of cancer and how much it has spread outside of the breast to lymph nodes (stages II or III) or to other parts of the body (stage IV) and may be combined t</span><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">o minimize the chances of the cancer coming back (recurrence). These include:</span></p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">surgery to remove the breast tumour;</li><li data-list=\"0\" data-level=\"1\">radiation therapy to reduce recurrence risk in the breast and surrounding tissues; and</li><li data-list=\"0\" data-level=\"1\">medications to kill cancer cells and prevent spread, including hormonal therapies, chemotherapy or targeted biological therapies.</li></ul><p>Treatments for breast cancer are more effective and are better tolerated when started early and taken to completion.&nbsp;The effectiveness of breast cancer therapies depends on completing the full course of treatment. Partial treatment is less likely to lead to a positive outcome.</p><p>Surgery may remove just the cancerous tissue (called a lumpectomy) or the whole breast (mastectomy).&nbsp;Lymph nodes are removed at the time of cancer surgery for invasive cancers. Complete removal of the lymph node bed under the arm (complete axillary dissection) was thought to be necessary in the past to prevent the spread of cancer. A smaller lymph node procedure called &ldquo;sentinel node biopsy&rdquo; is now preferred as it has fewer complications.</p><p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;\"><span lang=\"EN-GB\" style=\"font-family:'Calibri',sans-serif;mso-fareast-font-family:'Times New Roman';mso-font-kerning:0pt;mso-ligatures:none;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;\"><o:p></o:p></span>Radiation therapy treats residual microscopic cancers left behind in the breast tissue and/or lymph nodes and minimizes the chances of cancer recurring on the chest wall.</p><p>Advanced cancers can erode through the skin to cause open sores (ulceration) but are not necessarily painful. Women with breast wounds that do not heal should seek medical care to have a biopsy performed.</p><p>Medicines to treat breast cancers are selected based on the biological properties of the cancer as determined by special tests. The great majority of medicines used for breast cancer are already on the WHO Essential Medicines List (EML).</p><p>Medical treatments for breast cancers, which may be given before (&ldquo;neoadjuvant&rdquo;) or after (&ldquo;adjuvant&rdquo;) surgery, are based on the biological subtyping of the cancers. Certain subtypes of breast cancer, such as triple negative (those that do not express estrogen receptor (ER), progesterone receptor (PR) or HER-2 receptor), are more aggressive than others. </p><p>Cancers that express the estrogen receptor (ER) and/or progesterone receptor (PR) are likely to respond to endocrine (hormone) therapies such as tamoxifen or aromatase inhibitors.&nbsp;These medicines are taken orally for years and reduce the chance of recurrence of these &ldquo;hormone-positive&rdquo; cancers by nearly half.&nbsp;Endocrine therapies can cause symptoms of menopause but are generally well tolerated.</p><p>Cancers that do not express ER or PR are &ldquo;hormone receptor negative&rdquo; and need to be treated with chemotherapy unless the cancer is very small. The chemotherapy regimens available today are very effective in reducing the chances of cancer spread or recurrence and are generally given as outpatient therapy, not requiring hospital admission in the absence of complications.</p><p>Breast cancers that independently overexpress a molecule called the HER-2/neu oncogene (HER-2 positive) are amenable to treatment with targeted biological agents such as trastuzumab. When targeted biological therapies are given, they are combined with chemotherapy to make them effective at killing cancer cells.</p><p>Radiotherapy plays a very important role in treating breast cancer. With early-stage breast cancers, radiation can prevent a woman having to undergo a mastectomy. With later stage cancers, radiotherapy can reduce cancer recurrence risk even when a mastectomy has been performed. </p><p>Early access to a multidisciplinary team that includes oncologists, radiologists, pathologists, dieticians/nutritionists, physical therapists, social workers, mental health, palliative care and rehabilitation teams both during and after completion of treatment helps improve outcomes. It also helps patients maintain or restore their functioning, independence and participation in meaningful life roles and community activities more quickly than might otherwise be the case. </p><p>Prehabilitation, including lifestyle-based interventions (exercise, diet and nutritional supplementation and psychological support) between diagnosis and treatment has proven effective in minimizing complications related to the treatment. </p><p>Since the whole continuum of care is often complex, patient navigation&nbsp;helps streamline care pathways, improving health outcomes and patient satisfaction, and guiding individuals &ndash; especially in resource-limited or fragmented systems &ndash; through the cancer care continuum to ensure timely diagnosis and treatment completion. Benefits include increased screening rates, reduced hospital readmissions, better treatment understanding, and improved quality of life.</p><p><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Global impact</span></p><p>Age-standardized breast cancer mortality in high-income countries dropped by 40% between the 1980s and 2020.&nbsp;Countries that have succeeded in reducing breast cancer mortality have been able to achieve an annual breast cancer mortality reduction of 2&ndash;4% per year.&nbsp;</p><p>The strategies for improving breast cancer outcomes depend on fundamental health system strengthening to deliver the treatments that are already known to work. These are also important for the management of other cancers and other  noncommunicable diseases (NCDs).&nbsp;</p><p>The establishment of reliable referral pathways from primary care facilities to secondary hospitals to dedicated cancer centres is the same approach as is required for the management of cervical cancer, lung cancer, colorectal cancer and prostate cancer. To that end, breast cancer is a so-called index disease whereby pathways are created that can be followed for the management of other cancers.&nbsp;</p><h2>WHO response</h2><p>By providing public health education to improve awareness among women of the signs and symptoms of breast cancer and, together with their families, understand the importance of early detection and treatment, more women would consult medical practitioners when breast cancer is first suspected, have access to clinical evaluation and diagnosis and get referral for timely treatment before any cancer present is advanced. This is possible even in the absence of mammographic screening that is impractical in many countries at the present time.<strong></strong></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">In 2021, the World Health Organization established the Global Breast Cancer Initiative (GBCI), to bring together stakeholders from around the world and across sectors with the shared goal of reducing global breast cancer mortality by 2.5% per year, thereby averting 2.5&nbsp;million breast cancer deaths globally by 2040. The three pillars of action are: health promotion for early detection; timely diagnosis; and comprehensive breast cancer management.&nbsp;&nbsp;</span></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">&nbsp;</span></p><h3><strong>References</strong></h3><ol><li>Ferlay J EM, Lam F, Laversanne M, Colombet M, Mery L et al. Global Cancer Observatory: Cancer Today [website]. International Agency for Research on Cancer; 2026 (<a href=\"https://gco.iarc.fr/today\">https://gco.iarc.fr/today</a>)</li></ol><p></p>","ConditionName":"","OpenGraphTitle":"Breast cancer","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Breast cancer","ConditionLongerOverview":"","Title":"Breast cancer","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"Breast cancer is a prevalent and serious disease characterized by uncontrolled growth of abnormal cells in the breast, which can spread and become fatal if untreated. It primarily affects women but can also occur in men. Mortality is reduced when breast cancer is detected and treated early.","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on breast cancer, including information on prevalence, risk factors, symptoms, management, global impact and WHO's work on breast cancer.","PublicationDateAndTime":"2026-07-03T15:59:29Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on breast cancer, including information on prevalence, risk factors, symptoms, management, global impact and WHO's work on breast cancer.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<p><a href=\"https://www.who.int/initiatives/global-breast-cancer-initiative\">Global Breast Cancer Initiative</a></p><p><a href=\"https://www.who.int/podcasts/episode/science-in-5/episode--127---breast-cancer--take-charge-of-your-health\">Science in 5 podcast on breast cancer</a></p><p><a href=\"https://www.who.int/health-topics/cancer\">More on cancer </a></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/health-topics/cancer/who_20210301_nga-85.tmb-768v.jpg?sfvrsn=8b24a439_6","FormatedDate":"3 July 2026","TrimmedTitle":"Breast cancer"},{"Id":"8eaac807-306c-4937-977e-1f63c128afb3","LastModified":"2025-05-29T09:08:52Z","PublicationDate":"2020-07-30T13:56:56Z","DateCreated":"2020-07-30T13:56:56Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"quality-health-services","ItemDefaultUrl":"/quality-health-services","NewsNumberOfAdditionalItems":1,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Between 5.7 and 8.4&nbsp;million deaths are attributed to poor quality care each year in low- and middle-income countries (LMICs), which represents up to 15% of overall deaths in these countries <em>(1)</em>.</li><li>Sixty per cent of deaths in LMICs from conditions requiring health care occur due to poor quality care, whereas the remaining deaths result from non-utilization of the health system <em>(2)</em>.</li><li>Four in ten patients living with chronic conditions do not trust their healthcare system. Patients&rsquo; trust in health system goes hand-in-hand with high quality health care and is closely linked to personal experience of health care <em>(3)</em>.</li><li>Inadequate quality of care imposes costs of US$&nbsp;1.4&ndash;1.6 trillion each year in lost productivity in LMICs <em>(1)</em>.</li><li>In high-income countries, 1 in 10 patients is harmed while receiving hospital care, and 7 in every 100 hospitalized patients can expect to acquire a health care-associated infection. Four in 100 people die from unsafe care in the developing world <em>(4)</em>.</li><li>It has been estimated that high quality health systems could prevent 2.5&nbsp;million deaths from cardiovascular disease, 900&nbsp;000 deaths from tuberculosis, 1&nbsp;million newborn deaths and half of all maternal deaths each year <em>(2)</em>.</li></ul><hr /><br /><h2>Overview</h2><p>Quality of care is the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with evidence-based professional knowledge. This definition of quality of care spans promotion, prevention, treatment, rehabilitation and palliation, and implies that quality of care can be measured and continuously improved through the provision of evidence-based care that takes into consideration the needs and preferences of health service users &ndash; patients, families and communities.</p><p>Quality health services should be:</p><ul type=\"disc\"><li data-list=\"1\" data-level=\"1\"><strong>effective</strong>&nbsp;by providing evidence-based health care services to those who need them;</li><li data-list=\"1\" data-level=\"1\"><strong>safe</strong>&nbsp;by avoiding harm to the people for whom the care is intended;</li><li data-list=\"1\" data-level=\"1\"><strong>people-centred</strong>&nbsp;by providing care that responds to individual preferences, needs and values, within health services that are organized around the needs of people;</li><li data-list=\"1\" data-level=\"1\"><strong>timely</strong>&nbsp;by reducing waiting times and sometimes harmful delays for both those who receive and those who give care;&nbsp;</li><li data-list=\"1\" data-level=\"1\"><strong>equitable</strong>&nbsp;by providing the same quality of care regardless of age, sex, gender, race, ethnicity, geographic location, religion, socio-economic status, linguistic or political affiliation;</li><li data-list=\"1\" data-level=\"1\"><strong>integrated</strong>&nbsp;by providing care that is coordinated across levels and providers and makes available the full range of health services throughout the life course; and</li><li data-list=\"1\" data-level=\"1\"><strong>efficient</strong>&nbsp;by maximizing the benefit of available resources and avoiding waste.</li></ul><h2>Universal health coverage and quality: a global commitment</h2><p>The <a href=\"https://www.who.int/publications/i/item/9789240029040\">overarching aim of UHC</a> is for all people who need health services to receive high- quality care without financial hardship. Quality health services (promotive, preventive, curative, rehabilitative and palliative) is thus embedded within the definition of UHC. Even with increased access to services, health improvements can remain elusive unless those services are of sufficient quality to be effective&nbsp;<em>(5)</em>.</p><h2>Taking action for enhancing quality of care</h2><p>Quality health services are a product of the health system&rsquo;s environment and the actions of health care providers and individuals working within the system. To achieve the goal of access to high quality health services for all, governments should take an integrated approach and work with different key actors within the health system and beyond, including individuals and communities. The <a href=\"https://www.who.int/publications/i/item/9789240011632\">success and sustainability</a> of efforts to improve quality of care is dependent on effective integration of health actions and programmes across different levels of the health system.</p><p><strong>National strategic direction on quality:</strong>&nbsp;<a href=\"https://www.who.int/publications/i/item/9789241565561\"></a><a href=\"https://www.who.int/publications/i/item/9789241565561\">National policies and strategies</a> aimed at improving quality of care are essential to ensure action across the health system and need to be closely aligned with broader national health policy and planning. The national quality policy and strategy identifies a pragmatic package of interventions to strengthen the system environment, reduce harm, improve clinical care, and engage patients, families and communities. An  <a href=\"https://www.who.int/publications/i/item/9789241513906\">illustrative list</a> of interventions for each of these areas is available for countries to consider.</p><p><strong>Quality across the health system:</strong>&nbsp;In addition to an enabling policy environment, the provision of quality health services requires good governance; skilled and competent health workforce that is supported and motivated; financing mechanisms that enable and encourage quality care; information systems that continuously monitor and learn to drive better care; medicines, medical devices and technologies that are available, safe and appropriately regulated; and accessible and well-equipped health care facilities. </p><p><strong>Quality-driven primary health care approach:</strong>&nbsp;Primary health care (PHC) is pivotal for building a high quality health system and achieving universal health coverage.  <a href=\"https://www.who.int/publications/i/item/9789240090583\">Careful consideration</a> is needed to ensure PHC-oriented health systems deliver effective, safe and user-centred health services. PHC can not only improve quality from the perspective of people but also enhance their trust in the health system. </p><p><strong>Monitoring and evaluation:</strong>&nbsp;Quality of care needs to be continually <a href=\"https://www.who.int/publications/i/item/9789240105737\">measured</a> to monitor progress towards improvement goals. This requires context-specific indicators and accurate, timely and actionable data. The integration of global and national measurement efforts is critical to ensuring that countries collect data that matters and use that data to transform and improve their service delivery systems. The role, for instance, of <a href=\"https://www.who.int/publications/i/item/9789240010338\">adverse event reporting and learning systems</a> is critical in this context. </p><p><strong>Data-driven response and learning systems:</strong>&nbsp;It is critical to document and share on-the-ground experiences related to quality of care efforts. This is key to understand the realities of the health system, what works and what doesn&rsquo;t work. Such knowledge, emerging from implementation experiences must be shared globally and within the countries.&nbsp;</p><p><strong>Engaging users and communities</strong>: To improve quality of care, health systems need to listen to and learn from the population they serve.  <a href=\"https://www.who.int/publications/i/item/9789240027794\">Understanding people&rsquo;s views</a> can provide valuable insights on what is important for them. Robust and regular dialogue between governments and their population fosters trust as people feel that the policy-makers listen to their needs and interests and consider their perspectives <em>(6)</em>.</p><h2>WHO&rsquo;s response</h2><p>WHO works with Member States and partners to ensure that quality of health services is addressed at the national level and operational plans are in place to improve quality of care at national, sub-national and facility level.&nbsp;</p><p>Specifically, WHO:</p><ul><li>supports countries in the development, review and implementation of national policies and strategies for quality of care and patient safety;&nbsp;</li><li>works with countries and partners to enhance, sustain and scale up &nbsp;quality of care efforts from global to local level;</li><li>promotes patient safety initiatives to reduce harm to patients in the delivery of quality health services;</li><li>strengthens infection prevention and control capacity alongside efforts on water, sanitation and hygiene (WASH), as pivotal to quality health services;</li><li>strengthens use of quality of care measurement frameworks and indicators in the countries, and develops countries capacities in this regard;</li><li>provides support to countries in their work on community engagement for quality health services;</li><li>builds capacities of training institutions and health and care workers to develop a safe and supporting quality improvement environment and patient safety culture;</li><li>facilitates global collaboration and learning within and between countries through communities of practice hosted on the <a href=\"https://ihshub.org/page/home-ihs\">WHO Integrated Health Services Hub</a>; </li><li>reports on progress.</li></ul><p>&nbsp;</p><p><strong>References</strong></p><ol><li>Crossing the global quality chasm: improving health care worldwide. Washington, D.C.: The National Academies of Sciences, Engineering, Medicine; 2018. Available from: http://nationalacademies.org/hmd/Reports/2018/crossing-global-quality-chasm-improving-health-care-worldwide.aspx</li><li>Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, et al. High-quality health systems in the sustainable development goals era: time for a revolution. Lancet Glob Health. 2018 Nov;6(11):e1196&ndash;252. https://doi.org/10.1016/S2214-109X(18)30386-3</li><li>OECD (2025), Does Healthcare Deliver?: Results from the Patient-Reported Indicator Surveys (PaRIS), OECD Publishing, Paris, https://doi.org/10.1787/c8af05a5-en.</li><li>OECD (2022). The economics of patient safety: From analysis to action. OECD Publishing, Paris, https://dx.doi.org/10.1787/761f2da8-en.</li><li>Ghebreyesus TA. How could health care be anything other than high quality? Lancet Glob Health. 2018 Nov;6(11):e1140&ndash;1. Available from: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2818%2930394-2/fulltext</li><li>The People&rsquo;s Voice Survey on Health System Performance. The Lancet Global Health series 2023. Vol 12, No 1.</li></ol>","ConditionName":"","OpenGraphTitle":"Fact sheet: Quality health services","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Fact sheet: Quality health services","ConditionLongerOverview":"","Title":"Quality health services","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"Quality of care is the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with evidence-based professional knowledge.","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"Quality of care is the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with evidence-based professional knowledge.","PublicationDateAndTime":"2025-05-19T18:00:00Z","ConditionBriefOverview":"","MetaDescription":"Quality of care is the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with evidence-based professional knowledge.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<p><a href=\"https://www.who.int/teams/integrated-health-services\">Integrated Health Services</a></p><p><a href=\"https://www.who.int/health-topics/quality-of-care#tab=tab_1\">WHO's work on quality of care</a></p><p><a href=\"https://www.who.int/teams/integrated-health-services/quality-of-care/\">Quality health services</a></p><p><a href=\"https://www.who.int/teams/integrated-health-services/patient-safety\">Patient safety</a></p><p><a href=\"https://ihshub.org/page/home-ihs\">Integrated Health Services Hub</a></p><p><a href=\"https://www.who.int/health-topics/infection-prevention-and-control#tab=tab_1\">WHO's work on infection prevention and control</a></p><p><a href=\"https://www.who.int/health-topics/water-sanitation-and-hygiene-wash\">WHO's work on water, sanitation and hygiene</a></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/ihs/quality-health-services/global-learning-laboratory-for-quality-uhc/whocovid19-20200709-gh-224.tmb-768v.jpg?sfvrsn=7fc0356a_7","FormatedDate":"19 May 2025","TrimmedTitle":"Quality health services"},{"Id":"c96503b5-ff17-4c65-b70f-3e0a7e04d623","LastModified":"2026-01-08T11:31:12Z","PublicationDate":"2018-06-02T02:27:04Z","DateCreated":"2018-06-02T02:27:03Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"abortion","ItemDefaultUrl":"/abortion","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Six out of 10 unintended pregnancies end in induced abortion.</li><li>Abortion is a common health intervention. It is very safe when carried out using a method recommended by WHO, appropriate to the pregnancy duration and by someone with the necessary skills.</li><li>However, around 45% of abortions are unsafe.</li><li>Unsafe abortion is an important preventable cause of maternal deaths and morbidities. It can lead to physical and mental health complications and social and financial burdens for women, communities and health systems.</li><li>Lack of access to safe, timely, affordable and respectful abortion care is a critical public health and human rights issue.<br />&nbsp;</li></ul><hr /><p>&nbsp;</p><h2>Overview</h2><p>Around 73&nbsp;million induced abortions take place worldwide each year. Six out of 10 (61%) of all unintended pregnancies, and 3 out of 10 (29%) of all pregnancies, end in induced abortion <em>(1)</em>.</p><p>Comprehensive abortion care is included in the <a href=\"https://www.who.int/emergencies/diseases/novel-coronavirus-2019/related-health-issues\">list of essential health care services</a> published by WHO in 2020. Abortion is a simple health care intervention that can be safely and effectively managed by a wide range of health workers using medication or a surgical procedure. In the first 12 weeks of pregnancy, a medical abortion can also be\r\n    safely self-managed by the pregnant person outside of a health care facility (e.g. at home), in whole or in part. This requires that the woman has access to accurate information, quality medicines and support from a trained health worker (if she\r\n    needs or wants it during the process).</p><p>Comprehensive abortion care includes the provision of information, abortion management and post-abortion care. Abortion management includes induced abortion (the deliberate interruption of an ongoing pregnancy by medical or surgical means), care related to pregnancy loss (e.g., miscarriage/spontaneous abortion, missed abortion and intrauterine fetal demise), and management of complications after an abortion.</p><p>The information in this fact sheet focuses on care related to induced abortion.</p><h2>Scope of the problem</h2><p>When carried out using a method recommended by WHO appropriate to the pregnancy duration, and by someone with the necessary skills, abortion is a safe health care intervention <em>(2).</em> </p><p>However, when people with unintended pregnancies face barriers to attaining safe, timely, affordable, geographically reachable, respectful and non-discriminatory abortion care, they may resort to unsafe abortion.<sup>1</sup></p><p>Global estimates from 2010&ndash;2014 demonstrate that 45% of all induced abortions are unsafe. Of all unsafe abortions, one third were performed under the least safe conditions, i.e. by untrained persons using dangerous and invasive methods. More than half of all these unsafe abortions occurred in Asia, most of them in south and central Asia. In Latin America and Africa, the majority (approximately 3 out of 4) of all abortions were unsafe. In Africa, nearly half of all abortions occurred under the least safe circumstances <em>(3)</em>.</p><h2>Consequences of inaccessible quality abortion care</h2><p>Lack of access to safe, affordable, timely and respectful abortion care, and the stigma associated with abortion, pose risks to women&rsquo;s physical and mental well-being throughout the life-course. </p><p>Inaccessibility of quality abortion care risks violating a range of human rights of women and girls, including the right to life; the right to the highest attainable standard of physical and mental health; the right to benefit from scientific progress\r\n    and its realization; the right to decide freely and responsibly on the number, spacing and timing of children; and the right to be free from torture, cruel, inhuman and degrading treatment and punishment. </p><p>Maternal deaths due to unsafe abortion are often misclassified and underreported due to stigma. A review from 2009&ndash;20 found that 8% of maternal deaths were linked to abortion <em>(4).</em></p><p>While deaths from safe abortion are negligible, &lt;1/100&nbsp;000, in regions where unsafe abortions are common, the death rates are high, at &gt; 200/100 000 abortions <em>(4)</em>.&nbsp;Estimates from 2012 indicate that in developing countries alone, 7&nbsp;million women per year were treated in hospital facilities for complications of unsafe abortion <em>(5)</em>.</p><p>Physical health risks associated with unsafe abortion include:</p><ul><li>incomplete abortion (failure to remove or expel all pregnancy tissue from the uterus);</li><li>haemorrhage (heavy bleeding);</li><li>infection;</li><li>uterine perforation (caused when the uterus is pierced by a sharp object); and</li><li>damage to the genital tract and internal organs as a consequence of inserting dangerous objects into the vagina or anus.</li></ul><p>Restrictive abortion regulation can cause distress and stigma, and risk constituting a violation of human rights of women and girls, including the right to privacy and the right to non-discrimination and equality, while also imposing financial burdens on women and girls. Regulations that force women to travel to attain legal care, or require mandatory counselling or waiting periods, lead to loss of income and other financial costs, and can make abortion inaccessible to women with low resources <em>(6,7)</em>.</p><p>Estimates from 2006 show that complications of unsafe abortions cost health systems in developing countries US$&nbsp;553&nbsp;million per year for post-abortion treatments <em>(8)</em>. In addition, households experienced US$&nbsp;922&nbsp;million in loss of income due to long-term disability related to unsafe abortion <em>(8)</em>. Countries and health systems could make substantial monetary savings by providing greater access to modern contraception and quality induced abortion <em>(7,9)</em>.</p><p>A scoping review from 2021 also indicates that legalization of abortion affects women&rsquo;s education, participation in the labour market and positively contributes to GDP growth <em>(9)</em>. The legal status of abortion can further affect children&rsquo;s educational outcomes, and their earnings in the labour market later in life. By reducing the number of unwanted pregnancies and thus increasing the likelihood that children are born wanted, legalization of abortion can be linked to greater parental investments in children, including in girls&rsquo; schooling <em>(9)</em>.\r\n</p><h2>Expanding quality abortion care</h2><p>Evidence shows that restricting access to abortions does not reduce the number of abortions <em>(1)</em>; however, it does affect whether the abortions that women and girls attain are safe and dignified. The proportion of unsafe abortions are significantly higher in countries with highly restrictive abortion laws than in countries with less restrictive laws <em>(3)</em><em>.</em></p><p>Barriers to accessing safe and respectful abortion include high costs, stigma for those seeking abortions and health care workers, and the refusal of health workers to provide an abortion based on personal conscience or religious belief. Access is further impeded by restrictive laws and requirements that are not medically justified, including criminalization of abortion, mandatory waiting periods, provision of biased information or counselling, third-party authorization and restrictions regarding the type of health care providers or facilities that can provide abortion services.</p><p>Multiple actions are needed at the legal, health system and community levels so that everyone who needs abortion care has access to it. The three cornerstones of an enabling environment for quality comprehensive abortion care are:</p><ul><li>respect for human rights, including a supportive framework of law and policy;</li><li>the availability and accessibility of information; and</li><li>a supportive, universally accessible, affordable and well functioning health system.</li></ul><p>A well-functioning health system implies many factors, including: </p><ul><li>evidence-based policies;</li><li>universal health coverage;</li><li>the reliable supply of quality, affordable medical products and equipment;</li><li>that an adequate number of health workers, of different types, provide abortion care at a reachable distance to patients;</li><li>the delivery of abortion care through a variety of approaches, e.g. care in health facilities, digital interventions and self-care approaches, allowing for choices depending on the values and preferences of the pregnant person, available resources, and the national and local context;</li><li>that health workers are trained to provide safe and respectful abortion care, to support informed decision-making and to interpret laws and policies regulating abortion; </li><li>that health workers are supported and protected from stigma; and</li><li>provision of contraception to prevent unintended pregnancies.</li></ul><p>Availability and accessibility of information implies: </p><ul><li>provision of evidence-based comprehensive sexuality education; and</li><li>accurate, non-biased and evidence-based information on abortion and contraceptive methods.</li></ul><h2>WHO response</h2><p>WHO provides global technical and policy guidance on the use of contraception to prevent unintended pregnancy, provision of information on abortion care, abortion management (including miscarriage, induced abortion, incomplete abortion and fetal death) and post-abortion care. In 2022, WHO published an updated, consolidated guideline on abortion care, including all WHO recommendations and best practice statements across three domains essential to the provision of abortion care: law and policy, clinical services and service delivery. A <a href=\"https://www.who.int/publications/i/item/9789240104204\">second edition</a> was released in 2025.</p><p>WHO also maintains the <a href=\"https://abortion-policies.srhr.org\">Global Abortion Policies Database</a>. This interactive online database contains comprehensive information on the abortion laws, policies, health standards and guidelines for all countries.</p><p>Upon request, WHO provides technical support to countries to adapt sexual and reproductive health guidelines to specific contexts and strengthen national policies and programmes related to contraception and safe abortion care. A quality abortion care monitoring and evaluation framework is also in development.</p><p>WHO is a cosponsor of the <a href=\"https://www.who.int/teams/sexual-and-reproductive-health-and-research-(srh)/human-reproduction-programme\">HRP (UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction)</a>, which carries\r\n    out research on clinical care, abortion regulation, abortion stigma, as well as implementation research on community and health systems approaches to quality abortion care. It also monitors the global burden of unsafe abortion and its consequences.</p><p>&nbsp;</p><p><sup>1</sup> An &ldquo;unsafe abortion&rdquo; is defined as a procedure for terminating a pregnancy performed by persons lacking the necessary information or skills or in an environment not in conformity with minimal medical standards, or both. The persons, skills and medical standards considered safe in the provision of abortion are different for medical and surgical abortion and by pregnancy duration. In using this definition, what is considered &lsquo;safe&rsquo; or unsafe needs to be interpreted in line with the most current WHO technical and policy guidance <em>(2).</em></p><hr /><p>(1) Bearak J, Popinchalk A, Ganatra B, Moller A-B, Tun&ccedil;alp &Ouml;, Beavin C et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990&ndash;2019. Lancet Glob Health. 2020 Sep; 8(9):e1152-e1161. doi: 10.1016/S2214-109X(20)30315-6.</p><p>(2) Ganatra B, Tun&ccedil;alp &Ouml;, Johnston H, Johnson BR, G&uuml;lmezoglu A, Temmerman M. From concept to measurement: Operationalizing WHO's definition of unsafe abortion. Bull World Health Organ 2014;92:155; 10.2471/BLT.14.136333.</p><p>(3) Ganatra B, Gerdts C, Rossier C, Johnson Jr B R, Tuncalp &Ouml;, Assifi A et al. Global, regional, and subregional classification of abortions by safety, 2010&ndash;14: estimates from a Bayesian hierarchical model. The Lancet. 2017 Sep.</p><p>(4) Cresswell JA, Alexander M, Chong MYC et al. Global and regional causes of maternal deaths 2009-20: a WHO systematic analysis. Lancet Glob Health. 2025 Mar 7:S2214-109X(24)00560-6. doi: 10.1016/S2214-109X(24)00560-6.</p><p>(5) Singh S, Maddow-Zimet I. Facility-based treatment for medical complications resulting from unsafe pregnancy termination in the developing world, 2012: a review of evidence from 26 countries. BJOG 2015; published online Aug 19. DOI:10.1111/1471-0528.13552.</p><p>(6) Coast E, Lattof SR, Meulen Rodgers YV, Moore B, Poss C. The microeconomics of abortion: A scoping review and analysis of the economic consequences for abortion care-seekers. PLoS One. 2021 Jun 9;16(6):e0252005. doi: 10.1371/journal.pone.0252005. PMID: 34106927; PMCID: PMC8189560.</p><p>(7) Lattof SR, Coast E, Rodgers YVM, Moore B, Poss C. The mesoeconomics of abortion: A scoping review and analysis of the economic effects of abortion on health systems. PLoS One. 2020 Nov 4;15(11):e0237227. doi: 10.1371/journal.pone.0237227. PMID: 33147223; PMCID: PMC7641432.</p><p>(8) Vlassoff et al. Economic impact of unsafe abortion-related morbidity and mortality: evidence and estimation challenges. Brighton, Institute of Development Studies, 2008 (IDS Research Reports 59).</p><p>(9) Rodgers YVM, Coast E, Lattof SR, Poss C, Moore B. The macroeconomics of abortion: A scoping review and analysis of the costs and outcomes. PLoS One. 2021 May 6;16(5):e0250692. doi: 10.1371/journal.pone.0250692. PMID: 33956826; PMCID: PMC8101771.</p><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Abortion","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Abortion","ConditionLongerOverview":"","Title":"Abortion","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs388","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"<div><h3>Database</h3><p><a href=\"https://abortion-policies.srhr.org/\" target=\"_blank\">Global Abortion Policies Database</a></p></div><div><h3>Related health topic</h3><p><a href=\"https://www.who.int/health-topics/abortion\">Abortion</a></p><h3></h3><ul></ul></div>","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"Fact sheet on abortion: scope of the problem, consequences of inaccessible quality abortion care, expanding quality abortion care, and WHO action. ","PublicationDateAndTime":"2025-12-08T15:13:22Z","ConditionBriefOverview":"","MetaDescription":"Fact sheet on abortion: scope of the problem, consequences of inaccessible quality abortion care, expanding quality abortion care, and WHO action. ","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<ul><li><a href=\"https://www.who.int/publications/i/item/9789240104204\">Abortion care guideline</a></li><li><a href=\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31794-4/fulltext\">Classification of abortions by safety: article in The Lancet</a></li><li><a href=\"https://www.who.int/health-topics/quality-of-care\">WHO's work on quality of care</a></li><li><a href=\"https://www.who.int/emergencies/diseases/novel-coronavirus-2019/related-health-issues\">Maintaining essential health services during the COVID-19 outbreak</a></li><li><a href=\"https://www.who.int/teams/sexual-and-reproductive-health-and-research-(srh)\">Sexual and reproductive health and research including the Special Programme HRP</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/safe-abortion.tmb-768v.jpg?sfvrsn=3a6fffb9_44","FormatedDate":"8 December 2025","TrimmedTitle":"Abortion"},{"Id":"aa55e7b5-3461-4a33-b1b9-4a27375129fc","LastModified":"2026-11-02T17:42:26Z","PublicationDate":"2020-07-29T13:20:29Z","DateCreated":"2020-07-29T13:20:29Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"brucellosis","ItemDefaultUrl":"/brucellosis","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":null,"Content":"<p>Brucellosis is a bacterial disease caused by various <em>Brucella</em> species, which mainly infect cattle, swine, goats, sheep and dogs. Humans generally acquire the disease through direct contact with infected animals, by eating or drinking contaminated animal products or by inhaling airborne agents. Most cases are caused by ingesting unpasteurized milk or cheese from infected goats or sheep.<br /></p><p>Brucellosis is one of the most widespread zoonoses transmitted by animals and in endemic areas, human brucellosis has serious public health consequences. Expansion of animal industries and urbanization, and the lack of hygienic measures in animal husbandry and in food handling, partly account for brucellosis remaining a public health hazard.</p><p>&nbsp;</p><h2>Who is at risk?&nbsp;</h2><p>Brucellosis is found globally and is a reportable disease in most countries. It affects people of all ages and both sexes. In the general population, most cases are caused by the consumption of raw milk or its derivatives such as fresh cheese. Most of these cases are from sheep and goat products.</p><p>The disease is also considered an occupational hazard for people who work in the livestock sector. People who work with animals and are in contact with blood, placenta, foetuses and uterine secretions have an increased risk of contracting the disease. This method of transmission primarily affects farmers, butchers, hunters, veterinarians and laboratory personnel.</p><p>Worldwide,&nbsp;<em>Brucella melitensis</em>&nbsp;is the most prevalent species causing human brucellosis, owing in part to difficulties in immunizing free-ranging goats and sheep.</p><p>Human-to-human transmission is very rare.</p><p>&nbsp;</p><h2>Prevention and control</h2><p>Prevention of brucellosis is based on surveillance and the prevention of risk factors. The most effective prevention strategy is the elimination of infection in animals. Vaccination of cattle, goats and sheep is recommended in enzootic areas with high prevalence rates. Serological or other testing and culling can also be effective in areas with low prevalence. In countries where eradication in animals through vaccination or elimination of infected animals is not feasible, prevention of human infection is primarily based on raising awareness, food-safety measures, occupational hygiene and laboratory safety.</p><p>Pasteurization of milk for direct consumption and for creating derivatives such as cheese is an important step to preventing transmission from animals to humans. Education campaigns about avoiding unpasteurized milk products can be effective, as well as policies on its sale.</p><p>In agricultural work and meat-processing, protective barriers and correct handling and disposal of afterbirths, animal carcasses and internal organs is an important prevention strategy.&nbsp;</p><p>&nbsp;</p><h2>Treatment and care</h2><p>Brucellosis typically causes flu-like symptoms, including fever, weakness, malaise and weight loss. However, the disease may present in many atypical forms. In many patients the symptoms are mild and, therefore, the diagnosis may not be considered. The incubation period of the disease can be highly variable, ranging from 1 week to 2 months, but usually 2&ndash;4 weeks.</p><p>Treatment options include doxycycline 100 mg twice a day for 45 days, plus streptomycin 1 g daily for 15 days. The main alternative therapy is doxycycline at 100 mg, twice a day for 45 days, plus rifampicin at 15mg/kg/day (600-900mg) for 45 days. Experience suggests that streptomycin may be substituted with gentamicin 5mg/kg/daily for 7&ndash;10 days, but no study directly comparing the two regimes is currently available. The optimal treatment for pregnant women, neonates and children under 8 is not yet determined; for children, options include trimethoprim/sulfamethoxazole (co-trimoxazole) combined with an aminoglycoside (streptomycin, gentamycin) or rifampicin.</p><p><br /></p><h2>WHO response</h2><p>WHO provides technical advice to member states through provision of standards, information and guidance for the management of brucellosis in humans and animals. The Organization works to support the coordination and sharing of information between the public health and animal health sectors. In collaboration with the Food and Agricultural Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and the Mediterranean Zoonoses Control Programme (MZCP), WHO supports countries in the prevention and management of the disease through the Global Early Warning System for Major Animal Diseases (GLEWS).&nbsp;<br /></p><hr /><div>&nbsp;<ul><li><a href=\"https://www.who.int/publications/i/item/9789241547130\">Brucellosis in humans and animals</a><br />Food and Agriculture Organization of the United Nations, World Health Organization &amp; World Organisation for Animal Health</li><li><a href=\"https://apps.who.int/iris/bitstream/handle/10665/67088/WHO_CDS_CPE_SMT_2001.13.pdf\">WHO Recommended strategies for the prevention and control of communicable diseases</a></li></ul></div><p>&nbsp;</p>","ConditionName":null,"OpenGraphTitle":"Brucellosis","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":null,"SelfCareLongerSummary":null,"EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":null,"MetaTitle":"Brucellosis","ConditionLongerOverview":null,"Title":"Brucellosis","PreventionLongerSummary":null,"SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":null,"FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"Brucellosis is a bacterial disease caused by various Brucella species, which mainly infect cattle, swine, goats, sheep and dogs. Humans generally acquire the disease through direct contact with infected animals, by eating or drinking contaminated animal products or by inhaling airborne agents. Most cases are caused by ingesting unpasteurized milk or cheese from infected goats or sheep. \r\nBrucellosis is one of the most widespread zoonoses transmitted by animals and in endemic areas, human brucellosis has serious public health consequences. Expansion of animal industries and urbanization, and the lack of hygienic measures in animal husbandry and in food handling, partly account for brucellosis remaining a public health hazard. ","FeatureStoryNumberOfAdditionalItems":1,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"Brucellosis is a bacterial disease caused by various Brucella species, which mainly infect cattle, swine, goats, sheep and dogs. Humans generally acquire the disease through direct contact with infected animals, by eating or drinking contaminated animal products or by inhaling airborne agents. Most cases are caused by ingesting unpasteurized milk or cheese from infected goats or sheep. \r\nBrucellosis is one of the most widespread zoonoses transmitted by animals and in endemic areas, human brucellosis has serious public health consequences. Expansion of animal industries and urbanization, and the lack of hygienic measures in animal husbandry and in food handling, partly account for brucellosis remaining a public health hazard.\r\n","PublicationDateAndTime":"2020-07-29T13:19:00Z","ConditionBriefOverview":null,"MetaDescription":"Brucellosis is a bacterial disease caused by various Brucella species, which mainly infect cattle, swine, goats, sheep and dogs. Humans generally acquire the disease through direct contact with infected animals, by eating or drinking contaminated animal products or by inhaling airborne agents. Most cases are caused by ingesting unpasteurized milk or cheese from infected goats or sheep. \r\nBrucellosis is one of the most widespread zoonoses transmitted by animals and in endemic areas, human brucellosis has serious public health consequences. Expansion of animal industries and urbanization, and the lack of hygienic measures in animal husbandry and in food handling, partly account for brucellosis remaining a public health hazard.\r\n","MedicalTreatmentLongerSummary":null,"CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":null,"Highlight":"","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/ntd-library/brucellosis/4189986967-f88b95458f-k.tmb-768v.jpg?Culture=en&sfvrsn=8dda3d7e_12","FormatedDate":"29 July 2020","TrimmedTitle":"Brucellosis"},{"Id":"80ed66ac-1c74-49b1-b0a7-84a89e27b4d0","LastModified":"2026-10-26T13:53:51Z","PublicationDate":"2018-06-02T02:27:09Z","DateCreated":"2018-06-02T02:27:07Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"depression","ItemDefaultUrl":"/depression","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"There are effective treatments for depression. These include psychological treatment and medications. Seek care if you have symptoms of depression.","Content":"<p><h2>Key facts </h2><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">Depression is a common mental disorder.</li><li data-list=\"0\" data-level=\"1\">Globally, an estimated 5.2% of adults suffer from depression.</li><li data-list=\"0\" data-level=\"1\">More women are affected by depression than men.</li><li data-list=\"0\" data-level=\"1\">Depression can lead to suicide.</li><li data-list=\"0\" data-level=\"1\">There is effective treatment for mild, moderate and severe depression.</li></ul><hr /><p><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\"></span><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Overview</span></p><p></p><p>Depressive disorder (also known as&nbsp;depression) is a common mental disorder. It is different from regular mood changes and feelings about everyday life It involves a depressed mood or loss of pleasure or interest in activities for long periods of time.</p><p>Depression can affect all aspects of life, including relationships with family, friends and community. It can result from, or lead to, problems at school or work.</p><p>Depression can happen to anyone. People who have lived through abuse, severe losses or other stressful events are more likely to develop depression. Women are more likely to have depression than men.</p><p>In 2023, an estimated 4% of the population experienced depression, including 5.2% of adults (4.1% among men and 6.2% among women), and 5.4% of adults aged 70 years and older. Approximately 322&nbsp;million people in the world have depression&nbsp;<em>(1)</em>. Depression is about 1.5 times more common among women than among men. Worldwide, more than 10% of pregnant women and women who have just given birth experience depression&nbsp;<em>(2)</em>. In 2021, an estimated 727&nbsp;000 people lost their lives to suicide. Suicide is the third leading cause of death in 15&ndash;29-year-olds.</p><p>In high-income countries, only about one third of people with depression receive mental health treatment&nbsp;<em>(3)</em>.&nbsp;</p><p>Barriers to effective care include a lack of investment in mental health care, lack of trained health care providers and social stigma associated with mental disorders.</p><p></p><h2>Symptoms and patterns</h2><p>During a depressive episode, a person experiences a depressed mood (feeling sad, irritable, empty). They may feel a loss of pleasure or interest in activities.</p><p>A depressive episode is different from regular mood fluctuations. They last most of the day, nearly every day, for at least two weeks.</p><p>Other symptoms are also present, which may include:</p><ul><li>poor concentration</li><li>feelings of excessive guilt or low self-worth</li><li>hopelessness about the future</li><li>thoughts about dying or suicide</li><li>disrupted sleep</li><li>changes in appetite or weight</li><li>feeling very tired or low in energy.</li></ul><p>Depression can cause difficulties in all aspects of life, including in the community and at home, work and school.</p><p>A depressive episode can be categorized as mild, moderate, or severe depending on the number and severity of symptoms, as well as the impact on the individual&rsquo;s functioning.&nbsp;</p><p>There are different patterns of depressive episodes including:</p><ul><li>single episode depressive disorder, meaning the person&rsquo;s first and only episode;</li><li>recurrent depressive disorder, meaning the person has a history of at least two depressive episodes; and</li><li><a href=\"https://www.who.int/news-room/fact-sheets/detail/bipolar-disorder\">bipolar disorder</a>, meaning that depressive episodes alternate with periods of manic symptoms, which include euphoria or irritability, increased activity or energy, and other symptoms such as increased talkativeness, racing thoughts, increased self-esteem, decreased need for sleep, distractibility, and impulsive, reckless behaviour.&nbsp;&nbsp;</li></ul><h2>Contributing factors and prevention</h2><p>Depression results from a complex interaction of social, psychological, and biological factors. People who have gone through adverse life events (unemployment, bereavement, traumatic events) are more likely to develop depression. Depression can, in turn, lead to more stress and dysfunction and worsen the affected person&rsquo;s life situation and the depression itself.</p><p>Depression is closely related to, and affected by, physical health. Many of the factors that influence depression (such as physical inactivity or harmful use of alcohol) are also known risk factors for diseases such as cardiovascular disease, cancer, diabetes and respiratory diseases. In turn, people with these diseases may also find themselves experiencing depression due to the difficulties associated with managing their condition.</p><p>Prevention programmes have been shown to reduce depression. Effective community approaches to prevent depression include school-based programmes to enhance a pattern of positive coping in children and adolescents. Interventions for parents of children with behavioural problems may reduce parental depressive symptoms and improve outcomes for their children. Exercise programmes for older adults can also be effective in preventing depression.</p><h2>Diagnosis and treatment</h2><p>There are effective treatments for depression. These include psychological treatment and medicines. Seek care if you have symptoms of depression.</p><p>Psychological treatments are the first treatments for depression. They can be combined with antidepressant medicines in moderate and severe depression. Antidepressant medicines are not needed for mild depression.<br /></p><p>Psychological treatments can teach new ways of thinking, coping or relating to others. They may include talk therapy with professionals and supervised lay therapists. Talk therapy can happen in person or online. Psychological treatments may be accessed through self-help manuals, websites and apps.&nbsp;<br /></p><p>Effective psychological treatments for depression include:&nbsp;&nbsp;&nbsp;</p><ul><li>behavioural activation</li><li>cognitive behavioural therapy</li><li>interpersonal psychotherapy</li><li>problem-solving therapy.</li></ul><p>Antidepressant medicines include selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine.</p><p>Health-care providers should keep in mind the possible adverse effects associated with antidepressant medicines, the ability to deliver either intervention (in terms of expertise, and/or treatment availability), and individual preferences. </p><p>Antidepressant medicines should not be used for treating depression in children and are not the first line of treatment in adolescents, among whom they should be used with extra caution.</p><p>Different medicines and treatments are used for bipolar disorder. </p><h2>Self-care</h2><p>Self-care can play an important role in managing symptoms of depression and promoting overall well-being.<br /></p><p>What you can do:</p><ul><li>try to keep doing activities you used to enjoy</li><li>stay connected to friends and family</li><li>exercise regularly, even if it&rsquo;s just a short walk</li><li>stick to regular eating and sleeping habits as much as possible</li><li>avoid or cut down on alcohol and don&rsquo;t use illicit drugs, which can make depression worse</li><li>talk to someone you trust about your feelings&nbsp;</li><li>seek help from a healthcare provider.</li></ul><p>If you have thoughts of suicide:</p><ul><li>remember you are not alone, and that many people have gone through what you&rsquo;re experiencing and found help</li><li>talk to someone you trust about how you feel</li><li>talk to a health worker, such as a doctor or counsellor</li><li>join a support group.</li></ul><p>If you think you are in immediate danger of harming yourself, contact any available emergency services or a crisis line.</p><h2>WHO response</h2><p><a href=\"https://www.who.int/publications/i/item/9789240031029\">WHO&rsquo;s Comprehensive Mental Health Action Plan 2013&ndash;2030</a> highlights the steps required to provide appropriate interventions for people with mental disorders including depression.&nbsp;</p><p>Depression and self-harm/suicide are among the priority conditions covered by WHO&rsquo;s <a href=\"https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme\">Mental Health Gap Action Programme (mhGAP).</a> The programme aims to help countries increase services for people with mental, neurological and substance use disorders through care provided by health workers who are not specialists in mental health.&nbsp;</p><p>WHO has developed brief psychological intervention manuals for depression that can be delivered by lay therapists to individuals and groups. An example is the  <a href=\"https://www.who.int/publications/i/item/WHO-MSD-MER-18.5\">Problem Management Plus (PM+) manual</a>, which describes the use of behavioural activation, stress management, problem solving treatment and strengthening social support. The <a href=\"https://www.who.int/publications/i/item/WHO-MSD-MER-16.4\">Group Interpersonal Therapy for Depression manual </a>describes group treatment of depression. Finally, the  <a href=\"https://www.who.int/publications/i/item/WHO-MSD-MER-15.1\">Thinking Healthy manual</a> covers the use of cognitive-behavioural therapy for perinatal depression.</p><p>&nbsp;</p><p><strong>References</strong></p><p>1. 2023 Global Burden of Disease (GBD) [online database]. Seattle: Institute for Health Metrics and Evaluation; 2024 (<a href=\"https://vizhub.healthdata.org/gbd-results/\">https://vizhub.healthdata.org/gbd-results/</a>).</p><p>2. Woody CA, Ferrari AJ, Siskind DJ, Whiteford HA, Harris MG. A systematic review and meta-regression of the prevalence and incidence of perinatal depression. J Affect Disord. 2017;219:86&ndash;92&nbsp;(https://doi.org/10.1016/j.jad.2017.05.003).</p><p>3. Evans-Lacko S, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Benjet C, Bruffaerts R, et al. Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys. Psychol Med. 2018;48(9):1560&ndash;71 (https://doi.org/10.1017/s0033291717003336).</p><p><br /></p></p>","ConditionName":"Depressive disorder (depression)","OpenGraphTitle":"Depressive disorder (depression)","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"<p dir=\"ltr\" id=\"docs-internal-guid-4a455a76-7fff-9a10-a632-972ccd04e818\">Self-care can play an important role in managing symptoms of depression and promoting overall well-being.</p><p dir=\"ltr\">What you can do:</p><ul dir=\"ltr\" role=\"presentation\"><li>Try to keep doing activities you used to enjoy&nbsp;</li><li>Stay connected to friends and family</li><li>Exercise regularly, even if it&rsquo;s just a short walk</li><li>Stick to regular eating and sleeping habits as much as possible</li><li>Avoid or cut down on alcohol and don&rsquo;t use illicit drugs, which can make depression worse</li><li>Talk to someone you trust about your feelings&nbsp;</li><li>Seek help from a healthcare provider</li></ul><p dir=\"ltr\">If you have thoughts of suicide:</p><ul dir=\"ltr\" role=\"presentation\"><li>Remember you are not alone, and that many people have gone through what you&rsquo;re experiencing and found help</li><li>Talk to someone you trust about how you feel</li><li>Talk to a health worker, such as a doctor or counsellor</li><li>Join a support group</li></ul><p dir=\"ltr\">If you think you are in immediate danger of harming yourself, contact any available emergency services or a crisis line.</p>","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"<p dir=\"ltr\" id=\"docs-internal-guid-def8e1d8-7fff-c4cc-5e07-54b215870080\">A depressive episode is different from regular mood fluctuations. They last most of the day, nearly every day, for at least two weeks.</p><p dir=\"ltr\">Other symptoms are also present, which may include:</p><ul dir=\"ltr\" role=\"presentation\"><li>poor concentration</li><li>feelings of excessive guilt or low self-worth</li><li>hopelessness about the future</li><li>thoughts about dying or suicide</li><li>disrupted sleep</li><li>changes in appetite or weight</li><li>feeling very tired or low in energy</li></ul>","MetaTitle":"Depressive disorder (depression)","ConditionLongerOverview":"<p>Depression is different from regular mood changes and feelings about everyday life. It can affect all aspects of life, including relationships with family, friends and community. It can result from or lead to problems at school and at work.</p><p>Depression can happen to anyone. People who have lived through abuse, severe losses or other stressful events are more likely to develop depression. Women are more likely to have depression than men.</p>","Title":"Depressive disorder (depression)","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs369","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"Depression is a widespread mental disorder characterized by persistent sadness and loss of interest, affecting various aspects of life and more commonly impacting women. It can lead to severe consequences, including suicide, but effective treatments are available for all severity levels.\r\n","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on depression, providing information on prevalence, symptoms, prevention and contributing factors, diagnosis and treatment, and WHO's work in the area.","PublicationDateAndTime":"2026-09-11T15:48:43Z","ConditionBriefOverview":"Depressive disorder (also known as depression) is a common mental disorder. It involves a depressed mood or loss of pleasure or interest in activities for long periods of time.","MetaDescription":"WHO fact sheet on depression, providing information on prevalence, symptoms, prevention and contributing factors, diagnosis and treatment, and WHO's work in the area.","MedicalTreatmentLongerSummary":"<p dir=\"ltr\" id=\"docs-internal-guid-f8a69b5c-7fff-36ac-e822-bcda3f1d6b1d\">Psychological treatments are the first treatments for depression. They can be combined with antidepressant medications in moderate and severe depression. Antidepressant medications are not needed for mild depression.</p><p dir=\"ltr\">Psychological treatments can teach new ways of thinking, coping or relating to others. They may include talk therapy with professionals and supervised lay therapists. Talk therapy can happen in person or online. Psychological treatments may be accessed through self-help manuals, websites and apps.&nbsp;</p><p dir=\"ltr\">Effective psychological treatments for depression include:&nbsp;&nbsp;&nbsp;</p><ul dir=\"ltr\" role=\"presentation\"><li>behavioural activation</li><li>cognitive behavioural therapy</li><li>interpersonal psychotherapy</li><li>problem-solving therapy</li></ul><p dir=\"ltr\">Antidepressant medications include selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine.</p>","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"During a depressive episode, a person experiences a depressed mood (feeling sad, irritable, empty). They may feel a loss of pleasure or interest in activities.","Highlight":"<p dir=\"ltr\"><a href=\"https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme\">Mental Health Gap Action Programme (mhGAP)</a>&nbsp;</p><p dir=\"ltr\"><a href=\"https://www.who.int/health-topics/depression#tab=tab_1\">More on depression</a>&nbsp;</p><p dir=\"ltr\"><strong>Videos</strong></p><ul dir=\"ltr\"><li><a href=\"https://www.youtube.com/watch?v=XiCrniLQGYc\" target=\"_blank\">I had a black dog, his name was depression</a></li><li><a href=\"https://www.youtube.com/watch?v=2VRRx7Mtep8\" target=\"_blank\">Living with a black dog</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/gettyimages-1216841763.tmb-768v.jpg?Culture=en&sfvrsn=5483c03f_6","FormatedDate":"11 September 2026","TrimmedTitle":"Depressive disorder (depression)"},{"Id":"f4519088-cfee-4d91-a04d-c7810a273e98","LastModified":"2026-11-06T16:53:48Z","PublicationDate":"2018-06-02T02:27:11Z","DateCreated":"2018-06-02T02:27:09Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"falls","ItemDefaultUrl":"/falls","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>In 2023, WHO estimated there were approximately 842&nbsp;000 deaths from falls worldwide, making falls the second-leading cause of unintentional injury deaths, after road injuries.&nbsp;</li><li>About 71% of the estimated fall deaths in 2023 occurred among adults aged 60 years and older. </li><li>In the 2023 Global Health Estimates, falls ranked eighth among causes of disability-adjusted life years (DALYs) globally. </li><li>WHO&rsquo;s Step Safely technical package sets out life-course approaches combining safer people, safer environments, and safer policies and legislation. </li><li>Effective measures include exercise that challenges balance for older people, targeted home-hazard reduction, child-safety measures, and occupational fall-protection systems (<em>1&ndash;3)</em>.</li></ul><hr /><p>&nbsp; &nbsp;</p><h2>Overview</h2><p>A fall is an event in which a person comes to rest inadvertently on the ground, floor or another lower level. Falls may occur on the same level or from a height. Most falls are non-fatal, but injuries can have lasting physical, psychological and economic effects. </p><p>WHO&rsquo;s Global Health Estimates (GHE) estimated about 842&nbsp;000 deaths from falls worldwide in 2023. Falls were the second-leading cause of unintentional injury death, after road injuries. Non-fatal falls also cause fractures, head injury, loss of independence, disability and long-term care needs. </p><p>In WHO&rsquo;s 2023 GHE, falls ranked eighth among all causes of global disability-adjusted life years (DALYs), a measure combining healthy years lost through premature death and disability. Population ageing and hazards in built, domestic and occupational environments make prevention an important public-health priority.</p><p>The 2023 GHE attributed approximately 284&nbsp;200 fall deaths to the WHO South-East Asia Region and 239&nbsp;800 to the Western Pacific Region, representing about 62% of all fall deaths worldwide. Some 71% of deaths occurred in people aged 60 years or older. Patterns vary by age, sex and setting; children and workers face distinct hazards. These numbers represent deaths, not all falls or injuries. </p><p>In addition to fatal injuries, many falls require medical attention and contribute substantially to disability. These consequences are not captured by mortality figures alone. Estimates of non-fatal injury and demand for treatment should be drawn from sources designed to measure those outcomes, and interpreted alongside estimates of DALYs.</p><h2>Who is at risk?</h2><h3>Age</h3><p><strong>Older people: </strong>Risk increases with impairments in balance, strength, gait, vision, cognition or mobility, and with medications or conditions that cause dizziness or low blood pressure. Injuries can lead to a loss of confidence, reduced activity and a cycle of increasing frailty. Falls in homes, hospitals and residential care settings require different prevention approaches.</p><p><strong>Children and adolescents:</strong> Falls are associated with developmental stages and activities such as climbing, playing and exploration. Hazards include unprotected windows, stairs and balconies, unsafe playgrounds and inadequate supervision. Structural safety measures can protect children while allowing them to play and develop safely.</p><p><strong>Workers:</strong> Falls from height and slips and trips at work are serious risks in construction, agriculture, transport, maintenance and other occupations. Effective prevention requires assessment and control of hazards, safe equipment and appropriate oversight.</p><h3>Sex and other risk factors</h3><p>In the 2023 GHE, approximately 481&nbsp;000 deaths from falls occurred among males and 361&nbsp;000 among females worldwide. Patterns of non-fatal injury can differ. Other risk factors include alcohol and substance use; neurological or cardiovascular conditions; medicines that increase fall risk; impaired balance or vision; unsafe stairs, lighting or walking surfaces; poverty and substandard housing; and hazardous work at height. These risks often interact with one another and with the social and physical environment.</p><h2>Prevention</h2><p>WHO&rsquo;s <a href=\"https://www.who.int/publications/i/item/978924002191-4\">Step Safely: Strategies for preventing and managing falls across the life-course</a> (2021) is a practical technical package for policy-makers, practitioners, programme managers and advocates. It includes risk assessment, programme implementation and post-fall management, not just individual behaviour-change advice. Its three safe-systems domains are safer people, safer environments, and safer policies and legislation. It distinguishes interventions categorized as *strongly recommended*, *recommended*, *promising* or *prudent* according to the available evidence. </p><h3>For children and adolescents</h3><ul><li>provide targeted information and support to families, including home-safety visits and measures to protect windows, stairs and balconies;</li><li>make playground design and surfaces safer, with appropriate fall heights and protective surfacing; and</li><li>adopt and enforce product, building and childcare safety standards.</li></ul><h3>For workers</h3><ul><li>eliminate or minimize work at height where feasible; </li><li>use safe platforms, guardrails, scaffolding and fall-protection systems;</li><li>enforce occupational safety standards and provide training, supervision and incident reporting; and</li><li>combine equipment and environmental controls with effective organizational safety systems.</li></ul><h3><strong>For older people living in the community</strong></h3><ul><li>provide tailored exercises that challenge balance and improve functional strength, with regular progression and sufficient duration; Tai Chi is another useful option. A Cochrane review found exercise reduced the overall rate of falls by approximately 23% in trial populations <em>(1)</em>. </li><li>offer home fall-hazard assessment and modification particularly to people already at elevated risk; a 2023 Cochrane review found a 38% reduction in fall rates in these higher-risk groups, but not a demonstrated effect in unselected people <em>(2)</em>.</li><li>review medicines that increase fall risk and address problems including poor vision, unsafe footwear, dizziness, orthostatic hypotension and mobility limitations; and</li><li>provide individualized, multifactorial assessment and interventions for people with recurrent falls or at high risk <em>(3)</em>.</li></ul><h3>For older people in residential care or hospitals</h3><p>Interventions should be tailored to health status, level of risk, care environment and staffing. They may include medication review, appropriate supervised exercise, safer environments, staff practices and individualized assessment. Not all interventions effective among community-dwelling older people have the same evidence in institutions <em>(3)</em>.</p><p>Routine vitamin D supplementation should not be presented as a general fall-prevention strategy for all older adults. Evaluation and management of deficiency may be appropriate for individuals in whom it is clinically indicated; high-dose supplementation may have adverse effects <em>(3)</em>.</p><p>Education and raising awareness are useful components of prevention, but information alone should not be equated with interventions proven to reduce falls. Step safely calls for applying and evaluating policies, environmental changes and targeted prevention services across the life course <em>(2)</em>.</p><h2>Managing falls and fall-related injuries</h2><p>Falls prevention also requires timely and effective response after a fall. Relevant measures include first aid, emergency care, prompt recognition and management of fractures and head injury, rehabilitation, support to regain function and reassessment to reduce future risk. Step safely places injury management and targeted secondary prevention alongside measures to avert the initial fall. </p><h2>WHO response</h2><p>WHO provides comparative mortality and burden-of-disease estimates through the GHE and promotes effective fall prevention through Step safely, which supports local situation assessments, selection and adaptation of interventions, cross-sector coordination and evaluation. The package contributes to safer cities and homes, safer workplaces and healthier ageing. </p><p>&nbsp;</p><p><strong>References</strong></p><p>1. Sherrington C et al. Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2019;CD012424.&nbsp; <span style=\"text-decoration:underline;\">https://doi.org/10.1002/14651858.CD012424.pub2</span></p><p>2. Clemson L et al. Environmental interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2023;CD013258.&nbsp; <span style=\"text-decoration:underline;\">https://doi.org/10.1002/14651858.CD013258.pub2</span></p><p>3. Montero-Odasso M et al. World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing. 2022;51:afac205.&nbsp; <span style=\"text-decoration:underline;\">https://doi.org/10.1093/ageing/afac205</span></p><br />","ConditionName":"","OpenGraphTitle":"Falls","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Falls","ConditionLongerOverview":"","Title":"Falls","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs344","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":3,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on falls providing key facts and information on scope of the problem, who is at risk, prevention, WHO response.","PublicationDateAndTime":"2026-10-21T14:11:00Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on falls providing key facts and information on scope of the problem, who is at risk, prevention, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"","Highlight":"<p><a href=\"https://www.who.int/publications/i/item/978924002191-4\">Step Safely: Strategies for preventing and managing falls across the life-course</a></p><p><a href=\"https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death\">Global Health Estimates 2023: Deaths by Cause, Age, Sex, by Country and by Region, 2000&ndash;2023</a></p><p><a href=\"https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/global-health-estimates-leading-causes-of-dalys\">Global Health Estimates 2023: Disease burden by Cause, Age, Sex, by Country and by Region, 2000&ndash;2023</a></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/topics/populations-demographics-human-behaviour-and-injuries/ageing/ageing-kyrgyzstan-2022.tmb-768v.jpeg?sfvrsn=433692ca_6","FormatedDate":"21 October 2026","TrimmedTitle":"Falls"},{"Id":"a2556ae6-b305-44cb-80fc-840e28fddb81","LastModified":"2026-07-30T21:38:33Z","PublicationDate":"2018-06-02T02:27:13Z","DateCreated":"2018-06-02T02:27:12Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"soil-transmitted-helminth-infections","ItemDefaultUrl":"/soil-transmitted-helminth-infections","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":null,"Content":"<h2>Overview</h2><p>Soil-transmitted helminth (STH) infections are among the most common infections worldwide with an estimated 1.5 billion infected people or 24% of the world&rsquo;s population. These infections affect the poorest and most deprived communities with poor access to clean water, sanitation and hygiene in tropical and subtropical areas, with the highest prevalence reported from sub-Saharan Africa, China, South America and Asia. They are transmitted by eggs present in human faeces, which in turn contaminate soil in areas where sanitation is poor. Over 260 million preschool-age children, 654 million school-age children,108 million adolescent girls and 138.8 million pregnant and lactating women live in areas where these parasites are intensively transmitted, and are in need of treatment and preventive interventions.</p><p>Globally over 600 million people are estimated to be infected by&nbsp;<em>S. stercoralis</em>;&nbsp;however, since also this parasite is transmitted in areas where sanitation is poor, its geographical distribution overlaps with the one of the other soil-transmitted helminthiases.</p><h2>Types of species</h2><p>The main species that infect people are the roundworm (<em>Ascaris lumbricoides</em>), the whipworm (<em>Trichuris trichiura</em>) and hookworms (<em>Necator americanus</em>&nbsp;and&nbsp;<em>Ancylostoma duodenale</em>). These STH species are normally addressed as a group because they need similar diagnostic procedures and respond to the same medicines.</p><p><em>Strongyloides stercoralis</em>&nbsp;is an intestinal helminth with peculiar characteristics: the parasite requires different diagnostic methods than other soil-transmitted helminthiases, and for this reason is frequently not identified. In addition, the parasite is not sensitive to albendazole or mebendazole and therefore not impacted by large-scale preventive treatment campaigns targeting other soil-transmitted helminthiases.</p><h2>Transmission</h2><p>Soil-transmitted helminths are transmitted by eggs that are passed in the faeces of infected people. Adult worms live in the intestine where they produce thousands of eggs each day. In areas that lack adequate sanitation, these eggs contaminate the soil. This can happen in several ways:</p><ul><li>eggs that are attached to vegetables are ingested when the vegetables are not carefully cooked, washed or peeled;</li><li>eggs are ingested from contaminated water sources; and</li><li>eggs are ingested by children who play in the contaminated soil and then put their hands in their mouths without washing them.</li></ul><p>In addition, hookworm eggs hatch in the soil, releasing larvae that mature into a form that can actively penetrate the skin. People become infected with hookworm primarily by walking barefoot on the contaminated soil.</p><p>There is no direct person-to-person transmission, or infection from fresh faeces, because eggs passed in faeces need about 3 weeks to mature in the soil before they become infective.</p><p><em>A. lumbricoides,</em>&nbsp;<em>T. trichiura</em>&nbsp;and hookworms do not multiply in the human host; re-infection occurs only as a result of contact with infective stages in the environment.&nbsp;<em>S. stercoralis</em>&nbsp;can reproduce in the host, and in immunocompromised individuals its uncontrolled multiplication can be fatal.</p><h2>Nutritional effects</h2><p>Soil-transmitted helminths impair the nutritional status of the people they infect in multiple ways.</p><ul><li>The worms feed on host tissues, including blood, which leads to a loss of iron and protein.</li><li>Hookworms in addition cause chronic intestinal blood loss that can result in anaemia especially in adolescent girls and women of reproductive age.</li><li>The worms increase malabsorption of nutrients. In addition, roundworm may possibly compete for vitamin A in the intestine.</li><li>Some soil-transmitted helminths also cause loss of appetite and, therefore, a reduction of nutritional intake and physical fitness. In particular,&nbsp;<em>T. trichiura</em>&nbsp;can cause diarrhoea and dysentery.</li></ul><h2>Morbidity and symptoms</h2><p>Morbidity is related to the number of worms harboured. People with infections of light intensity (few worms) usually do not suffer from the infection. Heavier infections can cause a range of symptoms including intestinal manifestations (diarrhoea and abdominal pain), malnutrition, general malaise and weakness, and impaired growth and physical development.</p><p>Infections of very high intensity can cause intestinal obstruction that should be treated surgically.</p><p><em>S. stercoralis</em>&nbsp;may cause dermatological and gastro-intestinal morbidity and is also known to be associated with chronic malnutrition in children. In case of reduced host immunity, the parasite can cause the hyperinfection/dissemination syndrome that is invariably fatal if not promptly and properly cured and is often fatal despite the treatment.</p><h2>WHO strategy for control</h2><p>In 2001, delegates at the World Health Assembly unanimously endorsed a resolution (WHA54.19) urging endemic countries to start seriously tackling worms, specifically schistosomiasis and soil-transmitted helminths.</p><p>The strategy for control of soil-transmitted helminth infections is to control morbidity through the periodic treatment of at-risk people living in endemic areas. People at risk are:</p><ul><li>preschool children;</li><li>school-age children;</li><li>women of reproductive age (including pregnant women in the second and third trimesters and breastfeeding women); and</li><li>adults in certain high-risk occupations such as tea-pickers or miners.</li></ul><p>WHO recommends periodic medicinal treatment (deworming or preventive chemotherapy) without previous individual diagnosis to all at-risk people living in endemic areas. This intervention reduces morbidity by reducing the worm burden. In addition:</p><ul><li>health and hygiene education reduces transmission and reinfection by encouraging healthy behaviours; and</li><li>provision of adequate sanitation is also important but not always possible in resource-poor settings.</li></ul><p>Periodical treatment aims to reduce and maintain the intensity of infection low, and to protect infected at-risk populations from morbidity.</p><p>Deworming can be easily integrated with child health days or vitamin A supplementation programmes for preschool children, Human Papilloma Vaccine (HPV) programme for adolescent girls or integrated with school health programmes. </p><p>WHO added the control of morbidity due to&nbsp;<em>S. stercoralis</em>&nbsp;as an objective for 2030. This is possible because of&nbsp;the current availability of pre-qualified ivermectin at affordable cost. Distribution of ivermectin can be organized through the platforms used to control the other soil-transmitted helminthiases. Pilot interventions are presently in place to refine the strategy and evaluate its impact.</p><p>In 2021, over 500 million children were treated with anthelminthic medicines in endemic countries, corresponding to 62% of all children at risk. In addition, more than 99 million of women of reproductive age were treated with albendazole through the lymphatic filariasis elimination programmes. Between 2010 and 2019, the number of Disease Adjusted Life Years (DALYs) lost every year because of STH reduced by more than 50%, which correspond to the period of scaling up of preventive chemotherapy (PC) for STH in endemic countries.</p><p>WHO recommend to endemic countries to measure the success of their programmes through epidemiological assessments after 5 to 6 years of PC implementation with effective treatment coverage of &gt;=75% and to adjust their treatment frequency. The indicators to monitor the impact are the prevalence of any STH and the prevalence of moderate and heavy intensity.</p><h2>Treatment</h2><p>The WHO recommended medicines &ndash; albendazole (400&nbsp;mg) and mebendazole (500&nbsp;mg) &ndash; are effective, inexpensive and easy to administer by non-medical personnel (e.g. teachers). They have been through extensive safety testing and have been used in millions of people with few and minor side-effects.</p><p>Both albendazole and mebendazole are donated to national ministries of health through WHO in all endemic countries for the treatment of all children of school age.</p><p>Generic ivermectin for the control of&nbsp;<em>S. stercoralis</em>&nbsp;has been available at affordable price since 2021.&nbsp;</p><h2>WHO response</h2><p>There are six WHO 2030 global targets for soil-transmitted helminthiases:</p><ol><li>achieve and maintain elimination of STH morbidity in pre-school and school age children;</li><li>reduce the number of tablets needed in preventive chemotherapy for STH;</li><li>increase domestic financial support to preventive chemotherapy for STH;</li><li>establish an efficient STH control programme in adolescent, pregnant and lactating&nbsp;women;</li><li>establish an efficient strongyloidiasis control programme in&nbsp;school age children; and</li><li>ensure universal access to at least basic sanitation and hygiene by 2030 in STH-endemic areas.</li></ol><p>In order to achieve the 2030 NTD roadmap, WHO works with Member States and partners to achieve and maintain effective preventative chemotherapy coverage for STH in all at-risk groups, to measure the impact of the interventions in countries that have been implementing the programme for more than 5 years and to advocate for an integration of STH control in primary health care (PHC) for the sustainability of the programme.</p>","ConditionName":null,"OpenGraphTitle":"Soil-transmitted helminth infections","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":null,"SelfCareLongerSummary":null,"EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":null,"MetaTitle":"Soil-transmitted helminth infections","ConditionLongerOverview":null,"Title":"Soil-transmitted helminth infections","PreventionLongerSummary":null,"SourceKey":"/entity/mediacentre/factsheets/fs366","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":null,"FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities. They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor. The main species that infect people are the roundworm (Ascaris lumbricoides), the whipworm (Trichuris trichiura) and hookworms (Necator americanus and Ancylostoma duodenale).\r\n","FeatureStoryNumberOfAdditionalItems":3,"OtherRelated":"","FactSheetNumberOfAdditionalItems":5,"OpenGraphDescription":"Intestinal infections transmitted through soil, contaminated by human faeces, can cause malnutrition and stunted growth. An estimated 836 million children are in need of treatment. #BeatNTDs","PublicationDateAndTime":"2023-01-18T14:30:00Z","ConditionBriefOverview":null,"MetaDescription":"WHO fact sheet on soil-transmitted helminth infections caused by different species of parasitic worm. Includes key facts, definition, distribution, transmission, control and WHO response.","MedicalTreatmentLongerSummary":null,"CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":null,"Highlight":"<div class=\"arrowed-link\"><a href=\"https://www.who.int/health-topics/soil-transmitted-helminthiases\">WHO's work on intestinal worms</a></div><div class=\"arrowed-link\"><a href=\"https://apps.who.int/neglected_diseases/ntddata/sth/sth.html\">Data and statistics on soil-transmitted helminthiases</a></div><div class=\"arrowed-link\"><a href=\"https://apps.who.int/iris/bitstream/handle/10665/78794/ea54r19.pdf\">Resolution WHA54.19: Schistosomiasis and soil-transmitted helminth infections<br /></a></div><div class=\"arrowed-link\"><a href=\"https://www.who.int/teams/control-of-neglected-tropical-diseases\">More about Neglected Tropical Diseases</a></div>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/ntd-library/soil-transmitted-helminthiases/soil-transmitted-helminth-intestinal-worms-jpg.tmb-768v.jpg?Culture=en&sfvrsn=2961b199_38","FormatedDate":"18 January 2023","TrimmedTitle":"Soil-transmitted helminth infections"},{"Id":"474631b7-d62b-4502-84fc-5825f239067a","LastModified":"2026-10-15T02:56:44Z","PublicationDate":"2022-06-13T18:21:13Z","DateCreated":"2022-06-13T18:21:13Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"parkinson-disease","ItemDefaultUrl":"/parkinson-disease","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"There is no cure for Parkinson disease, but therapies including medicines, surgery and rehabilitation can reduce symptoms.","Content":"<p></p><h2>Overview</h2><p>Parkinson disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain and other health issues. </p><p>PD gets worse over time. There is no cure, but therapies and medicines can reduce symptoms. Common symptoms include tremors, painful muscle contractions and difficulty speaking.</p><p>Parkinson disease results in high rates of disability and the need for care. Many people with PD also develop dementia.</p><p>The disease usually occurs in older people, but younger people can also be affected. Men are affected more often than women. </p><p>The cause of PD is unknown but people with a family history of the disease have a higher risk. Exposure to air pollution, pesticides and solvents may increase risk. </p><h2>Symptoms</h2><p>Symptoms of Parkinson disease get worse over time. They can greatly reduce well-being and quality of life.</p><p>PD causes motors symptoms including:</p><ul><li>slow movement</li><li>tremor</li><li>involuntary movement</li><li>rigidity</li><li>trouble walking</li><li>imbalance.</li></ul><p>Non-motor symptoms:</p><ul><li>cognitive impairment</li><li>mental health disorders</li><li>dementia</li><li>sleep disorders</li><li>pain</li><li>sensory disturbances. </li></ul><p>Involuntary movements (dyskinesias) and painful muscle contractions (dystonias) can cause problems speaking and moving. These symptoms lead to high rates of disability and the need for care. Many people with PD also develop dementia during the course of their disease.</p><p>While PD is the most common movement disorder, other movement disorders exist such as multiple system atrophy, progressive supranuclear palsy, chorea, ataxia and dystonia. Some movement disorders have similar symptoms to PD such as tremor, slow movement and rigidity. All movement disorders share the same challenges as PD regarding diagnostic and treatment gaps and access to medication, particularly in low- and middle-income countries (LMIC).</p><h2>Assessment and disease burden</h2><p>PD<strong> </strong>is a clinical diagnosis that not only can be made by neurologists but also by trained non-specialist healthcare workers. Assessment and management of PD by trained non-specialized healthcare workers in primary&nbsp;care is particularly important in areas where specialist neurological services are unavailable, such as in some LMIC.<strong></strong></p><p>The prevalence of PD has doubled in the past 25 years. Global estimates in 2019 showed over 8.5 million individuals with PD. Current estimates suggest that, in 2019, PD resulted in 5.8 million disability adjusted life years (DALYs), an increase of 81% since 2000, and caused 329&nbsp;000 deaths, an increase of over 100% since 2000.</p><h2>Treatment and care</h2><p>There is no cure for Parkinson disease, but therapies including medicines, surgery and rehabilitation can reduce symptoms. </p><p>Levodopa/carbidopa, a combination medicine that increases the amount of dopamine in the brain, is the most common medication for PD <em>(1)</em>. Doctors may use other medicines such as anticholinergics to reduce involuntary muscle movement. &nbsp;</p><p>Deep brain stimulation and other therapies can help the tremors and reduce the need for medicines. </p><p>Rehabilitation including physiotherapy can offer relief for Parkinson disease and other degenerative neurologic disorders. Therapies include:</p><ul data-list=\"0\" data-level=\"1\"><li>strength training</li><li>gait and balance training </li><li>hydrotherapy. </li></ul><p>These therapies can help improve functioning and quality of life for people with PD. This can also reduce the strain on carers.</p><p>Many medications and surgical resources are not accessible, available or affordable everywhere, particularly low- and middle-income countries.</p><h2>Impact on families and carers</h2><p>Informal carers (i.e. most commonly family members and friends) spend<strong> </strong>many hours daily<strong> </strong>providing care for people living with PD.<strong> </strong>This can be overwhelming. Physical, emotional and financial pressures can cause great stress to families and carers, and support is required from the health, social, financial and legal systems. Useful support resources from other conditions can be drawn upon, such as WHO&rsquo;s <a href=\"https://www.who.int/publications-detail-redirect/9789241515863\">iSupport programme for dementia</a>.</p><h2>Human rights</h2><p>People with PD are often subject to stigma and discrimination, including unjust discrimination within the workplace and lack of opportunities to engage and participate in their communities.</p><p>People with PD require accessible health services for general healthcare needs like the rest of the population, including medicine access, promotive and preventive services and prompt diagnosis, treatment and care. A common barrier is created by healthcare providers&rsquo; inadequate knowledge and understanding of PD and myths that PD is a contagious illness or a normal part of aging.</p><h2>WHO response</h2><p>In May 2022, the World Health Assembly endorsed the Intersectoral global action plan on epilepsy and other neurological disorders 2022&ndash;2031. The action plan&nbsp;will address the challenges and gaps in providing care and services for people with epilepsy and other neurological disorders such as PD that exist worldwide and ensure a comprehensive, coordinated response across sectors. This includes raising policy prioritization and strengthening governance, providing effective, timely and responsive diagnosis, treatment and care, implementing strategies for promotion and prevention, fostering research and innovation and strengthening information systems.</p><p>A WHO technical brief entitled <a href=\"https://www.who.int/publications-detail-redirect/9789240050983\">Parkinson disease: a public health approach</a>&nbsp;is available for policy-makers, health programme managers and planners, healthcare providers, researchers, people with PD, carers and other stakeholders. It outlines the important action areas for intervention in PD including global health policies focused on prevention and risk reduction, education and awareness and access to treatment and care at various levels of the health system.</p>WHO&rsquo;s <a href=\"https://www.who.int/publications-detail-redirect/9789241515863\">iSupport</a>, a knowledge and skills training programme for carers of people living with dementia is available as an online course and a hardcopy manual. iSupport Lite includes easy-to-read posters and a brief video that can act as a quick reference or a refresher, reinforcing previously acquired caregiving skills and knowledge.<p></p><p>&nbsp;</p><p><strong>Notes</strong></p><ol><li>Levodopa/carbidopa is on the <a href=\"https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists\">WHO Model List of Essential Medicines</a>.<strong></strong></li></ol><p></p><p>&nbsp;</p>","ConditionName":"Parkinson disease","OpenGraphTitle":"Parkinson disease","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"<p>PD causes motor symptoms including:</p><ul><li>slow movement</li><li>tremor</li><li>involuntary movement</li><li>rigidity</li><li>trouble walking</li><li>imbalance</li></ul>Non-motor symptoms include:\r\n    <li>cognitive impairment</li><li>mental health disorders</li><li>dementia</li><li>sleep disorders</li><li>pain</li><li>sensory disturbances\r\n\r\n<p>Involuntary movements (dyskinesias) and painful muscle contractions (dystonias) can cause problems speaking and moving. These symptoms lead to high rates of disability and the need for care. Many people with PD also develop dementia during the course of their disease.</p></li>","MetaTitle":"Parkinson disease","ConditionLongerOverview":"<p>PD gets worse over time. There is no cure, but therapies and medicines can reduce symptoms. Common symptoms include tremors, painful muscle contractions and difficulty speaking.</p><p>Parkinson disease results in high rates of disability and the need for care. Many people with PD also develop dementia.</p><p>The disease usually occurs in older people, but younger people can also be affected. Men are affected more often than women.</p>","Title":"Parkinson disease","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"Parkinson disease (PD) is a degenerative condition of the brain associated with motor symptoms (slow movement, tremor, rigidity, walking and imbalance) and a wide variety of non-motor complications (cognitive impairment, mental health disorders, sleep disorders and pain and other sensory disturbances). ","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"Parkinson disease (PD) is a degenerative condition of the brain associated with motor symptoms (slow movement, tremor, rigidity, walking and imbalance) and a wide variety of non-motor complications (cognitive impairment, mental health disorders, sleep disorders and pain and other sensory disturbances). ","PublicationDateAndTime":"2023-08-09T18:00:00Z","ConditionBriefOverview":"Parkinson disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain and other health issues.","MetaDescription":"Parkinson disease (PD) is a degenerative condition of the brain associated with motor symptoms (slow movement, tremor, rigidity, walking and imbalance) and a wide variety of non-motor complications (cognitive impairment, mental health disorders, sleep disorders and pain and other sensory disturbances). ","MedicalTreatmentLongerSummary":"<p>Levodopa/carbidopa, a combination medicine that increases the amount of dopamine in the brain, is the most common medication for PD. Doctors may use other medicines such as anticholinergics to reduce involuntary muscle movement.</p><p>Deep brain stimulation and other therapies can help the tremors and reduce the need for medicines.</p><p>Rehabilitation including physiotherapy can offer relief for Parkinson disease and other degenerative neurologic disorders.</p><p>Therapies include:</p><ul><li>strength training</li><li>gait and balance training </li><li>hydrotherapy</li></ul><p>These therapies can help improve functioning and quality of life for people with PD. This can also reduce the strain on carers.</p>","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"Symptoms of Parkinson disease get worse over time. They can greatly reduce well-being and quality of life.","Highlight":"<ul type=\"disc\"><li><a href=\"https://www.who.int/health-topics/brain-health\">Brain health&nbsp;</a></li><li><a href=\"https://www.who.int/health-topics/dementia\">Dementia</a></li><li data-list=\"0\" data-level=\"1\"><a href=\"https://www.who.int/publications/i/item/9789240076624\">Intersectoral global action plan on epilepsy and other neurological disorders</a></li></ul><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/mental-health-and-substance-abuse/brain-health/alvaro-reyes-3cigxs7xekm-unsplash.tmb-768v.jpg?sfvrsn=8649b97f_6","FormatedDate":"9 August 2023","TrimmedTitle":"Parkinson disease"},{"Id":"1218b767-7885-499c-bd4d-3b42ed1c1a27","LastModified":"2025-10-03T12:48:08Z","PublicationDate":"2018-09-18T13:24:09Z","DateCreated":"2018-09-18T13:24:09Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"adolescent-mental-health","ItemDefaultUrl":"/adolescent-mental-health","NewsNumberOfAdditionalItems":0,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Globally, one in seven 10-19-year-olds experiences a mental disorder, accounting for 15% of the global burden of disease in this age group.</li><li>Depression, anxiety and behavioural disorders are among the leading causes of illness and disability among adolescents.</li><li>Suicide is the third leading cause of death among those aged 15&ndash;29 years old.</li><li>The consequences of failing to address adolescent mental health conditions extend to adulthood, impairing both physical and mental health and limiting opportunities to lead fulfilling lives as adults.</li></ul><h2>Introduction</h2><p>One in six people are aged 10&ndash;19 years. Adolescence is a unique and formative time. Physical, emotional and social changes, including exposure to poverty, abuse, or violence, can make adolescents vulnerable to mental health problems. Protecting adolescents from adversity, promoting socio-emotional learning and psychological well-being, and ensuring access to mental health care are critical for their health and well-being during adolescence and adulthood.</p><p>Globally, it is estimated that one in seven (14.3%) of 10&ndash;19-year-olds experience mental health conditions&nbsp;<em>(1)</em>, yet these remain largely unrecognized and untreated.</p><p>Adolescents with mental health conditions are particularly vulnerable to social exclusion, discrimination, stigma (affecting readiness to seek help), educational difficulties, risk-taking behaviours, physical ill-health and human rights violations.</p><h2>Mental health determinants</h2><p>Adolescence is a crucial period for developing social and emotional habits important for mental well-being. These include adopting healthy sleep patterns; exercising regularly; developing coping, problem-solving, and interpersonal skills; and learning to manage emotions. Protective and supportive environments in the family, at school and in the wider community are important.</p><p>Multiple factors affect mental health. The more risk factors adolescents are exposed to, the greater the potential impact on their mental health. Factors that can contribute to stress during adolescence include exposure to adversity, pressure to conform with peers and exploration of identity. Media influence and gender norms can exacerbate the disparity between an adolescent&rsquo;s lived reality and their perceptions or aspirations for the future. Other important determinants include the quality of their home life and relationships with peers. Violence (especially sexual violence and bullying), harsh parenting and severe and socioeconomic problems are recognized risks to mental health.</p><p>Some adolescents are at greater risk of mental health conditions due to their living conditions, stigma, discrimination or exclusion, or lack of access to quality support and services. These include adolescents living in humanitarian and fragile settings; adolescents with chronic illness, autism spectrum disorder, an intellectual disability or other neurological condition; pregnant adolescents, adolescent parents, or those in early or forced marriages; orphans; and adolescents from minority ethnic or sexual backgrounds or other discriminated groups.</p><h2>Emotional disorders</h2><p>Emotional disorders are common among adolescents. Anxiety disorders (which may involve panic or excessive worry) are the most prevalent in this age group and are more common among older than among younger adolescents. It is estimated that 4.1% of 10&ndash;14-year-olds and 5.3% of 15&ndash;19-year-olds experience an anxiety disorder <em>(1)</em>. Depression is estimated to occur among 1.3% of adolescents aged 10&ndash;14 years, and 3.4% of 15&ndash;19-year-olds <em>(1)</em>. Depression and anxiety share some of the same symptoms, including rapid and unexpected changes in mood.</p><p>Anxiety and depressive disorders can profoundly affect school attendance and schoolwork. Social withdrawal can exacerbate isolation and loneliness. Depression can lead to suicide.</p><h2>Behavioural disorders</h2><p>Behavioural disorders are more common among younger adolescents than older adolescents. Attention deficit hyperactivity disorder (ADHD), characterized by difficulty paying attention and/or excessive activity and acting without regard to consequences, occurs among 2.7% of 10&ndash;14-year-olds and 2.2% of 15&ndash;19-year-olds&nbsp;<em>(1)</em>. Conduct disorder (involving symptoms of destructive or challenging behaviour) occurs among 3.3% of 10&ndash;14-year-olds and 1.8% of 15&ndash;19-year-olds&nbsp;<em>(1)</em>. Behavioural disorders &nbsp;can affect adolescents&rsquo; education and increases the risk of criminal behaviour.</p><h2>Eating disorders</h2><p>Eating disorders, such as anorexia nervosa and bulimia nervosa, commonly emerge during adolescence and young adulthood. Eating disorders involve abnormal eating behaviour and preoccupation with food, accompanied in most instances by concerns about body weight and shape. Girls are more commonly affected than boys. Eating disorders can affect physical health and often co-exist with depression, anxiety and substance use disorders. They occur in an estimated 0.1% of 10&ndash;14-year-olds and 0.4% of 15&ndash;19-year-olds (1). They are associated with suicide. Anorexia nervosa can lead to premature death, often due to medical complications or suicide, and has higher mortality than any other mental disorder.</p><h2>Psychosis</h2><p>Conditions that include symptoms of psychosis most commonly emerge in late adolescence or early adulthood. Symptoms can include hallucinations or delusions. These experiences can impair an adolescent&rsquo;s ability to participate in daily life and education and often lead to stigma or human rights violations. Schizophrenia occurs in 0.1% of 15&ndash;19-year-olds <em>(1)</em>.</p><h2>Suicide and self-harm</h2><h2></h2><p>Suicide is the third leading cause of death in older adolescents and young adults (15&ndash;29 years)&nbsp;<em>(2)</em>. Risk factors for suicide are multifaceted, and include harmful use of alcohol, abuse in childhood, stigma against help-seeking, barriers to accessing care and access to means of suicide. Digital media, like any other media, can play a significant role in either enhancing or weakening suicide prevention efforts.</p><h2>Risk-taking behaviours</h2><p>Many risk-taking behaviours for health, such as substance use or sexual risk-taking, start during adolescence. Risk-taking behaviours can be an unhelpful strategy to cope with emotional difficulties and can severely impact an adolescent&rsquo;s mental and physical well-being.</p><p>Young people are especially vulnerable to developing harmful substance use patterns that can persist across the lifespan. In 2019, the prevalence of alcohol use among 15&ndash;19-year-olds was high worldwide (22%) with very few gender differences, and showing an increase in consumption in some regions <em>(3).</em></p><p>The use of tobacco and cannabis are additional concerns. Many adult smokers had their first cigarette prior to the age of 18 years. In 2022, the prevalence of cannabis use among adolescents was higher than that of adults globally (5.5 per cent compared with 4.4 per cent, respectively) <em>(4).</em></p><p>Perpetration of violence is a risk-taking behaviour that can increase the likelihood of low educational attainment, injury, involvement with crime or death. Interpersonal violence was ranked among the leading causes of death of older adolescents in 2021&nbsp;<em>(1)</em>.</p><h2>Promotion and prevention</h2><p>Mental health promotion and prevention interventions aim to<strong>&nbsp;</strong>strengthen an individual's capacity to regulate emotions, enhance alternatives to risk-taking behaviours, build resilience for managing difficult situations and adversity, and promote supportive social environments and social networks.</p><p>These programmes require a multi-level approach with varied delivery platforms&nbsp;&ndash;<strong>&nbsp;</strong>for example, digital media, health or social care settings, schools or the community &ndash; and varied strategies to reach adolescents, particularly the most vulnerable.</p><h2>Early detection and treatment</h2><p>It is crucial to address the needs of adolescents with mental health conditions. Avoiding institutionalization and over-medicalization, prioritizing non-pharmacological approaches, and respecting the rights of children in line with the United Nations Convention on the Rights of the Child and other human rights instruments are key for adolescents&rsquo; mental health.</p><h2>WHO response</h2><p>WHO works on strategies, programmes and tools to assist governments in responding to the health needs of adolescents.</p><p>For example, the Helping Adolescents Thrive (HAT) Initiative is a joint WHO-UNICEF effort to strengthen policies and programmes for the mental health of adolescents. More specifically, the efforts made through the Initiative are to promote mental health and prevent mental health conditions. They are also intended to help prevent self-harm and other risk behaviours, such as harmful use of alcohol and drugs, that have a negative impact on the mental&nbsp;&ndash;&nbsp;and physical&nbsp;&ndash;&nbsp;health of young people.</p><p>WHO has also developed a module on Child and Adolescent Mental and Behavioural Disorders as part of the mhGAP Intervention Guide 2.0. This Guide provides evidence-based clinical protocols for the assessment and management of a range of mental health conditions in non-specialized care settings.</p><p>Furthermore, WHO is developing and testing scalable psychological interventions to address emotional disorders of adolescents, and guidance on mental health services for adolescents.</p><p>WHO&rsquo;s Regional Office for the Eastern Mediterranean has developed a mental health training package for educators for improved understanding of the importance of mental health in the school setting and to guide the implementation of strategies to promote, protect and restore mental health among their students. It includes training manuals and materials to help scale up the number of schools promoting mental health.</p><p>(1)&nbsp;2021 Global Burden of Disease (GBD) [online database]. Seattle: Institute for Health Metrics and Evaluation; 2024 (<a href=\"https://vizhub.healthdata.org/gbd-results/\">https://vizhub.healthdata.org/gbd-results/</a>, accessed 13 August 2025).&nbsp;</p><p>(2)&nbsp;<a href=\"https://www.who.int/data/global-health-estimates\">WHO Global Health Estimates 2000-2021</a></p><p>(3)&nbsp;<a href=\"https://iris.who.int/bitstream/handle/10665/377960/9789240096745-eng.pdf?sequence=1\"></a><a href=\"https://www.who.int/publications/i/item/9789240096745\">Global status report on alcohol and health and treatment of substance use disorders. Geneva: World Health Organization; 2024.</a></p><p>(4) World Drug Report. Geneva: UNODC; 2024</p><p></p><div><p><br /></p></div>","ConditionName":"","OpenGraphTitle":"Mental health of adolescents","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Mental health of adolescents","ConditionLongerOverview":"","Title":"Mental health of adolescents","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":0,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":0,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"Adolescence (10-19 years) is a unique and formative time. Multiple physical, emotional and social changes, including exposure to poverty, abuse, or violence, can make adolescents vulnerable to mental health problems. Promoting psychological well-being and protecting adolescents from adverse experiences and risk factors that may impact their potential to thrive are critical for their well-being during adolescence and for their physical and mental health in adulthood.","PublicationDateAndTime":"2025-09-01T09:20:57Z","ConditionBriefOverview":"","MetaDescription":"Adolescence (10-19 years) is a unique and formative time. Multiple physical, emotional and social changes, including exposure to poverty, abuse, or violence, can make adolescents vulnerable to mental health problems. Promoting psychological well-being and protecting adolescents from adverse experiences and risk factors that may impact their potential to thrive are critical for their well-being during adolescence and for their physical and mental health in adulthood.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"","Highlight":"<ul></ul><p><a href=\"https://www.who.int/publications/i/item/9789240031029\">Comprehensive Mental Health Action Plan 2013-2030&nbsp;</a></p><p><a href=\"https://www.who.int/publications/i/item/9789240011854\">Guidelines on promotive and preventative mental health interventions for adolescents</a> </p><p><a href=\"https://www.who.int/publications/i/item/9789241549790\">Mental Health Gap Action Programme (mhGAP) Intervention Guide 2.0</a></p><p><a href=\"https://www.who.int/publications/i/item/9789240026629\">LIVE LIFE: an implementation guide for suicide prevention in countries</a></p><p><a href=\"https://applications.emro.who.int/docs/9789290225652-eng.pdf\" target=\"_blank\">Mental health in schools: a manual&nbsp;</a></p><p><a href=\"https://platform.who.int/data/maternal-newborn-child-adolescent-ageing/global-strategy-data\">Global Strategy for Women&rsquo;s, Children&rsquo;s and Adolescents&rsquo; Health 2016&ndash;2030</a></p><p><a target=\"_blank\" href=\"https://www.who.int/activities/improving-the-mental-and-brain-health-of-children-and-adolescents\">Improving the mental and brain health of children and adolescents</a></p><p><br /></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/adolescent-mental-health/adolescent-health-and-well-being.tmb-768v.jpg?sfvrsn=6dad43b3_6","FormatedDate":"1 September 2025","TrimmedTitle":"Mental health of adolescents"},{"Id":"c2e92072-869c-4940-ae67-d8bb9b9ef11e","LastModified":"2026-10-02T09:13:17Z","PublicationDate":"2018-06-02T02:27:15Z","DateCreated":"2018-06-02T02:27:14Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"mental-disorders","ItemDefaultUrl":"/mental-disorders","NewsNumberOfAdditionalItems":0,"MedicalTreatmentBriefSummary":"","Content":"<p>&nbsp;</p><h2>Key facts </h2><ul type=\"disc\"><li>Nearly 1 in 7 people in the world live with a mental disorder.</li><li>Mental disorders can severely disrupt daily life and cause long-term suffering if left untreated.</li><li>There are many different types of mental disorders.</li><li>Effective prevention and treatment options exist.</li><li>Most people do not have access to effective care.</li></ul><hr /><p>A mental disorder is characterized by a clinically significant disturbance in an individual&rsquo;s cognition, emotional regulation, or behaviour.&nbsp; It is usually associated with distress or impairment in important areas of functioning. There are\r\n    many different types of mental disorders.&nbsp; Mental disorders may also be referred to as mental health conditions. The latter is a broader term covering mental disorders, psychosocial disabilities and (other) mental states associated with significant\r\n    distress, impairment in functioning, or risk of self-harm.&nbsp; This fact sheet focuses on mental disorders as described by the International Classification of Diseases 11th Revision (ICD-11).<br /></p><p>In 2023, nearly 1 in every 7 people (1.2 billion) around the world were living with a mental disorder, with anxiety and depressive disorders the most common <em>(1)</em>. While effective prevention and treatment options exist, most people with mental disorders\r\n    do not have access to effective care. Many people also experience stigma, discrimination and violations of human rights.&nbsp;<br /></p><h2>Anxiety disorders</h2><p>In 2023, 470 million people were living with an anxiety disorder including 146 million children and adolescents <em>(1)</em>.&nbsp;Anxiety disorders are characterized by excessive fear and worry and related behavioural disturbances. Symptoms are severe enough to result in significant distress or significant impairment in functioning. There are several different kinds of anxiety disorders, such as: generalized anxiety disorder (characterized by excessive worry), panic disorder (characterized by panic attacks), social anxiety disorder (characterized by excessive fear and worry in social situations), separation anxiety disorder (characterized by excessive fear or anxiety about separation from those individuals to whom the person has a deep emotional bond), and others. Effective psychological treatment exists, and depending on the age and severity, medicines may also be considered.<br /></p><h2>Depression</h2><p>In 2023, 322 million people were living with depression, including 43 million children and adolescents <em>(1)</em>. Depression is different from usual mood fluctuations and short-lived emotional responses to challenges in everyday life.&nbsp;During a depressive episode, the person experiences depressed mood (feeling sad, irritable, empty) or a loss of pleasure or interest in activities, for most of the day, nearly every day, for at least two weeks. Several other symptoms are also present, which may include poor concentration, feelings of excessive guilt or low self-worth, hopelessness about the future, thoughts about dying or suicide, disrupted sleep, changes in appetite or weight, and feeling especially tired or low in energy.&nbsp;People with depression are at an increased risk of suicide. Effective psychological treatment exists, and depending on the age and severity, medicines may also be considered.<strong>&nbsp;</strong></p><h2>Bipolar disorder</h2><p>In 2023, 36 million people experienced bipolar disorder, including 3.3 million adolescents aged 10&ndash;19 years&nbsp;<em>(1)</em>.&nbsp;People with bipolar disorder experience alternating depressive episodes with periods of manic symptoms.&nbsp;During a depressive episode, the person experiences depressed mood (feeling sad, irritable, empty) or a loss of pleasure or interest in activities, for most of the day, nearly every day.&nbsp;Manic symptoms may include euphoria or irritability, increased activity or energy, and other symptoms such as increased talkativeness, racing thoughts, increased self-esteem, decreased need for sleep, distractibility, and impulsive, reckless behaviour.&nbsp;People with bipolar disorder are at an increased risk of suicide. Effective treatments exist including psychoeducation, strengthening of social functioning, and medicines.<br /></p><h2>Post-traumatic stress disorder (PTSD)</h2><p>PTSD may develop following exposure to an extremely threatening or horrific event or series of events. It is characterized by: 1) re-experiencing\r\n    the traumatic event or events in the present (intrusive memories, flashbacks, or nightmares); 2) avoidance of thoughts and memories of the event(s), or avoidance of activities, situations, or people reminiscent of the event(s); and 3) persistent perceptions\r\n    of heightened current threat. These symptoms persist for at least several weeks and cause significant impairment in functioning. Effective psychological treatment exists.&nbsp;</p><h2>Schizophrenia</h2><p>In 2023, schizophrenia affected approximately 27 million people or 1 in 300 people worldwide <em>(1)</em>.&nbsp;People with schizophrenia die on average nine years earlier than the general population <em>(2)</em>. Schizophrenia is characterized by significant impairments in perception and changes in behaviour.&nbsp;Symptoms may include persistent delusions, hallucinations, disorganized thinking, highly disorganized behaviour, or extreme agitation.&nbsp;People with schizophrenia may experience persistent difficulties with their cognitive functioning.&nbsp;Effective treatments exist, including medicines, psychoeducation, family interventions, and psychosocial rehabilitation. &nbsp;<br /></p><h2>Eating disorders</h2><p>In 2023, 18 million people experienced eating disorders, including 4.7 million children and adolescents <em>(1)</em>. Eating disorders, such as anorexia nervosa and bulimia nervosa, involve abnormal eating and preoccupation with food as well as prominent body weight and shape concerns. The symptoms or behaviours result in significant risk or damage to health, significant distress, or significant impairment of functioning. Anorexia nervosa often has its onset during adolescence or early adulthood and is associated with premature death due to medical complications or suicide. Individuals with bulimia nervosa are at a significantly increased risk for substance use, suicidality, and health complications. Effective treatments exist, including family-based treatment and cognitive-based therapy.<br /></p><h2>Disruptive behaviour and dissocial disorders</h2><p>In 2023, 39 million children and adolescents were living with conduct-dissocial disorder <em>(1)</em>. This disorder, also known as conduct disorder, is one of two disruptive behaviour and dissocial disorders, the other is oppositional defiant disorder.&nbsp;Disruptive behaviour and dissocial disorders are characterized by persistent behaviour problems, such as persistent defiance or disobedience, or behaviours that persistently violate the basic rights of others or major age-appropriate societal norms, rules, or laws. Onset of disruptive and dissocial disorders is commonly, though not always, during childhood. Effective psychological treatments exist, such as cognitive problem-solving and/or social skills training; they often involve parents, caregivers, and teachers.<br /></p><h2>Neurodevelopmental disorders</h2><p></p><p>Neurodevelopmental disorders are behavioural and cognitive disorders that&nbsp;arise during the developmental period and involve significant difficulties in the acquisition and execution of specific intellectual, motor, language, or social functions.</p><p>Neurodevelopmental disorders include disorders of intellectual development, autism spectrum disorder, and attention deficit hyperactivity disorder (ADHD) among others. ADHD is characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity with a direct negative impact on academic, occupational, or social functioning.&nbsp;Disorders of intellectual development are characterized by significant limitations in intellectual functioning and adaptive behaviour, which refers to difficulties with everyday conceptual<em>, social,&nbsp;</em>and<em>&nbsp;practical&nbsp;</em>skills that are performed in daily life. Autism spectrum disorder constitutes a diverse group of conditions characterized by some degree of difficulty with social communication and reciprocal social interaction, as well as persistent restricted, repetitive, and inflexible patterns of behaviour, interests, or activities.</p><p>Effective treatments exist, including psychosocial interventions, behavioural interventions, occupational and speech therapy. For certain diagnoses and age groups, medicines may also be considered.<br /></p><h2>Risk factors&nbsp;</h2><p>At any one time, a diverse set of individual, family, community, and structural factors may combine to protect or undermine mental health. Although most people are resilient, people who are exposed to adverse circumstances &ndash; including poverty, violence,\r\n    disability, and inequality &ndash; are at higher risk. Protective and risk factors include individual psychological and biological factors, such as emotional skills as well as genetics. Many of the risk and protective factors are influenced\r\n    through changes in brain structure and/or function.<br /></p><h2>Health systems and social support</h2><p></p><p>Health systems have not yet adequately responded to the needs of people with mental disorders and are significantly under resourced. The gap between the need for treatment and its provision is wide all over the world; care is often poor in quality when delivered. For example, only 40% of people with psychosis <em>(3)</em> and only one third of people with depression receive formal mental health care <em>(4)</em>.&nbsp;</p><p>People with mental disorders also require social support, including support in developing and maintaining personal, family, and social relationships.&nbsp;They may also need support accessing education, employment and housing, and participating in other meaningful activities.&nbsp;</p><p></p><h2>WHO response<br /></h2><p><a href=\"https://www.who.int/publications/i/item/9789240031029\">WHO&rsquo;s Comprehensive Mental Health Action Plan 2013&ndash;2030</a> recognizes the essential role of mental health in achieving health for all people. The plan includes four major objectives:</p><ul><li>to strengthen effective leadership and governance for mental health; </li><li>to provide comprehensive, integrated and responsive mental health and social care services in community-based settings; </li><li>to implement of strategies for promotion and prevention in mental health; and </li><li>to strengthen information systems, evidence, and research for mental health.</li></ul><p><a href=\"https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme\">WHO's Mental Health Gap Action Programme (mhGAP)</a> uses evidence-based technical guidance, tools and training packages to expand services in countries, especially in resource-poor settings. It focuses on a prioritized set of disorders, directing capacity\r\n    building towards non-specialized health-care providers in an integrated approach that promotes mental health at all levels of care. The <a href=\"https://www.who.int/publications/i/item/9789241549790\">WHO mhGAP Intervention Guide 2.0</a> is part of this programme and provides guidance on assessment and management of mental disorders for doctors, nurses, and other health workers in non-specialist health settings. &nbsp;</p><p>&nbsp;</p><p><span style=\"background-color:transparent;font-size:18px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">References</span></p><p></p><p>1) 2023 Global Burden of Disease (GBD) [online database]. Seattle: Institute for Health Metrics and Evaluation; 2024 (<a href=\"https://vizhub.healthdata.org/gbd-results/\">https://vizhub.healthdata.org/gbd-results/</a>).</p><p>(2) Yung NCL, Wong CSM, Chan JKN, Chen EYH, Chang WC. Excess mortality and life-years lost in people with schizophrenia and other non-affective psychoses: an 11-year population-based cohort study. Schizophr Bull. 2021;47(2):474&ndash;84 (https://doi.org/10.1093/schbul/sbaa137).</p><p>(3)&nbsp;Mental health atlas 2024. Geneva: World Health Organization; 2025.</p><p>(4) Moitra M, Santomauro D, Collins PY, Vos T, Whiteford H, Saxena S, et al. The global gap in treatment coverage for major depressive disorder in 84 countries from 2000&ndash;2019: a systematic review and Bayesian meta-regression analysis. PLoS Med. 2022;19(2):e1003901&nbsp;(https://<a href=\"https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003901\" target=\"_blank\">doi.org/10.1371/journal.pmed.1003901</a>).<br /></p>","ConditionName":"","OpenGraphTitle":"Mental disorders","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Mental disorders","ConditionLongerOverview":"","Title":"Mental disorders","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs396","PhotoStoryNumberOfAdditionalItems":0,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":0,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"WHO fact sheet on mental disorders, including sections on anxiety disorders, depression, bipolar disorder, Post-Traumatic Stress Disorder, schizophrenia, eating disorders, disruptive behaviour and dissocial disorders, neurodevelopmental disorders, risk factors, health systems and social support, as well as WHO's work in these areas. ","PublicationDateAndTime":"2026-09-11T15:00:56Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on mental disorders, including sections on anxiety disorders, depression, bipolar disorder, Post-Traumatic Stress Disorder, schizophrenia, eating disorders, disruptive behaviour and dissocial disorders, neurodevelopmental disorders, risk factors, health systems and social support, as well as WHO's work in these areas. ","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"","Highlight":"<ul><li><a href=\"https://www.who.int/health-topics/mental-health\">WHO's work on mental health</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/topics/health-and-well-being/mental-health-and-brain-health/friendship-bench-zimbabwe.tmb-768v.jpg?sfvrsn=9ef0c31d_6","FormatedDate":"11 September 2026","TrimmedTitle":"Mental disorders"},{"Id":"4c47ba11-bff4-496f-9519-81eee8b2fd0f","LastModified":"2025-03-10T08:09:10Z","PublicationDate":"2018-06-02T02:27:17Z","DateCreated":"2018-06-02T02:27:16Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"adolescents-health-risks-and-solutions","ItemDefaultUrl":"/adolescents-health-risks-and-solutions","NewsNumberOfAdditionalItems":2,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">Over 1.5 million adolescents and young adults aged 10&ndash;24 years died in 2021, about 4500 every day.</li><li data-list=\"0\" data-level=\"1\">Young adolescents aged 10&ndash;14 years have the lowest risk of death among all age groups.</li><li data-list=\"0\" data-level=\"1\">Injuries (including road traffic injuries and drowning), interpersonal violence, self-harm and maternal conditions are the leading causes of death among adolescents and young adults.</li><li data-list=\"0\" data-level=\"1\">Half of all mental health disorders in adulthood start by age 18, but most cases are undetected and untreated.</li><li data-list=\"0\" data-level=\"1\">Early onset of substance use is associated with higher risks of developing dependence and other problems during adult life, and younger people are disproportionately affected by substance use compared with older people.</li><li data-list=\"0\" data-level=\"1\">Globally, there were 42 births per 1000 to girls aged 15&ndash;19 years in 2021.</li></ul><hr /><p>&nbsp;</p><h2>Overview</h2><p>Survival chances for adolescents and young adults vary greatly across the world. In 2021, the average probability of a 10-year-old dying before age 24 was about 6 times higher in sub-Saharan Africa than in North America and Europe.</p><p>Within the age group 10&ndash;24 years, mortality rates are lowest among adolescents aged 10&ndash;14, and highest among young adults aged 20&ndash;24 years. Females generally have lower mortality rates for these ages than males.</p><p>The patterns of death of 10&ndash;14-year-olds are dominated by infectious diseases. Among older adolescents and young adults, a shift away from infectious diseases of childhood is seen, towards accidents and injuries, self-harm and interpersonal violence. Sex differences in mortality rates also become apparent in adolescence. </p><h2>Main health issues</h2><p>Many unintentional injuries such as road traffic and drowning are the leading cause of death and disability among adolescents. </p><ul><li><strong>Road traffic accidents</strong>\r\n <p>In 2021, over <a href=\"https://www.who.int/data/global-health-estimates\">100 000 adolescents</a> (10&ndash;19 years) died from road traffic accidents<em>.&nbsp;</em>Many of those who died were vulnerable road users, including pedestrians, cyclists or users of motorized two-wheelers. </p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/injuries-and-violence\">Injuries and violence fact sheet</a></p></li><li><strong>Drowning</strong>\r\n <p>Drowning is also among the top causes of death among adolescents; more than 40 000 adolescents, over three quarters of them boys, are estimated to have drowned in 2021.</p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/drowning\">Drowning fact sheet</a></p></li><li><strong>Violence</strong>\r\n <p>Interpersonal violence is among the leading causes of death in adolescents and young people globally. Its prominence varies substantially by world region. It causes nearly a third of all adolescent male deaths in the WHO Region of the Americas. &nbsp;</p><p>Violence during adolescence also increases the risks of injury, HIV and other sexually transmitted infections, mental health problems, poor school performance and dropout, early pregnancy, reproductive health problems, and communicable and noncommunicable diseases.</p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/youth-violence\">Youth violence fact sheet</a></p></li><li><strong>Alcohol and drug use</strong>\r\n <p>Drinking alcohol among adolescents is a major concern in many countries. Worldwide, more than a quarter of all people aged 15&ndash;19 years are current drinkers, amounting to 155 million adolescents. <a href=\"https://www.who.int/publications/i/item/9789241565639\">Prevalence</a> of heavy episodic drinking among adolescents aged 15&shy;&ndash;19 years was 13.6% in 2016, with males most at risk.</p><p><a href=\"https://wdr.unodc.org/wdr2020/field/WDR20_Booklet_2.pdf\">Cannabis</a> is the most widely used psychoactive drug among young people with about 4.7% of people aged 15&ndash;16 years using it&nbsp;at least once in 2018. Alcohol and drug use in children and adolescents is associated with neurocognitive alterations which can lead to behavioural, emotional, social and academic problems in later life.</p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/alcohol\">Alcohol fact sheet</a></p></li><li><strong>Tobacco use</strong></li><p>The vast majority of people using tobacco today began doing so when they were adolescents. Globally in 2018, at least <a href=\"https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(20)30390-4/fulltext\">1 in 10 adolescents</a> aged 13&ndash;15 years uses tobacco, although there are areas where this figure is much higher. E-cigarettes are particularly risky when used by children and adolescents. Nicotine is highly addictive and young people&rsquo;s brains develop up to their mid-twenties.</p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/tobacco\">Tobacco fact sheet</a></p><p><a href=\"https://www.who.int/news-room/questions-and-answers/item/tobacco-e-cigarettes\">E-cigarettes: how risky are they?</a></p><li><strong>Mental health</strong></li><p>Depression and anxiety are among the <a href=\"https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00566-0/fulltext\">leading causes of illness and disability</a> among adolescents, and suicide is among the leading causes of death in people aged 15&ndash;19 years. Half of all mental health disorders in adulthood start by age 18, but most cases are undetected and untreated.</p><p>Many factors have an impact on the well-being and mental health of adolescents. Violence, poverty, stigma, exclusion, and living in humanitarian and fragile settings can increase the risk of developing mental health problems. </p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/adolescent-mental-health\">Adolescent mental health fact sheet</a></p><li><strong>Communicable diseases </strong></li><p><strong>HIV</strong></p><p>An estimated <a href=\"https://aidsinfo.unaids.org/\">1.7 million adolescents</a> (age 10&ndash;19 years) were living with HIV in 2021 with around 90% in the WHO African Region. While there have been substantial declines in new infections amongst adolescents from a peak in 1994, <a href=\"https://data.unicef.org/topic/hivaids/adolescents-young-people/#:~:text=HIV%20in%20adolescents,of%20new%20adult%20HIV%20infections\">adolescents</a> still account for about 10% of new HIV infections, with three-quarters amongst adolescent girls. Additionally, while new infections may have fallen in many of the most severely affected countries, recent testing coverage <a href=\"https://www.who.int/publications/i/item/9789241549684\">remains low</a> suggesting that many adolescents and young people living with HIV may not know their status.</p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/hiv-aids\">HIV fact sheet</a></p><p><a href=\"https://www.who.int/news-room/facts-in-pictures/detail/hiv-aids\">HIV facts in pictures</a></p><p><strong>Tuberculosis</strong></p><p>Tuberculosis (TB) is a preventable and curable disease, but it continues to impact the lives and development of millions of children and adolescents. Children and young adolescents aged under 15 years represent about 11% of all people with TB globally. This means 1.1 million children and young adolescents aged under 15 years fall ill with TB every year, and more than 225 000 of them lose their lives.</p><p>Adolescents and young adults usually present with bacteriologically infectious TB characterized by cavities seen on chest x-rays. The <a href=\"https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2022\">Global Tuberculosis Report</a> shows that notification rates in adolescents aged 15&ndash;19 years are relatively high compared with younger adolescents. </p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/tuberculosis\">Tuberculosis fact sheet</a></p><p><strong>Other infectious diseases</strong></p><p>Diarrhoea and lower respiratory tract infections (pneumonia) are estimated to be among the top five causes of death for adolescents 10&ndash;14 years, with mortality rates being particularly high in African low- and middle-income countries. Thanks to improved childhood vaccination, adolescent deaths and disability from measles have fallen markedly. </p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease\">Diarrhoeal disease fact sheet</a></p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/pneumonia\">Pneumonia fact sheet</a></p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/measles\">Measles fact sheet</a></p><p>Early adolescence (9&ndash;14 years) is the optimal time for vaccination against HPV infection and it is estimated that if <a href=\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30068-4/fulltext\">90% of girls globally</a> get the HPV vaccine more than 40 million lives could be saved over the next century. However, it is estimated that in 2021 only 12% of girls globally received the vaccine.</p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer\">Human papillomavirus (HPV) and cervical cancer fact sheet</a></p><p>Overall there are proportionally fewer cases of and deaths from <a href=\"https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Children_and_adolescents-2021.1\">COVID-19 disease</a> for adolescents and young adults than for older adults. However, the pandemic has severe indirect <a href=\"https://data.unicef.org/resources/one-year-of-covid-19-and-school-closures/\">negative effects</a> on young people&rsquo;s well-being, including on their mental health, loss of education time through school closures, social isolation, physical inactivity, malnutrition and domestic violence.</p><li><strong>Early pregnancy and childbirth </strong></li><p>Approximately 12 million girls aged 15&ndash;19 years and at least 777 000 girls under 15 years give <a href=\"https://www.who.int/news-room/fact-sheets/detail/adolescent-pregnancy\">birth</a> each year in developing regions. Complications from pregnancy and childbirth are among the leading causes of death for girls aged 15&ndash;19 years globally.</p><p>The global adolescent birth rate in 2021 was 42 births per 1000 girls this age, and country rates range from 1 to over 200 births per 1000 girls annually. This indicates a marked decrease since 1990. This decrease is reflected in a similar decline in maternal mortality rates among girls aged 15&ndash;19 years.</p><p>One of the specific targets of the health Sustainable Development Goal (SDG 3) is that by 2030, the world should ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes.</p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/adolescent-pregnancy\">Adolescent pregnancy fact sheet</a></p><li><strong>Environmental health</strong></li><p>Many of the main causes of mortality in adolescents and young adults have strong links to the environment, including unintentional injuries and infectious diseases. Young people are at increased risk of environmental hazards and pollution due to their developmental physiology and immature systems. Primary environmental hazards and pollution affecting the health of adolescents and young adults include air pollution, chemicals and heavy metals, climate change, UV radiation, urban health and WASH. </p><p><a href=\"https://www.who.int/health-topics/children-environmental-health#tab=tab_1\">WHO's work on children's environmental health</a></p><li><strong>Overweight</strong></li><p>Globally, in 2016, over&nbsp;<a href=\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2817%2932129-3/fulltext?elsca1=tlpr\">1 in 6 adolescents</a>&nbsp;aged 10&ndash;19 years was overweight. Prevalence varied across WHO regions, from lower than 10% in the WHO South-East Asia Region to over 30% in the WHO Region of the Americas. </p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight\">Obesity and overweight fact sheet</a></p><li><strong>Nutrition</strong></li><p>Many boys and girls in developing countries enter adolescence undernourished, making them more vulnerable to disease and early death.</p><p>Iron deficiency anaemia was among the leading causes of\r\n        healthy years of life lost due to disability by adolescents aged 10&ndash;19 in 2021.\r\n        Iron and folic acid supplements are a solution that also helps to promote\r\n        health of adolescents. Regular deworming in areas where intestinal helminths\r\n        such as hookworm are common is recommended to prevent micronutrient (including\r\n        iron) deficiencies.</p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/malnutrition\">Malnutrition fact sheet</a></p><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/healthy-diet\">Healthy diet fact sheet</a></p></ul><ul><li><strong>Physical activity</strong>\r\n </li></ul><p style=\"margin-left:30px;\">Globally, in 2016, only 1 in 5 adolescents are estimated to\r\n    meet WHO guidelines on physical activity.&nbsp;Prevalence&nbsp;of inactivity is\r\n    high across all WHO regions, and higher in female as compared to male\r\n    adolescents <em>(8)</em>.</p><ul><p><a href=\"https://www.who.int/news-room/fact-sheets/detail/physical-activity\">Physical activity fact sheet</a><br /><br /></p></ul><h2>Rights of adolescents</h2><p>The rights of children under 18 years to survive, grow and\r\n    develop are enshrined in international legal documents. In 2013, the Committee\r\n    on the Rights of the Child (CRC) published guidelines on the right of children to\r\n    the enjoyment of the highest attainable standard of health, and a General\r\n    Comment on realizing the rights of children during adolescence was published in\r\n    2016. It highlights states&rsquo; obligations to recognize the special health and\r\n    development needs and rights of young people.</p><p>The Convention on the Elimination of Discrimination Against\r\n    Women (CEDAW) also sets out the rights of women and girls to health and\r\n    adequate health care.</p><h2>WHO response</h2><p>WHO works with Member States and partners to improve the\r\n    health of young people by producing evidence-based guidelines, advocating and\r\n    providing recommendations for adolescent-responsive health systems, and\r\n    documenting progress in adolescent health and development.</p><p>In 2023, WHO published an update of the <a href=\"https://www.who.int/publications/i/item/9789240081765\">Global Accelerated\r\n        Action for the Health of Adolescents (AA-HA!): Guidance to support country\r\n        implementation</a>. AA-HA! 2.0 has drawn on inputs received during consultations\r\n    with Member States, United Nations agencies, adolescents and young people,\r\n    civil society and other partners. It aims to assist governments in deciding\r\n    what they plan to do and how they plan to do it as they respond to the health\r\n    needs of adolescents.</p><p>To improve adolescent health measurement\r\n    globally, WHO in collaboration with UNAIDS, UNESCO, UNFAP, UNICEF, UN Women,\r\n    the World Bank Group, and the World Food Programme (WFP), has established\r\n    the&nbsp;<a href=\"https://www.who.int/data/maternal-newborn-child-adolescent-ageing/advisory-groups/gama\">Global\r\n Action for Measurement of Adolescent health (GAMA) Advisory Group</a>. A comprehensive\r\n    set of <a href=\"https://www.who.int/publications/i/item/9789240092198\">47 priority\r\n        indicators for global, regional and national adolescent health measurement</a> has\r\n    been published in 2024 using a structured participatory process.</p><p>&nbsp;</p><p><strong>References</strong></p><ol style=\"margin-top:0cm;\" type=\"1\"><li>United Nations Office on Drugs and Crime. Drug use and consequences. 2020. <a href=\"https://wdr.unodc.org/wdr2020/field/WDR20_Booklet_2.pdf\">https://wdr.unodc.org/wdr2020/field/WDR20_Booklet_2.pdf</a></li><li>Ma, Chuanwei et al. Prevalence and trends in tobacco use among adolescents aged 13&ndash;15 years in 143 countries,\r\n        1999&ndash;2018: findings from the Global Youth Tobacco Surveys. The Lancet Child\r\n        &amp; Adolescent Health, Volume 5, Issue 4, 245 &ndash; 255. <a href=\"https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(20)30390-4/abstract\">https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(20)30390-4/abstract</a></li><li>UNAIDS.\r\n <a href=\"https://aidsinfo.unaids.org/\">https://aidsinfo.unaids.org/</a>\r\n </li><li>UNICEF.\r\n Adolescent HIV prevention. <a href=\"https://data.unicef.org/topic/hivaids/adolescents-young-people/\">https://data.unicef.org/topic/hivaids/adolescents-young-people/</a></li><li>Brisson,\r\n Marc et al. Impact of HPV vaccination and cervical screening on cervical cancer\r\n        elimination: a comparative modelling analysis in 78 low-income and\r\n        lower-middle-income countries. The Lancet, Volume 395, Issue 10224, 575 &ndash; 590. <a href=\"https://www.thelancet.com/action/showCitFormats?doi=10.1016%2FS0140-6736%2820%2930068-4&amp;pii=S0140-6736%2820%2930068-4\">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30068-4/fulltext</a></li><li>United\r\n Nations Department of Economic and Social Affairs. World population prospects\r\n        2024. <a href=\"https://www.un.org/development/desa/pd/world-population-prospects-2024\">https://www.un.org/development/desa/pd/world-population-prospects-2024</a>&nbsp;</li><li><span style=\"mso-bidi-font-family:Aptos;mso-bidi-theme-font:minor-latin;\"><span style=\"mso-list:Ignore;\"><span style=\"font:7.0pt 'Times New Roman';\">&nbsp;</span></span></span>Abarca-G&oacute;mez,\r\n Leandra et al. Worldwide trends in body-mass index, underweight, overweight,\r\n        and obesity from 1975 to 2016: a pooled analysis of 2416 population-based\r\n        measurement studies in 128.9 million children, adolescents, and adults. The\r\n        Lancet, Volume 390, Issue 10113, 2627 &ndash; 2642. <a href=\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2817%2932129-3/fulltext\">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2817%2932129-3/fulltext</a></li><li><span style=\"mso-bidi-font-family:Aptos;mso-bidi-theme-font:minor-latin;\"><span style=\"mso-list:Ignore;\"></span></span>Guthold, Regina et al. Global trends in\r\n        insufficient physical activity among adolescents: a pooled analysis of 298\r\n        population-based surveys with 1&middot;6 million participants. The Lancet Child &amp;\r\n        Adolescent Health, Volume 4, Issue 1, 23 &ndash; 35. <a href=\"https://www.thelancet.com/article/S2352-4642(19)30323-2/fulltext\">https://www.thelancet.com/article/S2352-4642(19)30323-2/fulltext</a></li></ol><p><br /></p>","ConditionName":"","OpenGraphTitle":"Adolescent and young adult health","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Adolescent and young adult health","ConditionLongerOverview":"","Title":"Adolescent and young adult health","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs345","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":1,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on adolescents health risks and solutions: includes key facts and provides a definition, information on specific health issues, WHO response.","PublicationDateAndTime":"2024-11-26T11:40:46Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on adolescents health risks and solutions: includes key facts and provides a definition, information on specific health issues, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<h3>WHO's work on adolescent health</h3><ul><li><a href=\"https://www.who.int/health-topics/adolescent-health\">Adolescent health</a></li><li><a href=\"https://www.who.int/teams/sexual-and-reproductive-health-and-research-(srh)/areas-of-work/adolescent-and-sexual-and-reproductive-health-and-rights\">Adolescent sexual and reproductive health and rights</a></li><li><a href=\"https://www.who.int/publications/i/item/A71-19\">Global Strategy for Women's, Children's and Adolescent's Health &amp; Every Woman Every Child Initiative</a></li></ul><br /><h3>Publications</h3><ul><li><a href=\"https://www.who.int/publications/i/item/WHO-FWC-MCA-17.05\">Global accelerated action for the health of adolescents (AA-HA!): Guidance to support country implementation</a></li><li><a href=\"https://www.who.int/publications/i/item/9789241549332\">Global standards for quality health care services for adolescents</a></li><li><a href=\"https://www.who.int/publications/i/item/9789241508315\">Core competencies in adolescent health and development for primary care providers</a></li><li><a href=\"https://www.who.int/publications/i/item/WHO-FWC-MCA-14.05\">Health for the world's adolescents: a second chance in the second decade</a><br /></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/mca/adolescent-health/adolescent/teens_credit_vladimir-pustovit.tmb-768v.jpg?sfvrsn=5b4a8516_13","FormatedDate":"26 November 2024","TrimmedTitle":"Adolescent and young adult health"},{"Id":"d5e14d06-094a-41d6-9f5f-7cefb7711008","LastModified":"2026-10-26T13:58:49Z","PublicationDate":"2018-06-02T02:27:20Z","DateCreated":"2018-06-02T02:27:18Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"trachoma","ItemDefaultUrl":"/trachoma","NewsNumberOfAdditionalItems":1,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">Trachoma is a disease of the eye caused by infection with the bacterium <em>Chlamydia trachomatis</em>.</li><li data-list=\"0\" data-level=\"1\">It is a      public health problem in at least part of 29 countries and is responsible      for the blindness or visual impairment of about 1.9&nbsp;million people.</li><li data-list=\"0\" data-level=\"1\">Blindness from trachoma is difficult to reverse.</li><li data-list=\"0\" data-level=\"1\">Based on March      2026 data, 92&nbsp;million people live in trachoma endemic areas and are      at risk of trachoma blindness.</li><li data-list=\"0\" data-level=\"1\">Infection spreads through personal contact (via hands, clothes, bedding or hard      surfaces) and by flies that have been in contact with discharge from the      eyes or nose of an infected person. With repeated episodes of infection      over many years, the eyelashes may be drawn in so that they rub on the      surface of the eye. This causes pain and may permanently damage the      cornea.</li><li data-list=\"0\" data-level=\"1\">In 2025, 98&nbsp;829      people received surgical treatment for advanced stage of the disease, and 47.4&nbsp;million      people were treated with antibiotics. Global antibiotic coverage in 2025 was      47%.&nbsp;</li></ul><hr /><h2>Overview</h2><p>Trachoma is the leading infectious cause of blindness worldwide. It is caused by an obligate intracellular bacterium called <em>Chlamydia trachomatis</em>. The infection is transmitted by direct or indirect transfer of eye and nose discharges of infected people, particularly young children who harbour the principal reservoir of infection. These discharges can be spread by particular species of flies.</p><h2>Symptoms and transmission</h2><p>In areas where trachoma is endemic, active (inflammatory) trachoma is common among preschool-aged children, with the proportion of such children affected sometimes being as high as 90%. Infection becomes less frequent and shorter in duration with increasing age. Infection is usually acquired when living in close proximity to others with active disease, and the family is the main setting for transmission. An individual&rsquo;s immune system can clear a single episode of infection, but in endemic communities re-acquisition of the organism occurs frequently.</p><p>After years of repeated infection, the inside of the eyelid can become so severely scarred (trachomatous conjunctival scarring) that it turns inwards and causes the eyelashes to rub against the eyeball (trachomatous trichiasis), resulting in constant pain and light intolerance. This and other alterations of the eye can lead to scarring of the cornea. Left untreated, this condition leads to the formation of irreversible opacities, with resulting visual impairment or blindness. The age at which this occurs depends on several factors including local transmission intensity. In very highly endemic communities it can occur in childhood, though onset of visual impairment between the ages of 30 and 40 years is more typical.</p><p>Visual impairment or blindness results in a worsening of the life experience of affected individuals and their families, who are normally already amongst the poorest of the poor. Women are blinded up to 4 times as often as men, probably due to their close contact with infected children and their resulting greater frequency of infection episodes.</p><p>Environmental factors associated with more intense transmission of <em>C. trachomatis</em> include:</p><ul><li>inadequate hygiene</li><li>crowded households</li><li>inadequate access to water</li><li>inadequate access to and use of sanitation.</li></ul><h2>Distribution</h2><p>Trachoma is a public health problem in some of the poorest and most rural areas of Africa, Central and South America, Asia, Australia and the Middle East.</p><p>It is responsible for the blindness or visual impairment of about 1.9 million people. It causes about 1.4% of all blindness worldwide.</p><p>Overall, Africa remains the most affected continent and the one with the most intensive control efforts.</p><p>As of 4 September 2026, 33 countries &ndash; Algeria, Australia, Benin, Burundi, Cambodia, China, Egypt, El Salvador, Fiji, Gambia, Islamic Republic of Iran, Lao People&rsquo;s Democratic Republic, Libya, Ghana, India, Iraq, Malawi, Mali, Mauritania, Mexico, Morocco, Myanmar, Nepal, Oman, Pakistan, Papua New Guinea, Saudi Arabia, Senegal, Timor-Leste, Togo, Tunisia, Vanuatu and Viet Nam &ndash; had been validated by WHO as having eliminated trachoma as a public health problem.</p><h2>Economic impact</h2><p>The burden of trachoma on affected individuals and communities is enormous. The economic cost in terms of lost productivity from blindness and visual impairment is estimated at US$ 2.9&ndash;5.3 billion annually, increasing to US$ 8 billion when trichiasis is included.</p><h2>Prevention, control and elimination</h2><p>Elimination programmes in endemic countries are being implemented using the WHO-recommended SAFE strategy. This consists of:</p><ul><li><strong>S</strong>urgery to treat the blinding stage (trachomatous trichiasis);</li><li><strong>A</strong>ntibiotics to clear infection, particularly mass drug administration of the antibiotic azithromycin, which is donated by the manufacturer to elimination programmes, through the International Trachoma Initiative;</li><li><strong>F</strong>acial cleanliness; and</li><li><strong>E</strong>nvironmental improvement, particularly improving access to water and sanitation.</li></ul><p>Most endemic countries are accelerating the implementation of this strategy to achieve elimination targets.</p><p>Data reported to WHO by Member States for 2025 show that 98 829 people with trachomatous trichiasis were provided with corrective surgery in that year, and 47.4 million people in endemic communities were treated with antibiotics to eliminate trachoma.</p><p>Elimination efforts need to continue to ensure that we reach the target set by World Health Assembly resolution WHA 51.11, which is elimination of trachoma as a public health problem <em>(1)</em>. Particularly important is the engagement of multiple actors involved in water, sanitation and socioeconomic development.</p><h2>WHO response</h2><p>WHO adopted the SAFE strategy in 1993. WHO&rsquo;s mandate is to provide leadership and coordination to international efforts aiming to eliminate trachoma as a public health problem, and to report on progress towards that target.</p><p>In 1996, WHO launched the WHO Alliance for the Global Elimination of Trachoma by 2020. The Alliance is a partnership which supports implementation of the SAFE strategy by Member States, and the strengthening of national capacity through epidemiological surveys, monitoring, surveillance, project evaluation, and resource mobilization.</p><p>The World Health Assembly adopted resolution WHA51.11 in 1998, targeting the global elimination of trachoma as a public health problem with 2020 as the target date. The <a href=\"https://www.who.int/publications/i/item/9789240010352\">neglected tropical diseases road map 2021&ndash;2030</a>, endorsed by the World Health Assembly in 2020 through its decision 73(33), sets 2030 as the new target date for global elimination.</p><p>&nbsp;</p><h3>References</h3><p><em>(1)</em> Elimination of trachoma as a public health problem is defined as: (i) a prevalence of trachomatous trichiasis &ldquo;unknown to the health system&rdquo; of &lt;0.2% in adults aged &ge;15 years (approximately 1 case per 1000 total population), and (ii) a prevalence of trachomatous inflammation &ndash; follicular in children aged 1&ndash;9 years of less than 5%, sustained for at least two years in the absence of ongoing antibiotic mass treatment, in each formerly endemic district; plus (iii) the existence of a system able to identify and manage incident trachomatous trichiasis cases, using defined strategies, with evidence of appropriate financial resources to implement those strategies.</p><p>&nbsp;</p><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Trachoma","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Trachoma","ConditionLongerOverview":"","Title":"Trachoma","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs382","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"Trachoma is a disease of the eye caused by infection with the bacterium Chlamydia trachomatis. It is a public health problem in 32 countries and is responsible for the blindness or visual impairment of about 1.9 million people.\r\n","PublicationDateAndTime":"2026-09-07T15:13:19Z","ConditionBriefOverview":"","MetaDescription":"Fact sheet on trachoma, with key facts, clinical characteristics and morbidity, distribution, economic impact, prevention and control, and WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<div class=\"arrowed-link\"><a href=\"https://apps.who.int/iris/bitstream/handle/10665/79806/ear11.pdf\">Global elimination of blinding trachoma (WHA51.11)</a></div><div class=\"arrowed-link\"><a href=\"https://www.who.int/health-topics/trachoma\">WHO's work on trachoma</a></div><div class=\"arrowed-link\"><a href=\"https://www.who.int/teams/control-of-neglected-tropical-diseases/overview\">More on neglected tropical diseases</a></div>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/nepal-trachoma-certification.tmb-768v.jpg?sfvrsn=607fd601_19","FormatedDate":"7 September 2026","TrimmedTitle":"Trachoma"},{"Id":"8af9c11c-5961-41e4-a468-bb81207a90bb","LastModified":"2026-09-18T13:17:39Z","PublicationDate":"2018-06-02T02:27:22Z","DateCreated":"2018-06-02T02:27:20Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"infant-and-young-child-feeding","ItemDefaultUrl":"/infant-and-young-child-feeding","NewsNumberOfAdditionalItems":2,"MedicalTreatmentBriefSummary":"","Content":"<p>&nbsp;</p><h2>Key facts</h2><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">Every infant and child has the right to good nutrition according to the Convention on the Rights of the Child.</li><li data-list=\"0\" data-level=\"1\"><a href=\"https://www.who.int/publications/i/item/9789240112308\">An estimated</a> 150&nbsp;million children under 5 years of age were stunted (too short for age), 43&nbsp;million were wasted (too thin for height), and 36 million were living with overweight in 2024.</li><li data-list=\"0\" data-level=\"1\">Half of all child deaths are associated with malnutrition <em>(1).</em></li><li>WHO and UNICEF recommend all infants initiate breastfeeding within 1 hour of birth, breastfeed exclusively (are fed only breast milk) for the first 6 months of life and then continue breastfeeding up to 2 years of age or beyond while nutritionally adequate, safe complementary (solid) foods are introduced from six months.</li><li data-list=\"0\" data-level=\"1\">Nearly 400&nbsp;000 deaths amongst children under 5 years of age could be prevented every year if all infants were exclusively breastfed for the first six months and continued breastfeeding up to two years or beyond <em>(3)</em>. </li><li data-list=\"0\" data-level=\"1\"><a href=\"https://www.who.int/publications/i/item/9789241513807\">WHO recommends</a>&nbsp;governments scale up evidence-based support for breastfeeding, including by incorporating the Ten Steps to      Successful Breastfeeding as the standard of care in all maternity services and providing <a href=\"https://www.who.int/publications/i/item/9789240032323\">breastfeeding counselling</a> to all families with children under 2 years<em>.</em></li><li data-list=\"0\" data-level=\"1\">Globally, fewer than one-third (30.8%) of children aged 6 to 23 months were provided with a diet that met their nutritional needs (minimum dietary diversity) between 2018 and 2024, and only half of them were given as many meals as they need each day (minimum meal frequency) <em>(6, 7).</em></li></ul><hr /><h2>Overview</h2><p>In 2021, maternal and child malnutrition was estimated to be associated with 2.4&nbsp;million child deaths annually or more than 50% of all child deaths <em>(1).</em> Early, exclusive and continued breastfeeding can prevent pneumonia and diarrhoea, which are amongst the leading causes of child death. Infant and young child feeding is a key area to improve child survival and promote healthy growth and development. The first two years of a child&rsquo;s life are particularly important, as optimal nutrition during this period lowers morbidity and mortality, reduces the risk of chronic disease, and fosters better development overall. </p><p>However, many infants and children do not receive optimal feeding. For example, only about 47% of infants aged 0&ndash;6 months worldwide were exclusively breastfed over the period of 2018&ndash;2025 <em>(2)</em>.</p><p>Infants born to mothers receiving lifelong antiretroviral therapy (ART) can safely initiate breastfeeding in the first hour after birth, breastfeed exclusively for six months and continue breastfeeding until at least 12 months of age with very little risk of acquiring HIV <em>(8).</em> Mothers living with HIV should breastfeed for at least 12 months and may continue breastfeeding for up to 24 months or longer (similar to the general population) while being fully supported for ART adherence.<strong> </strong>In settings where national health authorities recommend breastfeeding for HIV-infected mothers, visit the<strong> </strong><a href=\"https://www.who.int/tools/elena/interventions/hiv-infant-feeding\">e-library of evidence for nutrition actions (eLENA)</a><strong>&nbsp;</strong>for guidelines and interventions to optimize adherence.</p><h2>Breastfeeding</h2><p>Early, exclusive and continued breastfeeding protect infants and children from infectious diseases. Infants who are mixed fed (partially breastfed) or not breastfed are much more likely to die from diarrhoea, pneumonia and other infectious diseases. While the effect is greater in low- and middle- income countries, infants in high-income countries who are not breastfed are also more likely to die in childhood <em>(9). </em></p><p>Breast milk is also an important source of energy and nutrients for <a href=\"https://www.who.int/publications/i/item/9789240081864\">children aged 6&ndash;23 months</a>. It can provide half or more of a child&rsquo;s energy needs between the ages of 6 and 12 months, and one third of energy needs between 12 and 24 months. Breast milk is also a critical source of energy and nutrients during illness, and it reduces mortality among children who are malnourished<em>.</em></p><p>Children and adolescents who were breastfed as babies are less likely to be overweight or obese. Additionally, they perform better on intelligence tests and have higher school attendance. Breastfeeding is associated with higher income in adult life. </p><p>Failure to invest in breastfeeding comes at a high cost. The cost of underfunding breastfeeding programmes is estimated to result in global economic losses of US$&nbsp;339&nbsp;billion each year, equivalent to 0.32% of global gross national income. Scaling up evidence-based health system support for breastfeeding, including facility- and community-based IYCF counselling and implementation of the Ten Steps to Successful Breastfeeding would generate returns of $59 for every $1 invested, with impacts driven largely by improvements in cognitive development, education outcomes and lifetime productivity <em>(3)</em>.</p><p>Longer durations of breastfeeding also contribute to the health and well-being of mothers. It reduces the risk of ovarian and breast cancer, increases the duration between pregnancies (breastfeeding an infant under six months exclusively causes hormonal changes that can delay the return of fertility) and reduces all-cause mortality. </p><p>Mothers and families need to be supported to breastfeed. Actions that help protect, promote and support breastfeeding include:</p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">adopting of policies such as the International Labour Organization&rsquo;s Maternity Protection Convention 183 and Recommendation No. 191, which complements Convention No. 183 by suggesting a longer duration of leave and higher benefits;</li><li data-list=\"0\" data-level=\"1\">introducing or strengthening legislation to restrict the marketing of formula milk and feeding bottles aligned with the International Code of Marketing of Breast-milk Substitutes and subsequent relevant World Health Assembly resolutions;</li><li data-list=\"0\" data-level=\"1\">integrating the Ten Steps to Successful Breastfeeding specified in the Baby-Friendly Hospital Initiative as the standard of care in all maternity services, including by:</li><ul type=\"circle\"><li data-list=\"0\" data-level=\"2\">ensuring all infants receive skin-to-skin contact between mother and baby immediately after birth and are supported to initiate breastfeeding within the first hour of life; </li><li data-list=\"0\" data-level=\"2\">supporting mothers to breastfeed responsively (that is, as often as the child wants, day and night);</li><li data-list=\"0\" data-level=\"2\">practising rooming-in (allowing mothers and infants to remain together 24 hours a day); and</li><li data-list=\"0\" data-level=\"2\">avoiding giving babies additional food or drink, even water, unless medically necessary;</li></ul><li data-list=\"0\" data-level=\"1\">providing supportive health services with infant and young child feeding counselling during all contacts with caregivers and young children, such as during antenatal and postnatal care, well child and sick child visits, and immunization; and</li><li data-list=\"0\" data-level=\"1\">providing community support, including mother support groups and community-based health promotion and education activities.</li></ul><p>Breastfeeding practices are highly responsive to supportive interventions, and the prevalence of exclusive and continued breastfeeding can be improved over the course of a few years. </p><h2>Complementary feeding</h2><p>Around the age of 6 months, an infant&rsquo;s need for energy and nutrients starts to exceed what is provided by breast milk, and <a href=\"https://www.who.int/publications/i/item/9789240081864\"></a><a href=\"https://www.who.int/publications/i/item/9789240081864\">additional (complementary) foods</a> are necessary to meet those needs. If complementary foods are not introduced around the age of 6 months, or if they are given before this age, growth may falter. Guiding principles for appropriate complementary feeding are:</p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">continue frequent breastfeeding up to 2 years of age or beyond; </li><li data-list=\"0\" data-level=\"1\"><a href=\"https://www.who.int/publications/i/item/9789240058651\"></a><a href=\"https://www.who.int/publications/i/item/9789240058651\">practise responsive feeding</a>: recognizing and responding to signs of hunger and fullness;      </li><li data-list=\"0\" data-level=\"1\">practise good hygiene and proper food handling; </li><li data-list=\"0\" data-level=\"1\">start at 6 months with small amounts of food and increase gradually as the child      gets older; </li><li data-list=\"0\" data-level=\"1\">gradually increase food consistency and variety; </li><li data-list=\"0\" data-level=\"1\">increase the number of times that the child is fed: 2&ndash;3 meals per day for infants      6&ndash;8 months of age and 3&ndash;4 meals per day for infants 9&ndash;23 months of age,      with 1&ndash;2 additional snacks as required; </li><li data-list=\"0\" data-level=\"1\">during illness, increase fluid intake including more frequent breastfeeding, and      offering soft, favourite foods. </li></ul><h2>Feeding in exceptionally difficult circumstances</h2><p>Families and children in difficult circumstances require special attention and practical support. Wherever possible, mothers and babies should remain together and get the support they need to exercise the most appropriate feeding option available. Breastfeeding remains the preferred mode of infant feeding in almost all difficult situations, for instance:</p><ul type=\"disc\"><li data-list=\"1\" data-level=\"1\">low-birth-weight or premature infants; </li><li data-list=\"1\" data-level=\"1\">mothers living with HIV in settings where mortality due to diarrhoea, pneumonia      and malnutrition remain prevalent;</li><li data-list=\"1\" data-level=\"1\">adolescent mothers; </li><li data-list=\"1\" data-level=\"1\">infants and young children who are malnourished; and </li><li data-list=\"1\" data-level=\"1\">families suffering the consequences of complex emergencies. </li></ul><h2>WHO response</h2><p>WHO is committed to supporting countries with implementation and monitoring of the <a href=\"https://www.who.int/publications/i/item/WHO-NMH-NHD-14.1\"></a><a href=\"https://www.who.int/publications/i/item/WHO-NMH-NHD-14.1\">Comprehensive implementation plan on maternal, infant and young child nutrition</a>, endorsed by Member States 2012 and reaffirmed in 2025. The plan includes 6 targets, one of which is to increase the rate of exclusive breastfeeding for the first 6 months of life to at least 60% by 2030. Activities that will help to achieve this include the multisectoral actions outlined in the <a href=\"https://www.who.int/publications/i/item/B09485\"></a><a href=\"https://www.who.int/publications/i/item/B09485\">Topical briefs on maternal, infant, young child nutrition</a>.</p><p>WHO provides guidance and technical assistance to countries on the implementation of the International Code of Marketing of Breast-milk Substitutes, the Baby-Friendly Hospital Initiative, breastfeeding counselling and support services, and breastfeeding monitoring.</p><p>UNICEF and WHO created the <a href=\"https://www.globalbreastfeedingcollective.org/\">Global Breastfeeding Collective</a> to rally political, legal, financial and public support for breastfeeding. The Collective brings together implementers and donors from governments, philanthropies, international organizations, and civil society. The Collective&rsquo;s vision is a world in which all mothers have the technical, financial, emotional, and public support they need to breastfeed.</p><p>UNICEF and WHO created the <a href=\"https://www.complementaryfeedingcollective.org/\">Global Complementary Feeding Collective</a> to accelerate efforts and systems-level change to improve complementary feeding. The Collective brings together global agencies dedicated to improving nutrition for children aged 6 to 23 months through improved programmes, policies and advocacy.</p><p>In addition, WHO and UNICEF<a href=\"https://www.who.int/publications/i/item/9789240032828\">Infant and young child feeding counselling: an integrated course: trainer&rsquo;s guide, 2nd ed</a> have developed <a href=\"https://www.who.int/publications/i/item/9789240032828\">courses</a> for training health workers to provide skilled support to breastfeeding mothers, counsel on complementary feeding, help them overcome problems, and monitor the growth of children, so they can identify early the risk of undernutrition or overweight/obesity.</p>WHO provides simple, coherent and feasible guidance to countries for promoting and supporting improved infant feeding by HIV-infected mothers to prevent mother-to-child transmission, good nutrition of the baby, and protect the health of the mother.<p><br /></p><p><strong>References</strong></p><ol><li>Ritchie H. Half of all child death are linked to malnutrition [website]. Our World in Data; 2024 (<a href=\"https://ourworldindata.org/half-child-deaths-linked-malnutrition?#article-citation\">https://ourworldindata.org/half-child-deaths-linked-malnutrition?#article-citation</a>). </li><li>Global Breastfeeding Scorecard, 2025: breastfeeding rates are increasing but improved support is needed. World Health Organization and United Nations Children&rsquo;s Fund; 2025 (<a href=\"https://doi.org/10.2471/B09718\">https://doi.org/10.2471/B09718</a>). License: CC BY-NC-SA 3.0 IGO</li><li>Nutrition International, United Nations Children&rsquo;s Fund, and World Health Organization. Global Investment Case for Improved Breastfeeding. Nutrition International; 2026 (<a href=\"https://www.globalbreastfeedingcollective.org/reports/global-investment-case-improved-breastfeeding\">https://www.globalbreastfeedingcollective.org/reports/global-investment-case-improved-breastfeeding</a>).</li><li>Victora C, Horta B, de Mola C et al.&nbsp; Association between breastfeeding and intelligence, educational attainment, and income at 30 years of age: a prospective birth cohort study from Brazil. The Lancet Global Health, 2015; 3, e199-e205 (<a href=\"https://doi.org/10.1016/S2214-109X(15)70002-1\" target=\"_blank\" title=\"Persistent link using digital object identifier\">https://doi.org/10.1016/S2214-109X(15)70002-1</a>). </li><li>Wang Y, Arvizu M, Rich-Edwards J et al. Breastfeeding duration and subsequent risk of mortality among US women: A prospective cohort study, eClinicalMedicine, 2022; 54 (<a href=\"https://doi.org/10.1016/j.eclinm.2022.101693\" target=\"_blank\" title=\"Persistent link using digital object identifier\">https://doi.org/10.1016/j.eclinm.2022.101693</a>). </li><li>FAO, IFAD, UNICEF, WFP and WHO. 2026. The State of Food Security and Nutrition in the World 2026 &ndash; Understanding and addressing the high cost of a healthy diet. Rome (<a href=\"https://doi.org/10.4060/cd8306en\">https://doi.org/10.4060/cd8306en</a>).</li><li>Diets [website]. United Nations Children&rsquo;s Fund (<a href=\"https://data.unicef.org/topic/nutrition/diets/\">https://data.unicef.org/topic/nutrition/diets/</a>). </li><li>Guideline: updates on HIV and infant feeding: the duration of breastfeeding, and support from health services to improve feeding practices among mothers living with HIV.&nbsp;World Health Organization; 2016 (<a href=\"https://iris.who.int/handle/10665/246260\">https://iris.who.int/handle/10665/246260)</a>.</li><li>Li R, Ware J, Chen A, Nelson JM, Kmet JM, Parks SE, Morrow AL, Chen J, Perrine CG. Breastfeeding and post-perinatal infant deaths in the United States, A national prospective cohort analysis. Lancet Reg Health Am. 2022 Jan;5:100094. (<a href=\"https://doi.org/10.1016/j.lana.2021.100094\" target=\"_blank\" title=\"Persistent link using digital object identifier\">https://doi.org/10.1016/j.lana.2021.100094</a>).</li></ol><p></p>","ConditionName":"","OpenGraphTitle":"Infant and young child feeding","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Infant and young child feeding","ConditionLongerOverview":"","Title":"Infant and young child feeding","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs342","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":3,"OtherRelated":"<h3>Infographics</h3><ul><li><a target=\"_blank\" href=\"https://www.who.int/multi-media/details/ten-steps-to-successful-breastfeeding\">Ten steps to successful breastfeeding</a></li></ul><p>&nbsp;</p><p>&nbsp;</p>","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"WHO fact sheet on infant and young child feeding providing key facts, breastfeeding, complementary feeding, feeding in difficult circumstances, HIV and infant feeding, WHO response.","PublicationDateAndTime":"2026-08-04T09:32:11Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on infant and young child feeding providing key facts, breastfeeding, complementary feeding, feeding in difficult circumstances, HIV and infant feeding, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<br /><ul><li><a target=\"_blank\" href=\"https://www.who.int/publications/i/item/9241562218\">Global Strategy for Infant and Young Child Feeding</a></li><li><a href=\"https://www.who.int/health-topics/breastfeeding\" style=\"font-family:inherit;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;font-size:inherit;\" target=\"_blank\">More on breastfeeding</a></li><li><a href=\"https://www.who.int/activities/promoting-baby-friendly-hospitals\" target=\"_blank\">Promoting baby-friendly hospitals</a></li><li data-list=\"0\" data-level=\"1\"><a href=\"https://www.who.int/teams/nutrition-and-food-safety/global-targets-2030\">Global Targets 2030: To improve maternal, infant and young child nutrition</a></li><li data-list=\"0\" data-level=\"1\"><a href=\"https://www.who.int/publications/i/item/9789240081864\">WHO Guideline for complementary feeding of infants and young children 6-23 months of age</a></li><li data-list=\"0\" data-level=\"1\"><a href=\"https://www.who.int/publications/i/item/9789240122109\">Ensuring competency for providers of breastfeeding support and care</a></li><li data-list=\"0\" data-level=\"1\"><a href=\"https://www.who.int/publications/i/item/9789240113732\">Infant and young child feeding: model chapter for textbooks for medical students and allied health professionals, 2nd ed.</a></li><li data-list=\"0\" data-level=\"1\"><a href=\"https://www.who.int/tools/elena/interventions/hiv-infant-feeding\">Infant feeding for the prevention of mother-to-child transmission of HIV</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/topics/womens-childrens-and-adolescent-health/breastfeeding/20260803-world-breastfeeding-week-pr.tmb-768v.jpg?sfvrsn=b363318a_7","FormatedDate":"4 August 2026","TrimmedTitle":"Infant and young child feeding"},{"Id":"69c2a5ab-e320-4ed7-b70c-c2d0baf8338b","LastModified":"2025-05-01T14:48:14Z","PublicationDate":"2018-06-02T02:27:24Z","DateCreated":"2018-06-02T02:27:23Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"female-genital-mutilation","ItemDefaultUrl":"/female-genital-mutilation","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts<br /></h2><ul><li>More than 230&nbsp;million girls and women alive\r\n        today have undergone female genital mutilation (FGM) in 30 countries in\r\n        Africa, the Middle East and Asia where FGM is practiced.</li><li>FGM is mostly carried out on young girls between infancy and age 15.</li><li>FGM is a violation of the human rights of girls and women.</li><li>Treatment of the health complications of FGM is\r\n        estimated to cost health systems US$&nbsp;1.4&nbsp;billion per year, a number\r\n        expected to rise unless urgent action is taken towards its abandonment.</li></ul><hr /><br /><h2>Overview</h2><p>Female genital mutilation (FGM) comprises all procedures that involve partial or total removal of the external female genitalia, or other injury to the female genital organs for non-medical reasons. The practice has no health benefits for girls and women and can result in severe bleeding and problems urinating, and later cysts, menstrual difficulties, infections, as well as complications in childbirth and increased risk of newborn deaths.</p><p>The practice of FGM is recognized internationally as a violation of the human rights of girls and women. It reflects deep-rooted inequality between the sexes and constitutes an extreme form of discrimination against girls and women. It is nearly always carried out on minors and is a violation of the rights of children. The practice also violates a person's right to health, security and physical integrity; the right to be free from torture and cruel, inhuman or degrading treatment; and the right to life, in instances when the procedure results in death. In several settings, there is evidence suggesting greater involvement of health workers in performing FGM due to the belief that the procedure is safer when medicalized. WHO strongly urges health workers not to perform FGM and has developed a global strategy and specific materials to support the health sector and health workers themselves to end FGM medicalization.\r\n</p><h2>Types of FGM </h2><p>Female genital mutilation is classified into 4 major types:</p><p><strong>Type 1:</strong>&nbsp;This is the partial or total removal of the clitoral glans (the external and visible part of the clitoris, which is a sensitive part of the female genitals), and/or the prepuce/clitoral hood (the fold of skin surrounding the clitoral glans).</p><p><strong>Type 2:</strong>&nbsp;This is the partial or total removal of the clitoral glans and the labia minora (the inner folds of the vulva), with or without removal of the labia majora (the outer folds of skin of the vulva).</p><p><strong>Type 3:</strong>&nbsp;Also known as&nbsp;infibulation, this is the narrowing of the vaginal opening through the creation of a covering seal. The seal is formed by cutting and repositioning the labia minora, or labia majora, sometimes through stitching, with or without removal of the clitoral prepuce/clitoral hood and glans.</p><p><strong>Type 4:</strong>&nbsp;This includes all other harmful procedures to the female genitalia for non-medical purposes, e.g., pricking, piercing, incising, scraping and cauterizing the genital area.</p><h2>No health benefits, only harm</h2><p>FGM has no health benefits, and it harms girls and women in many ways. It involves removing and damaging healthy and normal female genital tissue, and it interferes with the natural functions of girls' and women's bodies. Although all forms of FGM are associated with increased risk of health&nbsp;complications, the risk is greater with more severe forms of FGM.</p><p>Immediate complications of FGM can include:</p><ul><li>severe pain</li><li>excessive bleeding (haemorrhage)</li><li>genital tissue swelling</li><li>fever</li><li>infections e.g., tetanus</li><li>urinary problems</li><li>wound healing problems</li><li>injury to surrounding genital tissue</li><li>shock</li><li>death.</li></ul><p>Long-term complications can include:</p><ul><li>urinary problems (painful urination, urinary tract infections);</li><li>vaginal problems (discharge, itching, bacterial vaginosis and other infections);</li><li>menstrual problems (painful menstruations, difficulty in passing menstrual blood, etc.);</li><li>scar tissue and keloid;</li><li>sexual problems (pain during intercourse, decreased satisfaction, etc.);</li><li>increased risk of childbirth complications (difficult delivery, excessive bleeding, caesarean section, need to resuscitate the baby, etc.) and newborn deaths;</li><li>need for later surgeries: women with Type 3 might require deinfibulation (opening the infibulated scar to allow for sexual intercourse and childbirth. </li><li>psychological problems (depression, anxiety, post-traumatic stress disorder, low self-esteem, etc.).</li></ul><h2>Who is at risk?</h2><p>FGM is mostly carried out on young girls between infancy and adolescence, and occasionally on adult women. According to available data from 31 countries where FGM is practiced in the&nbsp;western, eastern, and north-eastern regions of Africa, and some countries in the Middle East and Asia, more than 230 million girls and women alive today have been subjected to the practice with more than 4 million girls estimated to be at risk of FGM annually. FGM is therefore of global concern.</p><h2>Cultural and social factors for performing FGM</h2><p>The reasons why FGM is performed vary from one region to another as well as over time and include a mix of sociocultural factors within families and communities.&nbsp;</p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">Where FGM is a social convention (social norm), the social pressure to conform to what others do and have been doing, as well as the need to be accepted socially and the fear of being rejected by the community, are strong motivations to perpetuate the practice. </li><li data-list=\"0\" data-level=\"1\">FGM is often considered a necessary part of raising a girl, and a way to prepare her for adulthood and marriage. This can include controlling her sexuality to promote premarital virginity and marital fidelity.</li><li data-list=\"0\" data-level=\"1\">Some people believe that the practice has religious support, although no religious scripts prescribe the practice. Religious leaders take varying positions with regard to FGM, with some contributing to its abandonment.</li></ul><h2>Reasons for medicalized FGM</h2><p>There are many reasons why health-care providers perform FGM. These include:</p><ul type=\"disc\"><li data-list=\"3\" data-level=\"1\">the belief that there is reduced risk of complications associated with medicalized FGM as compared to non-medicalized FGM;&nbsp;</li><li data-list=\"3\" data-level=\"1\">the belief that medicalization of FGM could be a first step towards full abandonment of the practice;</li><li data-list=\"3\" data-level=\"1\">health care providers who perform FGM are themselves members of FGM- practicing communities and are subject to the same social norms; and&nbsp;</li><li data-list=\"3\" data-level=\"1\">there may be a financial incentive to perform the practice.</li></ul><p>However, with WHO&rsquo;s support and training, many health care providers are becoming advocates for FGM abandonment within the clinical setting and with their families and communities. </p><h2>WHO response</h2><p>In 2008, the World Health Assembly passed resolution WHA61.16 on the elimination of FGM, emphasizing the need for concerted action in all sectors: health, education, finance, justice and women's affairs.</p><p>WHO supports a holistic health sector response to FGM prevention and care, by developing guidance and resources for health workers to prevent FGM and manage its complications and by supporting countries to adapt and implement these resources to local contexts. WHO also generates evidence to improve the understanding of FGM and what works to end this harmful practice. </p><p>Since then, WHO has developed a global strategy against FGM medicalization with partner organizations and continues to support countries in its implementation. <br /></p><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Female genital mutilation","DocumentNumberOfAdditionalItems":1,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Female genital mutilation","ConditionLongerOverview":"","Title":"Female genital mutilation","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs241","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"","FactSheetNumberOfAdditionalItems":1,"OpenGraphDescription":"Female genital mutilation (FGM) includes procedures that intentionally alter or cause injury to the female genital organs for non-medical reasons.","PublicationDateAndTime":"2025-01-31T14:44:00Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on female genital mutilation provides key facts and information on procedures, who is at risk, cultural and social causes, and WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<ul><li><a href=\"https://www.who.int/health-topics/female-genital-mutilation\">WHO's work on female genital mutilation</a></li><li><a target=\"_blank\" href=\"https://www.who.int/news-room/commentaries/detail/it-s-our-job-as-health-workers-to-do-no-harm\">Commentary: It's our job as health workers to \"do no harm\"</a></li><li><a href=\"https://www.who.int/publications/i/item/WHO-RHR-10.9\">Global strategy to stop health-care providers from performing female genital mutilation</a></li><li><a href=\"https://www.who.int/publications/i/item/9789241596442\">Eliminating female genital mutilation. An interagency statement</a></li><li><a href=\"https://www.who.int/publications/i/item/9789240107281\">WHO guideline on the prevention of female genital mutilation and clinical management of complications</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/reproductive-health/fgm/fgm-factsheet.tmb-768v.jpg?Culture=en&sfvrsn=5bed9115_5","FormatedDate":"31 January 2025","TrimmedTitle":"Female genital mutilation"},{"Id":"7be64b22-082b-4495-82f0-9d74ad7bd6fb","LastModified":"2026-01-22T16:02:06Z","PublicationDate":"2018-06-02T02:27:26Z","DateCreated":"2018-06-02T02:27:25Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"family-planning-contraception","ItemDefaultUrl":"/family-planning-contraception","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<p><p><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Key facts</span></p><ul><li>Among the 1.9 billion women of reproductive age (15&ndash;49 years) worldwide in 2021, 1.1 billion have a need for family planning; of these, 874 million are using modern contraceptive methods, and 164 million have an unmet need for contraception(1).</li><li>Access to contraception supports the fundamental human right to decide freely and responsibly the number and spacing of children. It also provides significant health benefits by preventing unintended pregnancies and reducing related health risks.</li><li>Many different contraceptive options are available to prevent unintended pregnancy, including both temporary (reversible) and permanent methods. </li><li>Only one contraceptive method, condoms, can prevent both pregnancy and the transmission of sexually transmitted infections, including HIV.</li></ul><hr /><h2><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Overview</span></h2><p>Family planning allows people to attain their desired number of children and determine the spacing of pregnancies. It is achieved through use of contraceptive methods and the treatment of infertility(2). Access to family planning supports people&rsquo;s right to make informed choices about their sexual and reproductive health. It plays a vital role in achieving broader development goals by promoting health, advancing gender equality, and supporting education and economic opportunity, contributions that align directly with SDG 3.7, which calls for universal access to sexual and reproductive health care, including family planning.</p><div><h2>Impact&nbsp;</h2><p>Family planning offers numerous benefits. By helping individuals avoid unintended pregnancies and plan births, it reduces pregnancy-related health risks, particularly for adolescent girls. Beyond health, family planning enables women to pursue education and employment opportunities, helping families and communities thrive. With 874 million women now using modern contraceptives, access to family planning supports public health, advances gender equality, strengthens health systems, and promotes economic development. An additional 70 million women are projected to gain access by 2030(3).</p><h2>Barriers</h2><p>Despite progress, many people still face challenges in accessing family planning services. These include limited availability of certain methods, particularly in low-resource or rural settings, and barriers related to age, income, or marital status. Fear of side effects, misinformation, and social or religious opposition may discourage use. In some cases, health services are of poor quality or providers may discourage certain methods due to bias. Gender inequality also plays a role, with some individuals needing their partner&rsquo;s consent or fearing stigma.&nbsp;</p><h2>Contraceptive methods</h2><p>There are many different contraceptive methods, each with their own advantages and effectiveness. All contraceptive methods included in the WHO guidelines have undergone rigorous testing for safety, efficacy, and effectiveness, and are considered safe for most individuals. </p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Some, like implants, intrauterine devices (IUDs), and sterilization, are highly effective and long-lasting. Others, such as pills, injections, patches, and vaginal rings, are used regularly and work well when taken correctly. Barrier methods like condoms are effective at preventing pregnancy, if used correctly. Condoms are the only method that also protects against sexually transmitted infections, including HIV. People may also use fertility awareness-based methods or withdrawal, which are less reliable.</span></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Choosing the right method depends on each individual&rsquo;s health, preferences, and needs. Health worker advice can help people identify appropriate contraceptive methods.</span></p><h2>Infertility</h2><p>Infertility, defined as the inability to conceive after 12 months of regular unprotected sex, affects around 1 in 6 adults during their lifetime. It can stem from many causes, including infections, medical conditions, or environmental and lifestyle factors. Both men and women can experience infertility, yet women often bear the larger burden of social blame. In some settings, this can lead to stigma or emotional distress. Treating infertility is part of a comprehensive approach to family planning. Importantly, modern contraceptive methods do not cause infertility. </p><h2>WHO response</h2><p>Achieving universal access and the realization of sexual and reproductive health services will be essential to fulfil the pledge of the 2030 Agenda for Sustainable Development that &ldquo;no one will be left behind&rdquo;. It requires intensified support for contraceptive services, including through the implementation of effective government policies and programmes.</p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">WHO is working to promote access and use of contraception by producing evidence-based guidelines on safety and service delivery and on ensuring human rights in contraceptive programmes. WHO assists countries to adapt and implement these tools. Additionally, WHO participates in developing new contraceptive technologies. &nbsp;We lead and carry out research to improve how people access and receive contraceptive information and services</span></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">&nbsp;</span></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">(1)&nbsp;</span><a href=\"https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2023/Feb/undesa_pd_2022_world-family-planning.pdf\">United Nations Department of Economic and Social Affairs, Population Division (2022). World Family Planning 2022: Meeting the changing needs for family planning: Contraceptive use by age and method. UN DESA/POP/2022/TR/NO. 4</a> </p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">(2) <a href=\"https://unterm.un.org/unterm2/en/view/156980fd-acd7-4009-8eb6-59dfd083dc44\">UNTERM - Family planning</a></span></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">(3)&nbsp;</span>United Nations Department\r\n        of Economic and Social Affairs, Population Division (2020). World Family\r\n        Planning 2020 Highlights: Accelerating action to ensure universal access to\r\n        family planning (ST/ESA/SER.A/450)</p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">&nbsp;</span></p></div><p>&nbsp;</p></p>","ConditionName":"","OpenGraphTitle":"Family planning/contraception methods","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Family planning/contraception methods","ConditionLongerOverview":"","Title":"Family planning/contraception methods","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs351","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"Fact sheet on family planning providing key facts and information on benefits of family planning, who provides family planning, contraceptive use, unmet need, contraceptive methods and WHO response.","PublicationDateAndTime":"2025-07-03T13:59:59Z","ConditionBriefOverview":"","MetaDescription":"Fact sheet on family planning providing key facts and information on benefits of family planning, who provides family planning, contraceptive use, unmet need, contraceptive methods and WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<ul><li><a href=\"https://www.who.int/health-topics/contraception\">Contraception</a></li><li><a href=\"https://cdn.who.int/media/docs/default-source/reproductive-health/contraception-family-planning/mechanisms-of-action-and-effectiveness-of-contraception-methods.pdf?sfvrsn=e39a69c2_1\">Mechanism of action and effectiveness of different contraceptive methods</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/reproductive-health/family-planning/fp-nigeria.tmb-768v.jpg?Culture=en&sfvrsn=bf5028d4_5","FormatedDate":"3 July 2025","TrimmedTitle":"Family planning/contraception methods"},{"Id":"8f90617c-0b9c-434c-b32b-77203d7d215f","LastModified":"2023-10-03T10:53:22Z","PublicationDate":"2018-06-02T02:27:28Z","DateCreated":"2018-06-02T02:27:27Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"botulism","ItemDefaultUrl":"/botulism","NewsNumberOfAdditionalItems":0,"MedicalTreatmentBriefSummary":"","Content":"<h2><span>Overview</span></h2><p><span>Foodborne botulism is a serious, potentially fatal disease. However, it is relatively rare. It is an intoxication usually caused by ingestion of potent neurotoxins, the botulinum toxins, formed in contaminated foods. Person to person transmission of botulism does not occur.</span></p><p><span>Spores produced by the bacteria <em>Clostridium botulinum</em> are heat-resistant and exist widely in the environment, and in the absence of oxygen they germinate, grow and then excrete toxins. There are 7 distinct forms of botulinum toxin, types A&ndash;G. Four of these (types A, B, E and rarely F) cause human botulism. Types C, D and E cause illness in other mammals, birds and fish.</span></p><p><span>Botulinum toxins are ingested through improperly processed food in which the bacteria or the spores survive, then grow and produce the toxins. Though mainly a foodborne intoxication, human botulism can also be caused by intestinal infection with <em>C. botulinum</em> in infants, wound infections, and by inhalation.</span></p><h2 class=\"section_head1\">Symptoms of foodborne botulism</h2><p><span>Botulinum toxins are neurotoxic and therefore affect the nervous system. Foodborne botulism is characterized by descending, flaccid paralysis that can cause respiratory failure. Early symptoms include marked fatigue, weakness and vertigo, usually followed by blurred vision, dry mouth and difficulty in swallowing and speaking. Vomiting, diarrhoea, constipation and abdominal swelling may also occur. The disease can progress to weakness in the neck and arms, after which the respiratory muscles and muscles of the lower body are affected. There is no fever and no loss of consciousness.</span></p><p><span>The symptoms are not caused by the bacterium itself, but by the toxin produced by the bacterium. Symptoms usually appear within 12 to 36 hours (within a minimum and maximum range of 4 hours to 8 days) after exposure. Incidence of botulism is low, but the mortality rate is high if prompt diagnosis and appropriate, immediate treatment (early administration of antitoxin and intensive respiratory care) are not given. The disease can be fatal in 5 to 10% of cases.</span></p><h2 class=\"section_head1\">Exposure and transmission</h2><h3 class=\"section_head3\">Foodborne botulism</h3><p><span><em>C. botulinum</em> is an anaerobic bacterium, meaning it can only grow in the absence of oxygen. Foodborne botulism occurs when <em>C. botulinum</em> grows and produces toxins in food prior to consumption. <em>C. botulinum</em> produces spores and they exist widely in the environment including soil, river and sea water.</span></p><p><span>The growth of the bacteria and the formation of toxin occur in products with low oxygen content and certain combinations of storage temperature and preservative parameters. This happens most often in lightly preserved foods and in inadequately processed, home-canned or home-bottled foods.</span></p><p><span><em>C. botulinum</em> will not grow in acidic conditions (pH less than 4.6), and therefore the toxin will not be formed in acidic foods (however, a low pH will not degrade any pre-formed toxin). Combinations of low storage temperature and salt contents and/or pH are also used to prevent the growth of the bacteria or the formation of the toxin.</span></p><p><span>The botulinum toxin has been found in a variety of foods, including low-acid preserved vegetables, such as green beans, spinach, mushrooms, and beets; fish, including canned tuna, fermented, salted and smoked fish; and meat products, such as ham and sausage. The food implicated differs between countries and reflects local eating habits and food preservation procedures. Occasionally, commercially prepared foods are involved.</span></p><p><span>Though spores of <em>C. botulinum</em> are heat-resistant, the toxin produced by bacteria growing out of the spores under anaerobic conditions is destroyed by boiling (for example, at internal temperature greater than 85 &deg;C for 5 minutes or longer). Therefore, ready-to-eat foods in low oxygen-packaging are more frequently involved in cases of foodborne botulism.</span></p><p><span>Food samples associated with suspect cases must be obtained immediately, stored in properly sealed containers, and sent to laboratories in order to identify the cause and to prevent further cases.</span></p><h3 class=\"section_head3\">Infant botulism</h3><p><span>Infant botulism occurs mostly in infants under 6 months of age. Different from foodborne botulism caused by ingestion of pre-formed toxins in food, it occurs when infants ingest <em>C. botulinum</em> spores, which germinate into bacteria that colonize in the gut and release toxins. In most adults and children older than about 6 months, this would not happen because natural defences in intestines that develop over time prevent germination and growth of the bacterium.</span></p><p><span><em>C. botulinum</em> in infants include constipation, loss of appetite, weakness, an altered cry and a striking loss of head control. Although there are several possible sources of infection for infant botulism, spore-contaminated honey has been associated with a number of cases. Parents and caregivers are therefore warned not to feed honey to the infants before the age of 1 year.</span></p><h3 class=\"section_head3\">Wound botulism</h3><p><span>Wound botulism is rare and occurs when the spores get into an open wound and are able to reproduce in an anaerobic environment. The symptoms are similar to the foodborne botulism, but may take up to 2 weeks to appear. This form of the disease has been associated with substance abuse, particularly when injecting black tar heroin.</span></p><h3 class=\"section_head3\">Inhalation botulism</h3><p><span>Inhalation botulism is rare and does not occur naturally, for example it is associated with accidental or intentional events (such as bioterrorism) which result in release of the toxins in aerosols. Inhalation botulism exhibits a similar clinical footprint to foodborne botulism. The median lethal dose for humans has been estimated at 2 nanograms of botulinum toxin per kilogram of bodyweight, which is approximately 3 times greater than in foodborne cases.</span></p><p><span>Following inhalation of the toxin, symptoms become visible between 1&ndash;3 days, with longer onset times for lower levels of intoxication. Symptoms proceed in a similar manner to ingestion of botulinum toxin and culminate in muscular paralysis and respiratory failure.</span></p><p><span>If exposure to the toxin via aerosol inhalation is suspected, additional exposure to the patient and others must be prevented. The patient's clothing must be removed and stored in plastic bags until it can be washed thoroughly with soap and water. The patient should shower and be decontaminated immediately.</span></p><h3 class=\"section_head3\">Other types of intoxication</h3><p><span>Waterborne botulism could theoretically result from the ingestion of the pre-formed toxin. However, as common water treatment processes (such as boiling, disinfection with 0.1% hypochlorite bleach solution) destroy the toxin, the risk is considered low.</span></p><p><span>Botulism of undetermined origin usually involves adult cases where no food or wound source can be identified. These cases are comparable to infant botulism and may occur when the normal gut flora has been altered as a result of surgical procedures or antibiotic therapy.</span></p><p><span>Adverse effects of the pure toxin have been reported as a result of its medical and/or cosmetic use in patients, see more on 'Botox' below.</span></p><h2 class=\"section_head1\">Botox</h2><p><span>The bacterium <em>C. botulinum</em> is the same bacterium that is used to produce Botox, a pharmaceutical product predominantly injected for clinical and cosmetic use. Botox treatments employ the purified and heavily diluted botulinum neurotoxin type A. Treatment is administered in the medical setting, tailored according to the needs of the patient and is usually well tolerated although occasional side effects are observed.</span></p><h2 class=\"section_head1\">Diagnosis and treatment</h2><p><span>Diagnosis is usually based on clinical history and clinical examination followed by laboratory confirmation including demonstrating the presence of botulinum toxin in serum, stool or food, or a culture of <em>C. botulinum</em> from stool, wound or food. Misdiagnosis of botulism sometimes occurs as it is often confused with stroke, Guillain-Barr&eacute; syndrome, or myasthenia gravis.</span></p><p><span>Antitoxin should be administered as soon as possible after a clinical diagnosis. Early administration is effective in reducing mortality rates. Severe botulism cases require supportive treatment, especially mechanical ventilation, which may be required for weeks or even months. Antibiotics are not required (except in the case of wound botulism). A vaccine against botulism exists but it is rarely used as its effectiveness has not been fully evaluated and it has demonstrated negative side effects.</span></p><h2 class=\"section_head1\">Prevention</h2><p><span>Prevention of foodborne botulism is based on good practice in food preparation particularly during heating/sterilization and hygiene. Foodborne botulism may be prevented by the inactivation of the bacterium and its spores in heat-sterilized (for example, retorted) or canned products or by inhibiting bacterial growth and toxin production in other products. The vegetative forms of bacteria can be destroyed by boiling but the spores can remain viable after boiling even for several hours. However, the spores can be killed by very high temperature treatments such as commercial canning.</span></p><p><span>Commercial heat pasteurization (including vacuum packed pasteurized products and hot smoked products) may not be sufficient to kill all spores and therefore the safety of these products must be based on preventing bacterial growth and toxin production. Refrigeration temperatures combined with salt content and/or acidic conditions will prevent the growth of the bacteria and formation of toxin.</span></p><p><span>The WHO <em>Five Keys to Safer Food</em> serve as the basis for educational programmes to train food handlers and educate the consumers. They are especially important in preventing food poisoning.</span></p><p><span>The <em>Five Keys</em> are:</span></p><ul><li>keep clean</li><li>separate raw and cooked </li><li>cook thoroughly </li><li>keep food at safe temperatures </li><li>use safe water and raw materials. </li></ul><h2 class=\"section_head1\">WHO's response</h2><p><span>Botulism outbreaks are rare but are public health emergencies that require rapid recognition to identify the disease source, distinguish outbreak types (between natural, accidental or potentially deliberate), prevent additional cases and effectively administer treatment to affected patients.</span></p><p><span>Successful treatment depends significantly on early diagnosis and the rapid administration of the botulinum antitoxin.</span></p><p><span>WHO's role in responding to outbreaks of botulism that may be of international concern is as follows.</span></p><p><span>Surveillance and detection: WHO supports the strengthening of national surveillance and international alert systems to ensure rapid local outbreak detection and an efficient international response. WHO&rsquo;s main tool for these activities of surveillance, coordination and response is the use of the International Network of Food Safety Authorities (INFOSAN) which links national authorities in Member States in charge of managing food safety events. This network is managed jointly by FAO and WHO.</span></p><p><span>Risk assessment: WHO response is based on a risk assessment methodology that includes consideration of whether the outbreak is natural, accidental, or, possibly, intentional. WHO also provides scientific assessments as basis for international food safety standards, guidelines and recommendations developed by the Codex Alimentarius Commission.</span></p><p><span>Containment at the disease source: WHO coordinates with national and local authorities in order to contain outbreaks at their source.</span></p><p><span>Delivery of assistance: WHO coordinates between international agencies, experts, national laboratories, airlines and commercial organizations to mobilize response equipment, materials and supplies, including the provision and administration of botulinum antitoxin.</span></p><div>&nbsp;</div>","ConditionName":"","OpenGraphTitle":"Botulism","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Botulism","ConditionLongerOverview":"","Title":"Botulism","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs270","PhotoStoryNumberOfAdditionalItems":0,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"WHO fact sheet on botulism: includes key facts, definition, symptoms, exposure, transmission, treatment, prevention, WHO response.","PublicationDateAndTime":"2023-09-25T17:58:49Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on botulism: includes key facts, definition, symptoms, exposure, transmission, treatment, prevention, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"","Highlight":"<ul><li><a target=\"_blank\" href=\"https://www.who.int/health-topics/food-safety\">More on food safety</a></li><li><a target=\"_blank\" href=\"https://www.who.int/publications/i/item/9789241594639\">WHO Five Keys to Safer Food</a></li><li><a target=\"_blank\" href=\"https://www.who.int/groups/international-food-safety-authorities-network-infosan\">Responding to food safety emergencies (INFOSAN)</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/food-safety/preserved-food.tmb-768v.jpg?Culture=en&sfvrsn=fab6deb7_6","FormatedDate":"25 September 2023","TrimmedTitle":"Botulism"},{"Id":"1e222e68-69d6-402d-b4dd-1791d01774d6","LastModified":"2026-05-20T05:14:25Z","PublicationDate":"2026-05-04T13:43:36Z","DateCreated":"2026-05-04T13:43:36Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"hantavirus","ItemDefaultUrl":"/hantavirus","NewsNumberOfAdditionalItems":4,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Hantaviruses are a group of viruses carried by rodents that can cause severe disease in humans.</li><li>People usually get infected through contact with infected rodents or their urine, droppings or saliva.</li><li>Infection with hantaviruses can cause a range of illnesses, including severe disease and death.</li><li>In the Americas, hantaviruses can cause hantavirus cardiopulmonary syndrome (HCPS), a severe respiratory illness, with a case fatality rate up to 50%.</li><li><em>Andes</em> virus, found in South America, is a currently known hantavirus for which limited human\u2011to\u2011human transmission among contacts has been documented.</li><li>In Europe and Asia, hantaviruses cause haemorrhagic fever with renal syndrome (HFRS).<br />&nbsp;</li></ul><hr /><p><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Overview</span></p><p>Hantaviruses are zoonotic viruses that naturally infect rodents and are occasionally transmitted to humans. Infection in people can result in severe illness and often death, although the diseases vary by type of virus and geographical location. In the Americas, infection has been known to lead to hantavirus cardiopulmonary syndrome (HCPS), a rapidly progressive condition affecting the lungs and heart, while in Europe and Asia hantaviruses have been known to cause haemorrhagic fever with renal syndrome (HFRS), which primarily affects the kidneys and blood vessels.</p><p>While there is no specific treatment that cures hantavirus diseases, early supportive medical care is key to improve survival and focuses on close clinical monitoring and management of respiratory, cardiac and kidney complications. Prevention depends largely on reducing contacts between people and infected rodents.</p><h2>Viral family and classification</h2><p>Hantaviruses belong to the family <em>Hantaviridae</em>, within the order <em>Bunyavirales</em>. Each hantavirus is typically associated with a specific rodent reservoir species, in which the virus causes long\u2011term infection without apparent illness.</p><p>Although many hantavirus species have been identified worldwide, only a limited number are known to cause human disease.</p><ul><li>Hantaviruses present in North, Central and South America are known to cause HCPS. The <em>Andes</em> virus is part of this family and is known to cause limited human-to-human transmission among close and prolonged contacts, primarily in Argentina and Chile.</li><li>Hantaviruses found in Europe and Asia are known to cause haemorrhagic fever with HFRS. Human-to-human transmission has not been documented in this part of the world.</li></ul><h2>Burden of disease</h2><p>Hantavirus infections are relatively uncommon globally but are associated with a case fatality rate of &lt;1&ndash;15% in Asia and Europe and up to 50% in the Americas. Worldwide, it is estimated that from 10&nbsp;000 to over 100&nbsp;000 infections occur each year <em>(1, 2, 3)</em>, with the largest burden in Asia and Europe.</p><ul><li>In East Asia, particularly China and the Republic of Korea, HFRS continues to account for many thousands of cases annually, although incidence has declined in recent decades.</li></ul><ul><li>In Europe, several thousand cases are reported each year, mainly from northern and central regions where <em>Puumala</em> virus circulates. In the Americas, HCPS is much rarer, with hundreds of cases reported each year across the continent. The United States of America has reported fewer than 1000 cases, while South American countries such as Argentina, Brazil Chile, and Paraguay report small numbers of cases annually. Despite the lower incidence, HCPS has a high case fatality rate, commonly between 20% and 40%, making it a disease of major public health concern.</li></ul><h2>Transmission</h2><p>Transmission of hantaviruses to humans occurs from contact with contaminated urine, droppings or saliva of infected rodents. Infection may also occur, although less commonly, through rodent bites. Activities that involve contact with rodents such as cleaning enclosed or poorly ventilated spaces, farming, forestry work and sleeping in rodent-infested dwellings increase exposure risk.</p><p>To date, human-to-human transmission has been documented only for <em>Andes</em> virus in the Americas and remains uncommon. When it occurs, transmission between people has been associated with close and prolonged contact, particularly among household members or intimate partners, and appears most likely during the early phase of illness, when the virus is more transmissible.</p><h2>Symptoms and clinical presentation</h2><p>In humans, symptoms usually begin between one and eight weeks after exposure, depending on the type of virus, and typically include fever, headache, muscle aches and gastrointestinal symptoms such as abdominal pain, nausea or vomiting. </p><ul><li>In HCPS, the disease may progress rapidly to cough, shortness of breath, accumulation of fluid in the lungs and shock. </li><li>In HFRS, later stages may include low blood pressure, bleeding disorders and kidney failure.</li></ul><h2>Diagnosis</h2><p>Early diagnosis of hantavirus infection can be challenging because early symptoms are common with other febrile or respiratory illnesses, such as influenza, COVID-19, viral pneumonia, leptospirosis, dengue or sepsis. A careful patient history is therefore essential, with particular attention to possible rodent exposure, occupational and environmental risks, travel history, and contact with known cases in areas where hantaviruses are present.</p><p>Laboratory confirmation relies on serological testing to detect hantavirus-specific IgM antibodies or rising IgG titres, as well as molecular methods such as reverse transcription polymerase chain reaction (RT-PCR) during the acute phase of illness, when viral RNA may be detectable in blood.</p><p>Samples collected from patients are a biohazard risk; laboratory testing on non-inactivated samples should be conducted under maximum biological containment conditions. All non-inactivated biological specimens should be packaged using the triple packaging system when transported nationally and internationally.</p><h2>Treatment</h2><p>There is no licenced specific antiviral treatment or vaccine for hantavirus infection. Care is supportive and focuses on close clinical monitoring and management of respiratory, cardiac and kidney complications. Early access to intensive care, when clinically indicated, improves outcomes, particularly for patients with hantavirus cardiopulmonary syndrome.</p><h2>Prevention and control</h2><p>Preventing hantavirus infection depends primarily on reducing contacts between people and rodents. Effective measures include:</p><ul><li>keeping homes and workplaces clean</li><li>sealing openings that allow rodents to enter buildings</li><li>storing food securely</li><li>using safe cleaning practices in areas contaminated by rodents</li><li>avoiding dry sweeping or vacuuming rodent droppings</li><li>dampening of contaminated areas before cleaning</li><li>strengthening hand hygiene practices.</li></ul><p>During outbreaks or when cases are suspected, early identification and isolation of cases, monitoring of close contacts, and application of standard infection prevention measures are important to limit further spread.</p><h2>Infection prevention and control in health-care settings</h2><p>Available evidence indicates that the risk of health-care associated transmission of hantavirus, including <em>Andes</em> virus, is very low when appropriate infection prevention and control measures are applied. In health-care environments, standard precautions should be applied for all patients, including hand hygiene, environmental cleaning and safe handling of blood and body fluids.</p><p>For suspected or confirmed hantavirus infection, use of standard precautions combined with transmission-based precautions during provision of care is advised. For aerosol-generating procedures, airborne precautions should be used. Early recognition of suspected cases, prompt isolation, and consistent adherence to recommended infection prevention and control measures remain essential to protect health-care personnel.</p><h2>WHO response</h2><p>WHO works with countries and partners to strengthen surveillance, laboratory capacity, risk communication and community engagement, early detection, patient care and outbreak response for hantavirus infections. This includes developing and updating evidence-based guidance on diagnosis, case management, infection prevention and control, and contact tracing. </p><p>WHO promotes integrated One Health approaches that address the links between human health, rodent reservoirs and the environment, and supports countries in reviewing emerging evidence to ensure recommendations remain up to date.</p><p>&nbsp;</p><p><strong>References</strong></p><p><em>1)</em> Jonsson, C. B., Figueiredo, L. T. M., Vapalahti, O. (2010). <em><a href=\"https://journals.asm.org/doi/10.1128/cmr.00062-09\" target=\"_blank\">A global perspective on hantavirus ecology, epidemiology, and disease</a>. </em>Clinical Microbiology Reviews, 23(2), 412 441.</p><p><em>2)</em> Li, et al. 2024. <em><a href=\"https://link.springer.com/article/10.1186/s12889-024-20014-w\" target=\"_blank\">Seroprevalence of hantavirus infection in non-epidemic settings over four decades: a systematic review and meta-analysis</a>.&nbsp;</em>BMC Public Health.</p><p><em>3)</em> Tian, H., Stenseth, N.C., 2019. <em><a href=\"https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006901\" target=\"_blank\">The ecological dynamics of hantavirus diseases</a>. </em>PLoS Neglected Tropical Diseases.</p><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Hantavirus","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Hantavirus","ConditionLongerOverview":"","Title":"Hantavirus","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on hantaviruses provides key facts and information on transmission, symptoms, diagnosis, treatment, prevention and control, and public health response.","PublicationDateAndTime":"2026-05-06T12:36:40Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on hantaviruses provides key facts and information on transmission, symptoms, diagnosis, treatment, prevention and control, and public health response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<p><p><strong>Video: hantavirus explainer</strong></p><iframe width=\"560\" height=\"315\" src=\"https://www.youtube.com/embed/bAtNUrRrj8M?si=m_zP61iyrBQJT3RJ\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\"></iframe><br />&nbsp;\r\n<div class=\"arrowed-link\"><a href=\"https://www.who.int/emergencies/outbreak-toolkit/disease-outbreak-toolboxes/hantavirus-outbreak-toolbox\">Hantavirus outbreak toolbox</a></div><h3>Hantavirus cluster linked to cruise ship</h3><p><a href=\"https://www.who.int/emergencies/emergency-events/item/2026-e000227\">Disease Outbreak News on hantavirus cluster linked to cruise ship travel, multi-country</a></p><p><a href=\"https://www.who.int/publications/m/item/who-technical-note-for-the-disembarkation-and-onward-management-of-passengers-and-crew-in-the-context-of-an-andes-virus-associated-cluster-mv-hondius-cruise-ship\">WHO Technical note for the disembarkation and onward management of passengers and crew in the context of an Andes virus-associated cluster MV Hondius cruise ship</a></p><p><a href=\"https://www.who.int/publications/m/item/management-of-contacts-of-andes-virus-(andv)-cases-fromthe-mv-hondius-cruise-ship\">Management of contacts of Andes virus (ANDV) cases from the MV Hondius cruise ship</a></p><p><a href=\"https://www.who.int/emergencies/alert-and-response\">Alert and response</a></p><h3>More information on hantavirus </h3><p><a href=\"https://www.who.int/health-topics/hantavirus\">WHO's work on hantavirus&nbsp;</a></p><h3></h3></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/headquarters/teams/who-health-emergencies-programme-(whe)/country-health-emergency-preparedness-ihr-(cpi)/deer-mouse.tmb-768v.jpg?sfvrsn=b169d756_6","FormatedDate":"6 May 2026","TrimmedTitle":"Hantavirus"},{"Id":"65015334-a17c-4409-a1a1-faa567efdde6","LastModified":"2023-03-10T12:30:14Z","PublicationDate":"2018-06-02T02:27:29Z","DateCreated":"2018-06-02T02:27:29Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"natural-toxins-in-food","ItemDefaultUrl":"/natural-toxins-in-food","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":null,"Content":"<h2><strong>What are natural toxins?</strong></h2><p>Natural toxins are toxic compounds that are naturally produced by living organisms. These toxins are not harmful to the organisms themselves but they may be toxic to other creatures, including humans, when eaten. These chemical compounds have diverse\r\n    structures and differ in biological function and toxicity.</p><p>Some toxins are produced by plants as a natural defense mechanism against predators, insects or microorganisms, or as consequence of infestation with microorganisms, such as mould, in response to climate stress (such as drought or extreme humidity).</p><p>Other sources of natural toxins are microscopic algae and plankton in oceans or sometimes in lakes that produce chemical compounds that are toxic to humans but not to fish or shellfish that eat these toxin-producing organisms. When people eat fish or\r\n    shellfish that contain these toxins, illness can rapidly follow.&nbsp;</p><p>Some of the most commonly found natural toxins that can pose a risk to our health are described below.&nbsp;&nbsp;</p><h2><strong>Aquatic biotoxins</strong></h2><p>Toxins formed by algae in the ocean and fresh water are called algal toxins. Algal toxins are generated during blooms of particular naturally occurring algal species. Shellfish such as mussels, scallops and oysters are more likely to contain these toxins\r\n    than fish. Algal toxins can cause diarrhea, vomiting, tingling, paralysis and other effects in humans, other mammals or fish. The algal toxins can be retained in shellfish and fish or contaminate drinking water. They have no taste or smell, and are\r\n    not eliminated by cooking or freezing. </p><p>Another example is ciguatera fish poisoning (CFP) which is caused by consuming fish contaminated with&nbsp;dinoflagellates<strong> </strong>that produce ciguatoxins. Some fish known to harbour ciguatoxins include&nbsp;barracuda, black grouper,&nbsp;dog\r\n    snapper,&nbsp;and king mackerel. Symptoms of ciguatera poisoning include nausea, vomiting, and neurologic symptoms, such as tingling sensation on fingers and toes.&nbsp;There is currently no specific treatment for ciguatera poisoning.</p><h2><strong>Cyanogenic glycosides</strong></h2><p>Cyanogenic glycosides are phytotoxins (toxic chemicals produced by plants) which occur in at least 2000 plant species, of which a number of species are used as food in some areas of the world. Cassava, sorghum, stone fruits, bamboo roots and almonds are\r\n    especially important foods containing cyanogenic glycosides. The potential toxicity of a cyanogenic plant depends primarily on the potential that its consumption will produce a concentration of cyanide that is toxic to exposed humans. &nbsp;In humans,\r\n    the clinical signs of acute cyanide intoxication can include: rapid respiration, drop in blood pressure, dizziness, headache, stomach pains, vomiting, diarrhoea, mental confusion, cyanosis with twitching and convulsions followed by terminal coma.\r\n    Death due to cyanide poisoning can occur when the cyanide level exceeds the limit an individual is able to detoxify. </p><h2><strong>Furocoumarins</strong></h2><p>These toxins are present in many plants such as&nbsp;parsnips (closely related to carrots and parsley), celery roots, citrus plants (lemon, lime, grapefruit, bergamot) and some medicinal plants. Furocoumarins are stress toxins and are released in response\r\n    to stress, such as physical damage to the plant. Some of these toxins can cause gastrointestinal&nbsp;problems in susceptible people. Furocoumarins are phototoxic, they can cause severe skin reactions under sunlight (UVA exposure). While mainly occurring\r\n    after dermal exposure, such reactions have also been reported after consumption of large quantities of certain vegetables containing high levels of furocoumarins.&nbsp;</p><h2><strong>Lectins </strong></h2><p>Many types of beans contain toxins called lectins, and kidney beans have the highest concentrations &ndash; especially red kidney beans. As few as 4 or 5 raw beans can cause severe stomachache, vomiting and diarrhoea. Lectins are destroyed when the dried\r\n    beans are soaked for at least 12 hours and then boiled vigorously for at least 10 minutes in water. Tinned kidney beans have already had this process applied and so can be used without further treatment.</p><h2><strong>Mycotoxins</strong></h2><p>Mycotoxins are naturally occurring toxic compounds produced by certain types of moulds. Moulds that can produce mycotoxins grow on numerous foodstuffs such as cereals, dried fruits, nuts and spices. Mould growth can occur before harvest or after harvest,\r\n    during storage, on/in the food itself often under warm, damp and humid conditions.</p><p>Most mycotoxins are chemically stable and survive food processing. The effects of food-borne mycotoxins can be acute with symptoms of severe illness and even death appearing quickly after consumption of highly contaminated food products. Long term effects\r\n    on health of chronic mycotoxin exposure include the induction of cancers and immune deficiency.<a style=\"font-size:13px;\" href=\"https://www.who.int/news-room/fact-sheets/detail/mycotoxins\"></a></p><ul><li><a href=\"https://www.who.int/news-room/fact-sheets/detail/mycotoxins\" target=\"_blank\">Fact sheet on Mycotoxins</a>\r\n </li></ul><h2>Solanines and chaconine</h2><p>All solanacea plants, which include tomatoes, potatoes, and eggplants, contain natural toxins called solanines and chaconine (which are glycoalkaloids). While levels are generally low, higher concentrations are found in potato sprouts and bitter-tasting\r\n    peel and green parts, as well as in green tomatoes. The plants produce the toxins in response to stresses like bruising, UV light, microorganisms and attacks from insect pests and herbivores. To reduce the production of solanines and chaconine it\r\n    is important to store potatoes in a dark, cool and dry place, and not to eat green or sprouting parts.</p><h2>Poisonous mushrooms</h2><p>Wild mushrooms may contain several toxins, such as muscimol and muscarine, which can cause vomiting, diarrhoea, confusion, visual disturbances, salivation, and hallucinations. Onset of symptoms occurs 6&ndash;24 hours or more after ingestion of mushrooms.\r\n    Fatal poisoning is usually associated with delayed onset of symptoms which are very severe, with toxic effect on the liver, kidney and nervous systems. Cooking or peeling does not inactivate the toxins. It is recommended to avoid any wild mushrooms,\r\n    unless definitively identified as non-poisonous.</p><h2><strong>Pyrrolizidine alkaloids </strong></h2><p>Pyrrolizidine Alkaloids (PAs) are toxins produced by an estimated 600 plant species. The main plant sources are the families <em>Boraginaceae</em>, <em>Asteraceae</em> and <em>Fabaceae</em>. Many of these are weeds that can grow in fields and contaminate\r\n    food crops. &nbsp;PAs can cause a variety of adverse health effects; they can be acutely toxic and of main concern is the DNA-damaging potential of certain PAs, potentially leading to cancer.</p><p>PAs are stable during processing, and have been detected in herbal teas, honey, herbs and spices and other food products, such as cereals and cereal products. &nbsp;Human exposure is estimated to be low, however. Due to the complexity of the subject and\r\n    the large number of related compounds, the overall health risk has not been fully evaluated yet. Guidance is under development by the FAO/WHO Codex Committee on Contaminants in Food on management strategies to prevent PA-containing plants from entering\r\n    the food chain.</p><h2><strong>How can I minimize the health risk from natural toxins?</strong></h2><p>When it comes to natural toxins it is important to note that they can be present in a variety of different crops and foodstuff.&nbsp; In a usual balanced, healthy diet, the levels of natural toxins are well below the threshold for acute and chronic toxicity.</p><p>To minimize the health risk from natural toxins in food, people are advised to: </p><ul><li>not assume that if something is 'natural' it is automatically safe;</li><li>throw away bruised, damaged or discoloured food, and in particular mouldy foods;</li><li>throw away any food that does not smell or taste fresh, or has an unusual taste; and</li><li>only eat mushrooms or other wild plants that have definitively been identified as nonpoisonous.</li></ul><h2><strong>WHO response</strong></h2><p>WHO, in collaboration with FAO, is responsible for assessing the risks to humans of natural toxins &ndash; through contamination in food &ndash; and for recommending adequate protections. </p><p>Risk assessments of natural toxins in food done by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) are used by governments and by the Codex Alimentarius Commission (the intergovernmental standards-setting body for food) to establish maximum\r\n    levels in food or provide other risk management advice to control or prevent contamination. Codex standards are the international reference for national food supplies and for trade in food, so that people everywhere can be confident that the food\r\n    they buy meets the agreed standards for safety and quality, no matter where it was produced. </p><h3>JECFA sets the tolerable intake level for natural toxins</h3><p>JECFA or ad hoc FAO/WHO scientific expert groups consist of independent, international experts who conduct scientific reviews of all available studies&nbsp;and other relevant data on specific natural toxins. The outcome of such health risk assessments\r\n    can either be a maximum tolerable intake (exposure) level, or other guidance to indicate the level of health concern (such as the Margin of Exposure), including advice on risk management measures to prevent and control contamination, and on the analytical\r\n    methods and monitoring and control activities.</p>Exposure to natural toxins needs to be kept as low as possible to protect people. Natural toxins not only pose a risk to both human and animal health, but also impact food security and nutrition by\r\nreducing people&rsquo;s access to healthy food. WHO encourages national authorities to monitor and ensure that levels of the most relevant natural toxins in their food supply are as low as possible and comply with both national and international maximum\r\nlevels, conditions and legislation.","ConditionName":null,"OpenGraphTitle":"","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":null,"SelfCareLongerSummary":null,"EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":null,"MetaTitle":"","ConditionLongerOverview":null,"Title":"Natural toxins in food","PreventionLongerSummary":null,"SourceKey":null,"PhotoStoryNumberOfAdditionalItems":0,"SelfCareBriefSummary":null,"FactFileNumberOfAdditionalItems":0,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"","PublicationDateAndTime":"2023-03-10T12:30:06Z","ConditionBriefOverview":null,"MetaDescription":"","MedicalTreatmentLongerSummary":null,"CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":null,"Highlight":"<ul><li><a href=\"https://www.who.int/activities/assessing-chemical-risks-in-food\" target=\"_blank\">Assessing chemical risks in food</a></li><li><a href=\"https://apps.who.int/foscollab?op=vs_html&amp;path=/WHO_HQ_Reports/G7/PROD/EXT/chemical_overview&amp;userid=G7_ro&amp;password=inetsoft123\" target=\"_blank\">WHO Food safety collaborative platform (FOSCOLLAB)</a> </li><li><a href=\"http://www.fao.org/fileadmin/user_upload/livestockgov/documents/1_CXS_193e.pdf\" target=\"_blank\">Codex general standard for contaminants and toxins in food and feed </a></li><li><a href=\"http://www.fao.org/fao-who-codexalimentarius/committees/committee/en/?committee=CCCF\" target=\"_blank\">Codex Committee on Contaminants in Foods (CCCF)</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/maldives-vegetables-market-healthy.tmb-768v.jpg?sfvrsn=97257d1f_25","FormatedDate":"10 March 2023","TrimmedTitle":"Natural toxins in food"},{"Id":"0c3e4f7e-b8d5-463f-a711-9298917aad4c","LastModified":"2026-06-18T16:29:04Z","PublicationDate":"2025-08-06T16:49:23Z","DateCreated":"2025-08-06T16:49:23Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"sickle-cell-disease","ItemDefaultUrl":"/sickle-cell-disease","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Sickle-cell disease is a serious inherited blood disorder caused by a mutation in the HBB gene, leading to abnormal, sickle-shaped red blood cells that block blood flow and cause severe health complications.</li><li>In 2021, an estimated 7.74 million people were living with sickle-cell disease globally, with 515 000 new births, primarily in sub-Saharan Africa, which accounts for nearly 80% of global cases.</li><li>Sickle-cell disease causes substantial under-5 mortality: 81 100 deaths in 2021, making it the 12th leading cause of death in this age group when considering the total mortality burden.</li><li>Traditional mortality recording underestimates sickle-cell disease impact &ndash; actual deaths are 11 times higher than cause-specific statistics suggest (376 000 vs 34 400 deaths in 2021).</li><li>Common complications include acute pain crises, anaemia, stroke, infections, kidney failure, and pregnancy-related risks.</li><li>Effective interventions exist, including disease modifying agents such as hydroxyurea and vaccinations to prevent infection.</li><li>Urgent action is needed to integrate sickle-cell disease care into primary health systems and ensure access to essential medicines.</li></ul><hr /><h2>Overview&nbsp;</h2><p>Sickle-cell disease (SCD) is a genetic disorder that affects haemoglobin, the molecule in red blood cells responsible for carrying oxygen. The disease causes red blood cells to become rigid and sickle-shaped, leading to blockages in blood flow and subsequent pain and organ damage. SCD is most common in individuals of African, Mediterranean, Middle Eastern, and Indian descent. The disease manifests in various forms, with sickle-cell anaemia being the most severe. Early diagnosis is crucial for managing the disease and preventing complications. Treatment focuses on alleviating symptoms and preventing crises, with advanced therapies like gene therapy offering hope for a cure.</p><h2>Causes and risk factors </h2><p>SCD is caused by a mutation in the HBB gene, which provides instructions for making haemoglobin. This mutation leads to the production of abnormal haemoglobin known as haemoglobin S. When a person inherits two copies of the haemoglobin S gene (one from each parent), they develop SCD. Individuals with one normal haemoglobin gene and one haemoglobin S gene have sickle-cell trait (SCT) and usually do not exhibit symptoms but can pass the gene to their offspring.</p><h2>Symptoms</h2><ul><li>Pain episodes (crises): sudden, severe pain due to blocked blood flow. These episodes can last for hours to days and can be severe enough to require hospitalization.</li><li>Anaemia: caused by the rapid breakdown of sickle-cells, leading to fatigue, weakness, and shortness of breath.</li><li>Swelling: particularly in the hands and feet, known as dactylitis, which is often the first symptom in babies.</li><li>Frequent infections: due to spleen damage, which makes patients more susceptible to infections such as pneumonia.</li><li>Delayed growth: in children and adolescents, due to chronic anaemia and other complications.</li><li>Vision problems: caused by blocked blood vessels in the eyes, which can lead to damage to the retina.</li></ul><h2>Diagnosis</h2><p>Sickle-cell anemia is typically diagnosed through a blood test. These tests look for the abnormal hemoglobin (HbS) that characterizes the disease. Additional tests, such as haemoglobin electrophoresis, can confirm the diagnosis and determine the specific type of SCD. Early diagnosis, such as through newborn screening, is essential for managing the disease and preventing severe complications.</p><h2>Treatment</h2><p>While there is no universal cure for SCD, various treatments can help manage symptoms and reduce complications:</p><p>Preventive care:</p><ul><li>routine vaccinations (pneumococcal, Haemophilus influenzae, hepatitis B)</li><li>folic acid supplements.</li></ul><p>Disease-modifying therapy:</p><ul><li>hydroxyurea: a medication that reduces the frequency of pain crises and the need for blood transfusions by increasing the production of fetal haemoglobin, which prevents the sickling of red blood cells;&nbsp;</li><li>pain management: using medications like acetaminophen, ibuprofen, and opioids to relieve pain during crises; and&nbsp;</li><li>blood transfusions: to treat severe anaemia and prevent stroke by increasing the number of normal red blood cells in circulation.<br /></li></ul><p>Curative options:</p><ul><li>bone marrow transplant: a potential cure for some patients, particularly children with severe SCD, by replacing the defective bone marrow with healthy marrow from a donor; and</li><li>gene therapy: emerging treatments that aim to correct the genetic mutation causing SCD, offering hope for a long-term cure.</li></ul><h2>Complications&nbsp;</h2><p>SCD can lead to numerous complications, including:</p><ul><li>early mortality especially in individuals without access to care;</li><li>severe infections (e.g. pneumococcal, salmonella);</li><li>stroke: due to blocked blood flow to the brain, which can cause long-term neurological damage;</li><li>acute chest syndrome: a life-threatening condition caused by sickle-cells blocking blood flow in the lungs, leading to chest pain, fever, and difficulty breathing;</li><li>organ damage: particularly to the spleen, liver, and kidneys, due to repeated blockages and lack of oxygen;</li><li>leg ulcers: chronic, painful sores on the legs that are difficult to heal;</li><li>priapism; and</li><li>pregnancy complications (maternal and neonatal risks).</li></ul><h2>Prevention and management&nbsp;</h2><p>Preventing complications and managing SCD involves regular medical care and lifestyle adjustments:</p><ul><li>regular check-ups: with a health-care provider specializing in SCD to monitor health and manage symptoms;</li><li>vaccinations: to prevent infections, particularly pneumococcal and meningococcal infections;</li><li>healthy lifestyle: including a balanced diet, adequate hydration, and avoiding extreme temperatures to reduce the risk of crises; and</li><li>education and support: for patients and families to understand the disease and its management, including recognizing early signs of complications and knowing when to seek medical help.</li></ul><p>For people living with sickle-cell disease, part of good health and well-being includes consideration about sexual and reproductive health. </p><p>Providers should talk to patients about sexual and reproductive health and their plans for pregnancy within the context of sickle-cell disease. Women living with sickle-cell disease need integrated care that informs them of the options for care in order to reduce any sickle-cell symptoms. Preventing complications can lead to better outcomes for women and their babies.</p><h3><span style=\"font-family:open_sanssemibold, Arial, Verdana, sans-serif;\"><strong>When considering pregnancy</strong></span></h3><p>Women with sickle-cell disease (SCD) should consider several important factors to ensure a healthy pregnancy and minimize risks. Here are some key considerations:</p><ul><li>counseling about genetic implications and the person&rsquo;s health status;</li><li>discussing continuing or discontinuing medication and supplements in alignment with the WHO guideline; and</li><li>joining a local sickle-cell disease support group to be connected with others who are going through similar challenges and to access emotional support and practical advice.&nbsp;</li></ul><h3>When planning pregnancy</h3><p>For women living with sickle-cell disease, planning for pregnancy will help to ensure good health for themselves and their babies.</p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Consideration should be given to:</span></p><ul><li>timing: planning the timing of pregnancy to ensure it occurs when the woman is in the best possible health; and</li><li>emergency planning: developing an emergency plan for managing sickle-cell crises during pregnancy.</li></ul><h2>WHO response</h2><p>The World Health Organization (WHO) recognizes SCD as a significant public health issue and works to improve the lives of those affected through various initiatives. WHO's efforts include:</p><ul><li>raising awareness: about SCD and its impact on global health through campaigns and educational programmes;</li><li>supporting research: to develop new treatments and potential cures, with attention to funding and facilitating clinical trials that include women of reproductive age and in pregnancy, in order to better understand the benefits and risks of treatments in and around the time of pregnancy;</li><li>early diagnosis and intervention, which can significantly improve outcomes for affected individuals;</li><li>collaborating with governments and organizations: to implement effective SCD management programmes and policies, ensuring access to care and treatment;</li><li>providing guidelines and resources: for health-care providers to improve patient care, including best practices for managing SCD during pregnancy, childbirth, and the interpregnancy period; and</li><li>PEN-Plus: a model that complements the WHO package of essential noncommunicable disease interventions and contributes to reducing premature mortality from severe noncommunicable disease by providing integrated care and services among Africa&rsquo;s poorest children and young adults.<br /></li></ul><p>By addressing the challenges of SCD through comprehensive strategies, WHO aims to reduce the disease's burden and enhance the quality of life for those affected.</p><p>&nbsp;</p><p><strong>References&nbsp;</strong></p><ul><li>Global, regional, and national prevalence and mortality burden of sickle-cell disease, 2000&ndash;2021: a systematic analysis from the Global Burden of Disease Study 2021. Thomson, Azalea M et al. The Lancet Haematology, Volume 10, Issue 8, e585 - e59</li><li>Sickle-cell disease: a strategy for the WHO African region. arf/rc60/8</li></ul>","ConditionName":"","OpenGraphTitle":"Sickle-cell disease","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Sickle-cell disease","ConditionLongerOverview":"","Title":"Sickle-cell disease","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"Sickle-cell disease (SCD) is a genetic disorder that affects haemoglobin, the molecule in red blood cells responsible for carrying oxygen. The disease causes red blood cells to become rigid and sickle-shaped, leading to blockages in blood flow and subsequent pain and organ damage. SCD is most common in individuals of African, Mediterranean, Middle Eastern, and Indian descent. The disease manifests in various forms, with sickle-cell anaemia being the most severe. Early diagnosis is crucial for managing the disease and preventing complications. Treatment focuses on alleviating symptoms and preventing crises, with advanced therapies like gene therapy offering hope for a cure.","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on sick-cell disease, including information on causes and risk factors, symptoms, diagnosis, treatment, prevention and management and WHO's work on the disease. ","PublicationDateAndTime":"2025-08-06T16:50:03Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on sick-cell disease, including information on causes and risk factors, symptoms, diagnosis, treatment, prevention and management and WHO's work on the disease. ","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<ul><li><a href=\"https://www.who.int/publications/i/item/9789240122666\">WHO consolidated guidelines for the management of common childhood illness: management of sickle-cell disease in children and adolescents</a></li><li><a style=\"text-align:inherit;text-transform:inherit;word-spacing:normal;white-space:inherit;\" href=\"https://www.who.int/publications/i/item/9789240109124\">WHO recommendations on the management of sickle-cell disease during pregnancy, childbirth and the interpregnancy period&nbsp;</a></li><li><a href=\"https://www.afro.who.int/publications/understanding-pen-plus-approach-care-expanding-access-care-severe-noncommunicable\">Understanding the PEN-Plus approach to care: expanding access to care for severe noncommunicable diseases in the WHO African Region</a></li><li><a href=\"https://www.afro.who.int/health-topics/sickle-cell-disease\">More on sickle-cell disease</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/topics/diseases-and-conditions/other-noncommunicable-diseases/child-treated-for-sickle-cell-disease.tmb-768v.jpg?sfvrsn=69396187_6","FormatedDate":"6 August 2025","TrimmedTitle":"Sickle-cell disease"},{"Id":"969a08e4-1c1e-4c26-9b68-4c41aabb16f0","LastModified":"2026-04-08T13:16:42Z","PublicationDate":"2018-06-02T02:27:31Z","DateCreated":"2018-06-02T02:27:30Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"blindness-and-visual-impairment","ItemDefaultUrl":"/blindness-and-visual-impairment","NewsNumberOfAdditionalItems":2,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Globally, at least 2.2&nbsp;billion people have a near or distance vision impairment. For at least 1&nbsp;billion of these people, vision impairment could have been prevented or is yet to be addressed.</li><li>The leading causes of vision impairment and blindness are refractive errors and cataracts.</li><li>It is estimated that 2 out of 3 people in low-income countries who need eyeglasses don&rsquo;t have access to them.</li><li>In addition, 1 in 2 people globally who need cataract surgery don&rsquo;t have access to that surgery.</li><li>Vision impairment poses an enormous global financial burden, with the annual global cost of productivity estimated to be US$&nbsp;411&nbsp;billion.</li><li>Vision loss can affect people of all ages; however, most people with vision impairment and blindness are over the age of 50 years.<br />&nbsp;</li></ul><hr /><br /><h2>Overview</h2><p>Vision plays a critical role in every facet and stage of our lives.</p><p>Vision impairment occurs when an eye condition affects our ability to see clearly. Everyone, if they live long enough, will experience at least one eye condition in their lifetime that will require appropriate care.</p><p>Vision impairment can have serious consequences for the individual across the life course. Many of these consequences can be mitigated by timely access to quality eye care. Eye conditions that can cause vision impairment and blindness &ndash; such as cataract or refractive error &ndash; are the main focus of eye care strategies; nevertheless, the importance of eye conditions that do not typically cause vision impairment &ndash; such as dry eye or conjunctivitis &ndash; should not be overlooked. These conditions are frequently among the leading reasons for presentation to eye care services.</p><h2>Causes</h2><p>Globally, the leading causes of vision impairment and blindness are:</p><ul><li>refractive errors</li><li>cataract</li><li>diabetic retinopathy</li><li>glaucoma</li><li>age-related macular degeneration.</li></ul><p>There is substantial variation in the causes of vision impairment between and within countries. Key factors are the availability and affordability of eye care services as well as the level of awareness of the population about conditions affecting vision and how to prevent and manage them. &nbsp;For example, the proportion of vision impairment attributable to unoperated cataract is higher in low- and middle-income countries than in high-income countries. In high-income countries, diseases such as glaucoma and age-related macular degeneration are more common.</p><p>Among children, congenital cataract is a leading cause of vision impairment in low-income countries, whereas in middle-income countries it is more likely to be retinopathy of prematurity.</p><p>Uncorrected refractive error remains a leading cause of vision impairment in all countries amongst both children and adult populations.</p><h2>Prevalence</h2><p>Globally, at least 2.2&nbsp;billion people have a near or distance vision impairment. In at least 1&nbsp;billion &ndash; or almost half &ndash; of these cases, vision impairment could have been prevented or has yet to be addressed.</p><p>Among these 1&nbsp;billion people, the main conditions causing distance vision impairment or blindness are cataract (94&nbsp;million), refractive error (88.4&nbsp;million), age-related macular degeneration (8&nbsp;million), glaucoma (7.7&nbsp;million), and diabetic retinopathy (3.9&nbsp;million)(1). The main condition causing near vision impairment is presbyopia (826&nbsp;million)(2).</p><p>In terms of regional differences, the prevalence of distance vision impairment in low- and middle-income regions is estimated to be 4 times higher than in high-income regions(1). With regards to near vision, rates of unaddressed near vision impairment are estimated to be greater than 80% in western, eastern and central sub-Saharan Africa, while comparative rates in high-income regions of North America, Australasia, western Europe, and of Asia-Pacific are reported to be lower than 10%(2).</p><p>Population growth and ageing are increasing the risk that more people acquire vision impairment.</p><h2>Impact of vision impairment</h2><h3>Personal impact</h3><p>Young children with early onset irreversible severe vision impairment can experience delayed motor, language, emotional, social and cognitive development, with lifelong consequences. School-age children with vision impairment can also experience lower levels of educational achievement.</p><p>Vision impairment severely impacts quality of life among adult populations. Adults with vision impairment can experience lower rates of employment and higher rates of depression and anxiety.</p><p>In the case of older adults, vision impairment can contribute to social isolation, difficulty walking, a higher risk of falls and fractures, and a greater likelihood of early entry into nursing or care homes.</p><h3>Economic impact</h3><p>Vision impairment poses an enormous global financial burden with an estimated annual global productivity loss of about US$&nbsp;411&nbsp;billion purchasing power parity(3). This figure far outweighs the estimated <a href=\"https://www.who.int/publications/i/item/9789241516570\">US$ 25 billion cost gap of addressing the unmet need of vision impairment</a>.</p><h2>Strategies to address eye conditions to avoid vision impairment</h2><p>There are effective interventions covering promotion, prevention, treatment and rehabilitation which address the needs associated with eye conditions and vision impairment. While many cases of vision loss can be prevented (such as those due to infections, trauma, unsafe traditional medicines, perinatal diseases, nutrition-related diseases, unsafe use or self-administration of topical treatment), this is not possible for all. For many eye conditions, e.g. diabetic retinopathy, early detection and timely treatment are crucial to avoid irreversible vision loss. Eyeglasses correction for refractive error and surgery for cataract are among the most cost-effective of all health-care interventions. Yet, <a href=\"https://cdn.who.int/media/docs/default-source/2021-dha-docs/refractive-error.pdf?sfvrsn=9e208b6b_3\">2 out of 3 people in low-income countries who need eyeglasses don&rsquo;t have access to them</a>(4) and 1 in 2 people globally who need cataract surgery can&rsquo;t access this.</p><p>Treatment is also available for many eye conditions that do not typically cause vision impairment, such as dry eye, conjunctivitis and blepharitis, but generate discomfort and pain. Treatment of these conditions is directed at alleviating the symptoms and preventing the evolution towards more severe stages of those diseases.</p><p>Vision rehabilitation (an essential component of eye care services that enables people living with irreversible low vision to maximize their functional abilities, enhance their quality of life and participate fully in society) is very effective in improving functioning for people with an irreversible vision loss that can be caused by eye conditions such as diabetic retinopathy, glaucoma, consequences of trauma, and age-related macular degeneration.</p><h2>WHO response</h2><p>WHO&rsquo;s work is guided by the recommendations of the <a href=\"https://www.who.int/publications/i/item/9789241516570\">WHO World report on vision (2019)</a> and the resolution on \"<a href=\"https://apps.who.int/gb/ebwha/pdf_files/WHA73/A73_R4-en.pdf\">Integrated, people-centred eye care, including preventable blindness and vision impairment</a>\" adopted at the Seventy-third World Health Assembly in 2020. The key strategy recommended in these documents is to make integrated people-centred eye care (IPEC) the care model of choice and to ensure its widespread implementation. It is expected that by shaping the global agenda on vision and eye care, the report and resolution will assist support efforts to reduce the burden of eye conditions and vision.</p><p>Some of WHO&rsquo;s key areas of work and activities in the prevention of blindness include:</p><ol><li>working with Member States and other partners in the field to monitor the <a href=\"https://apps.who.int/gb/ebwha/pdf_files/WHA74/A74(12)-en.pdf\">global targets for 2030</a> on integrated people-centred eye care;</li><li>supporting the integration of eye care in health systems through the implementation of a series of technical tools;</li><li>supporting capacity-building of health workers who can provide care for the eyes; </li><li>support countries to assess the provision of eye care services through the implementation of situation analysis tools;</li><li><a href=\"https://www.who.int/initiatives/specs-2030\">implementing SPECS 2030</a>, an initiative to support countries in reaching the more than 800&nbsp;million people in need of refractive error services;</li><li>raising awareness on eye care through the development and provision of a range of materials and resources; and</li><li>observing and promoting World Sight Day as an annual advocacy event.<br />&nbsp;</li></ol><hr /><br /><h3>References</h3><p>1. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e144-e160. doi: 10.1016/S2214-109X(20)30489-7.</p><p>2. Fricke, TR, Tahhan N, Resnikoff S, Papas E, Burnett A, Suit MH, Naduvilath T, Naidoo K, Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia: Systematic Review, Meta-analysis, and Modelling, Ophthalmology. 2018 May 9.</p><p>3. Burton MJ, Ramke J, Marques AP, Bourne RR, Congdon N, Jones I, et al. The Lancet Global Health commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021; 9(4):e489&ndash;e551.</p><p>4. Bourne RRA, Cicinelli MV, Selby DA, Sedighi T, Tapply IH, et al. Effective refractive error coverage in adults: a systematic review and meta-analysis of updated estimates from population-based surveys in 76 countries modelling the path towards the 2030 global target. Lancet Glob Health. 2025 Aug;13(8):e1396-e1405.</p><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Vision impairment and blindness","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Blindness and vision impairment","ConditionLongerOverview":"","Title":"Blindness and vision impairment","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs282","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on blindness and visual impairment providing key facts, definitions, causes, who is at risk, global and WHO response.","PublicationDateAndTime":"2026-02-10T09:09:56Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on blindness and visual impairment providing key facts, definitions, causes, who is at risk, global and WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<p><a href=\"https://www.who.int/health-topics/blindness-and-vision-loss\">WHO&rsquo;s work on eye care, vision impairment and blindness</a></p><p><a href=\"https://www.who.int/publications/i/item/9789240058002\">Report of the 2030 targets on effective coverage of eye care</a></p><p><a href=\"https://www.who.int/publications/i/item/9789240048959\">Package of eye care interventions</a></p><p><a href=\"https://www.who.int/publications/i/item/9789240050068\">Eye care in health systems: guide for action</a></p><p><a href=\"https://www.who.int/publications/i/item/9789241516570\">World report on vision</a><br /></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/vision-impairment-fact-sheet.tmb-768v.jpg?sfvrsn=9dcda712_18","FormatedDate":"10 February 2026","TrimmedTitle":"Blindness and vision impairment"},{"Id":"cc63bfb0-a44f-4205-8c21-825dfd2c2935","LastModified":"2026-01-28T15:29:59Z","PublicationDate":"2023-06-28T14:00:00Z","DateCreated":"2023-06-28T14:00:01Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"polycystic-ovary-syndrome","ItemDefaultUrl":"/polycystic-ovary-syndrome","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"<p>There is no cure for PCOS, but treatments can improve symptoms.</p>","Content":"<h2>Key facts</h2><ul><li>Polycystic ovary syndrome (PCOS) is a common hormonal disorder in which higher than normal androgen levels lead to irregular menstrual periods, abnormal ovulation, infertility, excess facial or body hair and/or acne in women (1).</li><li>PCOS affects an estimated 10&ndash;13% of reproductive-aged women. It is estimated that up 70% of women with PCOS worldwide do not know they have this condition.</li><li>PCOS is the most common cause of anovulation among women globally and a leading cause of infertility.</li><li>PCOS runs in families but can cause a range of different symptoms and affect women in different ways. PCOS is a chronic metabolic condition that persists beyond the reproductive years.</li><li>Women with PCOS are at higher risk for a variety of longer-term health problems that affect physical and emotional well-being compared to women without PCOS, including insulin resistance, type 2 diabetes mellitus and obesity.<br />&nbsp;</li></ul><hr /><br /><h2>Overview</h2><p>Polycystic ovary syndrome (PCOS) is a common hormonal disorder that affects women during their reproductive years and beyond, into later stages of life.</p><p>PCOS occurs when inappropriate hormonal signaling leads to higher than normal androgen levels and other hormonal imbalances. As a result, women with PCOS may experience irregular or infrequent menstrual periods, pain &ndash; including pain with heavy menstrual bleeding, abnormal ovulation, changes in hair (either excessive facial or body hair or female-pattern baldness), oilier skin, acne and/or cysts in the ovaries.</p><p>PCOS is a leading cause of irregular menstrual periods and one of the most common causes of infertility. Irregular or infrequent menstrual periods among women with PCOS may also raise their risk for endometrial hyperplasia and/or endometrial cancer. PCOS can start as early as during adolescence but is most commonly detected or diagnosed when women struggle to become pregnant.</p><p>Further, PCOS is a chronic metabolic condition associated with heightened long-term risk for insulin resistance, type 2 diabetes mellitus and obesity. There is currently no cure for PCOS, but lifestyle changes, medications and fertility treatments can reduce symptoms, increase fertility rates and protect longer-term health.</p><p>The cause of PCOS is unknown, but women with a family history of PCOS or type 2 diabetes are at higher risk.</p><h2>Scope of the problem</h2><p>PCOS a significant global public health problem and is one of the most common hormonal disorders affecting women, often becoming apparent during the reproductive years. An estimated 10&ndash;13% of women globally are thought to have PCOS, but up to 70% of affected women are undiagnosed.</p><p>The prevalence of PCOS may be higher among women in some racial or ethnic groups than others, and some women have higher genetic propensity for metabolic complications. However, structural racism and other social determinants of health shape the extent to which different groups of women with PCOS seek and receive quality health services.</p><h2>Symptoms</h2><p>Symptoms of PCOS can differ from person to person, and an individual&rsquo;s symptoms may change over time.</p><p>Possible symptoms include:</p><ul><li>intermittent, unpredictable or absent periods; or, for some women, heavy or long and/or painful periods</li><li>difficulty conceiving or infertility</li><li>excessive hair on the face or body</li><li>female-pattern baldness or hair thinning</li><li>acne or oily skin.</li></ul><p>Women with PCOS have an increased risk of developing other health conditions including:</p><ul><li>gestational diabetes or high blood pressure in pregnancy</li><li>weight gain, especially around the belly</li><li>type 2 diabetes</li><li>hypertension (high blood pressure)</li><li>high cholesterol</li><li>cardiovascular disease</li><li>obesity</li><li>sleep apnea</li><li>metabolic steatohepatitis </li><li>endometrial hyperplasia or endometrial cancer (abnormal growth or cancer, respectively, of the inner lining of the uterus).</li></ul><p>PCOS can adversely impact quality of life in substantial ways, and women with PCOS may experience anxiety, depression, eating disorders and/or a negative body image. Symptoms such as infertility, obesity and unwanted hair growth are subject to social stigma in many settings. This can affect social and family relationships, work, a sense of belonging in one&rsquo;s community, mental health and other aspects of well-being.</p><h2>Diagnosis</h2><p>PCOS is diagnosed by the presence of at least two of the following, once other causes for these symptoms have been excluded:</p><ol><li>signs or symptoms of high androgens (excess facial or bodily hair, loss of hair from the head, acne or oily skin) or an elevated blood level of testosterone;</li><li>irregular or absent menstrual periods; and</li><li>polycystic ovaries on an ultrasound in women.</li></ol><p>This means that some women with PCOS do not have polycystic ovaries, and ovarian cysts are not required for PCOS diagnosis. Blood tests can be used to identify higher than normal levels of androgen steroids in women who do not have visible excess hair or acne or to check whether ovulation is occurring normally in women who might have PCOS but who have regular menstrual cycles. When making a PCOS diagnosis, health workers consider genetic risk factors since women with a family history of PCOS or type 2 diabetes are at higher risk of PCOS. Health workers also take life stage into account because irregular periods can be normal at either the beginning (menarche) or end (perimenopause) of the reproductive years.</p><p>Women who are newly diagnosed with PCOS are recommended to have additional blood testing to evaluate for underlying insulin resistance and to assess their overall cardiovascular risk.</p><h2>Treatment</h2><p>There is no cure for PCOS, but treatments can improve quality of life, assist with fertility, reduce the risk of endometrial hyperplasia and/or endometrial cancer and help prevent long-term cardiovascular events. Seeking health care early to manage symptoms of PCOS can help women protect their health and well-being during and beyond their reproductive years.</p><p>Healthy lifestyle behaviors, including healthy eating and physical activity, are important for all women with PCOS, even if they do not lead to weight loss.</p><p>Combined oral contraceptive pills can help regulate the menstrual cycle and may reduce acne or excess facial and body hair. Androgen receptor blockers may also be used to treat excess hair or acne. Treatment choices should be based on shared decision-making, taking every individual&rsquo;s unique values and preferences into account.</p><p>Treatments for infertility due to PCOS include lifestyle changes, medicines or surgery to stimulate ovulation. In-vitro fertilization (IVF) and other assistive reproductive technologies may also be used. Women with PCOS can be supported to become pregnant but generally have higher risk of pregnancy complications that warrants additional monitoring.</p><h2>WHO response</h2><p>WHO promotes research regarding prevention, diagnosis and treatment of infertility for women with PCOS as well as broader menstrual health, seeking to identify and elevate the most important unanswered related questions. WHO works with Member States and partners to address PCOS as part of its broad efforts to improve women&rsquo;s health and well-being globally. WHO works with governmental and nongovernmental partners to enhance public awareness related to PCOS, and to generate guidance for health-care providers on how it can be recognized and treated.</p><p>WHO supports the generation of statistics on how common infertility and its causes (such as PCOS) are. WHO also helps Member States to pay more attention to infertility and its causes within national health policies, services and financing to ensure that everyone who needs health care related to infertility is able to obtain it without financial hardship.</p><p>&nbsp;</p><hr /><p>1) In this fact sheet, the term &ldquo;women&rdquo; is used inclusively to refer to all women, girls and gender-diverse individuals who menstruate and who may therefore be at risk of developing PCOS at some point in their life.</p><p>&nbsp;</p>","ConditionName":"Polycystic ovary syndrome","OpenGraphTitle":"Polycystic ovary syndrome","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"<p>Possible symptoms include:</p><ul><li>heavy, long, intermittent, unpredictable or absent periods</li><li>infertility</li><li>acne or oily skin</li><li>excessive hair on the face or body</li><li>male-pattern baldness or hair thinning</li><li>weight gain, especially around the belly</li></ul><p>People with PCOS are more likely to have other health conditions including:</p><ul><li>type 2 diabetes</li><li>hypertension (high blood pressure)</li><li>high cholesterol</li><li>heart disease</li><li>endometrial cancer (cancer of the inner lining of the uterus)</li></ul><p>PCOS can also cause anxiety, depression and a negative body image. Some symptoms such as infertility, obesity and unwanted hair growth can lead to social stigma. This can affect other life areas such as family, relationships, work and involvement in the community. </p>","MetaTitle":"Polycystic ovary syndrome","ConditionLongerOverview":"<p>PCOS can cause hormonal imbalances, irregular periods, excess androgen levels and cysts in the ovaries. Irregular periods, usually with a lack of ovulation, can make it difficult to become pregnant. PCOS is a leading cause of infertility.</p><p>PCOS is a chronic condition and cannot be cured. However, some symptoms can be improved through lifestyle changes, medications and fertility treatments.</p><p>The cause of PCOS is unknown but women with a family history or type 2 diabetes are at higher risk.</p>","Title":"Polycystic ovary syndrome","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on polycystic ovary syndrome (PCOS) including symptoms, treatments, diagnosis.","PublicationDateAndTime":"2026-01-22T13:13:56Z","ConditionBriefOverview":"<p>Polycystic ovary syndrome (PCOS) is a common hormonal condition that affects women of reproductive age. It usually starts during adolescence, but symptoms may fluctuate over time.</p>","MetaDescription":"WHO fact sheet on polycystic ovary syndrome (PCOS) including symptoms, treatments, diagnosis.","MedicalTreatmentLongerSummary":"<p>People who have irregular periods, trouble getting pregnant or excessive acne and hair growth should speak to a healthcare professional.</p><p>Some symptoms of PCOS can be reduced through lifestyle changes. Eating a healthy diet and getting enough exercise can help reduce weight and reduce the risk of type 2 diabetes.</p><p>Birth control medicines (contraceptive pill) can help regulate the menstrual cycle and reduce symptoms. Other medicines can reduce acne or unwanted hair growth caused by PCOS.</p><p>Treatments for infertility due to PCOS include lifestyle changes, medicines or surgery to stimulate regular ovulation. In-vitro fertilization (IVF) may be used but it has some risks.</p>","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"Symptoms of polycystic ovary syndrome can differ from person to person. Symptoms may change over time and often occur without a clear trigger.","Highlight":"<p><a href=\"https://www.who.int/health-topics/women-s-health\">WHO's work on women's health</a></p><p><a href=\"https://www.who.int/teams/sexual-and-reproductive-health-and-research-(srh)/overview\">Sexual and Reproductive Health and Research (SRH)</a></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/reproductive-health/infertility/pablo-heimplatz-unsplash.tmb-768v.jpg?Culture=en&sfvrsn=c020e841_6","FormatedDate":"22 January 2026","TrimmedTitle":"Polycystic ovary syndrome"},{"Id":"8b7b5bc2-5312-433f-b9ea-f1f118c46621","LastModified":"2026-10-19T02:57:45Z","PublicationDate":"2018-06-02T02:27:33Z","DateCreated":"2018-06-02T02:27:32Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"pesticide-residues-in-food","ItemDefaultUrl":"/pesticide-residues-in-food","NewsNumberOfAdditionalItems":0,"MedicalTreatmentBriefSummary":null,"Content":"<h2><span style=\"font-size:1em;\">Overview</span></h2><p><span style=\"font-size:1em;\"></span></p><!--[if gte mso 9]><xml>\r\n <o:OfficeDocumentSettings>\r\n  <o:AllowPNG/>\r\n </o:OfficeDocumentSettings>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves/>\r\n  <w:TrackFormatting/>\r\n  <w:PunctuationKerning/>\r\n  <w:ValidateAgainstSchemas/>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF/>\r\n  <w:LidThemeOther>EN-CA</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>AR-SA</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables/>\r\n   <w:SnapToGridInCell/>\r\n   <w:WrapTextWithPunct/>\r\n   <w:UseAsianBreakRules/>\r\n   <w:DontGrowAutofit/>\r\n   <w:SplitPgBreakAndParaMark/>\r\n   <w:EnableOpenTypeKerning/>\r\n   <w:DontFlipMirrorIndents/>\r\n   <w:OverrideTableStyleHps/>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"/>\r\n   <m:brkBin m:val=\"before\"/>\r\n   <m:brkBinSub m:val=\"&#45;-\"/>\r\n   <m:smallFrac m:val=\"off\"/>\r\n   <m:dispDef/>\r\n   <m:lMargin m:val=\"0\"/>\r\n   <m:rMargin m:val=\"0\"/>\r\n   <m:defJc m:val=\"centerGroup\"/>\r\n   <m:wrapIndent m:val=\"1440\"/>\r\n   <m:intLim m:val=\"subSup\"/>\r\n   <m:naryLim m:val=\"undOvr\"/>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"false\"\r\n  DefSemiHidden=\"false\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"376\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" QFormat=\"true\" Name=\"Normal\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 7\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 8\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 9\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 9\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 7\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 8\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 9\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"header\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footer\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index heading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"caption\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of figures\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope address\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope return\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"line number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"page number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of authorities\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"macro\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"toa heading\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" QFormat=\"true\" Name=\"Title\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Closing\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Signature\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Default Paragraph Font\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Message Header\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" QFormat=\"true\" Name=\"Subtitle\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Salutation\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Date\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Note Heading\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Block Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Hyperlink\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"FollowedHyperlink\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" QFormat=\"true\" Name=\"Strong\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" QFormat=\"true\" Name=\"Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Document Map\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Plain Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"E-mail Signature\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Top of Form\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Bottom of Form\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal (Web)\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Acronym\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Address\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Cite\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Code\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Definition\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Keyboard\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Preformatted\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Sample\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Typewriter\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Variable\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Table\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation subject\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"No List\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Contemporary\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Elegant\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Professional\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Balloon Text\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"Table Grid\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Theme\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Placeholder Text\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" QFormat=\"true\" Name=\"No Spacing\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Revision\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" QFormat=\"true\"\r\n   Name=\"List Paragraph\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" QFormat=\"true\" Name=\"Quote\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" QFormat=\"true\"\r\n   Name=\"Intense Quote\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" QFormat=\"true\"\r\n   Name=\"Subtle Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" QFormat=\"true\"\r\n   Name=\"Intense Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" QFormat=\"true\"\r\n   Name=\"Subtle Reference\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" QFormat=\"true\"\r\n   Name=\"Intense Reference\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" QFormat=\"true\" Name=\"Book Title\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Bibliography\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"TOC Heading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"41\" Name=\"Plain Table 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"42\" Name=\"Plain Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"43\" Name=\"Plain Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"44\" Name=\"Plain Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"45\" Name=\"Plain Table 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"40\" Name=\"Grid Table Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"Grid Table 1 Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"Grid Table 6 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"Grid Table 7 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"List Table 1 Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"List Table 6 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"List Table 7 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Mention\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Smart Hyperlink\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Hashtag\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Unresolved Mention\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Smart Link\"/>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0cm 5.4pt 0cm 5.4pt;\r\n\tmso-para-margin-top:0cm;\r\n\tmso-para-margin-right:0cm;\r\n\tmso-para-margin-bottom:8.0pt;\r\n\tmso-para-margin-left:0cm;\r\n\tline-height:107%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",sans-serif;\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:Arial;\r\n\tmso-bidi-theme-font:minor-bidi;\r\n\tmso-fareast-language:EN-US;}\r\n</style>\r\n<![endif]-->\r\n\r\n<p>There are more than 1000 pesticides used around the world to ensure food is\r\nnot damaged or destroyed by pests. Each pesticide has different properties and\r\ntoxicological effects.</p><p>Many of the older, less costly (off-patent) pesticides, such as\r\ndichlorodiphenyltrichloroethane (DDT) and lindane, can remain for years in soil\r\nand water. These chemicals have been banned by countries which signed the 2001\r\nStockholm Convention, an international treaty that aims to eliminate or\r\nrestrict the production and use of persistent organic pollutants.</p><p>The toxicity of a pesticide depends on its function and other factors. For\r\nexample, insecticides tend to be more toxic to humans than herbicides. The same\r\nchemical can have different effects at different doses, that is, the amount of chemical\r\nto which a person is exposed. Toxicity can also depend on the route by which\r\nthe exposure occurs, such as by swallowing, inhaling or direct contact with the\r\nskin.</p><p>None of the pesticides currently authorized for use on food in international\r\ntrade are genotoxic (damaging to DNA, which can cause mutations or cancer).\r\nAdverse effects from these pesticides occur only above a certain safe level of\r\nexposure. When people come into contact with large quantities of pesticide, the\r\nresult may be acute poisoning or long-term health effects that may include\r\ncancer and adverse effects on reproduction.</p><p><span></span></p><h2 class=\"section_head1\">Scope of the problem</h2><p><span></span></p><p>Pesticides are among the leading causes of death by self-poisoning, particularly in low- and middle-income countries.</p><p>Since pesticides are intrinsically toxic and deliberately spread in the environment, their production, distribution and use call for strict regulation and control. Regular monitoring of residues in food and the environment is also required.</p><p>WHO has two objectives in relation to pesticides:</p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">to ban the      pesticides that are most toxic to humans, as well as pesticides that      remain for the longest time in the environment;</li><li data-list=\"0\" data-level=\"1\">to protect public health by setting maximum limits for pesticide residues in food      and water.</li></ul><h2 class=\"section_head1\">Who is at risk?</h2><p><span></span></p><!--[if gte mso 9]><xml>\r\n <o:OfficeDocumentSettings>\r\n  <o:AllowPNG/>\r\n </o:OfficeDocumentSettings>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves/>\r\n  <w:TrackFormatting/>\r\n  <w:PunctuationKerning/>\r\n  <w:ValidateAgainstSchemas/>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF/>\r\n  <w:LidThemeOther>EN-CA</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>AR-SA</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables/>\r\n   <w:SnapToGridInCell/>\r\n   <w:WrapTextWithPunct/>\r\n   <w:UseAsianBreakRules/>\r\n   <w:DontGrowAutofit/>\r\n   <w:SplitPgBreakAndParaMark/>\r\n   <w:EnableOpenTypeKerning/>\r\n   <w:DontFlipMirrorIndents/>\r\n   <w:OverrideTableStyleHps/>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"/>\r\n   <m:brkBin m:val=\"before\"/>\r\n   <m:brkBinSub m:val=\"&#45;-\"/>\r\n   <m:smallFrac m:val=\"off\"/>\r\n   <m:dispDef/>\r\n   <m:lMargin m:val=\"0\"/>\r\n   <m:rMargin m:val=\"0\"/>\r\n   <m:defJc m:val=\"centerGroup\"/>\r\n   <m:wrapIndent m:val=\"1440\"/>\r\n   <m:intLim m:val=\"subSup\"/>\r\n   <m:naryLim m:val=\"undOvr\"/>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"false\"\r\n  DefSemiHidden=\"false\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"376\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" QFormat=\"true\" Name=\"Normal\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 7\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 8\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 9\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 9\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 7\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 8\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 9\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"header\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footer\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index heading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"caption\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of figures\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope address\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope return\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"line number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"page number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of authorities\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"macro\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"toa heading\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" QFormat=\"true\" Name=\"Title\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Closing\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Signature\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Default Paragraph Font\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Message Header\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" QFormat=\"true\" Name=\"Subtitle\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Salutation\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Date\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Note Heading\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Block Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Hyperlink\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"FollowedHyperlink\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" QFormat=\"true\" Name=\"Strong\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" QFormat=\"true\" Name=\"Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Document Map\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Plain Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"E-mail Signature\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Top of Form\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Bottom of Form\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal (Web)\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Acronym\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Address\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Cite\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Code\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Definition\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Keyboard\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Preformatted\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Sample\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Typewriter\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Variable\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Table\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation subject\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"No List\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Contemporary\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Elegant\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Professional\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Balloon Text\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"Table Grid\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Theme\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Placeholder Text\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" QFormat=\"true\" Name=\"No Spacing\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Revision\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" QFormat=\"true\"\r\n   Name=\"List Paragraph\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" QFormat=\"true\" Name=\"Quote\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" QFormat=\"true\"\r\n   Name=\"Intense Quote\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" QFormat=\"true\"\r\n   Name=\"Subtle Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" QFormat=\"true\"\r\n   Name=\"Intense Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" QFormat=\"true\"\r\n   Name=\"Subtle Reference\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" QFormat=\"true\"\r\n   Name=\"Intense Reference\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" QFormat=\"true\" Name=\"Book Title\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Bibliography\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"TOC Heading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"41\" Name=\"Plain Table 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"42\" Name=\"Plain Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"43\" Name=\"Plain Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"44\" Name=\"Plain Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"45\" Name=\"Plain Table 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"40\" Name=\"Grid Table Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"Grid Table 1 Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"Grid Table 6 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"Grid Table 7 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"List Table 1 Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"List Table 6 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"List Table 7 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Mention\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Smart Hyperlink\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Hashtag\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Unresolved Mention\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Smart Link\"/>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0cm 5.4pt 0cm 5.4pt;\r\n\tmso-para-margin-top:0cm;\r\n\tmso-para-margin-right:0cm;\r\n\tmso-para-margin-bottom:8.0pt;\r\n\tmso-para-margin-left:0cm;\r\n\tline-height:107%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",sans-serif;\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:Arial;\r\n\tmso-bidi-theme-font:minor-bidi;\r\n\tmso-fareast-language:EN-US;}\r\n</style>\r\n<![endif]-->\r\n\r\n<p>The population most at risk are those who are directly exposed to\r\npesticides. This includes agricultural workers who apply pesticides and anyone\r\nelse in the immediate area during, and shortly after, pesticides are spread.</p><p>The general population &ndash; those not in the area where pesticides are used &ndash;\r\nis exposed to significantly lower levels of pesticide residues through food and\r\nwater.</p><p><span></span></p><h2 class=\"section_head1\">Prevention and control</h2><p><span></span></p><!--[if gte mso 9]><xml>\r\n <o:OfficeDocumentSettings>\r\n  <o:AllowPNG/>\r\n </o:OfficeDocumentSettings>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves/>\r\n  <w:TrackFormatting/>\r\n  <w:PunctuationKerning/>\r\n  <w:ValidateAgainstSchemas/>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF/>\r\n  <w:LidThemeOther>EN-CA</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>AR-SA</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables/>\r\n   <w:SnapToGridInCell/>\r\n   <w:WrapTextWithPunct/>\r\n   <w:UseAsianBreakRules/>\r\n   <w:DontGrowAutofit/>\r\n   <w:SplitPgBreakAndParaMark/>\r\n   <w:EnableOpenTypeKerning/>\r\n   <w:DontFlipMirrorIndents/>\r\n   <w:OverrideTableStyleHps/>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"/>\r\n   <m:brkBin m:val=\"before\"/>\r\n   <m:brkBinSub m:val=\"&#45;-\"/>\r\n   <m:smallFrac m:val=\"off\"/>\r\n   <m:dispDef/>\r\n   <m:lMargin m:val=\"0\"/>\r\n   <m:rMargin m:val=\"0\"/>\r\n   <m:defJc m:val=\"centerGroup\"/>\r\n   <m:wrapIndent m:val=\"1440\"/>\r\n   <m:intLim m:val=\"subSup\"/>\r\n   <m:naryLim m:val=\"undOvr\"/>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"false\"\r\n  DefSemiHidden=\"false\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"376\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" QFormat=\"true\" Name=\"Normal\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 7\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 8\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 9\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 9\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 7\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 8\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 9\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"header\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footer\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index heading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"caption\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of figures\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope address\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope return\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"line number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"page number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of authorities\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"macro\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"toa heading\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" QFormat=\"true\" Name=\"Title\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Closing\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Signature\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Default Paragraph Font\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Message Header\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" QFormat=\"true\" Name=\"Subtitle\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Salutation\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Date\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Note Heading\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Block Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Hyperlink\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"FollowedHyperlink\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" QFormat=\"true\" Name=\"Strong\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" QFormat=\"true\" Name=\"Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Document Map\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Plain Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"E-mail Signature\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Top of Form\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Bottom of Form\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal (Web)\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Acronym\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Address\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Cite\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Code\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Definition\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Keyboard\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Preformatted\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Sample\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Typewriter\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Variable\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Table\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation subject\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"No List\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Contemporary\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Elegant\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Professional\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Balloon Text\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"Table Grid\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Theme\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Placeholder Text\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" QFormat=\"true\" Name=\"No Spacing\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Revision\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" QFormat=\"true\"\r\n   Name=\"List Paragraph\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" QFormat=\"true\" Name=\"Quote\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" QFormat=\"true\"\r\n   Name=\"Intense Quote\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" QFormat=\"true\"\r\n   Name=\"Subtle Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" QFormat=\"true\"\r\n   Name=\"Intense Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" QFormat=\"true\"\r\n   Name=\"Subtle Reference\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" QFormat=\"true\"\r\n   Name=\"Intense Reference\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" QFormat=\"true\" Name=\"Book Title\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Bibliography\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"TOC Heading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"41\" Name=\"Plain Table 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"42\" Name=\"Plain Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"43\" Name=\"Plain Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"44\" Name=\"Plain Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"45\" Name=\"Plain Table 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"40\" Name=\"Grid Table Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"Grid Table 1 Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"Grid Table 6 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"Grid Table 7 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"List Table 1 Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"List Table 6 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"List Table 7 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Mention\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Smart Hyperlink\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Hashtag\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Unresolved Mention\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Smart Link\"/>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0cm 5.4pt 0cm 5.4pt;\r\n\tmso-para-margin-top:0cm;\r\n\tmso-para-margin-right:0cm;\r\n\tmso-para-margin-bottom:8.0pt;\r\n\tmso-para-margin-left:0cm;\r\n\tline-height:107%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",sans-serif;\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:Arial;\r\n\tmso-bidi-theme-font:minor-bidi;\r\n\tmso-fareast-language:EN-US;}\r\n</style>\r\n<![endif]-->\r\n\r\n<p>Nobody should be exposed to unsafe amounts of pesticide.</p><p>People spreading pesticide on crops, in homes or in gardens should be\r\nadequately protected. People not directly involved in the spreading of\r\npesticides should stay away from the area while spreading takes place, and for\r\nsome time afterwards.</p><p>Food that is sold or donated (such as food aid) should equally comply with\r\npesticide regulations, in particular with maximum residue limits. People who use\r\npesticides when growing their own food should follow instructions for use and\r\nprotect themselves by wearing gloves and face masks as necessary.</p><p>Consumers can further limit their intake of pesticide residues by peeling or\r\nwashing fruit and vegetables, which also reduces other foodborne hazards such\r\nas harmful bacteria.</p><p><span></span></p><h2 class=\"section_head1\">Global impact</h2><p><span></span></p><!--[if gte mso 9]><xml>\r\n <o:OfficeDocumentSettings>\r\n  <o:AllowPNG/>\r\n </o:OfficeDocumentSettings>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:WordDocument>\r\n  <w:View>Normal</w:View>\r\n  <w:Zoom>0</w:Zoom>\r\n  <w:TrackMoves/>\r\n  <w:TrackFormatting/>\r\n  <w:PunctuationKerning/>\r\n  <w:ValidateAgainstSchemas/>\r\n  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>\r\n  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>\r\n  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>\r\n  <w:DoNotPromoteQF/>\r\n  <w:LidThemeOther>EN-CA</w:LidThemeOther>\r\n  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>\r\n  <w:LidThemeComplexScript>AR-SA</w:LidThemeComplexScript>\r\n  <w:Compatibility>\r\n   <w:BreakWrappedTables/>\r\n   <w:SnapToGridInCell/>\r\n   <w:WrapTextWithPunct/>\r\n   <w:UseAsianBreakRules/>\r\n   <w:DontGrowAutofit/>\r\n   <w:SplitPgBreakAndParaMark/>\r\n   <w:EnableOpenTypeKerning/>\r\n   <w:DontFlipMirrorIndents/>\r\n   <w:OverrideTableStyleHps/>\r\n  </w:Compatibility>\r\n  <m:mathPr>\r\n   <m:mathFont m:val=\"Cambria Math\"/>\r\n   <m:brkBin m:val=\"before\"/>\r\n   <m:brkBinSub m:val=\"&#45;-\"/>\r\n   <m:smallFrac m:val=\"off\"/>\r\n   <m:dispDef/>\r\n   <m:lMargin m:val=\"0\"/>\r\n   <m:rMargin m:val=\"0\"/>\r\n   <m:defJc m:val=\"centerGroup\"/>\r\n   <m:wrapIndent m:val=\"1440\"/>\r\n   <m:intLim m:val=\"subSup\"/>\r\n   <m:naryLim m:val=\"undOvr\"/>\r\n  </m:mathPr></w:WordDocument>\r\n</xml><![endif]--><!--[if gte mso 9]><xml>\r\n <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"false\"\r\n  DefSemiHidden=\"false\" DefQFormat=\"false\" DefPriority=\"99\"\r\n  LatentStyleCount=\"376\">\r\n  <w:LsdException Locked=\"false\" Priority=\"0\" QFormat=\"true\" Name=\"Normal\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 7\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 8\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 9\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index 9\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 7\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 8\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"toc 9\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"header\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footer\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"index heading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"35\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"caption\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of figures\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope address\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"envelope return\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"footnote reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"line number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"page number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote reference\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"endnote text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"table of authorities\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"macro\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"toa heading\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Bullet 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Number 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"10\" QFormat=\"true\" Name=\"Title\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Closing\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Signature\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Default Paragraph Font\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"List Continue 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Message Header\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"11\" QFormat=\"true\" Name=\"Subtitle\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Salutation\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Date\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text First Indent 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Note Heading\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Body Text Indent 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Block Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Hyperlink\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"FollowedHyperlink\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"22\" QFormat=\"true\" Name=\"Strong\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"20\" QFormat=\"true\" Name=\"Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Document Map\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Plain Text\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"E-mail Signature\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Top of Form\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Bottom of Form\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal (Web)\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Acronym\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Address\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Cite\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Code\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Definition\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Keyboard\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Preformatted\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Sample\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Typewriter\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"HTML Variable\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Normal Table\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"annotation subject\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"No List\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Outline List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Simple 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Classic 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Colorful 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Columns 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Grid 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 4\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 5\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 7\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table List 8\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table 3D effects 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Contemporary\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Elegant\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Professional\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Subtle 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 2\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Web 3\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Balloon Text\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"Table Grid\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Table Theme\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Placeholder Text\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"1\" QFormat=\"true\" Name=\"No Spacing\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Revision\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"34\" QFormat=\"true\"\r\n   Name=\"List Paragraph\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"29\" QFormat=\"true\" Name=\"Quote\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"30\" QFormat=\"true\"\r\n   Name=\"Intense Quote\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"19\" QFormat=\"true\"\r\n   Name=\"Subtle Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"21\" QFormat=\"true\"\r\n   Name=\"Intense Emphasis\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"31\" QFormat=\"true\"\r\n   Name=\"Subtle Reference\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"32\" QFormat=\"true\"\r\n   Name=\"Intense Reference\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"33\" QFormat=\"true\" Name=\"Book Title\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"37\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" Name=\"Bibliography\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"\r\n   UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"TOC Heading\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"41\" Name=\"Plain Table 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"42\" Name=\"Plain Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"43\" Name=\"Plain Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"44\" Name=\"Plain Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"45\" Name=\"Plain Table 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"40\" Name=\"Grid Table Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"Grid Table 1 Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"Grid Table 6 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"Grid Table 7 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"Grid Table 1 Light Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"Grid Table 6 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"Grid Table 7 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"List Table 1 Light\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"List Table 6 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"List Table 7 Colorful\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 1\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 2\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 3\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 4\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 5\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"46\"\r\n   Name=\"List Table 1 Light Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"51\"\r\n   Name=\"List Table 6 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" Priority=\"52\"\r\n   Name=\"List Table 7 Colorful Accent 6\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Mention\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Smart Hyperlink\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Hashtag\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Unresolved Mention\"/>\r\n  <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"\r\n   Name=\"Smart Link\"/>\r\n </w:LatentStyles>\r\n</xml><![endif]--><!--[if gte mso 10]>\r\n<style>\r\n /* Style Definitions */\r\n table.MsoNormalTable\r\n\t{mso-style-name:\"Table Normal\";\r\n\tmso-tstyle-rowband-size:0;\r\n\tmso-tstyle-colband-size:0;\r\n\tmso-style-noshow:yes;\r\n\tmso-style-priority:99;\r\n\tmso-style-parent:\"\";\r\n\tmso-padding-alt:0cm 5.4pt 0cm 5.4pt;\r\n\tmso-para-margin-top:0cm;\r\n\tmso-para-margin-right:0cm;\r\n\tmso-para-margin-bottom:8.0pt;\r\n\tmso-para-margin-left:0cm;\r\n\tline-height:107%;\r\n\tmso-pagination:widow-orphan;\r\n\tfont-size:11.0pt;\r\n\tfont-family:\"Calibri\",sans-serif;\r\n\tmso-ascii-font-family:Calibri;\r\n\tmso-ascii-theme-font:minor-latin;\r\n\tmso-hansi-font-family:Calibri;\r\n\tmso-hansi-theme-font:minor-latin;\r\n\tmso-bidi-font-family:Arial;\r\n\tmso-bidi-theme-font:minor-bidi;\r\n\tmso-fareast-language:EN-US;}\r\n</style>\r\n<![endif]-->\r\n\r\n<p>The United Nations Population Division estimates that by the year 2050 there\r\nwill be 9.7 billion people on Earth &ndash; around 30% more people than in 2017.\r\nNearly all of this population growth will occur in developing countries.</p><p>The Food and Agriculture Organization of the United Nations (FAO) estimates\r\nthat in developing countries, 80% of the increase in food production needed to keep\r\npace with population growth, is projected to come from either increases in\r\nyields and/or the number of times each year crops can be grown on the same\r\nland. Only 20% of extra food production is expected to result from an expansion\r\nof farming land.</p><p>Pesticides can prevent large crop losses and will therefore continue to play\r\na role in agriculture. However, the effects of exposure to pesticides on humans\r\nand the environment are a continuing concern.</p><p>The use of pesticides to produce food, both to feed local populations and\r\nfor export, should comply with good agricultural practices regardless of the\r\neconomic status of a country. Farmers should limit the amount of pesticide used\r\nto the minimum necessary to protect their crops.</p><p>It is also possible, under certain circumstances, to produce food without\r\nthe use of pesticides.</p><p><span></span></p><h2 class=\"section_head1\">WHO response</h2><p><span></span></p><p>WHO, in collaboration with FAO, is responsible for assessing the risks to humans from pesticides, whether through direct exposure or residues in food, &nbsp;and for recommending adequate protection measures.</p><p>Risk assessments for pesticide residues in food are conducted by an independent, international expert scientific group, the Joint FAO/WHO Meeting on Pesticide Residues (JMPR). These assessments are based on all data submitted for national registrations of pesticides worldwide, as well as all scientific studies published in peer-reviewed journals. After assessing the level of risk, JMPR establishes limits for safe intake to ensure that the amount of pesticide residue to which people are exposed through eating food over their lifetime will not result in adverse health effects.</p><p>These acceptable daily intakes are used by governments and international risk managers, such as the Codex Alimentarius Commission (the intergovernmental body that sets food standards), to establish maximum residue limits (MRLs) for pesticides in food. Codex standards are the reference for international trade in food, meaning that consumers everywhere can be confident that the food they buy meets the agreed standards for safety and quality, no matter where it has been produced. Currently there are Codex standards for more than 100 different pesticides.</p><p>WHO and FAO have jointly developed the <a href=\"https://www.who.int/publications/i/item/9789251085493\">International Code of Conduct on Pesticide Management</a>. The most recent edition of this voluntary framework was published in 2014. It guides government regulators, the private sector, civil society and other stakeholders on best practices in managing pesticides throughout their lifecycle, from production to disposal.</p><p><span></span></p>","ConditionName":null,"OpenGraphTitle":"Pesticide residues in food","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":null,"SelfCareLongerSummary":null,"EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":null,"MetaTitle":"","ConditionLongerOverview":null,"Title":"Pesticide residues in food","PreventionLongerSummary":null,"SourceKey":"/entity/mediacentre/factsheets/pesticide-residues-food","PhotoStoryNumberOfAdditionalItems":0,"SelfCareBriefSummary":null,"FactFileNumberOfAdditionalItems":0,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"","PublicationDateAndTime":"2022-09-15T12:29:00Z","ConditionBriefOverview":null,"MetaDescription":"","MedicalTreatmentLongerSummary":null,"CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":null,"Highlight":"<ul><li><a href=\"https://apps.who.int/iris/bitstream/handle/10665/44305/9789241599276_eng.pdf?sequence=1&amp;isAllowed=y\" target=\"_blank\">WHO pesticide evaluation scheme: 50 years of global leadership</a></li><li><a href=\"http://www.fao.org/fao-who-codexalimentarius/en/\" target=\"_blank\">The Codex Alimentarius Commission</a></li><li><a href=\"https://www.who.int/publications/i/item/9789251085493\">The International Code of Conduct on Pesticide Management</a></li><li><a href=\"http://www.pops.int/\" target=\"_blank\">Stockholm Convention on Persistent Organic Pollutants<p>&nbsp;</p></a><br /><p>&nbsp;</p></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/pesticides-india.tmb-768v.png?sfvrsn=279e5d45_44","FormatedDate":"15 September 2022","TrimmedTitle":"Pesticide residues in food"},{"Id":"83ce5158-3656-4b67-a365-c510cc96c5d6","LastModified":"2025-03-12T17:08:46Z","PublicationDate":"2023-08-23T16:35:59Z","DateCreated":"2023-08-23T16:35:59Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"human-papilloma-virus-and-cancer","ItemDefaultUrl":"/human-papilloma-virus-and-cancer","NewsNumberOfAdditionalItems":2,"MedicalTreatmentBriefSummary":"<p>There is currently no treatment for HPV infection. Treatments exist for genital warts, cervical precancers and cervical cancer.</p>","Content":"<h2>&nbsp; &nbsp;Key facts </h2><ul><li><strong>Human papillomavirus (HPV) is the name of a group of 200 known viruses. They do not cause concerns in most people, but infection with some high-risk types is common and can cause genital warts or cancer.</strong></li><li><strong>In 90% of people the body controls the infection by itself. Persistent HPV infection with high-risk HPV types is the cause of cervical cancer and is associated with cancers of the vulva, vagina, mouth/throat, penis and anus <em>(1)</em>.</strong></li><li><strong>In 2019, HPV caused an estimated 620 000 cancer cases in women and 70 000 cancer cases in men <em>(1)</em>.</strong><strong></strong><strong></strong></li><li><strong>Prophylactic vaccination against HPV can prevent these cancers. In addition, HPV-screening and treatment of pre-cancer lesions is an effective way to prevent cervical cancer. &nbsp;</strong></li></ul><hr /><h2>Overview</h2><p>Human papillomavirus (HPV) is a common sexually transmitted infection. Almost all sexually active people will be infected at some point in their lives, usually without symptoms.</p><p>HPV can affect the skin, genital area and throat. </p><p>Condoms help prevent HPV but do not offer total protection because they do not cover all the genital skin.</p><p>HPV usually goes away on its own without treatment. Some HPV infections cause genital warts. Others can cause abnormal cells to develop, which go on to become cancer.</p><p>Cancers from HPV can be prevented with vaccines.</p><p>The vaccine does not contain any live virus or DNA from the virus so it cannot cause cancer or other HPV-related illnesses. The HPV vaccine is not used to treat HPV infections or diseases caused by HPV, but instead to prevent the development of cancers.</p><p>Currently, cervical cancer is the only HPV-caused cancer for which screening tests are available. Screening tests are used to check for disease when there are no symptoms. The goal of screening for cervical cancer is to find precancerous cell changes before they become cancer and when treatment can prevent cancer from developing. Screening for cervical cancer is an important part of routine health care for people who have a cervix. This includes women and transgender men who still have a cervix. </p><p>Cervical cancer is the most common type of cancer caused by HPV, other less common cancers affecting men and women, including&nbsp;anal,&nbsp;vulvar,&nbsp;vaginal,&nbsp;mouth/throat&nbsp;and penile cancers.&nbsp;</p><h2>Scope of the problem </h2><p>The highest prevalence of cervical HPV among women is in sub-Saharan Africa (24%), followed by Latin America and the Caribbean (16%), eastern Europe (14%), and South-East Asia (14%) <em>(2)</em>. Prevalence in men is highly variable based on sexual trends.</p><p><a href=\"https://www.who.int/publications/i/item/who-wer9750-645-672\">Evidence showed</a> that prevalence of the virus is higher among women living with HIV, men who have sex with men, immunocompromised individuals, people with co-infection with other sexually transmitted infections (STI), people who receive immunosuppressive medications and children who have been through sexual abuse.</p><p>Globally, it is estimated that 620 000 new cancer cases in women and 70 000 new cancer cases in men were caused by HPV in 2019 <em>(1)</em>. Cervical cancer was the fourth leading cause of cancer and cancer deaths in women in 2022, with some 660 000 new cases and around 350 000 deaths worldwide <em>(3)</em>. Cervical cancers account for over 90% of HPV-related cancers in women <em>(1)</em>. </p><p>The highest rates of cervical cancer incidence and mortality are in low- and middle-income countries. This reflects major inequities driven by lack of access to national HPV vaccination, cervical screening and treatment services, and social and economic determinants.<br /></p><h2>Symptoms </h2><p>Most people will not have any symptoms from an HPV infection. The immune system usually clears HPV from the body within a year or two with no lasting effects.</p><p>Some HPV infections cause small rough lumps (genital warts) that can appear on the vagina, penis or anus and rarely the throat. They may be painful, itchy or bleed or cause swollen glands.</p><p>HPV infection that does not go away on its own can cause changes to cervical cells, which lead to precancers that may become cervical cancer if left untreated. It usually takes 15&ndash;20 years for cervical cancer to develop after HPV infection.</p><p>The early changes in cervical cells and precancers mostly do not cause symptoms. Symptoms of cervical cancer may include bleeding between periods or after sexual intercourse or a foul-smelling vaginal discharge. These symptoms may be due to other diseases. People with these symptoms should speak to their healthcare provider.</p><h2>Prevention</h2><p>Being vaccinated is the best way to prevent HPV infection, cervical cancer and other HPV-related cancers. Screening can detect cervical precancers that can be treated before they develop into cancer.</p><p>HPV vaccines should be given to all girls aged 9&ndash;14 years, before they become sexually active.</p><p>The vaccine may be given as 1 or 2 doses. People with reduced immune systems should receive 2 or 3 doses. Check with your healthcare provider to determine what is best for you.</p><p>Using condoms during sex is an important way to prevent HPV infection. Voluntary male circumcision also reduces the risk of infection. Being a non-smoker or stopping smoking reduces the chances of developing persistent HPV infection.</p><p>Testing cells from a woman&rsquo;s cervix for HPV is used to screen women for cervical cancer. Women should be screened every 5&ndash;10 years starting at age 30. Women living with HIV should be screened every 3 years starting at age 25.</p><p>After a positive HPV test (or other screening method), a healthcare provider can look for changes on the cervix or precancers that could develop into cervical cancer if left untreated. Treatment of precancers prevents cervical cancer. Precancers rarely cause symptoms, which is why regular screening to check cervical health is important.</p><p>Learn more about vaccination of boys and older age groups: <a href=\"https://www.who.int/publications/i/item/who-wer9750-645-672\">WHO position paper</a></p><h2>Treatment</h2><p>There is currently no treatment for HPV infection. Treatments exist for genital warts, cervical precancers and cervical cancer.</p><p>Non-cancerous genital warts and precancerous lesions in the cervix, vagina, vulva, anus or penis can be removed or treated by ablation (freezing or heating) or with surgery.</p><p>Currently, cancer of the cervix (cervical cancer) is the only HPV-caused cancer for which screening tests are available.</p><p>Treatments for cancers caused by HPV (including cervical cancer) are more effective if diagnosed early. Treatment should begin quickly after diagnosis.</p><p>Learn more about cervical precancer treatment here: <a href=\"https://www.who.int/news-room/fact-sheets/detail/cervical-cancer\">WHO fact sheet on cervical cancer</a></p><p>Management pathways for invasive cancer care are important tools to ensure that a patient is referred promptly and supported as they navigate the steps to diagnosis and treatment decisions. A multidisciplinary team should ensure diagnosis and staging (histological testing, pathology, imaging) takes place prior to treatment decisions which could include surgery, radiotherapy and systemic therapy such as chemotherapy. Treatment decisions should be in line with national guidelines and interventions should be supported by holistic psychological, spiritual, physical and palliative care. </p><p>As low- and middle-income countries scale-up cervical screening, more cases of invasive cervical cancer will be detected, especially in previously unscreened populations. Therefore, referral and treatment strategies need to be implemented and expanded alongside prevention services. </p><h2>WHO response</h2><p>Giving the global public health burden of cervical cancer caused by HPV, the World Health Assembly (WHA. 73.2) adopted the <a href=\"https://www.who.int/publications/i/item/9789240014107\">Global strategy to accelerate the elimination of cervical cancer as a public health problem</a><a href=\"https://euc-word-edit.officeapps.live.com/we/wordeditorframe.aspx?ui=en%2DUS&amp;rs=en%2DUS&amp;wopisrc=https%3A%2F%2Fworldhealthorg-my.sharepoint.com%2Fpersonal%2Feanderson_who_int%2F_vti_bin%2Fwopi.ashx%2Ffiles%2Fd03ef6f4eb5c495f866ef51fd348e19b&amp;wdlor=c870B26E3-0CA3-451B-A03A-F546355EDBAE&amp;wdenableroaming=1&amp;mscc=1&amp;wdodb=1&amp;hid=52065B5A-CEEC-43B9-9E29-FCBACA585C5C&amp;wdorigin=AuthPrompt&amp;jsapi=1&amp;jsapiver=v1&amp;newsession=1&amp;corrid=deb28248-6409-406f-a260-035009ece974&amp;usid=deb28248-6409-406f-a260-035009ece974&amp;sftc=1&amp;cac=1&amp;mtf=1&amp;sfp=1&amp;instantedit=1&amp;wopicomplete=1&amp;wdredirectionreason=Unified_SingleFlush&amp;rct=Normal&amp;ctp=LeastProtected#_ftn12\">&nbsp;</a>with the following targets: </p><ul><li>90% of girls fully vaccinated with HPV vaccine by age 15; </li><li>70% of women are screened with a high-performance test by 35, and again by 45 years of age; and </li><li>90% of women identified with cervical disease receive treatment (90% of women with pre-cancer treated; 90% of women with invasive cancer managed). </li></ul><p>Prevention of HPV-associated precancer and cancer is also a key element of WHO&rsquo;s <a href=\"https://www.who.int/publications-detail-redirect/9789240053779\"></a><a href=\"https://www.who.int/publications-detail-redirect/9789240053779\"></a><a href=\"https://www.who.int/publications/i/item/9789240053779\">Global health sector strategy on, respectively, HIV,</a><a href=\"https://www.who.int/publications-detail-redirect/9789240053779\">&nbsp;</a><a href=\"https://www.who.int/publications-detail-redirect/9789240053779\">hepatitis and sexually transmitted infections, 2022</a><a href=\"https://www.who.int/publications-detail-redirect/9789240053779\">&ndash;</a><a href=\"https://www.who.int/publications-detail-redirect/9789240053779\">2030</a>&nbsp;<a href=\"https://www.who.int/publications-detail-redirect/9789240053779\"></a>and the resolution WHA74.5 (2021) on oral health includes actions on mouth/throat cancers. </p><p>The joint work of the WHO at global, regional and national level, alongside UN sister agencies delivers to: </p><ol><li>increase political commitment to formulate policy and support implementation </li><li>offer contextualized technical assistance, lessons learned and best practices</li><li>develop norms and standards based on latest evidence</li><li>lead the global health ecosystem to achieve the targets and improve quality of care.<em> </em></li></ol><p><strong>&nbsp;</strong></p><p><strong>References</strong></p><ol><li>de Martel et al, Lancet Global Health 2019, <a href=\"https://pubmed.ncbi.nlm.nih.gov/31862245/\">https://pubmed.ncbi.nlm.nih.gov/31862245/</a></li><li>Bruni L et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789&ndash;1799. <a href=\"https://pubmed.ncbi.nlm.nih.gov/21067372/\">https://pubmed.ncbi.nlm.nih.gov/21067372/</a></li><li><a href=\"https://euc-word-edit.officeapps.live.com/we/wordeditorframe.aspx?ui=en%2DUS&amp;rs=en%2DUS&amp;wopisrc=https%3A%2F%2Fworldhealthorg-my.sharepoint.com%2Fpersonal%2Feanderson_who_int%2F_vti_bin%2Fwopi.ashx%2Ffiles%2Fd03ef6f4eb5c495f866ef51fd348e19b&amp;wdlor=c870B26E3-0CA3-451B-A03A-F546355EDBAE&amp;wdenableroaming=1&amp;mscc=1&amp;wdodb=1&amp;hid=52065B5A-CEEC-43B9-9E29-FCBACA585C5C&amp;wdorigin=AuthPrompt&amp;jsapi=1&amp;jsapiver=v1&amp;newsession=1&amp;corrid=deb28248-6409-406f-a260-035009ece974&amp;usid=deb28248-6409-406f-a260-035009ece974&amp;sftc=1&amp;cac=1&amp;mtf=1&amp;sfp=1&amp;instantedit=1&amp;wopicomplete=1&amp;wdredirectionreason=Unified_SingleFlush&amp;rct=Normal&amp;ctp=LeastProtected#_ftnref3\"></a>Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, Pi&ntilde;eros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer. Available from: <a href=\"https://gco.iarc.fr/tomorrow\">https://gco.iarc.fr/tomorrow</a></li></ol>","ConditionName":"Human papillomavirus (HPV)","OpenGraphTitle":"Human papillomavirus and cancer","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"Being vaccinated is the best way to prevent HPV infection, cervical cancer and other HPV-related cancers. Screening can detect cervical precancers that can be treated before they develop into cancer.","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"<p>Some HPV infections cause small rough lumps (genital warts) that can appear on the vagina, penis or anus and rarely the throat. They may be painful, itchy or bleed or cause swollen glands. </p><p>HPV infection that does not go away on its own can cause changes to cervical cells, which lead to precancers that may become cervical cancer if left untreated. It usually takes 15&ndash;20 years for cervical cancer to develop after HPV infection.</p><p>The early changes in cervical cells and precancers mostly do not cause symptoms. Symptoms of cervical cancer may include bleeding between periods or after sexual intercourse or a foul-smelling vaginal discharge. These symptoms may be due to other diseases. People with these symptoms should speak to their healthcare provider.</p>","MetaTitle":"Human papillomavirus and cancer","ConditionLongerOverview":"<p>HPV can affect the skin, genital area and throat. </p><p>Condoms help prevent HPV but do not offer total protection because they do not cover all the genital skin.</p><p>HPV usually goes away on its own without treatment. Some HPV infections cause genital warts. Others can cause abnormal cells to develop, which go on to become cancer.</p><p>Cancers from HPV can be prevented with vaccines.</p>","Title":"Human papillomavirus and cancer","PreventionLongerSummary":"<p>HPV vaccines should be given to all girls aged 9&ndash;14 years, before they become sexually active.</p><p>The vaccine may be given as 1 or 2 doses. People with reduced immune systems should receive 2 or 3 doses. Check with your healthcare provider to determine what is best for you.</p><p>Using condoms during sex is an important way to prevent HPV infection. Voluntary male circumcision also reduces the risk of infection. Being a non-smoker or stopping smoking reduces the chances of developing persistent HPV infection.</p><p>Testing cells from a woman&rsquo;s cervix for HPV is used to screen women for cervical cancer. Women should be screened every 5&ndash;10 years starting at age 30. Women living with HIV should be screened every 3 years starting at age 25.</p><p>After a positive HPV test (or other screening method), a healthcare provider can look for changes on the cervix or precancers that could develop into cervical cancer if left untreated. Treatment of precancers prevents cervical cancer. Precancers rarely cause symptoms, which is why regular screening to check cervical health is important. </p>","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on human papilloma virus and cancer, including overview, scope of the problem, symptoms, treatment, prevention and WHO response.","PublicationDateAndTime":"2024-03-05T05:00:00Z","ConditionBriefOverview":"<p>Human papillomavirus (HPV) is a common sexually transmitted infection. Almost all sexually active people will be infected at some point in their lives, usually without symptoms.</p>","MetaDescription":"WHO fact sheet on human papilloma virus and cancer, including overview, scope of the problem, symptoms, treatment, prevention and WHO response.","MedicalTreatmentLongerSummary":"<p>Non-cancerous genital warts and precancerous lesions in the cervix, vagina, vulva, anus or penis can be removed or treated by ablation (freezing or heating) or with surgery.</p><p>Currently, cancer of the cervix (cervical cancer) is the only HPV-caused cancer for which screening tests are available.</p><p>Treatments for cancers caused by HPV (including cervical cancer) are more effective if diagnosed early. Treatment should begin quickly after diagnosis.</p>","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"<p>Most people will not have any symptoms from an HPV infection. The immune system usually clears HPV from the body within a year or two with no lasting effects.</p>","Highlight":"","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/searo---images/countries/bangladesh/cat-1--ivd--hpv---2016-10-17-(1).tmb-768v.jpg?Culture=en&sfvrsn=c63c90b8_6","FormatedDate":"5 March 2024","TrimmedTitle":"Human papillomavirus and cancer"},{"Id":"e5039f73-9508-4980-b1a0-a0257f01a841","LastModified":"2026-01-19T14:18:39Z","PublicationDate":"2018-06-02T02:27:35Z","DateCreated":"2018-06-02T02:27:34Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"middle-east-respiratory-syndrome-coronavirus-(mers-cov)","ItemDefaultUrl":"/middle-east-respiratory-syndrome-coronavirus-(mers-cov)","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV) that was first identified in Saudi Arabia and Jordan in 2012.</li><li>Coronaviruses are a large family of viruses that can cause diseases ranging from the common cold to Severe acute respiratory syndrome (SARS) and Coronavirus disease-2019 (COVID-19).</li><li>Typical MERS symptoms include fever, cough and shortness of breath, commonly leading to pneumonia.</li><li>About 70% of new or emerging pathogens are of animal origin, including MERS-CoV which can be transmitted between dromedary camels and people; onwards person-to-person transmission can lead to outbreaks in hospitals and households.</li><li>Over 2600 laboratory-confirmed cases of human infection with MERS-CoV have been reported to WHO; the majority (84%) were reported from the Arabian Peninsula.</li><li>Approximately 37% of MERS cases reported to WHO have died, but this likely is an overestimation as surveillance systems may miss mild or asymptomatic MERS cases.</li><li>There is currently no specific treatment or vaccine licensed for MERS.<br />&nbsp;</li></ul><hr /><br /><h2>Overview</h2><p>Middle East respiratory syndrome (MERS) is one of three high-impact zoonotic coronavirus diseases with pandemic potential that has emerged in recent years. The other two are SARS and COVID-19. Coronaviruses can cause diseases ranging from the common cold to severe respiratory symptoms and even death.</p><p>MERS coronavirus (MERS-CoV) was first identified in Saudi Arabia and Jordan in 2012. Since then, 27 Member States from all WHO regions have reported cases of MERS-CoV infection to the WHO under the International Health Regulations (IHR, 2005), with 84% of all human cases reported by Saudi Arabia.</p><p>MERS-CoV is a zoonotic virus and dromedary camels are the primary reservoir. Infected dromedaries do not get sick, therefore diagnosis in animals relies on laboratory testing.</p><p>Since 2020 case reports have been sporadic, concentrated in the Arabian Peninsula and particularly in Saudi Arabia. Person-to-person transmission has been significantly reduced due to enhancements in surveillance, respiratory patient triage, and infection prevention and control.</p><p>There is currently no specific treatment or vaccine licensed for MERS. This, combined with the high case fatality ratio of 37% recorded for reported cases, makes MERS-CoV a WHO priority pathogen for research and development.</p><h2>Geographic distribution</h2><p>Since its first identification in 2012, 27 Member States from all WHO regions have reported cases of MERS-CoV infection to WHO under the International Health Regulations (IHR, 2005): Algeria, Austria, Bahrain, China, Egypt, France, Germany, Greece, the Islamic Republic of Iran, Italy, Jordan, Kuwait, Lebanon, Malaysia, the Netherlands, Oman, Philippines, Qatar, Republic of Korea, Kingdom of Saudi Arabia, Thailand, Tunisia, T&uuml;rkiye, the United Arab Emirates, the United Kingdom of Great Britain and Northern Ireland, the United States of America, and Yemen.</p><p>MERS-CoV appears to be circulating widely in dromedary camel populations throughout the Middle East and Africa regions and has also been detected in a few countries in South and Central Asia. Recent sero-prevalence studies in humans with occupational exposure to dromedary camels indicate that there is also zoonotic transmission occurring in Member States outside the Arabian Peninsula.</p><p>More than 84% of all human cases have been reported by Saudi Arabia, as a result of direct or indirect contact with infected dromedary camels or with infected individuals in health-care facilities. Cases identified outside the Middle East are usually individuals who appear to have been infected in the Middle East and travel to areas outside the region.</p><p>To date, a limited number of outbreaks have occurred outside the Middle East. The biggest was reported in May 2015, involving a hospital in the Republic of Korea. The index case in that outbreak had travel history to the Middle East and spread the virus further to both health-care workers and patients. As a result, 38 patients died, 186 people were infected, and Koreans experienced a national crisis. This is just one example of the devastating impact when MERS-CoV is introduced into the health-care system of a country that is not prepared to quickly identify, test, and control MERS.</p><h2>Transmission</h2><p>Around 70% of new or emerging diseases are of animal origin, including MERS-CoV which is transmitted between dromedary camels and people. Human infection occurs from direct contact with dromedaries and possibly indirectly through the handling or consumption of camel-related raw products or secretions (e.g. milk and urine).</p><p>Human-to-human transmission is possible and occurs predominantly among close contacts (family and household members) and in health-care settings (health-care workers and among patients). The largest outbreaks occurred in health-care facilities in the Republic of Korea, Saudi Arabia, and the United Arab Emirates.. Outside the health-care setting, human-to-human transmission has been limited and no sustained human-to-human transmission has been documented anywhere in the world.</p><p>In health-care facilities, transmission of MERS-CoV has been documented from patients to health-care workers and among patients within the same room, often before MERS-CoV was diagnosed and the patient was appropriately isolated, and health-care workers followed the correct precautions. However, it is not always possible to identify patients with MERS\u2010CoV early or without specific laboratory testing because symptoms and other clinical features are very similar to other respiratory diseases.</p><p>There have been clusters of cases and larger outbreaks reported in health-care facilities, especially when infection prevention and control practices are inadequate. Effective infection prevention and control measures are critical to prevent the spread of MERS-CoV and it is crucial for health-care facilities caring for patients with suspected or confirmed MERS-CoV infection to take the necessary precautions to minimize the risk of transmission from an infected patient to other patients, health-care workers, or visitors. Health and care workers should be educated and trained in infection prevention and control, sensitized for MERS case definitions, and should retain their skills and keep updated on new information in this area.</p><h2>Symptoms</h2><p>The clinical spectrum of MERS-CoV infection ranges from not exhibiting any detectable symptoms (asymptomatic), to mild respiratory symptoms, to severe acute respiratory disease and even death. A typical presentation of MERS consists of fever, cough and shortness of breath, often developing into pneumonia. Gastrointestinal symptoms, including diarrhoea, have also been reported. Severe illness can cause respiratory and organ failure, often requiring mechanical ventilation or support in an intensive care unit.</p><p>Older people (&gt;65), people with weakened immune systems, and those with chronic diseases such as renal disease, cancer, chronic lung disease, hypertension, cardiovascular disease and diabetes, appear to be at greater risk of developing severe or fatal disease.</p><h2>Treatment and prevention</h2><p>Currently, there are no licensed vaccines or therapeutics for MERS-CoV and treatment of patients is supportive, targeted to the clinical condition. However, several MERS-CoV-specific vaccines and treatments are under development, with concrete plans for Phase II clinical trials for some of them.</p><p>As a general precaution, individuals visiting farms, markets or other areas where animals are kept or displayed should practice good hygiene, such as washing hands before and after contact with animals and their products and avoiding contact with sick animals. The handling and consumption of raw or undercooked animal products, including milk and meat, carries a risk of infection from a variety of pathogens that can cause disease in humans. Animal products that are processed appropriately through cooking or pasteurization should be safe for consumption but should also be handled with care to avoid cross-contamination with uncooked foods. Camel meat and camel milk are nutritious products that can be consumed after pasteurization, cooking, or other heat treatments.</p><p>Individuals at greater risk of developing severe disease should avoid contact with dromedary camels, handling or drinking raw camel milk or camel urine, or eating meat that has not been properly cooked. </p><h2>Travel</h2><p>WHO does not recommend the application of any travel or trade restrictions or entry screening related to MERS-CoV.</p><p>WHO is consistently monitoring the global, regional and national MERS-CoV epidemiologic situation and regularly updates risk assessments and technical guidance, including guidance and advice regarding travel to mass gatherings in countries reporting MERS cases, such as Hajj and Umrah. Travelers returning from gatherings in countries reporting MERS-CoV cases are advised to seek medical advice if they develop any symptoms of acute respiratory illness within two weeks of their return, and to disclose their recent travel history to health-care providers.</p><h2>WHO response</h2><p>WHO is collaborating with public health, animal health experts, and international partners to better understand and respond to MERS-CoV. Efforts include improving surveillance for MERS-CoV and other respiratory pathogens in humans and animals, enhancing outbreak response through a One Health approach and prioritizing research to gather scientific evidence for informed decision-making and develop therapeutics and vaccines. WHO is also working with FAO, WOAH, and national governments to develop strategies to prevent zoonotic transmission, including vaccines for humans and camels. </p><p>Global coordination involves tracking epidemiological trends, conducting risk assessments, supporting field investigations, offering technical guidance and training, and guiding efforts to enhance infection prevention and control, clinical management and treatment approaches.</p><p>WHO urges Member States to maintain strong severe acute respiratory infection (SARI) surveillance, including MERS-CoV in areas where the virus is known to be circulating in dromedary camels, to review unusual pneumonia cases, and to apply appropriate infection prevention and control measures in health-care settings. Countries with travelers or migrant workers returning from the Middle East should test symptomatic individuals for MERS-CoV. As per the IHR (2005), all confirmed and probable MERS-CoV cases must be reported to WHO, including details on exposure, testing, and clinical course.</p><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Middle East respiratory syndrome coronavirus (MERS-CoV)","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Middle East respiratory syndrome coronavirus (MERS-CoV)","ConditionLongerOverview":"","Title":"Middle East respiratory syndrome coronavirus (MERS-CoV)","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/mers-cov","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"MERS-CoV is a zoonotic virus, which means it is a virus that is transmitted between animals and people.","PublicationDateAndTime":"2025-12-11T16:39:40Z","ConditionBriefOverview":"","MetaDescription":"Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a novel coronavirus (MERS\u2010CoV) that was first identified in Saudi Arabia in 2012.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<p>For more information on MERS-CoV, including WHO technical guidance:</p><p><a href=\"https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1\">WHO's work on Middle East respiratory syndrome coronavirus (MERS-CoV)</a></p><p><a href=\"https://www.who.int/emergencies/outbreak-toolkit/disease-outbreak-toolboxes/mers-outbreak-toolbox\">Middle East Respiratory Syndrome Outbreak Toolbox.</a> </p><p><a href=\"https://data.who.int/dashboards/mers\">WHO MERS-CoV dashboard</a></p><p><a href=\"https://www.who.int/emergencies/disease-outbreak-news\">Disease outbreak news</a>&nbsp; </p><p><a href=\"https://www.who.int/publications/i/item/WHO-MERS-RA-19.1\">MERS global summary and assessment of risk</a></p><p><a href=\"https://www.who.int/publications/m/item/update-88-mers-cov-a-circulating-coronavirus-with-epidemic-and-pandemic-potential-pandemic-preparedness--prevention-and-response-with-a-one-health-approach\">EPI-WIN Update 88: MERS-CoV, a circulating coronavirus with epidemic and pandemic potential - Pandemic preparedness, prevention and response with a One Health approach</a></p><p><a href=\"https://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html?format=html\">WHO-EMRO MERS monthly bulletin</a></p><p><br /></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/mers-cov.tmb-768v.jpg?sfvrsn=15bc7d52_44","FormatedDate":"11 December 2025","TrimmedTitle":"Middle East respiratory syndrome coronavirus (MERS-CoV)"},{"Id":"02c8fb17-11a8-4d0c-a461-a15be6186cdd","LastModified":"2026-07-30T22:08:04Z","PublicationDate":"2023-06-28T15:09:19Z","DateCreated":"2023-06-28T15:09:19Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"rheumatoid-arthritis","ItemDefaultUrl":"/rheumatoid-arthritis","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"<p>Rheumatoid arthritis is not curable. Management of rheumatoid arthritis often involves different health workers, who contribute to a rehabilitative strategy tailored to a person&rsquo;s needs and preferences.</p>","Content":"<h2>Overview</h2><p>Rheumatoid arthritis (RA) is a chronic disease that causes inflammation around the body and commonly presents with pain in the joints.</p><p>Untreated, RA can cause severe damage to the joints and their surrounding tissue. It can lead to heart, lung or nervous system problems.</p><p>Common symptoms include chronic pain, stiffness, tenderness, heat and swelling in the joints. RA can make it hard to move and perform daily activities. </p><p>The causes of rheumatoid arthritis are unknown. Risk factors include smoking, obesity and exposure to air pollution. Women and older people have a higher risk of developing RA. </p><p>If diagnosed timely, symptoms and disease progression can be controlled with pharmacological treatment, and optimal functioning can be maintained through rehabilitation (including the use of assistive products). In cases with severe joint damage, surgical procedures, including joint replacement, may help to restore movement or manage pain, and maintain physical function.</p><h2>Scope of the problem</h2><p>The typical onset of the disease occurs in adults in their sixties. Women are two-to-three times more often affected than men. The prevalence of rheumatoid arthritis is higher in industrialized countries, which may be explained by demographics (higher average age), exposures to environmental toxins and lifestyle risk factors, and under-diagnosis in low-and-middle-income countries.</p><h2>Signs and symptoms</h2><p>Rheumatoid arthritis causes inflammation and pain in one or more joints. It can happen in most joints, but it&rsquo;s most common in the small joints of the hands, wrists and feet. </p><p>RA is chronic and may worsen over time without treatment. It can lead to severe damage to the joint and surrounding tissue. It can also affect the heart, lung and nervous systems.</p><p>Early signs and symptoms:</p><ul><li>pain</li><li>stiffness</li><li>tenderness</li><li>swelling or redness in one or more joints, usually in a symmetrical pattern (e.g., both hands or both feet).</li></ul><p>The symptoms can worsen over time and spread to more joints including the knees, elbows or shoulders. RA can make it hard to perform daily activities like writing, holding objects with the hands, walking and climbing stairs.</p><p>People with RA often feel fatigue and general malaise (e.g., fever, poor sleep quality, loss of appetite) and may experience depressive symptoms. </p><p>Pain and difficulty moving can lead to problems with sexual function and intimate relationships. Trouble moving easily can cause lower physical fitness and lead to loss of independence, inability to work, reduced well-being and mental health problems. </p><h2>Causes and risk factors </h2><p>The specific causes for the disease are still unknown, but several modifiable lifestyle-associated (smoking, obesity) and non-modifiable (genetics, female gender, age) risk factors have been identified.</p><h2>Prevention and control</h2><p>Several key prevention strategies have been proposed to prevent rheumatoid arthritis and control the disease progression. In particular, reducing exposure to inhaled silica, dusts and occupational risks, and lifestyle related behaviours (e.g., prevention of/stop smoking, healthy nutrition, physical activity, maintaining a normal body weight, maintaining good dental hygiene) play an important role. Some evidence also suggests breastfeeding may be protective to the mother <em>(4)</em>.</p><h2>Treatment and management<br /></h2><p>Rheumatoid arthritis is not curable. Management of rheumatoid arthritis often involves different health workers, who contribute to a rehabilitative strategy tailored to a person&rsquo;s needs and preferences. </p><p>Early diagnosis and management can reduce symptoms, slow the disease and prevent disability. In some cases, the disease can go into remission.</p><p>Therapeutic approaches help to improve and maintain joint mobility and muscle strength, to reduce and cope with pain, and to increase exercise capacity and the ability to perform daily activities. </p><p>Assistive technologies (e.g., orthosis, assistive products for self-care) help people to protect their joints and to perform meaningful activities independently. </p><p>Medicines to reduce inflammation, pain and swelling may include:</p><ul><li>non-steroidal anti-inflammatory drugs (NSAIDs)</li><li>glucocorticoids</li><li>disease-modifying antirheumatic drugs (DMARDs) </li><li>biological agents.</li></ul><p>In severe cases, orthopaedic surgery can reduce pain and restore movement. Rehabilitation is essential to achieve the best outcomes following surgery.</p><p>It is important to keep a healthy lifestyle. Education and counselling are important to help people manage their symptoms and work-related tasks. <br /></p><h2>Self-care</h2><p>Rheumatoid arthritis is a chronic condition that impacts many aspects of life. Lifestyle changes are often needed for individuals and their families. <br /></p><p>Education and support help people with rheumatoid arthritis to develop strategies to cope with the disease. It is important to maintain a healthy lifestyle with regular physical activity and a nutritious diet. <br /></p><h2>WHO response</h2><p>WHO is taking action to extend access to care in rheumatoid arthritis in different ways:</p><p><strong>WHO Rehabilitation 2030 Initiative: </strong></p><p>The <a href=\"https://www.who.int/teams/noncommunicable-diseases/sensory-functions-disability-and-rehabilitation/rehabilitation/service-delivery/package-of-interventions-for-rehabilitation\">Package of Interventions for Rehabilitation</a> provides information on essential interventions for rehabilitation (including assistive products), and human and material resources for 20 health conditions, including rheumatoid arthritis.</p><p><strong>UN Decade of Healthy Ageing:</strong></p><p>WHO recommends a reorientation of health and care systems to promote healthy ageing and address the diverse needs of older persons. </p><p>The <a href=\"https://www.who.int/teams/maternal-newborn-child-adolescent-health-and-ageing/ageing-and-health/integrated-care-for-older-people-icope/development-of-who-guideline-on-management-of-chronic-primary-low-back-pain-in-adults\">Integrated Care for Older People (ICOPE)</a> approach promotes the person-centred assessment of the older person to guide the design of personalized, health and social care, including long-term care interventions. Specific recommendations are provided to prevent the loss of locomotor and psychological capacity because of pain.</p><p>&nbsp;</p><p><strong>References</strong></p><p>(1) GBD 2019: Global burden of 369 diseases and injuries in 204 countries and territories, 1990&ndash;2019: a systematic analysis for the Global Burden of Disease Study 2019. <a href=\"https://vizhub.healthdata.org/gbd-results/\">https://vizhub.healthdata.org/gbd-results/</a>.</p><p>(2) Cieza A, Causey K, Kamenow K, Wulf Hansen S, Chatterji S, Vos T. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Dec 19; 396(10267): 2006&ndash;17.</p><p>(3) Long H, Liu Q, Yin H, Diao N, Zhang Y, Lin J et al. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: Findings from the global burden of disease study 2019. Arthritis Rheumatol 2022; 74(7): 1172-83.</p><p>(4) Koller-Smith L, Mehdi AM, March L, Tooth L, Mishra GD, Thomas R. Rheumatoid arthritis is a preventable disease: 11 ways to reduce your patients' risk. Internal Medicine Journal 2022;52:711&ndash;6.</p><p>&nbsp;</p>","ConditionName":"Rheumatoid arthritis","OpenGraphTitle":"Rheumatoid arthritis","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"<p>Rheumatoid arthritis is a chronic condition that impacts many aspects of life. Lifestyle changes are often needed for individuals and their families.</p><p>Education and support help people with rheumatoid arthritis to develop strategies to cope with the disease. It is important to maintain a healthy lifestyle with regular physical activity and a nutritious diet.</p>","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"<p>RA is chronic and may worsen over time without treatment. It can lead to severe damage to the joint and surrounding tissue. It can also affect the heart, lung and nervous systems.</p><p>Early signs and symptoms:</p><ul><li>pain</li><li>stiffness</li><li>tenderness</li><li>swelling or redness in one or more joints, usually in a symmetrical pattern (e.g., both hands or both feet)</li></ul><p>The symptoms can worsen over time and spread to more joints including the knees, elbows or shoulders. RA can make it hard to perform daily activities like writing, holding objects with the hands, walking and climbing stairs.</p><p>People with RA often feel fatigue and general malaise (e.g., fever, poor sleep quality, loss of appetite) and may experience depressive symptoms.</p><p>Pain and difficulty moving can lead to problems with sexual function and intimate relationships. Trouble moving easily can cause lower physical fitness and lead to loss of independence, inability to work, reduced well-being and mental health problems.</p>","MetaTitle":"Rheumatoid arthritis","ConditionLongerOverview":"<p>Untreated, RA can cause severe damage to the joints and their surrounding tissue. It can lead to heart, lung or nervous system problems.</p><p>Common symptoms include chronic pain, stiffness, tenderness, heat and swelling in the joints. RA can make it hard to move and perform daily activities. </p><p>The causes of rheumatoid arthritis are unknown. Risk factors include smoking, obesity and exposure to air pollution. Women and older people have a higher risk of developing RA.</p>","Title":"Rheumatoid arthritis","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on rheumatoid arthritis including signs and symptoms, causes, treatments and WHO response.","PublicationDateAndTime":"2023-06-28T04:00:00Z","ConditionBriefOverview":"Rheumatoid arthritis (RA) is a chronic disease that causes inflammation around the body and commonly presents with pain in the joints.","MetaDescription":"WHO fact sheet on rheumatoid arthritis including signs and symptoms, causes, treatments and WHO response.","MedicalTreatmentLongerSummary":"<p>Early diagnosis and management can reduce symptoms, slow the disease and prevent disability. In some cases, the disease can go into remission.<br /></p><p>Therapeutic approaches help to improve and maintain joint mobility and muscle strength, to reduce and cope with pain, and to increase exercise capacity and the ability to perform daily activities. <br /></p><p>Assistive technologies (e.g., orthosis, assistive products for self-care) help people to protect their joints and to perform meaningful activities independently. <br /></p><p>Medicines to reduce inflammation, pain and swelling may include:</p><ul><li>non-steroidal anti-inflammatory drugs (NSAIDs)</li><li>glucocorticoids</li><li>disease-modifying antirheumatic drugs (DMARDs) </li><li>biological agents</li></ul><p>In severe cases, orthopaedic surgery can reduce pain and restore movement. Rehabilitation is essential to achieve the best outcomes following surgery.</p><p>It is important to keep a healthy lifestyle. Education and counselling are important to help people manage their symptoms and work-related tasks.</p>","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"<p>Rheumatoid arthritis causes inflammation and pain in one or more joints. It can happen in most joints, but it&rsquo;s most common in the small joints of the hands, wrists and feet.</p>","Highlight":"<ul><li><a href=\"https://www.who.int/health-topics/rehabilitation\" style=\"font-family:inherit;text-align:inherit;text-transform:inherit;word-spacing:normal;white-space:inherit;font-size:inherit;\">WHO's work on rehabilitation</a><br /></li><li><a href=\"https://www.who.int/publications/i/item/9789241549974\">Rehabilitation in health systems</a></li><li><a href=\"https://www.who.int/teams/noncommunicable-diseases/sensory-functions-disability-and-rehabilitation/global-estimates-of-the-need-for-rehabilitation\">G</a><a href=\"https://www.who.int/teams/noncommunicable-diseases/sensory-functions-disability-and-rehabilitation/global-estimates-of-the-need-for-rehabilitation\">lobal estimates of the need for rehabilitation</a></li></ul><p>&nbsp;</p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/mca/ageing/rehabilitation_051_who-norway_who-noor-sebastien-liste_.tmb-768v.jpg?sfvrsn=fb2992e6_12","FormatedDate":"28 June 2023","TrimmedTitle":"Rheumatoid arthritis"},{"Id":"b0d810e7-66a9-47a7-8b93-ff3e0a9b7924","LastModified":"2026-06-16T09:44:19Z","PublicationDate":"2018-06-02T02:27:37Z","DateCreated":"2018-06-02T02:27:36Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"youth-violence","ItemDefaultUrl":"/youth-violence","NewsNumberOfAdditionalItems":2,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Worldwide <a href=\"https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death\">around 193&nbsp;000</a> homicides occur among youth aged 15&ndash;29 years each year, which is 40% of the total number of homicides globally.</li><li>Homicide is among the leading cause of death in people aged 15&ndash;29 years, and most homicides involve male victims.</li><li>For each young person killed, many more sustain injuries requiring hospital treatment.</li><li>When it is not fatal, youth violence has a serious, often lifelong, impact on a person's physical, psychological and social functioning.<br />&nbsp;</li></ul><hr /><br /><h2>Overview</h2><p>Youth violence refers to violence that occurs among individuals aged 10&ndash;29 years who are unrelated and who may or may not know each other. It generally takes place outside of the home. It includes a range of acts including bullying, technology-facilitated violence, physical fighting, sexual and physical assault, gang-related violence and homicide. Youth violence results in deaths, injuries, disability and long-term health consequences. These include mental health problems and behaviours that include health-risks, which can lead to chronic diseases. It is associated with higher school-dropout rates, and negative impacts on cognitive development and opportunities to contribute to communities.</p><h2>Scope of the problem</h2><p>Worldwide an estimated 193 000 homicides occur among young people between 15&ndash;29 years of age each year, making it one of the leading causes of death for people in this age group. Youth homicide rates vary dramatically between and within countries. Between 2000 and 2019, rates of youth homicide decreased in most countries, although the decrease has been greater in high-income countries than in low- and middle-income countries. Most youth homicide victims are males, and most perpetrators are males.</p><p>For every young person killed by violence, more sustain injuries that require hospital treatment.</p><p>Sexual violence also affects a significant proportion of youth. For example, 1 in 5 girls and 1 in 7 boys report sexual abuse <em>(1)</em>.</p><p>Globally 25% of all children and adolescents are exposed to bullying.</p><p>Youth homicide and non-fatal violence not only contribute greatly to the global burden of premature death, injury and disability, but also have a serious, often lifelong, impact on a person's psychological and social functioning. They can lead to emotional distress, loneliness, anxiety, depression, self-harming behaviours, suicidal ideation, and suicidal attempts. This can affect victims' families, friends and communities. Youth violence increases the costs of health, welfare and criminal justice services; reduces productivity; and decreases the value of property.</p><h3>Risk factors</h3><p>Certain characteristics increase the likelihood that someone will perpetrate violence.</p><p>Risk factors for individuals:</p><ul><li>attention deficit, hyperactivity, conduct disorder, or other behavioural disorders</li><li>early involvement with alcohol, drugs and tobacco</li><li>reduced cognitive ability and educational achievement</li><li>low commitment to school and school failure</li><li>involvement in crime</li><li>exposure to violence in the family.</li></ul><p>Risk factors within close relationships (family, friends, intimate partners and peers):</p><ul><li>poor monitoring and supervision of children by parents</li><li>harsh, lax or inconsistent parental disciplinary practices</li><li>a low level of attachment between parents and children</li><li>low parental involvement in children's activities</li><li>parental substance use or criminality</li><li>parental depression</li><li>low family income</li><li>unemployment in the family</li><li>associating with delinquent peers and/or gang membership.</li></ul><p>Risk factors within the community and wider society:</p><ul><li>access to and harmful use of alcohol</li><li>access to firearms</li><li>gangs and illicit drugs</li><li>high income inequality</li><li>poverty</li><li>the quality of a country&rsquo;s governance (its laws and the extent to which they are enforced, as well as policies for education and social protection).</li></ul><h2>Prevention</h2><p>Promising prevention programmes include:</p><ul><li>life skills and social development programmes designed to help children and adolescents manage anger, resolve conflict, and develop the necessary social skills to solve problems;</li><li>whole school approaches to violence prevention in educational facilities;</li><li>programmes that support parents and teach positive parenting skills;</li><li>preschool programmes that provide children with academic and social skills at an early age;</li><li>therapeutic approaches for youths at high risk of being involved in violence;</li><li>reducing access to alcohol;</li><li>interventions to reduce the harmful use of drugs;</li><li>restrictive firearm licensing;</li><li>community and problem-oriented policing; and</li><li>interventions to reduce concentrated poverty and to upgrade urban environments.</li></ul><p>Preventing youth violence requires a comprehensive approach that recognizes the strong correlation between rates of youth violence and economic inequalities. The most impoverished sectors of societies, marked by significant wealth gaps between the rich and the poor, consistently exhibit the highest rates of youth violence. Economic disparities exacerbate frustration and despair among disadvantaged youth, leading to an environment where violence becomes a common outlet. To achieve sustainable prevention gains, it is important to address income inequality, increase economic mobility, and enhance access to education, social protection and employment opportunities.</p><p>Preventing youth violence requires a comprehensive approach that addresses the social determinants of violence, such as income inequality, rapid demographic and social change, and low levels of social protection.</p><p>Critical to reducing the immediate consequences of youth violence are improvements in pre-hospital and emergency care, including access to care.</p><h2>WHO response</h2><p>WHO and partners decrease youth violence through initiatives that help to identify, quantify and respond to the problem. These include:</p><ul><li>drawing attention to the magnitude of youth violence and the need for prevention;</li><li>building evidence on what works to<a href=\"https://www.who.int/publications/i/item/preventing-youth-violence-an-overview-of-the-evidence\">&nbsp;prevent youth violence</a>, including in the online space;</li><li>strengthening&nbsp;<a href=\"https://www.who.int/publications/i/item/school-based-violence-prevention-a-practical-handbook\">school-based violence</a>&nbsp;prevention programmes;</li><li>working with Member States and all relevant sectors to&nbsp;<a href=\"https://www.who.int/publications/i/item/9789241565356\">prevent youth violence and strengthen responses</a>&nbsp;to it; </li><li>advocating for the integration of evidence-based prevention strategies to prevent youth violence in adolescent and youth health initiatives; and</li><li>collaborating with international agencies and organizations to prevent youth violence globally.</li></ul><p>&nbsp;</p><p><strong>References</strong></p><p><em>1)</em> Unicef. Sexual violence. October 2024. <a href=\"https://data.unicef.org/topic/child-protection/violence/sexual-violence/#status\">https://data.unicef.org/topic/child-protection/violence/sexual-violence/#status</a></p><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Youth violence","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Youth violence","ConditionLongerOverview":"","Title":"Youth violence","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs356","PhotoStoryNumberOfAdditionalItems":0,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":0,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"WHO fact sheet on youth violence providing key facts and information on the scope of the problem, risk factors, prevention, WHO response.","PublicationDateAndTime":"2026-05-08T15:41:38Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on youth violence providing key facts and information on the scope of the problem, risk factors, prevention, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"","Highlight":"<ul><li><a href=\"https://www.who.int/publications/i/item/preventing-youth-violence-an-overview-of-the-evidence\">Preventing youth violence: an overview of the evidence</a></li><li><a href=\"https://www.who.int/publications/i/item/school-based-violence-prevention-a-practical-handbook\">Handbook on school-based violence prevention</a></li><li><a href=\"https://www.who.int/publications/i/item/9789241565356\">INSPIRE: Seven strategies for ending violence against children</a></li><li><a href=\"https://www.who.int/health-topics/violence-against-children\">WHO's work on youth violence</a></li><li><a href=\"https://www.who.int/teams/social-determinants-of-health/violence-prevention\">More on violence prevention</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/reproductive-health/sexual-health/duy-pham-unsplash.tmb-768v.jpg?Culture=en&sfvrsn=cae7fb52_6","FormatedDate":"8 May 2026","TrimmedTitle":"Youth violence"},{"Id":"c00648c5-b38a-4505-bb85-9e14fe8a7df4","LastModified":"2025-04-09T19:28:16Z","PublicationDate":"2018-09-21T08:13:03Z","DateCreated":"2018-09-20T15:39:12Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"oral-health","ItemDefaultUrl":"/oral-health","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"","Content":"<p>&nbsp;</p><h2>Key facts</h2><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">Oral diseases, while largely preventable, pose a major health burden for many countries and affect people throughout their lifetime, causing pain, discomfort, disfigurement and even death.</li><li data-list=\"0\" data-level=\"1\">It is estimated that oral diseases affect nearly 3.7 billion people.</li><li data-list=\"0\" data-level=\"1\">Untreated dental caries (tooth decay) in permanent teeth is the most common health condition according to the Global Burden of Disease 2021.</li><li data-list=\"0\" data-level=\"1\">Prevention and treatment for oral health conditions is expensive and usually not part of national universal health coverage (UHC) benefit packages.</li><li data-list=\"0\" data-level=\"1\">Most low- and middle-income countries do not have sufficient services available to prevent and treat oral health conditions.</li><li data-list=\"0\" data-level=\"1\">Oral diseases are caused by a range of modifiable risk factors common to many noncommunicable diseases (NCDs), including sugar consumption, tobacco use, alcohol use and poor hygiene, and their underlying social and commercial determinants.</li></ul><hr /><p><br /></p><h2>Overview</h2><p>Most oral health conditions are largely preventable and can be treated in their early stages. Most cases are dental caries (tooth decay), periodontal diseases, tooth loss and oral cancers. Other oral conditions of public health importance are orofacial clefts, noma (severe gangrenous disease starting in the mouth mostly affecting children) and oro-dental trauma.</p><p>Prevalence of the main oral diseases continues to increase globally with growing urbanization and changes in living conditions. This is primarily due to inadequate exposure to fluoride (in the water supply and oral hygiene products such as toothpaste), availability and affordability of food with high sugar content and poor access to oral health care services in the community. Marketing of food and beverages high in sugar, as well as tobacco and alcohol, have led to a growing consumption of products that contribute to oral health conditions and other NCDs.</p><h2>Dental caries (tooth decay)</h2><p>Dental caries results when plaque forms on the surface of a tooth and converts the free sugars (all sugars added to foods by the manufacturer, cook or consumer, plus sugars naturally present in honey, syrups and fruit juices) contained in foods and drinks into acids that destroy the tooth over time. A continued high intake of free sugars, inadequate exposure to fluoride and a lack of removal of plaque by toothbrushing can lead to caries, pain and sometimes tooth loss and infection.</p><h2>Periodontal (gum) disease</h2><p>Periodontal disease affects the tissues that both surround and support the teeth. The disease is characterized by bleeding or swollen gums (gingivitis), pain and sometimes bad breath. In its more severe form, the gum can come away from the tooth and supporting bone, causing teeth to become loose and sometimes fall out. Severe periodontal diseases are estimated to affect more than 1&nbsp;billion cases worldwide. The main risk factors for periodontal disease are poor oral hygiene and tobacco use.</p><h2>Edentulism (total tooth loss)</h2><p>Losing teeth is generally the end point of a lifelong history of oral disease, mainly advanced dental caries and severe periodontal disease, but can also be due to trauma and other causes. The estimated global average prevalence of complete tooth loss is almost 7% among people aged 20 years or older. For people aged 60 years or older, a much higher global prevalence of 23% has been estimated. Losing teeth can be psychologically traumatic, socially damaging and functionally limiting.</p><h2>Oral cancer</h2><p>Oral cancer includes cancers of the lip, other parts of the mouth and the oropharynx and combined rank as the 13<sup>th</sup> most common cancer worldwide. The global incidence of cancers of the lip and oral cavity is estimated to be 389&nbsp;846 new cases and 188 438 deaths in 2022 <em>(1).</em> Oral cancer is more common in men and in older people, more deadly in men compared to women and it varies strongly by socio-economic circumstances.</p><p>Tobacco, alcohol and areca nut (betel quid) use are among the leading causes of oral cancer. In North America and Europe, human papillomavirus infections are responsible for a growing percentage of oral cancers among young people.</p><h2>Oro-dental trauma</h2><p>Oro-dental trauma results from injury to the teeth, mouth and oral cavity. Latest estimates show that 1&nbsp;billion people are affected, with a prevalence of around 20% for children up to 12 years old. Oro-dental trauma can be caused by oral factors such as lack of alignment of teeth and environmental factors (such as unsafe playgrounds, risk-taking behaviour, road accidents and violence). Treatment is costly and lengthy and sometimes can even lead to tooth loss, resulting in complications for facial and psychological development and quality of life.</p><h2>Noma</h2><p>Noma is a severe gangrenous disease of the mouth and the face. It mostly affects children aged 2&ndash;6 years suffering from malnutrition, affected by infectious disease, living in extreme poverty with poor oral hygiene or with weakened immune systems.</p><p>Noma is mostly found in sub-Saharan Africa, although cases have also been reported in Latin America and Asia. Noma starts as a soft tissue lesion (a sore) of the gums. It then develops into an acute necrotizing gingivitis that progresses rapidly, destroying the soft tissues and further progressing to involve the hard tissues and skin of the face.</p><p>According to latest estimates (from 1998) there are 140&nbsp;000 new cases of noma annually. Without treatment, noma is fatal in 90% of cases. Survivors suffer from severe facial disfigurement, have difficulty speaking and eating, endure social stigma, and require complex surgery and rehabilitation. Where noma is detected at an early stage, its progression can be rapidly halted through basic hygiene, antibiotics and improved nutrition.</p><h2>Cleft lip and palate</h2><p>Orofacial clefts, the most common of craniofacial birth defects, have a global prevalence of between 1 in 1000&ndash;1500 births, with wide variation in different studies and populations<sup> </sup><em>(2)</em>. Genetic predisposition is a major cause. However, poor maternal nutrition, tobacco consumption, alcohol and obesity during pregnancy also play a role. In low-income settings, there is a high mortality rate in the neonatal period. If lip and palate clefts are properly treated by surgery, complete rehabilitation is possible.</p><h2>Risk factors</h2><p>Most oral diseases and conditions share modifiable risk factors such as tobacco use, alcohol consumption and an unhealthy diet high in free sugars that are common to other NCDs including cardiovascular disease, cancer, chronic respiratory disease and diabetes.</p><p>In addition, diabetes has been linked in a reciprocal way with the development and progression of periodontal disease. There is also a causal link between the high consumption of sugar and diabetes, obesity and dental caries.&nbsp;</p><h2>Oral health inequalities</h2><p>Oral diseases disproportionately affect the poor and socially disadvantaged members of society. There is a very strong and consistent association between socioeconomic status (income, occupation and educational level) and the prevalence and severity of oral diseases. This association exists from early childhood to older age and across populations in high-, middle- and low-income countries.</p><h2>Prevention</h2><p>The burden of oral diseases and other noncommunicable diseases can be reduced through public health interventions by addressing common risk factors.</p><p>These include:</p><ul><li>promoting a well-balanced diet low in free sugars and high in fruit and vegetables, and favouring water as the main drink;</li><li>stopping use of all forms of tobacco, including chewing of areca nuts;</li><li>reducing alcohol consumption; and</li><li>encouraging use of protective equipment when doing sports and travelling on bicycles and motorcycles (to reduce the risk of facial injuries).</li></ul><p>Adequate exposure to fluoride is an essential factor in the prevention of dental caries.</p><p>Twice-daily tooth brushing with fluoride-containing toothpaste (1000 to 1500 ppm) should be encouraged.</p><h2>Access to oral health services</h2><p>Unequal distribution of oral health professionals and a lack of appropriate health facilities to meet population needs in most countries means that access to primary oral health services is often low. Out-of-pocket costs for oral health care can be major barriers to accessing care. Paying for necessary oral health care is among the leading reasons for catastrophic health expenditures, resulting in an increased risk of impoverishment and economic hardship.&nbsp;</p><h2>WHO response</h2><p>The World Health Assembly approved a <a href=\"https://apps.who.int/gb/ebwha/pdf_files/WHA74/A74_R5-en.pdf\">Resolution on oral health</a> in 2021 at the Seventy-fourth World Health Assembly. The Resolution recommends a shift from the traditional curative approach towards a preventive approach that includes promotion of oral health within the family, schools and workplaces, and includes timely, comprehensive and inclusive care within the primary health-care system. The Resolution affirms that oral health should be firmly embedded within the NCD agenda and that oral health-care interventions should be included in national universal health coverage benefit packages.</p><p>In response to the mandate outlined in the resolution, the Secretariat developed the <a href=\"https://www.who.int/publications/i/item/9789240090538\">Global strategy on oral health</a>, adopted in May 2022 (decision WHA75.11), and included the<em> Global oral health action plan 2023\u20122030 (GOHAP) </em>in the report on NCDs, noted by the Seventy-sixth World Health Assembly in 2023 (WHA76.9).&nbsp;The GOHAP includes a range of actions for Member States, the WHO Secretariat, international partners, civil society organizations and the private sector.</p><p>In 2024, as an outcome of the first ever WHO Global Oral Health Meeting that took place 26&ndash;29 November in Bangkok, Thailand, the <a href=\"https://www.who.int/publications/m/item/bangkok-declaration---no-health-without-oral-health\">Bangkok Declaration &ndash; No Health Without Oral Health</a> was adopted. This Declaration advocates for elevating oral diseases as a global public health priority. The Bangkok Declaration reiterates Member States' commitment to the landmark 2021 resolution on oral health, which advances the prevention and control of oral diseases as part of the NCD, UHC and environmental agendas. It&nbsp;emphasizes the need to strengthen health systems through primary health care approaches, ensuring that environmental sustainability and climate resilience are central components.</p><p>&nbsp;</p><p></p><p><strong>References</strong></p><p></p><p>1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi&ntilde;eros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today</p><p>2. Salari N, Darvishi N, Heydari M, Bokaee S, Darvishi F, Mohammadi M. Global prevalence of cleft palate, cleft lip and cleft palate and lip: A comprehensive systematic review and meta-analysis. J Stomatol Oral Maxillofac Surg. 2021;S2468-7855(21)00118X. doi:10.1016/j.jormas.2021.05.008.&nbsp;</p><p>&nbsp;</p>\r\n<p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Oral health","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Oral health","ConditionLongerOverview":"","Title":"Oral health","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"","PublicationDateAndTime":"2025-03-17T21:43:00Z","ConditionBriefOverview":"","MetaDescription":"","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<div class=\"arrowed-link\"><a href=\"https://www.who.int/health-topics/oral-health\">WHO's work on oral health</a>\r\n</div><div class=\"arrowed-link\"><a href=\"https://www.who.int/team/noncommunicable-diseases/global-status-report-on-oral-health-2022\">Global oral health status report</a></div>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/children-smiling-madagascar-900-jpg.tmb-768v.jpg?sfvrsn=816f3fea_44","FormatedDate":"17 March 2025","TrimmedTitle":"Oral health"},{"Id":"f7ab459a-65d1-407a-9021-0a26935c9aa1","LastModified":"2026-10-30T16:01:06Z","PublicationDate":"2018-06-02T02:27:40Z","DateCreated":"2018-06-02T02:27:38Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"schizophrenia","ItemDefaultUrl":"/schizophrenia","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">Schizophrenia causes psychosis, is associated with considerable      disability and major disruptions to everyday life, including personal,      family, social, educational and occupational functioning.</li><li data-list=\"0\" data-level=\"1\">Globally, 1 in 300 (or 27 million) people live with schizophrenia.</li><li data-list=\"0\" data-level=\"1\">More than two out of three people with psychosis do not receive      specialist mental health care.</li><li data-list=\"0\" data-level=\"1\">Stigma, discrimination and violation of human rights of people      with schizophrenia are common.</li><li data-list=\"0\" data-level=\"1\">A range of effective care options for people with schizophrenia      exists and at least one in three people with schizophrenia will be able to      fully recover.</li></ul><hr /><h2>Symptoms</h2><p></p><p>Schizophrenia is characterized by significant impairments in the way reality is perceived and changes in behaviour related to:</p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">persistent delusions: the person has fixed beliefs that      something is true, despite evidence to the contrary;</li><li data-list=\"0\" data-level=\"1\">persistent hallucinations: the person may hear, smell, see,      touch or feel things that are not there;</li><li data-list=\"0\" data-level=\"1\">experiences of influence, control or passivity: the experience      that one&rsquo;s feelings, impulses, actions or thoughts are not generated by      oneself, are being placed in one&rsquo;s mind or withdrawn from one&rsquo;s mind by      others, or that one&rsquo;s thoughts are being broadcast to others;</li><li data-list=\"0\" data-level=\"1\">disorganized thinking, which is often observed as jumbled or      irrelevant speech;</li><li data-list=\"0\" data-level=\"1\">highly disorganized behaviour, e.g. the person does things that      appear bizarre or purposeless, or the person has unpredictable or      inappropriate emotional responses that interfere with their ability to      organize their behaviour;</li><li data-list=\"0\" data-level=\"1\">so-called negative symptoms, such as very limited speech,      restricted experience and expression of emotions, inability to experience      interest or pleasure, and social withdrawal; and/or&nbsp;</li><li data-list=\"0\" data-level=\"1\">extreme agitation or slowing of movements, maintenance of      unusual postures.</li></ul><p>People with schizophrenia often also experience persistent difficulties with their cognitive or thinking skills, such as memory, attention and problem-solving.</p><p>At least one third of people with schizophrenia achieve complete remission of symptoms <em>(1)</em>. Some people with schizophrenia experience worsening and remission of symptoms periodically throughout their lives, others a gradual worsening of symptoms over time.</p><p></p><h2>Magnitude and impact</h2><p></p><p>Schizophrenia affects approximately 1 in 300 (0.29% or 27 million) people worldwide, rising to 1 in 206 people (0.49%) among adults aged 20 and over <em>(2)</em>. It is not as common as many other mental disorders. Onset is most often during late adolescence and the twenties, and onset tends to happen earlier among men than among women.</p><p>Schizophrenia is frequently associated with significant distress and impairment in personal, family, social, educational, occupational and other important areas of life.</p><p>People with schizophrenia die nine years earlier than the general population&nbsp;<em>(3)</em>. This is often due to physical illnesses, such as cardiovascular, metabolic and infectious diseases.</p><p>People with schizophrenia often experience human rights violations both inside mental health institutions and in community settings. Stigma against people with this condition is intense and widespread, causing social exclusion, and impacting their relationships with others, including family and friends. This contributes to discrimination, which in turn can limit access to general health care, education, housing and employment.&nbsp;</p><p>During humanitarian and public health emergencies, extreme stress and fear, breakdown of social supports, isolation and disruption of health-care services and supply of medication can occur. These changes can have an impact on the lives of people with schizophrenia, such as exacerbation of existing symptoms. During emergencies, people with schizophrenia are more vulnerable than others to various human rights violations, including neglect, abandonment, homelessness, abuse and exclusion.</p><p></p><h2>Causes of schizophrenia</h2><p>Research has not identified one single cause of schizophrenia. It is thought that interaction between genes and a range of environmental factors may cause schizophrenia. Psychosocial factors may also affect the onset and course of schizophrenia. Heavy use of cannabis is associated with an elevated risk of the disorder.</p><h2>Services</h2><p></p><p>Currently, the vast majority of people with schizophrenia around the world are not receiving mental health care. Approximately <a href=\"https://www.who.int/publications/i/item/9789241547741\"></a><a href=\"https://www.who.int/publications/i/item/9789241547741\">50% of people</a> in mental hospitals have a schizophrenia diagnosis. Only <a href=\"https://www.who.int/publications/i/item/9789240114487\"></a><a href=\"https://www.who.int/publications/i/item/9789240114487\">29% of people</a> with psychosis receive specialist mental health care. Most resources for mental health services are inefficiently spent on care within mental hospitals.</p><p>There is clear evidence that mental hospitals are not effective in providing the care that people with mental health conditions need and, regularly, violate the basic human rights of persons with schizophrenia. Efforts to transfer care from mental health institutions to the community need to be expanded and accelerated. Such efforts start with the development of a range of quality community-based mental health services. Options for community-based mental health care include integration in primary health and general hospital care, community mental health centres, day centres, supported housing, and outreach services for home-based support. The engagement of the person with schizophrenia, family members and the wider community in providing support is important.</p><p></p><h2>Management and support</h2><p>A range of effective care options for people with schizophrenia exist, and these include medication, psychoeducation, family interventions, cognitive-behavioural therapy and psychosocial rehabilitation (e.g. life skills training). Facilitated assisted\r\n    living, supported housing and supported employment are essential care options that should be available for people with schizophrenia.&nbsp; A recovery-oriented approach &ndash; giving people agency in treatment decisions &ndash; is essential for people\r\n    with schizophrenia and for their families and/or caregivers as well.</p><h2>WHO response</h2><p><a href=\"https://www.who.int/publications/i/item/9789240031029\">WHO&rsquo;s Comprehensive mental health action plan 2013&ndash;2030</a> highlights the steps required to provide appropriate services for people with mental disorders including schizophrenia. A key recommendation of the action plan is to shift services from institutions to the community. The WHO Special Initiative for Mental Health aims to further progress towards objectives of the action plan by ensuring 100&nbsp;million more people have access to quality and affordable care for mental health conditions.</p><p><a href=\"https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme\">WHO's Mental Health Gap Action Programme (mhGAP) </a>uses evidence-based technical guidance, tools and training packages to expand service in countries, especially in resource-poor settings. It focuses on a prioritized set of conditions, including psychosis,\r\n    directing capacity building towards non-specialized health-care providers in an integrated approach that promotes mental health at all levels of care. Currently mhGAP is being implemented in more than 100 WHO Member States.</p><p>The <a href=\"https://www.who.int/teams/mental-health-and-substance-use/policy-law-rights/qr-e-training\">WHO QualityRights Project</a> involves improving the quality of care and human rights conditions in mental health and social care facilities and to empower organizations to advocate for the rights and health of people with mental health conditions and psychosocial\r\n    disabilities.&nbsp; </p><p>The WHO guidance on community mental health services and person-centred and rights-based approaches&nbsp; provides information and support to all stakeholders who wish to develop or transform their mental health system and services to align with international\r\n    human rights standards including the UN Convention on the Rights of Persons with Disabilities.</p><h2><strong>References</strong></h2><p></p><p>(1) Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001;178:506-17.</p><p>(2)&nbsp;2023 Global Burden of Disease (GBD) [online database]. Seattle: Institute for Health Metrics and Evaluation; 2025 (<a href=\"https://vizhub.healthdata.org/gbd-results/\">https://vizhub.healthdata.org/gbd-results/</a>. </p><p>(3)<em>&nbsp;</em>Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia.&nbsp;<em>Annual Review of Clinical Psychology</em>, 2014;10, 425-438.</p><p></p><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Schizophrenia","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Schizophrenia","ConditionLongerOverview":"","Title":"Schizophrenia","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs397","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on schizophrenia, including key facts, symptoms, causes, services and management and what WHO is doing in this area.","PublicationDateAndTime":"2026-09-11T16:59:13Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on schizophrenia, including key facts, symptoms, causes, services and management and what WHO is doing in this area.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<p><a href=\"https://www.who.int/publications/i/item/9789240031029\">WHO&rsquo;s Comprehensive Mental Health Action Plan 2013-2030</a></p><p><a href=\"https://www.who.int/initiatives/who-special-initiative-for-mental-health\">WHO Special Initiative for Mental Health</a></p><p><a href=\"https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre\">WHO's Mental Health Gap Action Programme (mhGAP</a>)</p><p><a href=\"https://www.who.int/publications/i/item/who-qualityrights-guidance-and-training-tools\">QualityRights materials for training, guidance and transformation</a></p><p><a href=\"https://www.who.int/publications/i/item/guidance-and-technical-packages-on-community-mental-health-services\">Guidance and technical packages on community mental health services</a> </p><p><a href=\"https://www.who.int/health-topics/mental-health#tab=tab_1\">More on mental health</a> </p><p>&nbsp;</p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/schizophrenia-jpg.tmb-768v.jpg?sfvrsn=8650686f_44","FormatedDate":"11 September 2026","TrimmedTitle":"Schizophrenia"},{"Id":"b3b8bacf-b8f4-4405-bf12-23b138cf18ff","LastModified":"2026-09-16T14:50:52Z","PublicationDate":"2018-06-02T02:27:42Z","DateCreated":"2018-06-02T02:27:40Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"mental-health-strengthening-our-response","ItemDefaultUrl":"/mental-health-strengthening-our-response","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Globally, more than a billion people live with a mental health condition.&nbsp;</li><li>Affordable, effective and feasible strategies exist to promote, protect and restore mental health.</li><li>The need for action on mental health is indisputable and urgent.</li><li>Mental health has intrinsic and instrumental value and is integral to our well-being.</li></ul><hr /><h2>Overview</h2><p>Mental health is a state of mental well-being that enables people to cope with the stresses of life, realize their abilities, learn and work well, and contribute to their community. It has intrinsic and instrumental value and is a basic human right. </p><p>Mental health exists on a complex continuum, which is experienced differently from one person to the next. At any one time, a diverse set of individual, family, community and structural factors may combine to protect or undermine mental health. Although most people are resilient, people who are exposed to adverse circumstances are at higher risk of developing a mental health condition.</p><p>Mental health conditions include mental disorders and psychosocial disabilities as well as other mental states associated with significant distress, impairment in functioning, or risk of self-harm. Many mental health conditions can be effectively treated at relatively low cost, yet health systems remain significantly under-resourced and treatment gaps are wide all over the world.</p><h2>Risks and protective factors</h2><p>The risks and protective factors that influence mental health operate at multiple levels.</p><p>Individual factors such as emotional skills, substance use and genetics can increase vulnerability to mental health problems.</p><p>Social and environmental factors &ndash; including poverty, violence, inequality and environmental deprivation &ndash; also increase the risk of experiencing mental health conditions.</p><p>Risks can emerge at any stage of life, but those occurring during sensitive developmental periods, especially early childhood, are particularly harmful. For example, harsh parenting and physical punishment can damage child health and bullying is a leading risk factor for mental health conditions.</p><p>Protective factors similarly occur throughout our lives and help build resilience. They include individual social and emotional skills, positive social interactions, access to quality education, decent work, safe neighbourhoods and strong community ties.</p><p>Mental health risks and protective factors can be found at different scales. Local challenges affect individuals, families and communities, while global threats &ndash; such as economic downturns, disease outbreaks, humanitarian emergencies, forced displacement and climate change &ndash; impact entire populations.</p><p>No single factor can reliably predict mental health outcomes. Many people exposed to risk factors never develop a mental health condition, while others may be affected without any known risk. However, the interplay of these determinants collectively shapes mental health over time.</p><h2>Mental health promotion and prevention</h2><p>Promotion and prevention efforts aim to improve mental health by addressing individual, social and structural determinants of mental health. Interventions can be designed for individuals, specific groups or whole populations.</p><p>Because many determinants lie outside the health sector, effective promotion and prevention programmes require cross-sector collaboration. Education, labour, justice, transport, environment, housing, and welfare sectors all have vital roles. The health sector can contribute by embedding promotion and prevention into its services and by leading or supporting multisectoral coordination.</p><p>Suicide prevention is a global priority and part of the Sustainable Development Goals. Key strategies include limiting access to means, promoting responsible media reporting, supporting social and emotional learning for adolescents, and ensuring early intervention. Banning highly hazardous pesticides is a particularly inexpensive and cost&ndash;effective intervention for reducing suicide rates.</p><p>Promoting child and adolescent mental health is another priority. Effective approaches include policies and laws that protect mental health, support for caregivers, school-based programmes and improvements to community and online environments. Among these, school-based social and emotional learning programmes are especially effective across all income levels.</p><p>Mental health at work is a growing area of interest and can be supported through legislation and regulation, workplace policies, manager training and targeted interventions for workers.</p><h2>Mental health care and treatment</h2><p>National efforts to strengthen mental health must focus not only on promoting mental well-being for all, but also on addressing the needs of people with mental health conditions.</p><p>This is best achieved through community-based mental health care, which is more accessible and acceptable than institutional care, helps prevent human rights violations, and delivers better recovery outcomes. Such care should be provided through a coordinated network of services that comprise:</p><ul type=\"disc\"><li>integrated mental health services within general health care, typically in general hospitals and through task-sharing with non-specialist care providers in primary health care;</li><li>dedicated community mental health services, such as community mental health centres and teams, psychosocial rehabilitation, peer support and supported living; and</li><li>mental health support in non-health settings, including child protection services, school health programmes, and prisons.</li></ul><p>The vast care gap for common mental health conditions such as depression and anxiety means countries must also explore innovative approaches to expand and diversify care. These include non-specialist psychological interventions and digital self-help tools, which can be scaled efficiently and affordably.</p><h2>WHO response</h2><p>All WHO Member States have committed to the&nbsp;<a href=\"https://www.who.int/publications/i/item/9789240031029\">Comprehensive mental health action plan 2013&ndash;2030</a>, which aims to improve mental health through four key strategies focused on leadership, community-based care, promotion and prevention, and data. WHO&rsquo;s latest analysis of country performance against the action plan,&nbsp;<a href=\"https://www.who.int/publications/i/item/9789240114487\">Mental health atlas 2024</a>&nbsp;, showed that progress towards the agreed targets remains insufficient.</p><p>To accelerate action, WHO&rsquo;s&nbsp;<a href=\"https://www.who.int/publications/i/item/9789240049338\">World mental health report: transforming mental health for all</a>&nbsp;urges countries to focus on three transformative pathways:</p><ul type=\"disc\"><li>deepen the value given to mental health by individuals, communities and governments, backed by meaningful engagement and investment across sectors;</li><li>reshape environments &ndash; in homes, schools, workplaces and communities &ndash; to better protect mental health and prevent mental health conditions; and</li><li>strengthen mental health care by building community-based networks of accessible, affordable and quality services and supports that meet the full spectrum of needs.</li></ul><p>WHO places strong emphasis on human rights, empowering people with lived experience, and fostering multisectoral collaboration.</p><p>WHO continues to work nationally and internationally &ndash; including in humanitarian settings &ndash; to provide strategic leadership, evidence, tools and technical support to help governments and partners drive a collective transformation towards better mental health for all.&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Mental health","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Mental health","ConditionLongerOverview":"","Title":"Mental health","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs220","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"WHO fact sheet on mental health covering risks and protective factors, promotion and prevention, care and treatment, and WHO's work in this area.","PublicationDateAndTime":"2026-09-11T15:04:40Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on mental health providing key facts and information on determinants, strategies and interventions, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<p><strong>Publications</strong></p><ul><li><a href=\"https://www.who.int/publications/i/item/9789240113817\">World mental health today: latest data</a><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\"></span></li></ul><p><strong>More about mental health<a href=\"https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme\"></a></strong></p><ul><li><a href=\"https://www.who.int/teams/mental-health-and-substance-use/overview\">WHO's work on mental health</a></li><li><a href=\"https://www.who.int/health-topics/mental-health\">Read more about mental health</a></li><li><a href=\"https://www.who.int/campaigns/world-mental-health-day\">World Mental Health Day</a></li></ul><p><strong>&nbsp;</strong></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/topics/health-and-well-being/mental-health-and-brain-health/community-mental-health-teams.tmb-768v.jpg?sfvrsn=9bedd74b_6","FormatedDate":"11 September 2026","TrimmedTitle":"Mental health"},{"Id":"74a31541-d03a-4416-81a1-b8b7de89b244","LastModified":"2026-07-30T21:56:17Z","PublicationDate":"2018-06-02T02:27:43Z","DateCreated":"2018-06-02T02:27:42Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"palliative-care","ItemDefaultUrl":"/palliative-care","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"","Content":"<div><span style=\"font-size:1em;\">Palliative care is an approach that improves the quality of life of patients (adults and children) and their families who are facing problems associated with life-threatening illness. It prevents and relieves suffering through the early identification, correct assessment and treatment of pain and other problems, whether physical, psychosocial or spiritual.</span></div><p><span>Addressing suffering involves taking care of issues beyond physical symptoms. Palliative care uses a team approach to support patients and their caregivers. This includes addressing practical needs and providing bereavement counselling. It offers a support system to help patients live as actively as possible until death.</span></p><p><span>Palliative care is explicitly recognized&nbsp;under the human right to health. It should be provided through person-centered and integrated health services that pay special attention to the specific needs and preferences of individuals.&nbsp;</span></p><p><span>Palliative care is required for a wide range of diseases. The majority of adults in need of palliative care have chronic diseases such as cardiovascular diseases (38.5%), cancer (34%), chronic respiratory diseases (10.3%), AIDS (5.7%) and diabetes (4.6%). Many other conditions may require palliative care, including kidney failure, chronic liver disease, multiple sclerosis, Parkinson&rsquo;s disease, rheumatoid arthritis, neurological disease, dementia, congenital anomalies and drug-resistant tuberculosis.</span></p><p><span>Pain and&nbsp;</span>difficulty in breathing are two of&nbsp;<span>the most frequent and serious symptoms experienced by patients in need of palliative care. For example, 80% of patients with AIDS or cancer, and 67% of patients with cardiovascular disease or chronic obstructive pulmonary disease will experience moderate to severe pain at the end of their lives.&nbsp;</span>Opioids are essential for managing pain.&nbsp;</p><p><span>Opioids can also alleviate other common distressing physical symptoms including breathlessness. Controlling such symptoms at an early stage is an ethical duty to relieve suffering and to respect&nbsp;</span>a person&rsquo;s dignity.</p><h2 class=\"section_head2\">Insufficient access to palliative care</h2><p>Each year an estimated&nbsp;56.8 million&nbsp;people are in need of palliative care,&nbsp;most&nbsp;of whom live in low- and middle-income countries.&nbsp;<span>For children, 98% of those needing palliative care live in low- and middle-income countries with almost half of them living in Africa. </span></p><p><span>Worldwide, a number of significant barriers must be overcome to address the unmet need for palliative care:\r\n</span></p><ul><li>national health policies and systems often do not include palliative care at all;</li><li>training on palliative care for health professionals is often limited or non-existent; and</li><li>population access to opioid pain relief is inadequate and fails to meet international conventions on access to essential medicines.</li></ul><p>According to a WHO survey relating to noncommunicable diseases conducted among 194 Member States in 2019: funding for palliative care was available in 68% of countries and only 40% of countries reported that the services reached at least half of patients in need <em>(1).</em> </p><p>The International Narcotics Control Board found that in 2018, 79 per cent of the world&rsquo;s population, mainly people in low- and middle-income countries, consumed only 13 per cent of the total amount of morphine used for the management of pain and suffering, or 1 per cent of the 388 tons of morphine manufactured worldwide. Although that was an improvement over 2014, when 80 per cent of the world&rsquo;s population consumed only 9.5 per cent of the morphine used for the management of pain and suffering, the disparity in the consumption of narcotic drugs for palliative care between low- and middle-income countries and high-income countries continues to be a matter of concern <em>(2)</em>.<span></span></p><p><span>Other barriers to palliative care include:</span></p><ul><li>lack of awareness among policy-makers, health professionals and the public about what palliative care is, and the benefits it can offer patients and health systems;</li><li>cultural and social barriers, such as beliefs about death and dying; </li><li>misconceptions about palliative care, such as that it is only for patients with cancer, or for the last weeks of life; and</li><li>misconceptions that improving access to opioid analgesia will lead to increased substance abuse.</li></ul><h2 class=\"section_head2\">What can countries do?</h2><p><span>National health systems are responsible for including palliative care in the continuum of care for people with chronic and life-threatening conditions, linking it to prevention, early detection and treatment programmes. This includes, as a minimum, the following components:</span></p><ul><li>health system policies that integrate palliative care services into the structure and financing of national health-care systems at all levels of care;</li><li>policies for strengthening and expanding human resources, including training of existing health professionals, embedding palliative care into the core curricula of all new health professionals, as well as educating volunteers and the public; and</li><li>a medicines policy which ensures the availability of essential medicines for managing symptoms, in particular opioid analgesics for the relief of pain and respiratory distress.</li></ul><p><span>Palliative care is most effective when considered early in the course of the illness. Early palliative care not only improves quality of life for patients but also reduces unnecessary hospitalizations and use of health-care services.</span></p><p><span>Palliative care needs to be provided in accordance with the principles of universal health coverage. All people, irrespective of income, disease type or age, should have access to a nationally- determined set of basic health services, including palliative care. Financial and social protection systems need to take into account the human right to palliative care for poor and marginalized population groups.</span></p><p>As part of multidisciplinary teams, the nursing workforce should be trained in  palliative<a id=\"_anchor_1\" href=\"file:///C:/Users/areid/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/RR38AXQP/Palliative%20Care-fact%20sheet-updated%2023%20July%202020_ab-cv_ab_cv-final.docx#_msocom_1\" language=\"JavaScript\" name=\"_msoanchor_1\"></a>care skills, especially those who work with patients with serious illness.</p><p><span>Specialist palliative care is one component of palliative care service delivery. But a sustainable, quality and accessible palliative care system needs to be integrated into primary health care, community and home-based care, as well as supporting care providers such as family and community volunteers. Providing palliative care should be considered an ethical duty for health professionals.\r\n</span></p><h2 class=\"section_head1\">WHO response<span></span></h2><p>Palliative care medicines, including those for pain relief, are included in WHO Essential Medicines List and the WHO Essential Medicines List for Children. Palliative care is recognized in key global mandates and strategies on universal health coverage, noncommunicable diseases, and people-centred and integrated health services. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents were released in 2019 <em>(3)</em>.</p><p><span>In 2014, the first ever global resolution on palliative care, World Health Assembly resolution WHA67.19, called upon WHO and Member States to improve access to palliative care as a core component of health systems, with an emphasis on primary health care and community/home-based care. WHO&rsquo;s work to strengthen palliative care focuses on the following areas:</span></p><ul><li>integrating palliative care into all relevant global disease control and health system plans;</li><li>assessing the development of palliative care services;</li><li>developing guidelines and tools on integrated palliative care across disease groups and levels of care, addressing ethical issues related to the provision of comprehensive palliative care;</li><li>supporting Member States in improving access to palliative care medicines through improved national regulations and delivery systems;</li><li>a special focus on palliative care for people living with HIV, including development of guidelines;</li><li>promoting increased access to palliative care for children (in collaboration with UNICEF);</li><li>monitoring global palliative care access and evaluating progress made in palliative care programmes;</li><li>developing indicators for evaluating palliative care services;</li><li>encouraging adequate resources for palliative care programmes and research, especially in resource-limited countries; and</li><li>building evidence of models of palliative care that are effective in low- and middle-income settings.</li></ul><p>&nbsp;</p><p>&nbsp;</p><hr /><p><span><em>&nbsp;</em></span></p><p><em>(1)</em> Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 global survey. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. </p><p><em>(2)</em> The Report of the International Narcotics Control Board for 2019 (E/INCB/2019/1) &nbsp;<a href=\"https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2019/Narcotic_Drugs_Technical_Publication_2019_web.pdf\">https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2019/Narcotic_Drugs_Technical_Publication_2019_web.pdf</a> </p><p><em>(3) </em>WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. <a href=\"https://www.who.int/publications/i/item/who-guidelines-for-the-pharmacological-and-radiotherapeutic-management-of-cancer-pain-in-adults-and-adolescents\">https://www.who.int/publications/i/item/who-guidelines-for-the-pharmacological-and-radiotherapeutic-management-of-cancer-pain-in-adults-and-adolescents</a><em></em></p><p><span>&nbsp;</span></p>","ConditionName":"","OpenGraphTitle":"Palliative care","DocumentNumberOfAdditionalItems":1,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Palliative care","ConditionLongerOverview":"","Title":"Palliative care","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs402","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":3,"OtherRelated":"","FactSheetNumberOfAdditionalItems":1,"OpenGraphDescription":"Los cuidados paliativos constituyen un planteamiento que mejora la calidad de vida de los pacientes (adultos y ni\u00f1os) y sus allegados cuando afrontan problemas inherentes a una  enfermedad potencialmente mortal.","PublicationDateAndTime":"2020-08-05T10:56:35Z","ConditionBriefOverview":"","MetaDescription":"Los cuidados paliativos constituyen un planteamiento que mejora la calidad de vida de los pacientes (adultos y ni\u00f1os) y sus allegados cuando afrontan problemas inherentes a una  enfermedad potencialmente mortal.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<p><ul><li><a href=\"https://apps.who.int/iris/bitstream/handle/10665/250584/9789241565417-eng.pdf?sequence=1\">Planning and Implementing palliative care services: a guide for programme managers.</a><br /></li><li><a href=\"https://apps.who.int/iris/bitstream/handle/10665/274559/9789241514477-eng.pdf?ua=1\">Integrating palliative care and symptom relief into primary health care. A WHO guide for planners, implementers and managers.</a></li><li><a href=\"https://apps.who.int/iris/bitstream/handle/10665/274561/9789241514453-eng.pdf?ua=1\">Integrating palliative care and symptom relief into paediatrics. A WHO guide for planners, implementers and managers.</a><br /></li><li><a href=\"https://apps.who.int/iris/bitstream/handle/10665/274565/9789241514460-eng.pdf?ua=1\">Integrating palliative care and symptom relief into the response to humanitarian emergencies and crises. A WHO guide for planners, implementers and managers.</a></li></ul><p>&nbsp;</p><p>&nbsp;</p></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/children-palliative-care-jpg.tmb-768v.jpg?sfvrsn=a2eca396_44","FormatedDate":"5 August 2020","TrimmedTitle":"Palliative care"},{"Id":"d42a87ec-b7f2-41a0-b1b4-597d63b5dfc5","LastModified":"2026-06-11T13:22:40Z","PublicationDate":"2021-12-19T12:46:10Z","DateCreated":"2021-12-19T12:46:11Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"child-mortality-under-5-years","ItemDefaultUrl":"/child-mortality-under-5-years","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<p><h2>Key facts</h2><ul><li>In 2024, an estimated 4.9 million children under the age of 5 years died worldwide, equivalent to one death every 6 seconds.</li><li>Neonatal deaths (the first 28 days of life) accounted for 2.3 million deaths, representing 47% of all under\u2011five deaths.</li><li>The global under\u2011five mortality rate (U5MR) declined to 37.4 deaths per 1000 live births in 2024, less than half its level in 2000. </li><li>Progress in reducing under\u2011five mortality has slowed markedly since 2015, with stagnation in the total number of under\u2011five deaths between 2022 and 2024.</li><li>Sub\u2011Saharan Africa and Southern Asia together accounted for more than 80% of all under\u2011five deaths in 2024, despite representing less than 60% of global live births.</li><li>Children born in sub\u2011Saharan Africa remain at the highest risk, with a U5MR of 71.6 deaths per 1000 live births, nearly 14 times higher than in Europe and Northern America.</li><li>The leading causes of under\u2011five death are preterm birth complications, intrapartum\u2011related events (birth asphyxia/trauma), pneumonia, diarrhoea and malaria, all of which are largely preventable or treatable.</li></ul><hr /><h2>Overview&nbsp;</h2><p>Substantial progress has been made in reducing child mortality over the past three decades. Since 1990, the global under\u2011five mortality rate has declined by approximately 60%, reflecting expanded access to immunization, improved nutrition, better management of childhood illnesses and wider availability of skilled health personnel at birth.</p><p>However, most progress occurred prior to 2015. Between 2015 and 2024, the annual rate of reduction in under\u2011five mortality fell by more than half compared with 2000&ndash;2015. The total number of under\u2011five deaths has stagnated in recent years, remaining at roughly 4.8&ndash;4.9 million annually since 2022. This trend is particularly concerning given the large number of deaths due to preventable causes.</p><p>Nearly half of all under\u2011five deaths now occur in the neonatal period, reflecting slower declines in neonatal mortality compared with mortality among children aged 1&ndash;59 months. Prematurity, intrapartum events (birth asphyxia/trauma), lower respiratory infections (pneumonia) and sepsis were the most common causes of mortality among neonates &ndash; accounting for almost 8 in 10 neonatal deaths. Preventing newborn deaths requires quality antenatal, intrapartum and postnatal care, including access to skilled health personnel at birth and essential newborn care.</p><p>Child survival prospects remain deeply unequal. In 2024, more than four in five under-five deaths worldwide occurred in sub-Saharan Africa (2.8 million, 58 per cent of under-five deaths) and Southern Asia (1.2 million, 25 per cent of under-five deaths), underscoring the geographic concentration of the global child mortality burden. Fragile and conflict\u2011affected settings and low\u2011income countries face particularly high risks, driven by weak health systems, limited access to essential services, poverty and population growth.</p><p>If current trends continue, more than 27 million children are projected to die before reaching their fifth birthday between 2025 and 2030, most from preventable causes.</p><h2>Who is most at risk?</h2><p>There are fewer countries with extremely high under-five mortality, but they are primarily located in sub-Saharan Africa. In 2024, only three countries &ndash; Niger, Nigeria and Somalia &ndash; had U5MRs above 100 deaths per 1000 live births, down from 41 countries in 2000.</p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Newborns in settings without access to quality care at birth. The vast majority of newborn deaths take place in low and middle-income countries.</span></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Children living in fragile and conflict-affected settings (FCS) face substantially higher mortality rates. In 2024, children in FCS countries faced a U5MR nearly three times higher than children in non-FCS countries.</span></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Children from the poorest households, rural areas, and those born to mothers with limited education. Under-five mortality was approximately 1.5 times higher in rural than urban areas, and higher risks were associated with young maternal age, shorter birth intervals, and high birth order.&nbsp;</span></p><h2>What can be done?<o:p></o:p></h2><p>Ending preventable child deaths requires:</p><ul><li>strengthening health systems, particularly maternal, newborn and child health services;</li><li>ensuring skilled health personnel at birth and quality newborn care;</li><li>expanding prevention and treatment of pneumonia, diarrhoea and malaria;</li><li>improving nutrition, water and sanitation; and</li><li>protecting child health investments, especially in high\u2011burden and fragile settings.</li></ul><p>Families should be advised to:</p><ul><li>seek prompt medical care if necessary (danger signs include feeding problems, or if a newborn or young child has reduced activity, difficulty breathing, a fever, fits or convulsions, or feels cold);</li><li>register all births; and</li><li>bring babies for timely vaccination according to national schedules.</li></ul><p><br /></p></p>","ConditionName":"","OpenGraphTitle":"Child mortality (under 5 years)","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Child mortality (under 5 years)","ConditionLongerOverview":"","Title":"Child mortality (under 5 years)","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"Substantial progress has been made in reducing child mortality over the past three decades. Since 1990, the global under\u2011five mortality rate has declined by approximately 60%, reflecting expanded access to immunization, improved nutrition, better management of childhood illnesses and wider availability of skilled health personnel at birth.\r\n\r\nHowever, most progress occurred prior to 2015. Between 2015 and 2024, the annual rate of reduction in under\u2011five mortality fell by more than half compared with 2000\u20132015. The total number of under\u2011five deaths has stagnated in recent years, remaining at roughly 4.8\u20134.9 million annually since 2022. This trend is particularly concerning given the large number of deaths due to preventable causes.\r\n","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet with data and trends on under-5 mortality.","PublicationDateAndTime":"2026-05-01T14:24:42Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet with data and trends on under-5 mortality.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<p><a href=\"https://www.who.int/health-topics/newborn-health\">More information on newborn health</a></p><p><a href=\"https://www.who.int/health-topics/child-health\">More information on child health </a></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/topics/womens-childrens-and-adolescent-health/newborn-health/health-worker-with-mother-and-baby-in-india.tmb-768v.jpg?sfvrsn=17d5a69b_6","FormatedDate":"1 May 2026","TrimmedTitle":"Child mortality (under 5 years)"},{"Id":"7518c97e-d747-460b-8d54-6c35e35ada12","LastModified":"2024-08-13T15:21:05Z","PublicationDate":"2018-06-02T02:27:46Z","DateCreated":"2018-06-02T02:27:44Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"alcohol","ItemDefaultUrl":"/alcohol","NewsNumberOfAdditionalItems":0,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Alcohol or alcoholic beverages contain ethanol, a psychoactive and toxic substance that can cause dependence.&nbsp;</li><li>Worldwide, around 2.6 million deaths were caused by alcohol consumption in 2019. Of these, 1.6 million deaths were from noncommunicable diseases, 700 000 deaths from injuries and 300&nbsp;000 deaths from communicable diseases.&nbsp;</li><li>The alcohol-attributable mortality was heaviest among men, accounting for 2 million deaths compared to 600 000 deaths among women, in 2019.</li><li>An estimated 400 million people, or 7% of the world&rsquo;s population aged 15 years and older, lived with alcohol use disorders. Of this, 209 million people (3.7% of the adult world population) lived with alcohol dependence.</li><li>Alcohol consumption, even at low levels can bring health risks, but most alcohol related harms come from heavy episodic or heavy continuous alcohol consumption.&nbsp;</li><li>Effective alcohol control interventions exist and should be utilized more, at the same time it is important for people to know risks associated with alcohol consumption and take individual actions to protect from its harmful effects.&nbsp;&nbsp;\r\n    </li><h2>Overview</h2><p>Alcohol and alcoholic beverages contain ethanol, which is a psychoactive and toxic substance with dependence-producing properties. Alcohol has been widely used in many cultures for centuries, but it is associated with significant health risks and harms.&nbsp;</p><p>Worldwide, 2.6 million deaths were attributable to alcohol consumption in 2019, of which 2 million were among men and 0.6 million among women. The highest levels of alcohol-related deaths per 100 000 persons are observed in the WHO European and African Regions with 52.9 deaths and 52.2 deaths per 100 000 people, respectively.</p><p>People of younger age (20&ndash;39 years) are disproportionately affected by alcohol consumption with the highest proportion (13%) of alcohol-attributable deaths occurring within this age group in 2019.</p><p>The data on global alcohol consumption in 2019 shows that an estimated 400 million people aged 15 years and older live with alcohol use disorders, and an estimated 209 million live with alcohol dependence.</p><p>There has been some progress; from 2010 to 2019, the number of alcohol-attributable deaths per 100 000 people decreased by 20.2% globally.&nbsp;</p><p>There has been a steady increase in the number of countries developing national alcohol policies. Almost all countries implement alcohol excise taxes. However, countries report continued interference from the alcohol industry in policy development.</p><p>Based on 2019 data, about 54% out of 145 reporting countries had national guidelines/standards for specialized treatment services for alcohol use disorders, but only 46% of countries had legal regulations to protect the confidentiality of people in treatment.&nbsp;&nbsp;</p><p>Access to screening, brief intervention and treatment for people with hazardous alcohol use and alcohol use disorder remains very low, as well as access to medications for treatment of alcohol use disorders. Overall, the proportion of people with alcohol use disorders in contact with treatment services varies from less than 1% to no more than 14% in all countries where such data are available.</p><h2>Health risks of alcohol use</h2><p>Alcohol consumption is found to play a causal role in more than 200 diseases, injuries and other health conditions. However, the global burden of disease and injuries caused by alcohol consumption can be quantified for only 31 health conditions on the basis of the available scientific evidence for the role of alcohol use in their development, occurrence and outcomes.&nbsp;</p><p>Drinking alcohol is associated with risks of developing noncommunicable diseases such as liver diseases, heart diseases, and different types of cancers, as well as mental health and behavioural conditions such as depression, anxiety and alcohol use disorders.</p><p>An estimated 474 000 deaths from cardiovascular diseases were caused by alcohol consumption in 2019.&nbsp;</p><p>Alcohol is an established carcinogen and alcohol consumption increases the risk of several cancers, including breast, liver, head and neck, oesophageal and colorectal cancers. In 2019, 4.4% of cancers diagnosed globally and 401 000 cancer deaths were attributed to alcohol consumption.</p><p>Alcohol consumption also causes significant harm to others, not just to the person consuming alcohol. A significant part of alcohol-attributable disease burden arises from injuries such as road traffic accidents. In 2019, of a total of 298 000 deaths from alcohol-related road crashes, 156 000 deaths were caused by someone else&rsquo;s drinking.&nbsp;</p><p>Other injuries, intentional or unintentional, include falls, drowning, burns, sexual assault, intimate partner violence and suicide.&nbsp;</p><p>A causal relationship has been established between alcohol use and the incidence or outcomes of infectious diseases such as tuberculosis and HIV.</p><p>Alcohol consumption during pregnancy increases the risk of having a child with fetal alcohol spectrum disorders (FASDs), the most severe form of which is fetal alcohol syndrome (FAS), which is associated with developmental disabilities and birth defects. Alcohol consumption during pregnancy can also increase the risk of pre-term birth complications including miscarriage, stillbirth and premature delivery.&nbsp;</p><p>Younger people are disproportionately negatively affected by alcohol consumption, with the highest proportion (13%) of alcohol-attributable deaths in 2019 occurring among people aged between 20 and 39 years.</p><p>In the long term, harmful and hazardous levels of alcohol consumption can lead to social problems including family problems, issues at work, financial problems, and unemployment.</p><h2>Factors affecting alcohol consumption and alcohol-related harm</h2><p>There is no form of alcohol consumption that is risk-free. Even low levels of alcohol consumption carry some risks and can cause harm.</p><p>The level of risk depends on several factors, including the amount consumed, frequency of drinking, the health status of the individual, age, sex, and other personal characteristics, as well as the context in which alcohol consumption occurs.&nbsp;</p><p>Some groups and individuals who are vulnerable or at risk may have a higher susceptibility to the toxic, psychoactive and dependence-inducing properties of alcohol. On the other hand, individuals who adopt lower-risk patterns of alcohol consumption may not necessarily face a significantly increased likelihood of negative health and social consequences.</p><p>Societal factors which affect the levels and patterns of alcohol consumption and related problems include cultural and social norms, availability of alcohol, level of economic development, and implementation and enforcement of alcohol policies.&nbsp;</p><p>The impact of alcohol consumption on chronic and acute health outcomes is largely determined by the total volume of alcohol consumed and the pattern of drinking, particularly those patterns which are associated with the frequency of drinking and episodes of heavy drinking. Most alcohol related harms come from heavy episodic or heavy continuous alcohol consumption.</p><p>The context plays an important role in the occurrence of alcohol-related harm, particularly as a result of alcohol intoxication. Alcohol consumption can have an impact not only on the incidence of diseases, injuries and other health conditions, but also on their outcomes and how these evolve over time.</p><p>There are gender differences in both alcohol consumption and alcohol-related mortality and morbidity. In 2019, 52% of men were current drinkers, while only 35% of women had been drinking alcohol in the last 12 months. Alcohol per capita consumption was, on average, 8.2 litres for men compared to 2.2 litres for women. In 2019, alcohol use was responsible for 6.7% of all deaths among men and 2.4% of all deaths among women.&nbsp;</p><h2>WHO response</h2><p>The Global alcohol action plan 2022&ndash;2030, endorsed by WHO Member States, aims to reduce the harmful use of alcohol through effective, evidence-based strategies at national, regional and global levels. The plan outlines six key areas for action: high-impact strategies and interventions, advocacy and awareness, partnership and coordination, technical support and capacity-building, knowledge production and information systems, and resource mobilization.&nbsp;</p><p>Implementation of global strategy and action plan will accelerate global progress towards attaining alcohol-related targets under the Sustainable Development Goal 3.5 on strengthening the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol.&nbsp;</p><p>Achieving this will require global, regional and national actions on the levels, patterns and contexts of alcohol consumption and the wider social determinants of health, with a particular focus on implementing high-impact cost effective interventions.&nbsp;&nbsp;</p><p>It is vital to address the determinants that drive the acceptability, availability and affordability of alcohol consumption through cross-sectoral, comprehensive and integrated policy measures. It is also of critical importance to achieve universal health coverage for people living with alcohol use disorders and other health conditions due to alcohol use by strengthening health system responses and developing comprehensive and accessible systems of treatment and care that for those in need.</p><p>The SAFER initiative, launched in 2018 by WHO and partners, supports countries to implement the high-impact, cost-effective interventions proven to reduce the harm caused by alcohol consumption.&nbsp;</p><p>The WHO Global Information System on Alcohol and Health (GISAH) presents data on levels and patterns of alcohol consumption, alcohol-attributable health and social consequences and policy responses across the world.</p><p>Achieving a reduction in the harmful use of alcohol in line with the targets included in the Global alcohol action plan, the SDG 2030 agenda and the WHO Global monitoring framework for noncommunicable diseases, requires concerted action by countries and effective global governance.&nbsp;&nbsp;</p><p>Public policies and interventions to prevent and reduce alcohol-related harm should be guided and formulated by public health interests and based on clear public health goals and the best available evidence.&nbsp;</p><p>Engaging all relevant stakeholders is essential but the potential conflicts of interest, particularly with the alcohol industry, must be carefully assessed before engagement. Economic operators should refrain from activities that might prevent, delay or stop the development, enactment, implementation and enforcement of high-impact strategies and interventions to reduce the harmful use of alcohol.&nbsp;&nbsp;</p><p>By working together, with due diligence and protection from conflicts of interest, the negative health and social consequences of alcohol can be effectively reduced.</p><div><br /></div></ul>","ConditionName":"","OpenGraphTitle":"Alcohol","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Alcohol","ConditionLongerOverview":"","Title":"Alcohol","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs349","PhotoStoryNumberOfAdditionalItems":0,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":0,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"This WHO fact sheet on alcohol provides key facts, who is at risk, ways to reduce the burden, and WHO;s response.","PublicationDateAndTime":"2024-06-28T20:16:24Z","ConditionBriefOverview":"","MetaDescription":"This WHO fact sheet on alcohol provides key facts, who is at risk, ways to reduce the burden, and WHO;s response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"","Highlight":"<p><a href=\"https://www.who.int/publications/i/item/9789240096745\">Global status report on alcohol and health and treatment of substance use disorders</a></p><p><a href=\"https://www.who.int/publications/i/item/9789241599931\">Global strategy to reduce the harmful use of alcohol</a></p><p><a href=\"https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/alcohol/our-activities/towards-and-action-plan-on-alcohol\">Global Alcohol Action Plan 2022&ndash;2030</a></p><p><a href=\"https://www.who.int/initiatives/SAFER\">SAFER Alcohol Control Initiative</a></p><p><a href=\"https://www.who.int/health-topics/alcohol\">More on alcohol</a><span style=\"text-decoration:underline;\"></span></p><p>&nbsp;</p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/alcohol.tmb-768v.jpg?sfvrsn=b1725de7_44","FormatedDate":"28 June 2024","TrimmedTitle":"Alcohol"},{"Id":"58ca1ac3-113e-4bd3-9151-459540f9075a","LastModified":"2026-11-05T16:29:29Z","PublicationDate":"2018-06-02T02:27:50Z","DateCreated":"2018-06-02T02:27:49Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"obesity-and-overweight","ItemDefaultUrl":"/obesity-and-overweight","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<p><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Key facts</span></p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">In 2024, 1 in 7 people (1.1 billion) in the world were living with obesity.</li><li data-list=\"0\" data-level=\"1\">Worldwide adult obesity has more than doubled since 1990, and adolescent obesity has      quadrupled.</li><li data-list=\"0\" data-level=\"1\">In 2024, 45% of adults 18 years and over (2.6 billion) were overweight. Of      these, 940 million were living with obesity (16% of all adults). </li><li data-list=\"0\" data-level=\"1\">In 2024, 35&nbsp;million children under the age of 5 were overweight.</li><li data-list=\"0\" data-level=\"1\">In 2024, 400&nbsp;million children and adolescents aged 5&ndash;19 years were      overweight, including 170&nbsp;million who were living with obesity.</li></ul><p><hr /></p><h2>Overview</h2><p>Obesity is a chronic disease affecting 1.1 billion people worldwide <em>(1)</em>.</p><p>It is driven by complex interactions between environmental, social, biological and behavioural determinants. The global rise of obesity is contributing to the increasing burden of type 2 diabetes, cardiovascular disease, liver and kidney disease, and several cancers <em>(3)</em>.</p><p>Obesity affects people in all regions of the world and has risen alongside improvements in food security, socioeconomic development and major changes in diets, physical activity patterns, and broader social and behavioural norms. Together, these shifts have created environments that promote unhealthy weight gain and make prevention and treatment &nbsp;more difficult. As a result, obesity has become a major global public health challenge.</p><p>A diagnosis of overweight or obesity is made by measuring a person&rsquo;s weight and height and by calculating their body mass index (BMI): weight (kg)/height&sup2; (m&sup2;). Other measures, such as waist circumference, can also be used to identify overweight or obesity. </p><p>The BMI categories for defining overweight and obesity vary by age and sex for adults, adolescents, children and infants.</p><h2>Definition of overweight and obesity</h2><p>WHO defines overweight and obesity as outlined below.</p><h3>Adults</h3><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">overweight is a BMI greater than or equal to 25; and</li><li data-list=\"0\" data-level=\"1\">obesity is a BMI greater than or equal to 30.</li></ul><h3>Children</h3><p>For children, age needs to be considered when defining overweight and obesity.</p><h3></h3><h3>Children and adolescents aged 5&ndash;19 years</h3><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">overweight is BMI-for-age greater than 1 standard deviation above the WHO Growth      Reference median; and</li><li data-list=\"0\" data-level=\"1\">obesity is greater than 2 standard deviations above the WHO Growth Reference      median.</li></ul><p>Charts and tables: <a href=\"https://www.who.int/tools/growth-reference-data-for-5to19-years\">WHO growth reference for children aged between 5&ndash;19 years</a></p><h3>Children under 5 years of age</h3><ul><li>overweight is weight-for-height greater than 2 standard deviations above WHO Child Growth Standards median; and</li><li>obesity is weight-for-height greater than 3 standard deviations above the WHO Child Growth Standards median.</li></ul><p>Charts and tables: <a href=\"https://www.who.int/tools/child-growth-standards\">WHO child growth standards for children aged under 5 years</a></p><h2>Prevalence of overweight and obesity</h2><p>In 2024, 2.6&nbsp;billion adults aged 18 years and older were overweight, including 940&nbsp;million adults who were living with obesity&nbsp;<em>(1)</em>. This corresponds to 45% of adults aged 18 years and over (44% of men and 45% of women) who were overweight; this is an increase from 1990, when 25% of adults aged 18 years and over were overweight. Prevalence of overweight varied by region, from 32% in the WHO South-East Asia Region and the African Region to 68% in the Region of the Americas.</p><p>About 16% of adults aged 18 years and older worldwide were living with obesity in 2024. The worldwide prevalence of obesity more than doubled between 1990 and 2024.</p><p>In 2024, an estimated 35&nbsp;million children under the age of 5 years were overweight&nbsp;<em>(2)</em>. Once considered a high-income country problem, overweight is on the rise in low- and middle-income countries. In Africa, the number of overweight children under 5 years has increased by nearly 12% since 2000. Almost half of the children under 5 years who were overweight in 2024 lived in Asia.</p><p>In 2024, 400&nbsp;million children and adolescents aged 5&ndash;19 years were overweight. The prevalence of overweight (including obesity) among children and adolescents aged 5&ndash;19 has risen dramatically from just 8% in 1990 to 20% in 2024. The rise has occurred similarly among both boys and girls: in 2024, 19% of girls and 21% of boys were overweight.</p><p>While just 2% of children and adolescents aged 5&ndash;19 were living with obesity in 1990 (31&nbsp;million young people), by 2024, 8% of children and adolescents were living with obesity (170&nbsp;million young people).</p><p>Obesity prevalence is currently increasing faster in low- and middle-income countries and in many rural populations worldwide than in the urban populations and high-income countries it was once associated with.</p><h2>Causes of overweight and obesity</h2><p>Obesity is a chronic disease resulting from complex interactions between environmental and psychosocial influences and biological susceptibility.</p><p>The global health challenge of obesity is driven by increasingly obesogenic environments that limit access to healthy, affordable and sustainably produced foods; constrain opportunities for safe physical activity; and are shaped by market forces and inadequate legal and regulatory frameworks. These drivers are compounded by insufficient health system capacity to prevent, identify and manage obesity early. Addressing the challenge requires coordinated action across food systems, the built environment, regulatory and fiscal policies, and health systems to strengthen prevention, early diagnosis and multimodal chronic care including treatment, care and ongoing support.</p><p>Obesity is characterized by dysregulation of neurobiological and metabolic pathways involved in appetite, energy balance and adipose tissue function, with genetic variation influencing individual susceptibility. </p><h2>Health and economic consequences</h2><p>The health risks caused by overweight and obesity are increasingly well documented and understood.</p><p>In 2023, higher-than-optimal BMI caused an estimated 3.7&nbsp;million deaths by increasing the number of deaths from diseases such as cardiovascular diseases, diabetes and cancers <em>(3)</em>.</p><p>Overweight and obesity in childhood and adolescence adversely affect physical, mental and social well-being and should be identified and addressed as early as possible. They are associated with stigma, discrimination, bullying, poorer quality of life and impaired school performance. Without timely intervention, obesity often persists into adulthood, increasing the risk and accelerating the onset of noncommunicable diseases (NCDs), including type 2 diabetes and cardiovascular disease. Early prevention and effective treatment can reduce these long-term health risks and improve outcomes across the life course.</p>The economic impact of obesity is also important. If nothing is done, the global costs of overweight and obesity are predicted to reach US$&nbsp;3&nbsp;trillion per year by 2030 and more than US$&nbsp;18&nbsp;trillion by 2060&nbsp;<em>(4)</em>.<h2>Facing a double burden of malnutrition</h2><p>Many low- and middle-income countries face a so-called double burden of malnutrition.</p><p>While these countries continue to deal with the problems of infectious diseases and undernutrition, they are also experiencing a rapid upsurge in noncommunicable disease risk factors such as obesity and overweight.</p><p>Children in low- and middle-income countries are more vulnerable to inadequate pre-natal, infant and young child nutrition. At the same time, the children are exposed to high-fat, high-sugar, high-salt, energy-dense and micronutrient-poor foods, which tend to be lower in cost but also lower in nutrient quality. These dietary patterns, in conjunction with lower levels of physical activity, result in sharp increases in childhood obesity while undernutrition issues remain unsolved.</p><h2>Prevention and management<br /></h2><p>Overweight and obesity, as well as their related noncommunicable diseases, are largely preventable and manageable.</p><p>At the individual level, the risk of overweight and obesity can be reduced through preventive actions taken throughout the life course, from before conception through older age. These include:</p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">achieving a healthy weight before pregnancy and ensuring appropriate weight gain      during pregnancy; </li><li data-list=\"0\" data-level=\"1\">practising exclusive breastfeeding for the first 6 months of life and continuing      breastfeeding up to 2 years of age or beyond; </li><li data-list=\"0\" data-level=\"1\">supporting healthy eating, physical activity, good sleep, and limiting sedentary      behaviour and screen time throughout childhood and adolescence; </li><li data-list=\"0\" data-level=\"1\">limiting the consumption of sugar-sweetened beverages and energy-dense,      nutrient-poor foods; </li><li data-list=\"0\" data-level=\"1\">eating a healthy diet rich in fruits, vegetables, legumes, whole grains, and      nuts, while limiting foods high in fats, sugars, and salt; </li><li data-list=\"0\" data-level=\"1\">engaging in regular physical activity throughout life; </li><li data-list=\"0\" data-level=\"1\">getting adequate sleep and supporting emotional well-being; and </li><li data-list=\"0\" data-level=\"1\">avoiding tobacco use and the harmful use of alcohol.</li></ul><p>Health practitioners need to:</p><ul><li>routinely assess weight status and identify overweight and obesity early; </li><li>provide evidence-based counselling on healthy diet, physical activity, sleep and other healthy behaviours to all;</li><li>assess obesity-related complications, comorbidities, hypertension, diabetes, disability, mental health and other NCD risk factors; </li><li>deliver or refer people with obesity to comprehensive, person-centred multimodal chronic care, including behavioural interventions, nutritional counselling, psychological support, pharmacological treatment, and metabolic and bariatric surgery, as appropriate;</li><li>develop individualized, long-term care plans with regular follow-up to improve cardiometabolic health, support sustained weight management, reduce obesity-related complications, and improve quality of life; and</li><li>monitor treatment response, service coverage, quality of care and long-term health outcomes of treatment. </li></ul>Obesity is a societal rather than solely an individual responsibility. Dietary and physical activity patterns are strongly influenced by environmental, commercial and societal conditions that shape &ndash; and often constrain &ndash; individual choice. Halting the rise in obesity therefore requires coordinated multisectoral action to create supportive environments that make healthy diets and regular physical activity the easiest, most accessible and affordable choices, while strengthening health systems to expand equitable access to prevention, early intervention and comprehensive obesity chronic care.<div><div><div id=\"_com_1\"><p><strong>Key policy actions include:</strong></p></div></div></div><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">structural, fiscal and regulatory measures to create healthy food environments that      make healthier food options available, affordable and desirable; </li><li data-list=\"0\" data-level=\"1\">actions across food systems, education, urban planning, transport and social      protection to address the wider determinants of health and promote healthy      eating and physical activity throughout the life course; and </li><li data-list=\"0\" data-level=\"1\">health system responses that strengthen primary health care to identify risk,      prevent, diagnose, treat and manage obesity and NCD through integrated,      person-centred multimodal chronic care programmes.<br /></li></ul><p>The food industry can play a significant role in promoting healthy diets by:</p><ul type=\"disc\"><li data-list=\"1\" data-level=\"1\">reducing the fat, sugar and salt content of processed foods;</li><li data-list=\"1\" data-level=\"1\">ensuring that healthy and nutritious choices are available and affordable to all      consumers;</li><li data-list=\"1\" data-level=\"1\">restricting marketing of foods high in sugars, salt and fats, especially those foods      aimed at children and teenagers; and</li><li data-list=\"1\" data-level=\"1\">ensuring the availability of healthy food choices and supporting regular physical      activity practice in the workplace.</li></ul><h2>WHO response</h2><p>WHO has recognized the urgent need to tackle the global health obesity challenge. WHO Member States have called for accelerated global action to address the double burden of malnutrition, including through effective prevention and management of obesity.</p><p>WHO has developed a series of&nbsp;best buys for NCD prevention and management&nbsp;that are feasible, evidence-based and cost effective. The economic return on investment of healthy diet-related best buys is estimated at&nbsp;14 times for every unit of currency invested.</p><p>Almost&nbsp;9 out of 10 countries&nbsp;have adopted policy goals towards obesity reduction. Higher-income countries more often have adopted specific healthy diet-related best buys policies, and on a mandatory basis, than lower-income countries.</p><p>In 2022, Member States endorsed the&nbsp;<a href=\"https://www.who.int/publications/b/69195\">WHO Acceleration Plan to Stop Obesity</a>. It supports countries in transforming food and urban environments, creating knowledge, motivation and skills among the general population and people living with obesity, and strengthening health systems to expand equitable access to obesity prevention and treatment services. It has expanded to&nbsp;34 frontrunner countries, representing&nbsp;1.3 billion people&nbsp;and one third of the global population living with obesity.</p><p>In December 2025, WHO published <a href=\"https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity\"></a><a href=\"https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity\">the&nbsp;guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults</a>. It supports their safe, equitable and appropriate inclusion as one component of&nbsp;multimodal chronic obesity care, alongside behavioural, nutritional, psychological and other evidence-based interventions.</p><p>WHO is working alongside countries to prepare health systems to scale up comprehensive obesity chronic care programmes and support monitoring of service coverage, quality of care and health outcomes.</p><p>&nbsp;</p><h3>References</h3><p>1. NCD Risk Factor Collaboration (NCD-RisC). Obesity rise plateaus in developed nations and accelerates in developing nations.&nbsp;<em>Nature</em>&nbsp;653, 510&ndash;518 (2026). https://doi.org/10.1038/s41586-026-10383-0</p><p>2. United Nations Children&rsquo;s Fund (UNICEF), World Health Organization, International Bank for Reconstruction and Development/The World Bank. Levels and trends in child malnutrition: Key Findings of the 2025 Edition of the Joint Child Malnutrition Estimates. Geneva: World Health Organization; 2025</p><p>3. GBD 2023 Disease and Injury and Risk Factor Collaborators. &ldquo;Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990&ndash;2023: a systematic analysis for the Global Burden of Disease Study 2023&rdquo;.&nbsp;<em>Lancet.</em>&nbsp;2025; 406:10513 1873.</p><p>4. Okunogbe et al., &ldquo;<a href=\"https://data.worldobesity.org/resources/WOF-Economic-Impacts-2-V2.pdf\" target=\"_blank\">Economic Impacts of Overweight and Obesity</a>.&rdquo; 2nd Edition with Estimates for 161 Countries. World Obesity Federation, 2022.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Obesity and overweight","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Obesity and overweight","ConditionLongerOverview":"","Title":"Obesity and overweight","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs311","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"Obesity and overweight fact sheet from WHO providing key facts and information on causes, health consequences, double burden of disease, prevention, WHO response.","PublicationDateAndTime":"2026-10-07T07:00:00Z","ConditionBriefOverview":"","MetaDescription":"Obesity and overweight fact sheet from WHO providing key facts and information on causes, health consequences, double burden of disease, prevention, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"","Highlight":"<p><a href=\"https://www.who.int/publications/i/item/9241592222\">Global Strategy on Diet, Physical Activity and Health</a></p><p><a href=\"https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/body-mass-index?introPage=intro_3.html\">Body Mass Index (BMI)</a>&nbsp;</p><p><a href=\"https://www.who.int/tools/child-growth-standards\">WHO Child Growth Standards (under 5 years of age)</a></p><p><a href=\"https://www.who.int/tools/growth-reference-data-for-5to19-years\">Growth reference data for 5-19 years</a></p><p><a href=\"https://www.who.int/health-topics/obesity\">WHO's work on obesity</a></p><p><a href=\"https://www.who.int/health-topics/nutrition\">WHO's work on nutrition</a></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/topics/diseases-and-conditions/obesity/medical-visit.tmb-768v.jpg?sfvrsn=1cc5b3e5_6","FormatedDate":"7 October 2026","TrimmedTitle":"Obesity and overweight"},{"Id":"f8e80212-e9cc-4dab-93e8-e08b769f40e4","LastModified":"2026-07-28T08:39:00Z","PublicationDate":"2018-06-02T02:27:52Z","DateCreated":"2018-06-02T02:27:50Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"hepatitis-d","ItemDefaultUrl":"/hepatitis-d","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"","Content":"<p>&nbsp;</p><h2>Key facts</h2><ul><li>Hepatitis D virus (HDV) is a virus that requires hepatitis B virus (HBV) for its replication. Chronic HDV occurs only in people living with HBV.</li><li>HDV affects globally nearly 5% (an estimated 12 million) of people who have a chronic infection with HBV.</li><li>Populations that are more likely to have HBV and HDV co-infection include indigenous populations, recipients of haemodialysis and people who inject drugs.</li><li>Chronic HDV infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards liver-related death and hepatocellular carcinoma.</li><li>HDV has recently been classified as carcinogenic to humans, just like hepatitis B and C.</li><li>Hepatitis D infection can be prevented by hepatitis B immunization.</li><li>Novel treatment options with better safety profiles and outcomes are emerging and have been approved in Europe.</li></ul><hr /><h2>Overview</h2><p>Hepatitis D is an inflammation of the liver caused by the hepatitis D virus (HDV), which requires hepatitis B virus (HBV) for its replication. Hepatitis D infection cannot occur in the absence of HBV. HDV&ndash;HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards hepatocellular carcinoma and liver-related death. Vaccination against hepatitis B can prevent HDV infection. HDV has recently been classified as carcinogenic to humans (class I) by the IARC Monographs Programme, just like hepatitis B and C.</p><h2>Geographical distribution</h2><p>In a study published in the&nbsp;<em>Journal of Hepatology</em>&nbsp;in 2020&nbsp;<em>(1)</em>, conducted in collaboration with WHO, it was estimated that hepatitis D virus (HDV) affects nearly 5% of people globally who have a chronic infection with hepatitis B virus (HBV) and that HDV co-infection could explain about 1 in 5 cases of liver disease and liver cancer in people with HBV infection. The study has identified several geographical hotspots of high prevalence of HDV infection including Mongolia, the Republic of Moldova, and countries in western and central Africa.</p><h2>Transmission</h2><p>HDV is blood borne and transmitted in the same way as HBV. Transmission may occur through contact with infected human blood or other bodily fluids. It may also be transmitted through sexual intercourse, or rarely from a mother to her child before or around birth (vertical transmission). HDV can also spread within families in endemic areas. </p><p>Chronic HBV carriers are at risk of infection with HDV. People who are not immune to HBV (either by natural disease or immunization with the hepatitis B vaccine) are at risk of infection with HBV, which puts them at risk of HDV infection.</p><p>Those who are more likely to have HBV and HDV co-infection include indigenous people, people who inject drugs and people with hepatitis C virus or HIV infection. The risk of HDV infection also appears to be potentially higher in recipients of haemodialysis, men who have sex with men and commercial sex workers.&nbsp;</p><p>Vaccination against HBV can prevent HDV coinfection and hence expansion of childhood HBV immunization programmes has resulted in a decline in hepatitis D incidence worldwide.</p><h2>Symptoms</h2><p>Simultaneous infection with HBV and HDV can lead to mild-to-severe hepatitis with signs and symptoms of indistinguishable from those of other types of acute viral hepatitis infections. These features typically appear 3&ndash;7 weeks after initial infection and include fever, fatigue, loss of appetite, nausea, vomiting, dark urine, pale-coloured stools, jaundice (yellow eyes) and even fulminant hepatitis. However, recovery is usually complete, development of fulminant hepatitis is infrequent, and progression to chronic hepatitis D is rare (less than 5% of acute hepatitis).</p><p>In a superinfection, HDV can infect a person already chronically infected with HBV. The superinfection of HDV on chronic hepatitis B accelerates progression to a more severe disease in all ages and in 70\u201290% of persons. HDV superinfection markedly accelerates progression to cirrhosis when compared with HBV mono-infected persons. Patients with HDV induced cirrhosis are at an increased risk of hepatocellular carcinoma (HCC); however, the mechanism in which HDV causes more severe hepatitis and a faster progression of fibrosis than HBV alone remains unclear.</p><h2>Diagnosis</h2><p>Diagnosing chronic HDV requires serology to demonstrate exposure (past or current infection) and molecular methods to demonstrate the presence of HDV RNA and active infection. </p><p>However, HDV diagnostics are not widely available &ndash; especially in low- and middle-income countries &ndash; and there is only little standardization for HDV RNA assays, which are essential to detect active, viremic infection and for monitoring response to antiviral therapy.</p><h2>Treatment</h2><p>Until recently, pegylated interferon &alpha; (PEG-IFN&alpha;) had been the only treatment option for chronic HDV.&nbsp; However, its use has been limited by poor treatment outcomes, side-effects and contraindications. Only about 20&ndash;30% of those treated with PEG-IFN&alpha; achieve complete virological response under treatment, and relapse is frequent. <br /></p><p>The HDV treatment landscape is now rapidly evolving, with some novel agents showing favourable results. In 2023, Bulevirtide, an entry inhibitor that is given once daily through subcutaneous injection, received approval for treatment of chronic HDV by the European Medicines Agency (EMA) among adults with compensated liver disease. Several multi-centre studies continue to evaluate best treatment dosage, treatment duration and possible combination with PEG-IFN&alpha;. <br /></p><p>Nucleoside analogues used for hepatitis B treatment have shown no direct benefit in controlling HDV although they are generally used for managing the chronic HBV infection. </p><h2>Prevention</h2><p>Prevention services of hepatitis D should focus on reducing HBV transmission through hepatitis B immunization, including timely birth dose, additional antiviral prophylaxis for eligible pregnant women, blood safety, safe injection practices in health-care settings and harm reduction services with clean needles and syringes. Hepatitis B immunization does not provide protection against HDV for those already infected with HBV.</p><h2>WHO response</h2><p>Global health sector strategies on, respectively, HIV, viral hepatitis, and sexually transmitted infections for the period 2022&ndash;2030&nbsp;(GHSS)&nbsp;guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS, viral hepatitis (especially chronic hepatitis B and C)&nbsp; and sexually transmitted infections by 2030.</p><p>The GHSS recommends shared and disease-specific country approaches supported by actions through WHO and partners. They consider the epidemiological, technological and contextual shifts of previous years, foster learnings across the disease areas, and create opportunities to leverage innovations and new knowledge for effective responses to the diseases. They call to scale up prevention, testing and treatment of viral hepatitis with a focus to reach populations and communities most affected and at risk for each disease, as well as addressing gaps and inequities. They promote synergies under a universal health coverage and primary health care framework and contribute to achieving the goals of the 2030 Agenda for Sustainable Development.</p><p>Additionally, WHO released updated <a href=\"https://www.who.int/publications/i/item/9789240090903\">Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection</a> in 2024. These guidelines now include formal recommendations for testing and confirmatory diagnosis of HDV. WHO is working as well to include the key HDV tests into its essential diagnostics list and is working with partners and member states to highlight the importance of a public health response to HDV. </p><p>WHO organizes annual <a href=\"https://www.who.int/campaigns/world-hepatitis-day\">World Hepatitis Day campaigns</a>&nbsp; on 28 July to increase awareness and understanding of viral hepatitis. <br /></p>","ConditionName":"","OpenGraphTitle":"Hepatitis D","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Hepatitis D","ConditionLongerOverview":"","Title":"Hepatitis D","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/hepatitis-d","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"Hepatitis D is an inflammation of the liver caused by the hepatitis D virus (HDV), which requires hepatitis B virus (HBV) for its replication. Hepatitis D infection cannot occur in the absence of hepatitis B virus. HDV\u2013HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards hepatocellular carcinoma and liver-related death.","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"<div><h3></h3></div><div><p><strong>Guidelines &amp; manuals</strong></p><ul><li><a href=\"https://www.who.int/publications/i/item/9789241549059\">Hepatitis B treatment</a></li><li><a href=\"https://www.who.int/publications/i/item/9789241510288\">Monitoring and evaluation of hepatitis B and C</a></li><li><a href=\"https://www.who.int/publications/i/item/9789241509350\">Manual for the development of national viral hepatitis plans</a></li></ul></div><div><p><strong>More about hepatitis</strong></p><ul><li><a href=\"https://www.who.int/health-topics/hepatitis\">General information on hepatitis&nbsp;</a></li><li><a href=\"https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/overview\">Technical information on hepatitis</a></li></ul><p><strong>Publications</strong></p><ul><li><a target=\"_blank\" href=\"https://www.who.int/publications/i?healthtopics=6668dc3c-517a-4a79-877f-8bd07c63247c\"></a><a href=\"https://who.int/publications/i?healthtopics=6668dc3c-517a-4a79-877f-8bd07c63247c\" target=\"_blank\">All WHO hepatitis publications</a></li></ul></div>","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"WHO fact sheet including information on transmission, symptoms, prevention, diagnosis, treatment and WHO activities. ","PublicationDateAndTime":"2026-07-28T15:30:14Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet including information on transmission, symptoms, prevention, diagnosis, treatment and WHO activities. ","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"","Highlight":"<div><div><p><a href=\"https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/reports/global-hepatitis-report-2026\">Global hepatitis report 2026</a></p></div><div><p><a href=\"https://www.who.int/campaigns/world-hepatitis-day\">World Hepatitis Day</a></p></div><div><p><a href=\"https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/strategies/global-health-sector-strategies\"></a><a href=\"https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/strategies/global-health-sector-strategies\">Global health sector strategy on viral hepatitis</a></p></div></div>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/hepatitis-south-sudan.tmb-768v.jpg?sfvrsn=79f6eef2_44","FormatedDate":"28 July 2026","TrimmedTitle":"Hepatitis D"},{"Id":"a49adcb0-a33b-40db-8b67-8745033cbf55","LastModified":"2026-09-15T19:47:27Z","PublicationDate":"2018-06-02T02:27:54Z","DateCreated":"2018-06-02T02:27:52Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"cardiovascular-diseases-(cvds)","ItemDefaultUrl":"/cardiovascular-diseases-(cvds)","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<div><h2>Key facts</h2><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">Cardiovascular diseases (CVDs) are the leading cause of death      globally.</li><li data-list=\"0\" data-level=\"1\">An estimated 19.8 million people died from CVDs in 2022,      representing approximately 32% of all global deaths. Of these deaths, 85% were due to      heart attack and stroke.</li><li data-list=\"0\" data-level=\"1\">Over three quarters of CVD deaths take place in low- and      middle-income countries.</li><li data-list=\"0\" data-level=\"1\">Out of the 18 million premature deaths (under the age of 70) due to      noncommunicable diseases in 2021, at least 38% were caused by CVDs.</li><li data-list=\"0\" data-level=\"1\">Most cardiovascular diseases can be prevented by addressing      behavioural and environmental risk factors such as tobacco use, unhealthy      diet (including excess salt, sugar, and fats) and obesity, physical inactivity, harmful use of alcohol and air pollution.</li><li data-list=\"0\" data-level=\"1\">It is important to detect cardiovascular disease as early as      possible so that management with counselling and medicines can begin.</li></ul><h2>Overview<br /></h2></div><p>Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels. They include:</p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">coronary heart disease &ndash; a disease of the blood vessels supplying the heart muscle;</li><li data-list=\"0\" data-level=\"1\">cerebrovascular disease &ndash; a disease of the blood vessels supplying the brain;</li><li data-list=\"0\" data-level=\"1\">peripheral arterial disease &ndash; a disease of blood vessels supplying the arms and legs;</li><li data-list=\"0\" data-level=\"1\">rheumatic heart disease &ndash; damage to the heart muscle and heart valves from rheumatic fever, caused by streptococcal bacteria;</li><li data-list=\"0\" data-level=\"1\">congenital heart disease &ndash; birth defects that affect the normal development and functioning of the heart caused by malformations of the heart structure from birth; and</li><li data-list=\"0\" data-level=\"1\">deep vein thrombosis and pulmonary embolism &ndash; blood clots in the leg veins, which can dislodge and move to the heart and lungs.</li></ul><p>Heart attacks and strokes are usually acute events and are mainly caused by a blockage that prevents blood from flowing to the heart or brain. The most common reason for this is a build-up of fatty deposits on the inner walls of the blood vessels that\r\n    supply the heart or brain. Strokes can be caused by bleeding from a blood vessel in the brain or from blood clots.<span></span></p><h2 class=\"section_head1\">Risk factors for cardiovascular disease</h2><p>The most important behavioural risk factors of heart disease and stroke are unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. Amongst environmental risk factors, air pollution is an important factor. The effects of behavioural risk factors may show up in individuals as raised blood pressure, raised blood glucose, raised blood lipids, and overweight and obesity. These &ldquo;intermediate risks factors&rdquo; can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure and other complications.</p><p>Cessation of tobacco use, reduction of salt in the diet, eating more fruit and vegetables, regular physical activity and avoiding harmful use of alcohol have been shown to reduce the risk of cardiovascular disease. Health policies that create conducive environments for making healthy choices affordable and available, as well as improving air quality and reducing pollution, are essential for motivating people to adopt and sustain healthy behaviours.</p><p>There are also a number of underlying determinants of CVDs. These are a reflection of the major forces driving social, economic and cultural change &ndash; globalization, urbanization and population ageing. Other determinants of CVDs include poverty,\r\n    stress and hereditary factors. </p><p>In addition, drug treatment of hypertension, diabetes and high blood lipids are necessary to reduce cardiovascular risk and prevent heart attacks and strokes among people with these conditions.&nbsp;<span></span></p><h2 class=\"section_head1\">Common symptoms of cardiovascular diseases</h2><h3 class=\"section_head2\">Symptoms of heart attacks and strokes </h3><p>Often, there are no symptoms of the underlying disease of the blood vessels. A heart attack or stroke may be the first sign of underlying disease. Symptoms of a heart attack include:</p><ul type=\"disc\"><li data-list=\"1\" data-level=\"1\">pain or discomfort in the centre of the chest; and/or</li><li data-list=\"1\" data-level=\"1\">pain or discomfort in the arms, the left shoulder, elbows, jaw, or back.</li></ul><p>In addition the person may experience difficulty in breathing or shortness of breath; nausea or vomiting; light-headedness or faintness; a cold sweat; and turning pale. Women are more likely than men to have shortness of breath, nausea, vomiting, and\r\n    back or jaw pain.</p><p>The most common symptom of a stroke is sudden weakness of the face, arm, or leg, most often on one side of the body. Other symptoms include sudden onset of:</p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">numbness of the face, arm, or leg, especially on one side of the body;</li><li data-list=\"0\" data-level=\"1\">confusion, difficulty speaking or understanding speech;</li><li data-list=\"0\" data-level=\"1\">difficulty seeing with one or both eyes;</li><li data-list=\"0\" data-level=\"1\">difficulty walking, dizziness and/or loss of balance or coordination;</li><li data-list=\"0\" data-level=\"1\">severe headache with no known cause; and/or</li><li data-list=\"0\" data-level=\"1\">fainting or unconsciousness.</li></ul><p>People experiencing these symptoms should seek medical care immediately.<span></span></p><h2>Characteristics of rheumatic heart disease</h2><p>Rheumatic heart disease is caused by damage to the heart valves and heart muscle from the inflammation and scarring caused by rheumatic fever. Rheumatic fever is caused by an abnormal response of the body to infection with streptococcal bacteria, which\r\n    usually begins as a sore throat or tonsillitis in children.</p><p>Rheumatic fever mostly affects children in developing countries, especially where poverty is widespread. Globally, about 2% of deaths from cardiovascular diseases are related to rheumatic heart disease.<span></span></p><h3 class=\"section_head2\">Symptoms of rheumatic heart disease</h3><p>Symptoms of rheumatic heart disease include: shortness of breath, fatigue, irregular heartbeats, chest pain and fainting.</p><p>Symptoms of rheumatic fever include: fever, pain and swelling of the joints, nausea, stomach cramps and vomiting.</p><h2 class=\"section_head1\">Why cardiovascular diseases are a development issue in low- and middle-income countries</h2><p>Approximately 80% of the world's deaths from CVDs occur in low- and middle-income countries. People living in low- and middle-income countries often do not have the benefit of primary health care programmes for early detection and treatment of people\r\n    with risk factors for CVDs. People in low- and middle-income countries who suffer from CVDs and other noncommunicable diseases have less access to effective and equitable health care services which respond to their needs. As a result, for many people\r\n    in these countries detection is often late in the course of the disease and people die at a younger age from CVDs and other noncommunicable diseases, often in their most productive years.</p><p>The poorest people in low- and middle-income countries are most affected. At the household level, evidence is emerging that CVDs and other noncommunicable diseases contribute to poverty due to catastrophic health spending and high out-of-pocket expenditure.\r\n    At the macro-economic level, CVDs place a heavy burden on the economies of low- and middle-income countries.</p><h2 class=\"section_head1\">How the burden of cardiovascular diseases can be reduced</h2><p>The key to cardiovascular disease reduction lies in the inclusion of cardiovascular disease management interventions in universal health coverage packages, although in a high number of countries health systems require significant investment and reorientation\r\n    to effectively manage CVDs.</p><p>Evidence from 18 countries has shown that hypertension programmes can be implemented efficiently and cost-effectively at the primary care level which will ultimately result in reduced coronary heart disease and stroke. Patients with cardiovascular disease\r\n    should have access to appropriate technology and medication. Basic medicines that should be available include: </p><ul type=\"disc\"><li data-list=\"1\" data-level=\"1\">aspirin</li><li data-list=\"1\" data-level=\"1\">beta-blockers</li><li data-list=\"1\" data-level=\"1\">calcium channel blockers</li><li data-list=\"1\" data-level=\"1\">angiotensin-converting enzyme inhibitors</li><li data-list=\"1\" data-level=\"1\">diuretics</li><li data-list=\"1\" data-level=\"1\">statins.</li></ul><p>An acute event such as a heart attack or stroke should be promptly managed. </p><p>Sometimes, surgical operations are required to treat CVDs. They include:</p><ul type=\"disc\"><li data-list=\"0\" data-level=\"1\">coronary artery bypass;</li><li data-list=\"0\" data-level=\"1\">balloon angioplasty (where a small balloon-like device is threaded through an artery to open the blockage);</li><li data-list=\"0\" data-level=\"1\">valve repair and replacement;</li><li data-list=\"0\" data-level=\"1\">heart transplantation; and</li><li data-list=\"0\" data-level=\"1\">artificial heart operations.</li></ul><p>Medical devices are required to treat some CVDs. Such devices include pacemakers, prosthetic valves, and patches for closing holes in the heart.<span></span></p><h2 class=\"section_head1\">WHO response</h2><p>WHO works to drive and support the implementation of effective actions for the prevention, management, and control of CVDs and their associated risk factors, especially in low- and middle-income countries. To this end, WHO:</p><ul><li>develops evidence-based guidelines and tools for the prevention and management of major noncommunicable diseases, including CVDs;</li><li>develops norms and standards for cardiovascular risk assessment, hypertension diagnosis, and CVD care;</li><li>raises awareness about the growing global burden of CVDs; and</li><li>conducts global surveillance on CVDs and their key risk factors.</li></ul><p>In 2016, to further scale up action, WHO launched the Global HEARTS Initiative, aiming to support countries in strengthening CVD prevention and control through primary health care, particularly in low- and middle-income countries.&nbsp;</p><p>In 2013, WHO Member States agreed on global mechanisms to reduce the avoidable NCD burden including a \"Global action plan for the prevention and control of NCDs 2013-2020\". This Plan has the aim of reducing the number of premature deaths from NCDs by 25% by 2025\r\n    through nine voluntary global targets. Two of the targets directly focus on preventing and controlling CVDs.</p><p>Target 6: Reduce global prevalence of raised blood pressure by 25% between 2010 and 2025.</p><p>Target 8: At least 50% of eligible people should receive drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes by 2025.</p><p>In addition, target 9 states that there should be 80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major NCDs in both public and private facilities. </p><p>Achieving these targets will require significant investment in and strengthening of health systems. </p><p>WHO is also working on increasing the normative guidance available for the management of acute coronary syndrome and stroke.</p>","ConditionName":"","OpenGraphTitle":"Cardiovascular diseases (CVDs)","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Cardiovascular diseases (CVDs)","ConditionLongerOverview":"","Title":"Cardiovascular diseases (CVDs)","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs317","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO cardiovascular diseases fact sheet providing key facts and information on risk factors, symptoms, rheumatic heart disease, treatment and prevention, WHO response.","PublicationDateAndTime":"2025-07-31T14:30:04Z","ConditionBriefOverview":"","MetaDescription":"WHO cardiovascular diseases fact sheet providing key facts and information on risk factors, symptoms, rheumatic heart disease, treatment and prevention, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<p><strong>Related links</strong><span style=\"background-color:transparent;font-family:inherit;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;font-size:inherit;\"></span></p><ul><li><a href=\"https://www.who.int/publications/i/item/9789241506236\">Global action plan for the prevention and control of NCDs 2013-2020</a></li><li><a href=\"https://www.who.int/publications/i/item/9789240001367\">HEARTS: Technical package for cardiovascular disease management in primary health care</a><a href=\"https://www.who.int/health-topics/cardiovascular-diseases\"></a></li><li><a href=\"https://www.who.int/health-topics/cardiovascular-diseases\">Health topic: cardiovascular diseases</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/wpro/health-topic/cardiovascular-diseases/medicines_ethiopia.tmb-768v.png?Culture=en&sfvrsn=48f3d3f8_6","FormatedDate":"31 July 2025","TrimmedTitle":"Cardiovascular diseases (CVDs)"},{"Id":"5eaab35e-b115-4efc-889f-c8ea0f3555c4","LastModified":"2026-04-08T13:26:53Z","PublicationDate":"2018-06-02T02:27:58Z","DateCreated":"2018-06-02T02:27:56Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"deafness-and-hearing-loss","ItemDefaultUrl":"/deafness-and-hearing-loss","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>By 2050, nearly 2.5&nbsp;billion people are projected to have some degree of hearing loss, and more than 700&nbsp;million will require hearing rehabilitation.</li><li>Around 95.1 million children aged 5-19 years live with hearing loss worldwide.</li><li>Unaddressed hearing loss poses an annual global cost of almost US$&nbsp;1&nbsp;trillion. </li><li>Over 1&nbsp;billion young adults are at risk of permanent, avoidable hearing loss due to unsafe listening practices.</li><li>An annual additional investment of less than US$&nbsp;1.40 per person is needed to scale up ear and hearing care services globally.</li><li>Over a 10-year period, this promises a return of nearly US$&nbsp;16 for every US dollar invested.<br />&nbsp;</li></ul><hr /><br /><h2>Overview</h2><p>Over 5% of the world&rsquo;s population &ndash; or 430&nbsp;million people &ndash; require rehabilitation to address their disabling hearing loss (including 34 million children). It is estimated that by 2050 over 700&nbsp;million people &ndash; or 1 in every 10 people &ndash; will have disabling hearing loss.</p><p>Disabling hearing loss refers to hearing loss greater than 35 decibels (dB) in the better hearing ear. Nearly 80% of people with disabling hearing loss live in low- and middle-income countries. The prevalence of hearing loss increases with age, among those older than 60 years, over 25% are affected by disabling hearing loss.</p><h2>Hearing loss and deafness</h2><p>A person who is not able to hear as well as someone with normal hearing &ndash; hearing thresholds of 20&nbsp;dB or better in both ears &ndash; is said to have hearing loss. Hearing loss may be mild, moderate, moderately severe, severe or profound. It can affect one ear or both ears and leads to difficulty in hearing conversational speech or loud sounds.</p><p>Hard of hearing refers to people with hearing loss ranging from mild to severe. People who are hard of hearing usually communicate through spoken language and can benefit from hearing aids, cochlear implants, and other assistive devices as well as captioning.</p><p>Deaf people mostly have profound hearing loss, which implies very little or no hearing. They can benefit from cochlear implants. Some of them use sign language for communication.</p><h2>Causes of hearing loss and deafness</h2><p>Although these factors can be encountered at different periods across the life span, individuals are most susceptible to their effects during critical periods in life. </p><h3>Prenatal period</h3><ul><li>genetic factors including hereditary and non-hereditary hearing loss</li><li>intrauterine infections &ndash; such as rubella and cytomegalovirus infection.</li></ul><h3>Perinatal period</h3><ul><li>birth asphyxia (a lack of oxygen at the time of birth)</li><li>hyperbilirubinemia (severe jaundice in the neonatal period) </li><li>low-birth weight</li><li>other perinatal morbidities and their management.</li></ul><h3>Childhood and adolescence</h3><ul><li>chronic ear infections (chronic suppurative otitis media)</li><li>collection of fluid in the ear (chronic <strong>nonsuppurative</strong> otitis media)</li><li>meningitis and other infections.</li></ul><h3>Adulthood and older age</h3><ul><li>chronic diseases</li><li>smoking</li><li>otosclerosis</li><li>age-related sensorineural hearing loss</li><li>sudden sensorineural hearing loss.</li></ul><h3>Factors across the life span&nbsp;</h3><ul><li>cerumen impaction (impacted ear wax)&nbsp;</li><li>trauma to the ear or head</li><li>loud noise/loud sounds exposure</li><li>ototoxic medicines</li><li>work related ototoxic chemicals</li><li>nutritional deficiencies&nbsp;</li><li>viral infections and other ear conditions</li><li>delayed onset or progressive genetic hearing loss.</li></ul><h2>The impact of unaddressed hearing loss</h2><p>When unaddressed, hearing loss impacts many aspects of life at individual level:</p><ul><li>limitations in communication and speech</li><li>adversely affected cognition</li><li>social isolation, loneliness&nbsp;and stigma</li><li>impact on society and economy</li><li>effects on years lived with disability (YDLs) and disability adjusted life years (DALYs)</li><li>limitations in access to education&nbsp;and employment</li><li>increased risk of developing dementia and accelerated cognitive decline when hearing loss remains unaddressed. </li></ul><h2>Prevention</h2><p>Many of the causes that lead to hearing loss can be avoided through public health strategies and clinical interventions implemented across the life course. </p><p>Prevention of hearing loss is essential throughout the life course, from prenatal and perinatal periods to older age. In children, nearly 60% of hearing loss is due to avoidable causes that can be prevented through implementation of public health\r\n    measures. Likewise, most common causes of hearing loss in adults, such as exposure to loud sounds and ototoxic medicines, are preventable.</p><p>Effective strategies for reducing hearing loss at different stages of the life course include:&nbsp;</p><ul><li>immunization</li><li>good maternal and childcare practices</li><li>genetic counselling</li><li>identification and management of common ear conditions</li><li>occupational hearing conservation&nbsp;programmes&nbsp;for noise and chemical exposure</li><li>safe listening strategies for the reduction of exposure to loud sounds in recreational settings</li><li>rational use of medicines to prevent ototoxic hearing loss.&nbsp;&nbsp;</li></ul><h2>Identification and management</h2><p>Early identification&nbsp;of hearing loss and ear diseases is key to effective management.</p><p>This requires systematic screening for detection of hearing loss and related ear diseases in those who are most at risk. This includes: </p><ul><li>newborn babies and infants</li><li>pre-school and school-age children</li><li>people exposed to noise or chemicals at work</li><li>people receiving ototoxic medicines</li><li>older adults.</li></ul><p>Hearing assessment and ear examination can&nbsp;be conducted in clinical and community settings. Tools such as the <a href=\"https://www.who.int/teams/noncommunicable-diseases/sensory-functions-disability-and-rehabilitation/hearwho\">hearWHO app</a>, WHOears app and other technology-based solutions make it possible to screen for ear diseases and hearing loss with\r\n    limited training and resources.</p><p>Once hearing loss is identified, it is essential that it is addressed as early as possible and in an appropriate manner, to mitigate any adverse impact.</p><h2>Rehabilitation for hearing loss</h2><p>Rehabilitation helps people with hearing loss to function at their optimum, which means they can be as independent as possible in everyday activities. Specifically, rehabilitation helps them to participate in education, work, recreation and meaningful roles, for example in their families or communities, throughout their lives. Interventions for rehabilitation for people with hearing loss include: </p><ul><li>the provision of, and training in the use of, hearing technologies (e.g. hearing aids, cochlear implants, bone conduction implants and middle ear implants);</li><li>speech and language therapy to enhance perceptive skills and develop communication and linguistic abilities;</li><li>training in the use of sign language and other means of sensory substitution (e.g. speech reading, use of print on palm, Tadoma, signed communication); </li><li>the provision of hearing assistive technology, and services (e.g. frequency modulation and loop systems, alerting devices, telecommunication devices, captioning services and sign language interpretation); and</li><li>counselling, training and support to enhance engagement in education, work and community life.</li></ul><h2>WHO response</h2><p>WHO&rsquo;s work on ear and hearing care is to promote integrated people-centred ear and hearing care (IPC-EHC).</p><p>WHO&rsquo;s work is guided by the recommendations of the WHO <a href=\"https://www.who.int/publications/i/item/9789240020481\">World report on hearing</a> (2021), the <a href=\"https://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_R13-en.pdf\">World Health Assembly resolution on prevention of deafness and hearing loss</a>&nbsp;and the <a href=\"https://apps.who.int/gb/ebwha/pdf_files/WHA78/A78_R7-en.pdf\">World Health Assembly on sensory impairment resolution</a>. </p><p>WHO&rsquo;s work includes:</p><ul><li>guiding, assisting and supporting Member States to increase awareness of ear and hearing care issues;</li><li>facilitating data generation and dissemination of ear and hearing care-related data and information, such as through the <a href=\"https://www.who.int/publications/i/item/9789240020481\">World report on hearing</a>;</li><li>providing technical resources and guidance to facilitate planning and health systems capacity building for ear and hearing care;</li><li>providing guidance on prevention of hearing loss;</li><li>promoting early identification of hearing loss through hearing screening across the life course, vision and hearing screening handbook and <a href=\"https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-technology/assistive-technology/learning-on-tap\">TAP modules</a>;</li><li>providing guidance to strengthen rehabilitation for people with hearing loss through the Package of ear and hearing care interventions;</li><li>supporting health workforce training in ear and hearing care through the <a href=\"https://www.who.int/teams/noncommunicable-diseases/sensory-functions-disability-and-rehabilitation/primary-ear-and-hearing-care-training-manual\">Primary ear and hearing care training resources</a>, and TAP modules;</li><li>promoting safe listening to reduce the risk of recreational noise-induced hearing loss through the <a href=\"https://www.who.int/activities/making-listening-safe\">WHO Make Listening Safe initiative</a>;</li><li>observing and promoting&nbsp;<a href=\"https://www.who.int/campaigns/world-hearing-day\">World Hearing Day</a>&nbsp;as an annual advocacy event;</li><li>building partnerships to develop strong hearing care programmes, including initiatives for including affordable and accessible ear and hearing care services and <a href=\"https://www.who.int/publications/i/item/9789240087927\">hearing aids in service delivery approaches suitable for low-and middle- income countries</a> and cochlear implants; and</li><li>advocating for ear and hearing care through the&nbsp;<a href=\"https://www.who.int/activities/promoting-world-hearing-forum\">World Hearing Forum</a>.</li></ul><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Deafness and hearing loss","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Deafness and hearing loss","ConditionLongerOverview":"","Title":"Deafness and hearing loss","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs300","PhotoStoryNumberOfAdditionalItems":0,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":0,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"<p><a href=\"https://www.who.int/news-room/questions-and-answers/item/deafness-and-hearing-loss--tinnitus\">Questions and answers on tinnitus</a><p>&nbsp;</p></p>","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"Deafness and hearing loss fact sheet from WHO: providing key facts and information on causes, impact, prevention, identification, management and WHO response.","PublicationDateAndTime":"2026-03-03T10:31:51Z","ConditionBriefOverview":"","MetaDescription":"Deafness and hearing loss fact sheet from WHO: providing key facts and information on causes, impact, prevention, identification, management and WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"","Highlight":"<div class=\"arrowed-link\"><a href=\"https://www.who.int/teams/noncommunicable-diseases/sensory-functions-disability-and-rehabilitation/highlighting-priorities-for-ear-and-hearing-care\">World report on hearing</a></div><div class=\"arrowed-link\"><a href=\"https://www.who.int/health-topics/hearing-loss\">WHO's work on prevention of deafness and hearing loss</a></div><div class=\"arrowed-link\"><a href=\"https://www.who.int/activities/making-listening-safe\">Make Listening Safe</a></div><div class=\"arrowed-link\"><a href=\"https://apps.who.int/iris/bitstream/handle/10665/280085/9789241515276-eng.pdf\">WHO-ITU global standard for personal audio systems and devices</a></div>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/health-topics/deafness-and-hearing-loss/hearing-check-zambia.tmb-768v.jpeg?sfvrsn=e3fb3bc8_12","FormatedDate":"3 March 2026","TrimmedTitle":"Deafness and hearing loss"},{"Id":"55ff7ab8-659a-40e4-8a5e-5525e678488f","LastModified":"2024-12-04T13:34:38Z","PublicationDate":"2018-06-02T02:28:00Z","DateCreated":"2018-06-02T02:27:59Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"west-nile-virus","ItemDefaultUrl":"/west-nile-virus","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"","Content":"<div><span>West Nile Virus (WNV) can cause neurological disease and death in people. WNV is commonly found in Africa, Europe, the Middle East, North America and West Asia. WNV is maintained in nature in a cycle involving transmission between birds and mosquitoes. Humans, horses and other mammals can be infected.</span></div>\r\n<p>\r\n<span>West Nile Virus (WNV) is a member of the <em>flavivirus</em> genus and belongs to the Japanese encephalitis antigenic complex of the family <em>Flaviviridae</em>. </span></p>\r\n<h2 class=\"section_head1\">Outbreaks</h2>\r\n<p>\r\n<span>West Nile Virus (WNV) was first isolated in a woman in the West Nile district of Uganda in 1937. It was identified in birds (crows and columbiformes) in Nile delta region in 1953. Before 1997 WNV was not considered pathogenic for birds, but at that time in Israel a more virulent strain caused the death of different bird species presenting signs of encephalitis and paralysis. Human infections attributable to WNV have been reported in many countries in the World for over 50 years. </span></p>\r\n<p>\r\n<span>In 1999 a WNV circulating in Israel and Tunisia was imported in New York producing a large and dramatic outbreak that spread throughout the continental United States of America (USA) in the following years. The WNV outbreak in USA (1999-2010) highlighted that importation and establishment of vector-borne pathogens outside their current habitat represent a serious danger to the world. </span></p>\r\n<p>\r\n<span>The largest outbreaks occurred in Greece, Israel, Romania, Russia and USA. Outbreak sites are on major birds migratory routes. In its original range, WNV was prevalent throughout Africa, parts of Europe, Middle East, West Asia, and Australia. Since its introduction in 1999 into USA, the virus has spread and is now widely established from Canada to Venezuela.</span></p>\r\n<h2 class=\"section_head1\">Transmission</h2>\r\n<p>\r\n<span>Human infection is most often the result of bites from infected mosquitoes. Mosquitoes become infected when they feed on infected birds, which circulate the virus in their blood for a few days. The virus eventually gets into the mosquito's salivary glands. During later blood meals (when mosquitoes bite), the virus may be injected into humans and animals, where it can multiply and possibly cause illness.</span></p>\r\n<p>\r\n<span>The virus may also be transmitted through contact with other infected animals, their blood, or other tissues.</span></p>\r\n<p>\r\n<span>A very small proportion of human infections have occurred through organ transplant, blood transfusions and breast milk. There is one reported case of transplacental (mother-to-child) WNV transmission.</span></p>\r\n<p>\r\n<span>To date, no human-to-human transmission of WNV through casual contact has been documented, and no transmission of WNV to health care workers has been reported when standard infection control precautions have been put in place.</span></p>\r\n<p>\r\n<span>Transmission of WNV to laboratory workers has been reported. </span></p>\r\n<h2 class=\"section_head1\">Signs and symptoms</h2>\r\n<p>\r\n<span>Infection with WNV is either asymptomatic (no symptoms) in around 80% of infected people, or can lead to West Nile fever or severe West Nile disease. </span></p>\r\n<p>\r\n<span>About 20% of people who become infected with WNV will develop West Nile fever. Symptoms include fever, headache, tiredness, and body aches, nausea, vomiting, occasionally with a skin rash (on the trunk of the body) and swollen lymph glands. </span></p>\r\n<p>\r\n<span>The symptoms of severe disease (also called neuroinvasive disease, such as West Nile encephalitis or meningitis or West Nile poliomyelitis) include headache, high fever, neck stiffness, stupor, disorientation, coma, tremors, convulsions, muscle weakness, and paralysis. It is estimated that approximately 1 in 150 persons infected with the West Nile virus will develop a more severe form of disease. Serious illness can occur in people of any age, however people over the age of 50 and some immunocompromised persons (for example, transplant patients) are at the highest risk for getting severely ill when infected with WNV.</span></p>\r\n<p>\r\n<span>The incubation period is usually 3 to 14 days.</span></p>\r\n<h2 class=\"section_head1\">Diagnosis</h2>\r\n<p>\r\n<span>West Nile virus can be diagnosed by a number of different tests:</span></p>\r\n<ul>\r\n    <li>IgG antibody sero-conversion (or significant increase in antibody titers) in two serial specimen collected at a one week interval by enzyme-linked immunosorbent assay (ELISA);</li>\r\n    <li>IgM antibody capture enzyme-linked immunosorbent assay (ELISA);</li>\r\n    <li>neutralisation assays;</li>\r\n    <li>viral detection by reverse transcription polymerase chain reaction (RT-PCR) assay, and</li>\r\n    <li>virus isolation by cell culture.</li>\r\n</ul>\r\n<p>\r\n<span>IgM can be detected in nearly all cerebrospinal fluid (CSF) and serum specimens received from WNV infected patients at the time of their clinical presentation. Serum IgM antibody may persist for more than a year. </span></p>\r\n<h2 class=\"section_head1\" style=\"text-align: left;\">Treatment and vaccine</h2>\r\n<p>\r\n<span>Treatment is supportive for patients with neuro-invasive West Nile virus, often involving hospitalization, intravenous fluids, respiratory support, and prevention of secondary infections. No vaccine is available for humans.</span></p>\r\n<h2 class=\"section_head1\">Vector and animal hosts</h2>\r\n<p>\r\n<span>WN virus is maintained in nature in a mosquito-bird-mosquito transmission cycle. Mosquitoes of the genus <em>Culex</em> are generally considered the principal vectors of WNV, in particular <em>Cx. Pipiens</em>. WNV is maintained in mosquito populations through vertical transmission (adults to eggs). </span></p>\r\n<p>\r\n<span>Birds are the reservoir hosts of WNV. In Europe, Africa, Middle East and Asia, mortality in birds associated with WNV infection is rare. In striking contrast, the virus is highly pathogenic for birds in the Americas. Members of the crow family (<em>Corvidae</em>) are particularly susceptible, but virus has been detected in dead and dying birds of more than 250 species. Birds can be infected by a variety of routes other than mosquito bites, and different species may have different potential for maintaining the transmission cycle.</span></p>\r\n<p>\r\n<span>Horses, just like humans, are &ldquo;dead-end&rdquo; hosts, meaning that while they become infected, they do not spread the infection. Symptomatic infections in horses are also rare and generally mild, but can cause neurologic disease, including fatal encephalomyelitis. </span></p>\r\n<h2 class=\"section_head1\">Prevention</h2>\r\n<h3 class=\"section_head2\">Preventing transmission in horses</h3>\r\n<p>\r\n<span>Since WNV outbreaks in animals precede human cases, the establishment of an active animal health surveillance system to detect new cases in birds and horses is essential in providing early warning for veterinary and human public health authorities. In the Americas, it is important to help the community by reporting dead birds to local authorities. </span></p>\r\n<p>\r\n<span>Vaccines have been developed for horses. Treatment is supportive and consistent with standard veterinary practices for animals infected with a viral agent.</span></p>\r\n<h3 class=\"section_head2\">Reducing the risk of infection in people</h3>\r\n<p>\r\n<span>In the absence of a vaccine, the only way to reduce infection in people is by raising awareness of the risk factors and educating people about the measures they can take to reduce exposure to the virus.</span></p>\r\n<p>\r\n<span>Public health educational messages should focus on the following:</span></p>\r\n<ul>\r\n    <li>Reducing the risk of mosquito transmission. Efforts to prevent transmission should first focus on personal and community protection against mosquito bites through the use of mosquito nets, personal insect repellent, by wearing light coloured clothing (long-sleeved shirts and trousers) and by avoiding outdoor activity at peak biting times. In addition community programmes should encourage communities to destroy mosquito breeding sites in residential areas.</li>\r\n    <li>Reducing the risk of animal-to-human transmission. Gloves and other protective clothing should be worn while handling sick animals or their tissues, and during slaughtering and culling procedures. </li>\r\n    <li>Reducing the risk of transmission through blood transfusion and organ transplant. Blood and organ donation restrictions and laboratory testing should be considered at the time of the outbreak in the affected areas after assessing the local/regional epidemiological situation.</li>\r\n</ul>\r\n<h3 class=\"section_head2\">Vector Control </h3>\r\n<p>\r\n<span>Effective prevention of human WNV infections depends on the development of comprehensive, integrated mosquito surveillance and control programmes in areas where the virus occurs. Studies should identify local mosquito species that play a role in WNV transmission, including those that might serve as a &ldquo;bridge&rdquo; from birds to human beings. Emphasis should be on integrated control measures including source reduction (with community participation), water management, chemicals, and biological control methods. </span></p>\r\n<h3 class=\"section_head2\">Preventing infection in health-care settings</h3>\r\n<p>\r\n<span>Health-care workers caring for patients with suspected or confirmed WNV infection, or handling specimens from them, should implement standard infection control precautions. Samples taken from people and animals with suspected WNV infection should be handled by trained staff working in suitably equipped laboratories.</span></p>\r\n<h2 class=\"section_head1\">WHO response </h2>\r\n<p>\r\n<span>The WHO regional office for Europe and WHO region of the Americas are intensively supporting WNV surveillance and outbreak response activities respectively in Europe and in North America, Latin America and the Caribbean, together with country offices and international partners.</span></p>\r\n<div>&nbsp;</div>","ConditionName":"","OpenGraphTitle":"West Nile virus","DocumentNumberOfAdditionalItems":1,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"West Nile virus","ConditionLongerOverview":"","Title":"West Nile virus","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs354","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":3,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"WHO fact sheet on West Nile virus: includes key facts, definition, outbreaks, transmission, diagnosis, treatment, prevention, WHO response.","PublicationDateAndTime":"2017-10-03T07:24:00Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on West Nile virus: includes key facts, definition, outbreaks, transmission, diagnosis, treatment, prevention, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<ul><li><a href=\"http://www.cdc.gov/ncidod/dvbid/westnile/\" target=\"_new\">West Nile virus in the USA</a></li><li><a href=\"https://www.canada.ca/en/public-health/services/diseases/west-nile-virus.html\" target=\"_blank\">West Nile virus in Canada</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/health-topics/west-nile-virus/cx-pipiens-f4671-f-schaffner.tmb-768v.png?sfvrsn=4c4e5bba_8","FormatedDate":"3 October 2017","TrimmedTitle":"West Nile virus"},{"Id":"0c559b9b-edc1-442d-8dd2-87927204a7dc","LastModified":"2025-03-25T19:24:21Z","PublicationDate":"2018-06-02T02:28:02Z","DateCreated":"2018-06-02T02:28:01Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"civil-registration-and-vital-statistics","ItemDefaultUrl":"/civil-registration-and-vital-statistics","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>It is estimated that 36 million babies born each year are not registered, as only about 50% of countries have the capacity to register at least 90% of births.</li><li>Registered births ranged from 98% in the WHO European Region, 96% in the Region of the Americas, 91% in Western Pacific Region, 78% in South-East Asia Region, 69% in the Eastern Mediterranean Region and only 44% in African Region. </li><li>Nearly 40% of the world&rsquo;s deaths are not registered, and only 8% of reported deaths in low-income countries have documented causes.</li><li>The latest global assessment of health data capacity in countries (SCORE assessment) in 164 countries found that the percentage of registered deaths ranged from 98% in the WHO European Region, 91% in the Region of the Americas, 82% in the Western Pacific Region, 61% in South-East Asia Region, 55% in Eastern Mediterranean Region and 10% in African Region<em> (1).</em> </li><li>It is estimated that 14.9 million extra deaths were associated with the COVID-19 pandemic, and 84 of 197 (43%) countries did not have mortality data to contribute to the estimation.</li></ul><p><hr /></p><h2>Overview</h2><p>Countries use civil registration to record vital events such as birth, marriage, divorce, adoption, death and cause of death. Information on births and deaths by location, age, sex and cause is the cornerstone of public health and social development planning. </p><p>The main source of vital statistics is civil registration. &ldquo;Civil registration is defined as the continuous, permanent, compulsory and universal recording of the occurrence and characteristics of vital events pertaining to the population, as provided through decree or regulation in accordance with the legal requirements in each country&rdquo;<em>(2)</em>. The availability of detailed vital statistics for a country or area illustrates national capacity in the compilation of these statistics from civil registration systems <em>(3)</em>.</p><p>Birth registration provides a basis for social inclusion and individual legal identity, which is a human right.&nbsp; Registering births, deaths and causes of death allows countries to identify their most pressing health and social issues such as fertility rates or resolution of criminal cases. </p><h2>Barriers and challenges</h2><p>Civil registration and vital statistic (CRVS) systems are complex, but advances in computerization are removing barriers, facilitating registration procedures and enabling data exchange and production. An integrated CRVS system analyses and uses these data to allocate resources appropriately, develop policies and make decisions that will influence the path towards the Sustainable Development Goal (SDG) targets. </p><p>Many barriers still prevent people from registering births and deaths, including when countries do not have the necessary laws or infrastructure to register all births and deaths. Censuses and surveys can be used to estimate population numbers, but these are not designed to capture information on all causes of death. Some countries have set up sample registration systems that can generate nationally representative mortality data. </p><p>In the absence of medical certification of causes of death, the WHO standard verbal autopsy questionnaires can be used to generate population-level cause-of-death statistics. </p><p>The COVID-19 pandemic highlighted the important use of mortality data. The analysis of excess mortality, which is the extra number of deaths compared to what would be expected in normal times, revealed the true impact of the pandemic. Excess mortality includes deaths resulting directly from COVID-19 and those indirectly related to it, for example when over-stretched healthcare systems struggle to provide care to patients during the pandemic. From January 2020 to December 2021, around <a href=\"https://www.who.int/data/stories/global-excess-deaths-associated-with-covid-19-january-2020-december-2021\"></a><a href=\"https://www.who.int/data/stories/global-excess-deaths-associated-with-covid-19-january-2020-december-2021\">14.9 million extra deaths</a> happened because of the pandemic.</p><h2>WHO response</h2><h3>Advocating</h3><p>The CRVS system is considered as the most reliable source of statistics on births, migration, life expectancy, deaths and causes of death. </p><p>WHO is working with partners to prioritize CRVS strengthening at global, regional and country levels. The WHO <a href=\"https://www.who.int/data/data-collection-tools/civil-registration-and-vital-statistics-(crvs)\"></a><a href=\"https://www.who.int/data/data-collection-tools/civil-registration-and-vital-statistics-(crvs)\">CRVS Strategic Implementation Plan 2021&ndash;2025</a> is based on four strategic objectives to accelerate CRVS system strengthening in Member States through more effective engagement and leadership by the health sector. Moreover, by virtue of its reach and proximity to the population it serves, the health sector is ideally placed to support the registration of births and deaths where laws permit. WHO, in collaboration with UNICEF, has published <a href=\"https://iris.who.int/handle/10665/341911\">guidance on the health sector contributions</a> towards improving the civil registration of births and deaths in low-income countries.</p><h3>Setting norms and standards</h3><p>WHO sets the norms and standards for the generation of cause-of-death statistics to ensure comparability across countries. For more than a century, the International Classification of Diseases (ICD) has been the basis for comparable statistics on causes of mortality and morbidity between places and over time. Originating in the 19th century, the latest version, <a href=\"https://www.who.int/standards/classifications/classification-of-diseases\"></a><a href=\"https://www.who.int/standards/classifications/classification-of-diseases\">ICD-11</a>, was adopted by the 72<sup>nd</sup> World Health Assembly in 2019 and came into effect on 1 January 2022.&nbsp; &nbsp;</p><h3>Supporting countries</h3><p>Strengthening CRVS systems requires collaboration with partners to align investment and avoid duplication of efforts. The <a href=\"https://www.healthdatacollaborative.org/our-response/working-groups/civil-registration-and-vital-statistics/\">Health Data Collaborative</a> has set up a CRVS technical group to support coordinated country-level engagement. The three levels of WHO (headquarters, regional and country offices) coordinate technical support to countries. WHO also supports regional initiatives led by development partners to promote CRVS in the global agenda.</p><h3>Monitoring global health</h3><p>In order to monitor and improve global health, WHO has set up the WHO Mortality Database since 1950 with the aim to gather information about deaths and causes of death. With data from more than 120 countries&rsquo; CRVS systems, the <a href=\"https://www.who.int/data/data-collection-tools/who-mortality-database\">WHO Mortality Database</a> is the premier data source for international comparative epidemiological studies of mortality by cause. It has underpinned global policies to improve population health such as reduction in tobacco smoking, prevention of mortality from road traffic accidents and noncommunicable diseases.</p><p>By monitoring the global availability and quality of cause-of-death data, WHO can identify gaps in systems, resources and support that need to be prioritized to improve health situations.</p><h3>Understanding country health information systems</h3><p>Information on births, deaths and causes of deaths is an integral part of a country&rsquo;s health information system. Health professionals use the information to plan for health services and monitor the effectiveness of their interventions. In this regard, the <a href=\"https://www.who.int/data/data-collection-tools/score\"></a><a href=\"https://www.who.int/data/data-collection-tools/score\">SCORE for Health Data Technical Package</a> was developed by WHO and partners to assist Member States in strengthening country data systems and capacity to monitor progress towards the health-related SDGs, universal health care, and other national and subnational health priorities and targets.</p><p>The SCORE for Health Data Technical Package converges comprehensive strategies and interventions for strengthening country health information systems. Launched in August 2020, the report is a concrete starting point to improve the availability of timely, reliable and comparable health data to track progress towards the Triple Billion targets and health-related Sustainable Development Goals.</p><p>The C in SCORE stands for Count, which is to count births, deaths and causes of deaths, including the full birth and death registration and certification and report on causes of death. The SCORE assessment has enabled countries to look at the maturity of their CRVS systems, identify gaps and moved CRVS to the top of their priorities.</p><p>&nbsp;</p><p><strong>References</strong></p><ol><li>SCORE for Health Data Technical Package, Global report on health data systems and capacity, 2020.<br /></li><li>Principles and Recommendations for a Vital Statistics System, Revision 3, Sales No.E.13.XVII.10, United Nations, New York, 2014.<br /></li><li>Population and Vital Statistics Report, Statistical Papers Series A, Vol. LXXIV January 2022.<br /></li></ol> ","ConditionName":"","OpenGraphTitle":"Civil registration and vital statistics","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Civil registration and vital statistics","ConditionLongerOverview":"","Title":"Civil registration and vital statistics","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs324","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":3,"OtherRelated":"","FactSheetNumberOfAdditionalItems":1,"OpenGraphDescription":"WHO fact sheet on civil registration and vital statistics providing key facts and information on definition, reasons for importance, barriers, measures for low-income countries.","PublicationDateAndTime":"2024-02-27T15:38:00Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on civil registration and vital statistics providing key facts and information on definition, reasons for importance, barriers, measures for low-income countries.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<ul><li><a href=\"https://www.who.int/data/data-collection-tools/score\">SCORE for Health Data Technical Package</a></li><li><a href=\"https://www.who.int/standards/classifications/classification-of-diseases\">International Statistical Classification of Diseases and Related Health Problems (ICD-11)</a></li><li><a href=\"https://www.who.int/data/data-collection-tools/who-mortality-database\">WHO Mortality Database</a></li><li><a href=\"https://www.who.int/data/data-collection-tools/civil-registration-and-vital-statistics-(crvs)\">Civil registration and vital statistics (CRVS)</a></li><li><a href=\"https://www.who.int/data/data-collection-tools/health-service-data\">Health service data</a></li><li><a href=\"https://www.who.int/publications/i/item/strengthening-civil-registration-and-vital-statistics-for-births-deaths-and-causes-of-death\">Strengthening civil registration and vital statistics for births, deaths and causes of death</a></li><li><a href=\"https://getinthepicture.org/sites/default/files/resources/Strategic%20planning%20to%20strengthen%20civil%20registration%20and%20vital%20statistics%20systems%20Guidance%20for%20using%20findings%20from%20a%20comprehensive%20assessment_0.pdf\">Strategic planning to strengthen civil registration and vital statistics systems (getinthepicture.org)</a></li></ul><p><br /></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/ihs/mackenzie_sudan-data-collector-in-eu.tmb-768v.jpg?sfvrsn=4515bf4f_6","FormatedDate":"27 February 2024","TrimmedTitle":"Civil registration and vital statistics"},{"Id":"5c382f9a-54fb-4bf1-82ab-844864143120","LastModified":"2026-08-26T09:41:04Z","PublicationDate":"2018-06-02T02:28:05Z","DateCreated":"2018-06-02T02:28:03Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"measles","ItemDefaultUrl":"/measles","NewsNumberOfAdditionalItems":1,"MedicalTreatmentBriefSummary":"<p>There is no specific treatment for measles. Caregiving should focus on relieving symptoms, making the person comfortable and preventing complications.</p>","Content":"<h2>Key facts</h2><ul><li>Measles is a highly contagious, serious airborne disease caused by a virus that can lead to severe complications and death.</li><li>Measles vaccination averted nearly 59 million deaths between 2000 and 2024.</li><li>Even though a safe and cost-effective vaccine is available, in 2024, there were an estimated 95 000 measles deaths globally, mostly among unvaccinated or under vaccinated children under the age of 5 years.</li><li data-list=\"0\" data-level=\"1\">The proportion of children receiving a first dose of measles vaccine was 84% in 2025, slightly below the 2019 level of 86%.</li></ul><hr /><br /><h2>Overview</h2><p>Measles is a highly contagious disease caused by a virus. It spreads easily when an infected person breathes, coughs or sneezes. It can cause severe disease, complications, and even death.</p><p>Measles can affect anyone but is most common in children.</p><p>Measles infects the respiratory tract and then spreads throughout the body. Symptoms include a high fever, cough, runny nose and a rash all over the body.</p><p>Being vaccinated is the best way to prevent getting sick with measles or spreading it to other people. The vaccine is safe and helps your body fight off the virus.</p><p>Before the introduction of measles vaccine in 1963 and widespread vaccination, major epidemics occurred approximately every two to three years and caused an estimated 2.6&nbsp;million deaths each year.</p><p>An estimated 95 000 people died from measles in 2024 &ndash; mostly children under the age of five years, despite the availability of a safe and cost-effective vaccine.</p><p>Accelerated immunization activities by countries, WHO, the Measles &amp; Rubella Partnership, and other international partners successfully prevented an estimated 59 million deaths between 2000 and 2024. Vaccination decreased an estimated measles deaths from 780 000 in 2000 to 95 000 in 2024&nbsp;<em>(1)</em>.</p><h2><span style=\"background-color:transparent;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Signs and symptoms</span></h2><p>Symptoms of measles usually begin 7&ndash;14 days after exposure to the virus. A prominent rash is the most visible symptom.</p><p>Early symptoms usually last 4&ndash;7 days. They include:</p><ul><li>fever</li><li>running nose</li><li>cough</li><li>red and watery eyes</li><li>small white spots inside the cheeks.</li></ul><p>The rash appears 3 to 5 days after the first symptoms, usually on the face and upper neck. It spreads over about 3 days, eventually downward to the trunk, arms, legs and feet. It usually lasts 4&ndash;8 days before fading.</p><p>Most deaths from measles are from complications related to the disease.</p><p>Complications can include:</p><ul><li>blindness</li><li>encephalitis (an infection causing brain swelling and potentially brain damage)</li><li>severe diarrhoea and related dehydration</li><li>ear infections</li><li>severe breathing problems including pneumonia.</li></ul><p>If a woman catches measles during pregnancy, this can be dangerous for the mother and can result in miscarriage or her baby being born prematurely with a low birth weight.</p><p>Complications are most common in children under 5 years and adults over age 30. They are more likely in children who are malnourished, especially those without enough vitamin A or with a weak immune system from HIV or other diseases. Measles itself also weakens the immune system and can make the body &ldquo;forget&rdquo; how to protect itself against infections, leaving children extremely vulnerable.</p><h2>Who is at risk?</h2><p>Any non-immune person (not vaccinated or vaccinated but did not develop immunity) can become infected. Unvaccinated young children and pregnant persons are at highest risk of severe measles complications.</p><p>Measles is still common, particularly in parts of Africa, the Middle East and Asia. The overwhelming majority of measles deaths occur in countries with low per capita incomes or weak health infrastructures that struggle to reach all children with immunization.</p><p>Damaged health infrastructure and health services in countries experiencing or recovering from a natural disaster or conflict interrupt routine immunization and overcrowding in residential camps increases the risk of infection. Children with malnutrition or other causes of a weak immune system are at highest risk of death from measles.</p><h2>Transmission</h2><p>Measles is one of the world&rsquo;s most contagious diseases, spread by contact with infected nasal or throat secretions (coughing or sneezing) or breathing the air that was breathed by someone with measles. The virus remains active and contagious in the air or on infected surfaces for up to two hours. For this reason, it is very infectious. One person infected by measles can generate up to 18 secondary infections. </p><p>It can be transmitted by an infected person from four days prior to the onset of the rash to four days after the rash erupts.</p><p>Measles outbreaks can result in severe complications and deaths, especially among young, malnourished children. In countries close to measles elimination, cases imported from other countries remain an important source of infection.</p><h2>Treatment</h2><p></p><p>There is no specific treatment for measles. Caregiving should focus on relieving symptoms, making the person comfortable and preventing complications.&nbsp;</p><p>Drinking enough water and treatments for dehydration can replace fluids lost to diarrhoea or vomiting. Eating a healthy diet is also important.</p><p>Doctors may use antibiotics to treat pneumonia and ear and eye infections.</p><p>Two doses of vitamin A are recommended for all suspected measles cases in children under 5 years of age, immediately on diagnosis and repeated the next day, according to the dosing indicated by the health practitioner. A third dose is recommended for any clinical signs of vitamin A deficiency with eye complications and should be given 4&ndash;6 weeks later. This restores low levels of vitamin A that occur even in well-nourished children. It can help prevent other complications from measles, including eye damage and blindness. Vitamin A supplements may also reduce the number of measles deaths.</p><p></p><h2>Prevention</h2><p>Community-wide vaccination is the most effective way to prevent measles. All children should be vaccinated against measles. The vaccine is safe, effective and inexpensive.</p><p>Children should receive two doses of the vaccine to ensure they are immune. The first dose is usually given at 9 months of age in countries where measles is common and 12&ndash;15 months in other countries. A second dose should be given later in childhood, usually at 15&ndash;18 months.</p><p>The measles vaccine is given alone or often combined with vaccines for mumps, rubella and/or varicella.</p><p>Routine measles vaccination, combined with mass immunization campaigns in countries with high case rates are crucial for reducing global measles deaths. The measles vaccine has been in use for about 60 years and costs less than US$&nbsp;1 per child. The measles vaccine is also used in emergencies to stop outbreaks from spreading. The risk of measles outbreaks is particularly high amongst refugees, who should be vaccinated as soon as possible.</p><p>Combining vaccines slightly increases the cost but allows for shared delivery and administration costs and importantly, adds the benefit of protection against rubella, the most common vaccine preventable infection that can infect babies in the womb.</p><p>In 2025, 77% of children received both doses of the measles vaccine, and about 84% of the world's children received one dose of measles vaccine by their first birthday. Two doses of the vaccine are recommended to ensure immunity and prevent outbreaks, as not all children develop immunity from the first dose.</p><p>Approximately 29 million infants remained under-protected against measles in 2025, according to WHO and UNICEF estimates.&nbsp;</p><h2>WHO response</h2><p>In 2020, WHO and global stakeholders endorsed the Immunization Agenda 2021&ndash;2030. The Agenda aims to achieve the regional targets as a core indicator of impact, positioning measles as a tracer of a health system&rsquo;s ability to deliver essential childhood vaccines.</p><p>WHO published the&nbsp;<a href=\"https://www.who.int/publications-detail-redirect/measles-and-rubella-strategic-framework-2021-2030\">Measles and rubella strategic framework&nbsp;</a>in 2020, establishing seven necessary strategic priorities to achieve and sustain the regional measles and rubella elimination goals.</p><p>Without sustained attention, hard-fought gains can easily be lost. Where children are unvaccinated, outbreaks occur. Based on current trends of measles vaccination coverage and incidence, the&nbsp;<a href=\"https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization\">WHO Strategic Advisory Group of Experts on Immunization (SAGE)</a>&nbsp;concluded that measles elimination is under threat, as the disease resurged in numerous countries that achieved, or were close to achieving, elimination.</p><p>WHO continues to strengthen the&nbsp;<a href=\"https://www.who.int/europe/initiatives/measles-and-rubella-laboratory-network\">Global Measles and Rubella Laboratory Network</a>&nbsp;(GMRLN) to ensure timely diagnosis of measles and track the virus&rsquo; spread to assist countries in coordinating targeted vaccination activities and reduce deaths from this vaccine-preventable disease.</p><h3>The IA2030 Measles &amp; Rubella Partnership</h3><p><a href=\"https://measlesrubellainitiative.org/learn/about-us/#:~:text=The%20Measles%20%26%20Rubella%20Initiative%20is%20a%20global,and%20Prevention%2C%20UNICEF%20and%20the%20World%20Health%20Organization.\">The Immunization Agenda 2030 Measles &amp; Rubella Partnership</a>&nbsp;(M&amp;RP) is a partnership led by the American Red Cross, United Nations Foundation, Centers for Disease Control and Prevention (CDC), Gavi, the Vaccines Alliance, the Gates Foundation, UNICEF and WHO, to achieve the IA2030 measles and rubella specific targets. Launched in 2001, as the Measles and Rubella Initiative, the revitalized Partnership is committed to ensuring no child dies from measles or is born with congenital rubella syndrome. The Partnership helps countries plan, fund and measure efforts to permanently stop measles and rubella</p><p>&nbsp;</p><p><strong>References</strong></p><p>1. <a href=\"https://iris.who.int/server/api/core/bitstreams/8c65dd54-ee98-4438-938c-e7114851f870/content\">Progress towards measles elimination &ndash; worldwide, 2000&ndash;2024, Weekly epidemiological record, No 48, 2025, 100, 591&ndash;604</a><br /></p><p>&nbsp;</p>","ConditionName":"Measles","OpenGraphTitle":"Measles","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"<p>Early symptoms usually last 4&ndash;7 days. They include:</p><ul><li>running nose</li><li>cough</li><li>red and watery eyes</li><li>small white spots inside the cheeks</li></ul><p>The rash begins about 7&ndash;18 days after exposure, usually on the face and upper neck. It spreads over about 3 days, eventually to the hands and feet. It usually lasts 5&ndash;6 days before fading.</p><p>Most deaths from measles are from complications related to the disease. </p><p>Complications can include:</p><ul><li>blindness</li><li>encephalitis (an infection causing brain swelling and potentially brain damage)</li><li>severe diarrhoea and related dehydration</li><li>ear infections</li><li>severe breathing problems including pneumonia</li></ul><p>If a woman catches measles during pregnancy, this can be dangerous for the mother and can result in her baby being born prematurely with a low birth weight.</p>","MetaTitle":"Measles","ConditionLongerOverview":"<p>Measles can affect anyone but is most common in children. </p><p>Measles infects the respiratory tract and then spreads throughout the body. Symptoms include a high fever, cough, runny nose and a rash all over the body. </p><p>Being vaccinated is the best way to prevent getting sick with measles or spreading it to other people. The vaccine is safe and helps your body fight off the virus.</p>","Title":"Measles","PreventionLongerSummary":"<p>Community-wide vaccination is the most effective way to prevent measles. All children should be vaccinated against measles. The vaccine is safe, effective and inexpensive.</p><p>Children should receive two doses of the vaccine to ensure they are immune. The first dose is usually given at 9 months of age in countries where measles is common and 12&ndash;15 months in other countries. A second dose should be given later in childhood, usually at 15&ndash;18 months.</p><p>The measles vaccine is given alone or often combined with vaccines for mumps, rubella and/or varicella.</p>","SourceKey":"/entity/mediacentre/factsheets/fs286","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"Measles is a highly contagious, serious disease caused by a virus. Before the introduction of measles vaccine in 1963 and widespread vaccination, major epidemics occurred approximately every 2\u20133 years and measles caused an estimated 2.6 million deaths each year.","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"WHO fact sheet on measles providing key facts and information on signs and symptoms, who is at risk, transmission, treatment, prevention and WHO's work on in this area. ","PublicationDateAndTime":"2026-07-15T00:00:00Z","ConditionBriefOverview":"Measles is a highly contagious disease caused by a virus. It spreads easily when an infected person breathes, coughs or sneezes. It can cause severe disease, complications, and even death.","MetaDescription":"WHO fact sheet on measles providing key facts and information on signs and symptoms, who is at risk, transmission, treatment, prevention and WHO's work on in this area. ","MedicalTreatmentLongerSummary":"<p>Drinking enough water and treatments for dehydration can replace fluids lost to diarrhoea or vomiting. Eating a healthy diet is also important.</p><p>Doctors may use antibiotics to treat pneumonia and ear and eye infections.</p><p>All children or adults with measles should receive two doses of vitamin A supplements, given 24 hours apart. This restores low vitamin A levels that occur even in well-nourished children. It can help prevent eye damage and blindness. Vitamin A supplements may also reduce the number of measles deaths.</p>","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"<p>Symptoms of measles usually begin 10&ndash;14 days after exposure to the virus. A prominent rash is the most visible symptom.</p>","Highlight":"<ul><li><a href=\"https://www.who.int/publications/m/item/immunization-agenda-2030--mid-term-review\">Immunization Agenda 2023: mid-term review</a><a href=\"https://www.who.int/publications/i/item/measles-and-rubella-strategic-framework-2021-2030\"></a></li><li><a href=\"https://www.who.int/publications/i/item/measles-and-rubella-strategic-framework-2021-2030\">Measles and rubella strategic framework: 2021-2030</a></li><li><a href=\"https://measlesrubellainitiative.org/\">Measles &amp; Rubella Partnership</a></li><li><a href=\"https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/measles\">Immunization, Vaccines and Biologicals: measles</a></li><li><a href=\"https://www.who.int/health-topics/measles\">More information on WHO's work on measles </a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/wpro/health-topic/child-health/f6-09112015-fj-05627.tmb-768v.jpg?Culture=en&sfvrsn=84402f2b_15","FormatedDate":"15 July 2026","TrimmedTitle":"Measles"},{"Id":"0b466a3d-1adc-4ac4-859b-d00f47839538","LastModified":"2024-11-29T13:29:36Z","PublicationDate":"2018-06-02T02:28:06Z","DateCreated":"2018-06-02T02:28:05Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"vector-borne-diseases","ItemDefaultUrl":"/vector-borne-diseases","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Vector-borne diseases account for more than 17% of all infectious diseases, causing more than 700 000 deaths annually. They can be caused by either parasites, bacteria or viruses.</li><li>Malaria is a parasitic infection transmitted by <em>Anopheline</em> mosquitoes. It causes an estimated 249 million cases globally, and results in more than 608 000 deaths every year. Most of the deaths occur in children under the age of 5 years.</li><li>Dengue is the most prevalent viral infection transmitted by <em>Aedes</em> mosquitoes. More than 3.9 billion people in over 132 countries are at risk of contracting dengue, with an estimated 96 million symptomatic cases and an estimated 40 000 deaths every year.</li><li>Other viral diseases transmitted by vectors include chikungunya fever, Zika virus fever, yellow fever, West Nile fever, Japanese encephalitis (all transmitted by mosquitoes), tick-borne encephalitis (transmitted by ticks) and Oropouche fever (transmitted by Culicoides flies)</li><li>Many of vector-borne diseases are preventable through protective measures and community mobilization.</li></ul><p>&nbsp;</p><hr /><p>&nbsp;</p><h2>Overview</h2><p>Vectors are living organisms that can transmit infectious pathogens between humans, or from animals to humans. Many of these vectors are bloodsucking insects which ingest disease-producing microorganisms during a blood meal from an infected host (human or animal) and later transmit it into a new host, after the pathogen has replicated. Often, once a vector becomes infectious, they are capable of transmitting the pathogen for the rest of their life during each subsequent bite/blood meal.</p><h2>Vector-borne diseases</h2><p>Vector-borne diseases are human illnesses caused by parasites, viruses and bacteria that are transmitted by vectors. Every year there are more than 700 000 deaths from diseases such as malaria, dengue, schistosomiasis, human African trypanosomiasis, leishmaniasis, Chagas disease, yellow fever, Japanese encephalitis and onchocerciasis.</p><p>The burden of these diseases is highest in tropical and subtropical areas, and they disproportionately affect the poorest populations. Since 2014, major outbreaks of dengue, malaria, chikungunya, yellow fever and Zika have afflicted populations, claimed lives, and overwhelmed health systems in many countries. Other diseases such as chikungunya, leishmaniasis and lymphatic filariasis cause chronic suffering, life-long morbidity, disability and occasional stigmatization.</p><p>Distribution of vector-borne diseases is determined by a complex set of demographic, environmental and social factors. Global travel and trade, unplanned urbanization, climate change and silent spread and adaptation of the vectors have all contributed to the spread of vector-borne diseases. </p><p>Climate change substantially affects pathogens (parasites, viruses and bacteria), vectors, and reservoir hosts, with implications for the transmission of many vector-borne diseases. Several vectors have expanded their latitude and altitude ranges, and the length of the season during which they are active is increasing. These trends are expected to continue as the climate continues to get warmer.</p><h2>List of vector-borne diseases, according to their vector</h2>The following table is a non-exhaustive list of vector-borne disease, ordered according to the vector by which it is transmitted. The list also illustrates the type of pathogen that causes the disease in humans.<p>&nbsp;</p><table class=\"MsoTableGrid k-table\" style=\"border-collapse:collapse;border:none;height:695px;\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><tbody><tr style=\"height:27px;\"><td colspan=\"2\" style=\"width:139.25pt;border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><strong><span style=\"text-decoration:underline;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;\" lang=\"EN\">Vector<o:p></o:p></span></span></strong></p></td><td style=\"width:3.25in;border:solid windowtext 1.0pt;border-left:none;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><strong><span style=\"text-decoration:underline;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;\" lang=\"EN\">Disease\r\n caused<o:p></o:p></span></span></strong></p></td><td style=\"width:94.25pt;border:solid windowtext 1.0pt;border-left:none;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><strong><span style=\"text-decoration:underline;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;\" lang=\"EN\">Type\r\n of pathogen<o:p></o:p></span></span></strong></p></td></tr><tr style=\"height:141px;\"><td rowspan=\"3\" style=\"width:71.75pt;border-top:none;border-left:1pt solid windowtext;border-bottom:1pt solid windowtext;border-right:none;padding:0in 5.4pt;\" width=\"96\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Mosquito<o:p></o:p></span></p></td><td style=\"width:67.5pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-top-alt:solid windowtext .25pt;mso-border-bottom-alt:solid windowtext .25pt;mso-border-right-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"90\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span class=\"SpellE\"><em style=\"mso-bidi-font-style:normal;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Aedes</span></em>\r\n </span><em style=\"mso-bidi-font-style:normal;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\"><o:p></o:p></span></em></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Chikungunya<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Dengue<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Lymphatic filariasis<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Rift Valley fever<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Yellow Fever<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Zika<o:p></o:p></span></p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:FR;mso-bidi-font-weight:bold;\" lang=\"FR\">Virus<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:FR;mso-bidi-font-weight:bold;\" lang=\"FR\">Virus<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:FR;mso-bidi-font-weight:bold;\" lang=\"FR\">Parasite<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:FR;mso-bidi-font-weight:bold;\" lang=\"FR\">Virus<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:FR;mso-bidi-font-weight:bold;\" lang=\"FR\">Virus<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:FR;mso-bidi-font-weight:bold;\" lang=\"FR\">Virus<o:p></o:p></span></p></td></tr><tr style=\"height:50px;\"><td style=\"width:67.5pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-top-alt:solid windowtext .25pt;mso-border-bottom-alt:solid windowtext .25pt;mso-border-right-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"90\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><em style=\"mso-bidi-font-style:normal;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Anopheles<o:p></o:p></span></em></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Lymphatic filariasis<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Malaria</span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\"><o:p>O'nyong'nyong virus </o:p>\r\n </span></p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Parasite<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Parasite</span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\"><o:p>Virus</o:p>\r\n </span></p></td></tr><tr style=\"height:74px;\"><td style=\"width:67.5pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-top-alt:solid windowtext .25pt;mso-border-bottom-alt:solid windowtext .25pt;mso-border-right-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"90\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><em style=\"mso-bidi-font-style:normal;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Culex<o:p></o:p></span></em></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Japanese encephalitis<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Lymphatic filariasis<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">West Nile fever<o:p></o:p></span></p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Virus<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Parasite<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Virus<o:p></o:p></span></p></td></tr><tr style=\"height:27px;\"><td colspan=\"2\" style=\"width:139.25pt;border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Aquatic snails<o:p></o:p></span></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Schistosomiasis (<span class=\"SpellE\">bilharziasis</span>)\r\n <o:p></o:p></span>\r\n </p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Parasite<o:p></o:p></span></p></td></tr><tr style=\"height:27px;\"><td colspan=\"2\" style=\"width:139.25pt;border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Culicoides flies<o:p></o:p></span></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Oropouche fever\r\n                        <o:p></o:p></span>\r\n </p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Virus<o:p></o:p></span></p></td></tr><tr style=\"height:27px;\"><td colspan=\"2\" style=\"width:139.25pt;border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Blackflies<o:p></o:p></span></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span class=\"SpellE\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Onchocerciasis</span></span>\r\n <span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\"> (river blindness)\r\n                        <o:p></o:p></span>\r\n </p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Parasite<o:p></o:p></span></p></td></tr><tr style=\"height:50px;\"><td colspan=\"2\" style=\"width:139.25pt;border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Fleas<o:p></o:p></span></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Plague (transmitted from rats to humans)<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span class=\"SpellE\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Tungiasis</span></span>\r\n <span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">\r\n <o:p></o:p></span>\r\n </p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Bacteria<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span class=\"SpellE\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Ecto</span></span><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">parasite\r\n <o:p></o:p></span>\r\n </p></td></tr><tr style=\"height:50px;\"><td colspan=\"2\" style=\"width:139.25pt;border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Lice<o:p></o:p></span></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Typhus<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Louse-borne relapsing fever<o:p></o:p></span></p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Bacteria<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Bacteria<o:p></o:p></span></p></td></tr><tr style=\"height:55px;\"><td colspan=\"2\" style=\"width:139.25pt;border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Sandflies<o:p></o:p></span></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:1pt solid windowtext;border-right:1pt solid windowtext;padding:0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Leishmaniasis<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span class=\"SpellE\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Sandfly</span></span>\r\n <span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\"> fever (<span class=\"SpellE\">phlebotomus</span> fever)\r\n                        <o:p></o:p></span>\r\n <span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">\r\n <o:p></o:p></span>\r\n </p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:12px;\">Parasite</span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Virus<o:p></o:p></span></p></td></tr><tr style=\"height:141px;\"><td colspan=\"2\" style=\"width:139.25pt;border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Ticks<o:p></o:p></span></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:1pt solid windowtext;border-right:1pt solid windowtext;padding:0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Crimean-Congo <span class=\"SpellE\">haemorrhagic</span> fever\r\n                        <o:p></o:p></span>\r\n </p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Lyme disease<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Relapsing fever (borreliosis)<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span class=\"SpellE\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Rickettsial</span></span>\r\n <span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\"> diseases (<span class=\"SpellE\">eg</span>: spotted fever and Q fever)\r\n                        <o:p></o:p></span>\r\n </p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Tick-borne encephalitis<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span class=\"SpellE\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Tularaemia</span></span>\r\n <span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">\r\n <o:p></o:p></span>\r\n </p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Virus<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Bacteria<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Bacteria<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Bacteria<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Virus<o:p></o:p></span></p><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Bacteria<o:p></o:p></span></p></td></tr><tr style=\"height:27px;\"><td colspan=\"2\" style=\"width:139.25pt;border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Triatome bugs<o:p></o:p></span></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Chagas disease (American trypanosomiasis)<o:p></o:p></span></p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Parasite<o:p></o:p></span></p></td></tr><tr style=\"height:27px;\"><td colspan=\"2\" style=\"width:139.25pt;border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"186\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Tsetse flies<o:p></o:p></span></p></td><td style=\"width:3.25in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"312\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Sleeping sickness (African trypanosomiasis)<o:p></o:p></span></p></td><td style=\"width:94.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .25pt;mso-border-left-alt:solid windowtext .25pt;mso-border-alt:solid windowtext .25pt;padding:0in 5.4pt 0in 5.4pt;\" width=\"126\" valign=\"top\"><p class=\"MsoNormal\" style=\"margin-top:2.4pt;margin-right:0in;margin-bottom:2.4pt;margin-left:0in;mso-para-margin-top:.2gd;mso-para-margin-right:0in;mso-para-margin-bottom:.2gd;mso-para-margin-left:0in;line-height:130%;mso-outline-level:4;\"><span style=\"font-size:9.0pt;mso-bidi-font-size:12.0pt;line-height:130%;mso-fareast-font-family:'Times New Roman';mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin;color:#3C4245;mso-ansi-language:EN;mso-bidi-font-weight:bold;\" lang=\"EN\">Parasite<o:p></o:p></span></p></td></tr></tbody></table><p>&nbsp;</p><p><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\">WHO response</span><br /></p><p>The <a href=\"https://www.who.int/publications/i/item/9789241512978\">Global Vector Control Response (GVCR) 2017&ndash;2030</a>&nbsp;was approved by the World Health Assembly in 2017. It provides strategic guidance to countries and development partners for urgently strengthening vector control as a fundamental approach to preventing disease and responding to outbreaks. To achieve this, a re-alignment of vector control programmes is required, supported by increased technical capacity, improved infrastructure, strengthened monitoring and surveillance systems, and greater community mobilization. Ultimately, this will support the implementation of a comprehensive approach to vector control that will enable the achievement of disease-specific national and global goals and contribute to the achievement of the Sustainable Development Goals and universal health coverage.</p><p>WHO Secretariat provides strategic, normative, and technical guidance to countries and development partners to strengthen vector control as a fundamental approach based on GVCR to prevent disease and respond to outbreaks. Specifically, WHO responds to vector-borne diseases by:</p><ul><li>providing evidence-based guidance for controlling vectors and protecting people against infection;</li><li>providing technical support to countries so that they can effectively manage cases and outbreaks;</li><li>supporting countries to improve their reporting systems and capture the true burden of the disease;</li><li>providing training (capacity building) on clinical management, diagnosis and vector control with support from some of its collaborating centres; and</li><li>supporting the development and evaluation of new tools, technologies and approaches for vector-borne diseases, including vector control and disease management technologies.</li></ul><p>A crucial element in reducing the burden of vector-borne diseases is behavioural change. WHO works with partners to provide education and improve public awareness, so that people know how to protect themselves and their communities from mosquitoes, ticks, bugs, flies and other vectors.</p><p>Access to water and sanitation is a very important factor in disease control and elimination. WHO works together with many different government sectors to improve water storage, sanitation, thereby helping to control these diseases at the community level.</p>","ConditionName":"","OpenGraphTitle":"Vector-borne diseases","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Vector-borne diseases","ConditionLongerOverview":"","Title":"Vector-borne diseases","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs387","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":3,"OtherRelated":"","FactSheetNumberOfAdditionalItems":1,"OpenGraphDescription":"WHO fact sheet on vector-borne diseases, including key facts, overview, and WHO response. \r\n\r\nVector-borne diseases are illnesses caused by pathogens and parasites in human populations. WHO works with partners to provide education and improve awareness so that people know how to protect themselves and their communities from mosquitoes, ticks, bugs, flies and other vectors.","PublicationDateAndTime":"2024-09-26T18:59:00Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on vector-borne diseases, including key facts, overview, and WHO response. \r\n\r\nVector-borne diseases are illnesses caused by pathogens and parasites in human populations. WHO works with partners to provide education and improve awareness so that people know how to protect themselves and their communities from mosquitoes, ticks, bugs, flies and other vectors.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<div><p><a href=\"https://cms.who.int/Sitefinity/adminapp/Item ID is not a valid Guid: 2C884433-549C-40A8-887D-267B492353577D-267B49235357&amp;\">WHO's work on vector control</a></p><p><a href=\"https://www.who.int/publications/i/item/9789241512978\">Global vector control response 2017&ndash;2030</a></p></div><p><br /></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/malaria-vector-control.tmb-768v.jpg?sfvrsn=3bcf3a5d_44","FormatedDate":"26 September 2024","TrimmedTitle":"Vector-borne diseases"},{"Id":"d6400eff-ea74-447e-9bdf-705f60fb86f6","LastModified":"2025-04-02T19:29:46Z","PublicationDate":"2023-11-15T15:41:23Z","DateCreated":"2023-11-15T15:41:24Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"chromoblastomycosis","ItemDefaultUrl":"/chromoblastomycosis","NewsNumberOfAdditionalItems":2,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key Facts<strong> </strong></h2><ul><li><strong>Chromoblastomycosis is an infection under the skin caused by fungi.</strong></li><li><strong>It occurs sporadically in tropical and subtropical climates, and its global incidence is unknown.</strong></li><li><strong>The infection can be disfiguring, causing wart-like lesions of the skin which spread slowly to adjacent areas. It causes disfigurement and disability, and in rare cases skin cancer.</strong></li><li><strong>Chromoblastomycosis is diagnosed with laboratory tools such as microscopy and culture. More accurate molecular diagnostic methods are in development. </strong></li><li><strong>Safe and effective antifungal medicines are available for treatment.</strong><strong></strong></li></ul><br /><hr /><h2>Overview</h2><p>Chromoblastomycosis is a sporadically occurring infection seen in tropical and subtropical climates caused by a number of different pigmented fungi, the most common of which are <em>Fonsecaea pedrosoi</em>, <em>Fonsecaea monophora</em> and <em>Cladophialophora carrionii</em>. Other fungi can also cause chromoblastomycosis. </p><p>Chromoblastomycosis can cause disability due to limb enlargement, which may lead to inability to work and considerable social stigma. Rarely, the fungi that cause chromoblastomycosis can infect other organs, such as the brain, or lead to skin cancer.</p><p><span style=\"background-color:transparent;font-size:25px;font-weight:700;text-align:inherit;word-spacing:normal;caret-color:auto;white-space:inherit;\">Who is at risk?&nbsp;</span></p><p>Chromoblastomycosis affects normal healthy people and is mainly seen in adults. Agricultural workers are the most common occupational group to be infected.&nbsp; </p><h2>Signs and symptoms</h2><p>Chromoblastomycosis presents with wart-like lesions on exposed areas of the skin such as the legs or forearms. These can exceed 10 centimetres in diameter. </p><p>Patches of skin may also appear flattened (plaque-like) and show central scarring or atrophy, but they are not itchy or painful. Pain and itching can appear in moderate or severe disease. Small dark spots can be seen on the surface of lesions and represent clusters of the pigmented fungal cells &ndash; an important diagnostic clue. </p><p>Large lesions cause severe limb swelling and discomfort, limiting movement. In longstanding cases, secondary bacterial infections are common and the smell from affected limbs may be unpleasant, which may also lead to social exclusion. There is a risk of development of squamous cell carcinoma of the skin in longstanding untreated lesions.</p><p>Although the infection usually remains in one body region, local spread through the lymphatics, and very rarely blood stream dissemination to the central nervous system, can occur.</p><h2>Transmission</h2><p>This infection occurs when fungi from the natural environment invade deeper parts of an individual&rsquo;s skin after their skin is damaged by a superficial abrasion or a penetrating injury. An infected person cannot directly transmit the infection to other people. Intermediate vectors, such as mosquitoes, do not transmit chromoblastomycosis.</p><h2>Treatment</h2><p>Chromoblastomycosis can be treated with oral itraconazole or terbinafine. Voriconazole, intravenous amphotericin B and oral flucytosine have also been used. </p><p>Other methods of treatment include local application of heat, cryotherapy and photodynamic therapy<strong>. </strong>Surgical reductions have been used but should be given following initial chemotherapy to avoid local recurrence. </p><p>Early treatment is key, providing the best results after about 3&ndash;6 months. Patients with large or extensive chromoblastomycosis and limb swelling often require over a year of treatment and there may be residual lymphoedema in such cases. </p><p>There is no evidence that different fungal species respond differently to the antifungal medicines recommended for treatment.</p><h2>Challenges&nbsp;</h2><p>The earliest lesions of chromoblastomycosis are small, raised lumps or nodules on the skin surface with no specific visible diagnostic features. Therefore, diagnosis depends on demonstrating the characteristic thick-walled, single or multicellular clusters of pigmented fungal cells, known as muriform or sclerotic bodies, either in scrapings from lesions or in histopathology of biopsy material. </p><p>Clusters of these cells can be found in the dark spots seen on the surface of the skin lesions and these provide the best sites for taking a skin scraping with a scalpel blade or for a biopsy. </p><p>Culture or molecular diagnosis is helpful in confirming the diagnosis but decisions on treatment can be made without identification of the organism. All laboratory diagnostic methods require specialized skills and training, and there is currently insufficient diagnostic expertise in many endemic areas. </p><p>The cost of effective antifungal medicines in endemic countries is a major challenge that can limit successful completion of treatment as patients often cannot afford them.<strong></strong></p><h2>Global impact&nbsp;</h2><p>The largest number of cases of chromoblastomycosis has occurred in Central America and northern South America, Africa, China and the West Pacific. Brazil, Costa Rica, Dominican Republic, Madagascar and Venezuela (Bolivarian Republic of) have reported the most cases. The global incidence of chromoblastomycosis is unknown. </p><h2>WHO response</h2><p>Chromoblastomycosis is recognized as a neglected tropical disease (NTD) and is included in the <a href=\"https://www.who.int/publications/i/item/9789240010352\">NTD road map 2021&minus;2030</a> to increase surveillance and visibility of the disease. </p><p>In 2022, WHO published the <a href=\"https://iris.who.int/handle/10665/355448\"></a><a href=\"https://www.who.int/publications/i/item/9789240051423\">skin NTD framework </a>to promote integration across different skin diseases and support the evolving Programme for Skin NTDs. </p><p>One of the key challenges of chromoblastomycosis is the lack of information on its global prevalence as cases are not currently reported. Skin NTD programmes are expected to provide more data on incidence of the infection. </p><p>The 2021&minus;2030 roadmap promotes early identification of affected individuals. This can be achieved through training of health care workers aimed at improving awareness and disease recognition. Capacity strengthening on skin NTDs is key. Chromoblastomycosis is included in several WHO technical resources such as the <a href=\"https://www.who.int/publications/i/item/9789241513531\">Skin NTD training manual</a> and <a href=\"https://www.who.int/news/item/09-10-2023-skin-related-neglected-tropical-diseases--who-launches-new-version-of-the-who-skin-ntds-mobile-application\">mobile app</a> as well as a dedicated online course available on the OpenWHO platform: <a href=\"https://openwho.org/courses/NTDs-chromoblastomycosis\">Chromoblastomycosis: training for national and district-level health workers.</a></p><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Chromoblastomycosis","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Chromoblastomycosis","ConditionLongerOverview":"","Title":"Chromoblastomycosis","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on chromoblastomycosis, including key facts, signs and symptoms, transmission, treatment and WHO's response.","PublicationDateAndTime":"2023-11-15T05:00:00Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on chromoblastomycosis, including key facts, signs and symptoms, transmission, treatment and WHO's response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<ul><li><a href=\"https://www.who.int/publications/i/item/9789240010352\">NTD Roadmap 2021&ndash;2030</a></li><li><a href=\"https://www.who.int/publications/i/item/9789241513531\">Recognizing neglected tropical diseases through changes on the skin: a training guide for front-line health workers</a></li><li><a href=\"https://www.who.int/publications/i/item/9789240051423\">Strategic framework for integrated control and management of skin-related neglected tropical diseases</a></li><li><a href=\"https://www.who.int/health-topics/mycetoma-chromoblastomycosis-and-other-deep-mycoses\">WHO's work on chromoblastomycosis and other deep mycoses</a></li></ul><p></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/ntd-library/mycetoma-chromoblastomycosis-and-other-deep-mycoses/chromoblastomycosis----subcutaneous-dematiaceous-fungal-infection-resulting-from-skin-inoculation.tmb-768v.png?Culture=en&sfvrsn=2ecdc1f8_6","FormatedDate":"15 November 2023","TrimmedTitle":"Chromoblastomycosis"},{"Id":"3cbb27d7-3c23-4447-a17a-21467f4d419d","LastModified":"2026-07-28T09:04:28Z","PublicationDate":"2018-06-02T02:28:08Z","DateCreated":"2018-06-02T02:28:07Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"hepatitis-b","ItemDefaultUrl":"/hepatitis-b","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"<p>There is no specific treatment for acute hepatitis B. Chronic hepatitis B can be treated with medicines.</p>","Content":"<h2>Key facts</h2><ul><li>Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease.</li><li>The virus is most commonly transmitted from mother to child during birth and delivery, in early childhood, as well as through contact with blood or other body fluids during sex with an\r\n        infected partner, unsafe injections or exposures to sharp instruments.</li><li>WHO estimates that 240&nbsp;million people were living with chronic hepatitis B infection in 2024, with 0.9&nbsp;million new infections each year.</li><li>In 2024, hepatitis B resulted in an estimated 1.1&nbsp;million deaths, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).</li><li>Hepatitis B can be prevented by vaccines that are safe, available and effective.<br />&nbsp;</li></ul><hr /><br /><h2>Overview</h2><p>Hepatitis B (HBV) is an infection of the liver caused by the hepatitis B virus. The infection can be acute (short and severe) or chronic (long term).</p><p>Hepatitis B can cause a chronic infection and puts people at high risk of death from cirrhosis and liver cancer.</p><p>It can spread through contact with infected body fluids like blood, vaginal fluids, semen and saliva in the presence of open cuts and sores. It can also be passed from a mother to her baby.</p><p>Hepatitis B can be prevented with a safe and effective vaccine. The vaccine is usually given soon after birth with boosters a few weeks later. It offers nearly 100% protection against the virus.</p><p>Hepatitis B is a major global health problem. The burden of infection is highest in the WHO Western Pacific Region and the WHO African Region, where 102&nbsp;million and 64&nbsp;million people, respectively, are chronically infected. Forty-three million people are infected in the WHO South-East Asia Region, 16&nbsp;million in the WHO Eastern Mediterranean Region, 9.7&nbsp;million in the WHO European Region and 5&nbsp;million in the WHO Region of the Americas.</p><p>In 2024, the global prevalence of chronic HBV infection among children aged under 5 years was estimated at 0.6% (95% uncertainty interval (UI): 0.5&ndash;0.8%). The WHO African Region, with a prevalence of 1.4%, remains far from the 2030 target of 0.1% and continues to face the greatest burden, owing to a combination of high maternal prevalence and inadequate coverage of universal childhood vaccination, in addition to poor access to timely birth-dose vaccination in highly endemic countries. The WHO Eastern Mediterranean Region also has a prevalence that is far above the 2030 target, at 0.5%. In contrast, 2 WHO regions have already achieved levels that have surpassed the 2030 target: the European Region and the Region of the Americas. The WHO Western Pacific Region and the South-East Asia Region have made impressive progress and now require further intensification of efforts to achieve the 2030 target.</p><p>According to latest WHO estimates, the proportion of children under 5 years of age chronically infected with hepatitis B dropped to just under 1% in 2019 down from around 5% in the pre-vaccine era ranging from the 1980s to the early 2000s.</p><h2>Transmission</h2><p>In highly endemic areas, hepatitis B is most commonly spread from mother to child at birth (perinatal transmission) or horizontal transmission through person-to-person contact in the presence of open cuts and sores, especially from an infected child to an uninfected child during the first 5 years of life. The development of chronic infection is very common in infants infected from their mothers or before the age of 5 years.</p><p>Hepatitis B is also spread by needlestick injury, tattooing, piercing and exposure to infected blood and body fluids, such as saliva and menstrual, vaginal and seminal fluids. Transmission of the virus may also occur through the sharing or reuse of contaminated needles and syringes or sharp objects either in health care settings, in the community or among persons who inject drugs. Sexual transmission is more prevalent in unvaccinated persons with multiple sexual partners.</p><p>Hepatitis B infection acquired in adulthood leads to chronic hepatitis in less than 5% of cases, whereas infection in infancy and early childhood leads to chronic hepatitis in about 95% of cases. This is the basis for strengthening and prioritizing infant and childhood vaccination.</p><h2>Symptoms</h2><p>Most people do not experience any symptoms when newly infected.</p><p>Some people have acute illness with symptoms that last several weeks:</p><ul><li>yellowing of the skin and eyes (jaundice)</li><li>dark urine</li><li>feeling very tired</li><li>nausea</li><li>vomiting</li><li>pain in the abdomen.</li></ul><p>When severe, acute hepatitis can lead to liver failure, which can lead to death.</p><p>Although most people will recover from acute illness, some people with chronic hepatitis B will develop progressive liver disease and complications like cirrhosis and hepatocellular carcinoma (liver cancer). These diseases can be fatal.</p><h2>HBV-HIV coinfection</h2><p>The global prevalence of HBV infection in HIV-infected persons is estimated at 7.4% <em>(1)</em>. Since 2015, WHO has recommended treatment for everyone diagnosed with HIV infection, regardless of the stage of disease. Tenofovir, which is included in the treatment combinations recommended as first-line therapy for HIV infection, is also active against HBV.</p><h2>Diagnosis</h2><p>It is not possible on clinical grounds to differentiate hepatitis B from hepatitis caused by other viral agents; hence laboratory confirmation of the diagnosis is essential. Several blood tests are available to diagnose and monitor people with hepatitis B. Some laboratory tests can be used to distinguish acute and chronic infections, whilst other can assess and monitor the severity of liver disease. Physical examination, ultrasound and elastography can also be performed to assess degree of liver fibrosis and scarring and monitor progression of liver disease. WHO recommends that all blood donations be tested for hepatitis B to ensure blood safety and avoid accidental transmission.</p><p>As of 2024, 65&nbsp;million people or 27% of people estimated to be living with hepatitis B were aware of their infection status. </p><p>In settings with intermediate and high Hepatitis B surface antigen (HBsAg) seroprevalence in the general population (defined as &gt;2% HBsAg seroprevalence), WHO recommends that all adults have access to and be offered HBsAg testing with linkage to prevention and care and treatment services as needed. WHO also recommends targeted testing, in all settings, of people with suspicions of liver disease, blood donors, and all pregnant women, the latter in order to provide the opportunity to institute measures for prevention of mother-to-child transmission (MTCT). In addition, WHO recommends testing among specific high-risk groups, including migrants from endemic regions, partners or family members of infected persons, health-care workers, people who inject drugs (PWID), people in prisons and other closed settings, men who have sex with men (MSM) sex workers, transgender people and people living with HIV.</p><h2>Treatment</h2><p>There is no specific treatment for acute hepatitis B. Chronic hepatitis B can be treated with antiviral medications.</p><p>Care for people with acute hepatitis B should focus on managing symptoms. They should eat a healthy diet and drink plenty of liquids to prevent dehydration from vomiting and diarrhoea.</p><p>Chronic hepatitis B infection can be treated with oral medicines, including tenofovir or entecavir.</p><p>Treatment can</p><ul><li>slow the advance of cirrhosis</li><li>reduce cases of liver cancer</li><li>improve long term survival.</li></ul><p>Most people who start hepatitis B treatment must continue it for life.</p><p>In 2024 only 10&nbsp;million people were on antiviral treatment, this being equivalent to 4.3% of all people living with chronic hepatitis B.</p><p>With the updated <a href=\"https://www.who.int/publications/i/item/9789240090903\">Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection</a>, released in 2024, it is estimated that more than 50% of people with chronic hepatitis B infection will require treatment, depending on setting and eligibility criteria.</p><p>In low-income settings, most people with liver cancer present late in the course of the disease and die within months of diagnosis. In high-income countries, patients present to hospital earlier in the course of the disease and have access to surgery and chemotherapy, which can prolong life for several months to a few years. Liver transplantation is sometimes used in people with cirrhosis or liver cancer in technologically advanced countries, with varying success.</p><h2>Prevention</h2><p>Hepatitis B is preventable with a vaccine.</p><p>All babies should receive the hepatitis B vaccine as soon as possible after birth (within 24 hours). This is followed by two or three doses of hepatitis B vaccine at least four weeks apart.</p><p>Booster vaccines are not usually required for people who have completed the three-dose vaccination series.</p><p>The vaccine protects against hepatitis B for at least 20 years and probably for life.</p><p>Hepatitis B can be passed from mother to child. This can be prevented by taking antiviral medicines to prevent transmission, in addition to the vaccine shortly after birth.</p><p>To reduce the risk of getting or spreading hepatitis B:</p><ul><li>practice safe sex by using condoms;</li><li>avoid sharing needles or any equipment used for injecting drugs, piercing, or tattooing;</li><li>wash your hands thoroughly with soap and water after coming into contact with blood, body fluids, or contaminated surfaces; and</li><li>get a hepatitis B vaccine if working in a health-care setting.</li></ul><h2>WHO response</h2><p><a href=\"https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/strategies/global-health-sector-strategies\">Global health sector strategies</a> on, respectively, HIV, viral hepatitis, and sexually transmitted infections for the period 2022&ndash;2030 (GHSSs) guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS, viral hepatitis (especially chronic hepatitis B and C) and sexually transmitted infections by 2030.</p><p>The GHSS recommend shared and disease-specific country actions supported by actions by WHO and partners. They consider the epidemiological, technological, and contextual shifts of previous years, foster learnings across the disease areas, and create opportunities to leverage innovations and new knowledge for effective responses to the diseases. They call to scale up prevention, testing and treatment of viral hepatitis with a focus to reach populations and communities most affected and at risk for each disease, as well as addressing gaps and inequities. They also promote synergies under a universal health coverage and primary health care framework and contribute to achieving the goals of the 2030 Agenda for Sustainable Development. WHO supports countries to develop national strategies in line with this vision.</p><p>Furthermore, WHO develops and updates guidelines for the prevention, testing and treatment of HBV and supports countries in their efforts to reflect the latest science and recommendations in their public health response.</p><p>WHO organizes annual <a href=\"https://www.who.int/campaigns/world-hepatitis-day\">World Hepatitis Day campaigns</a>&nbsp;on 28 July to increase awareness and understanding of viral hepatitis.<br />&nbsp;</p><p><strong>References</strong></p><p><em>(1)</em> Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A et al. Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis. J Viral Hepat. 2020;27(3):294-315 (<a href=\"https://doi.org/10.1111/jvh.13217\" target=\"_blank\">https://doi.org/10.1111/jvh.13217</a>).</p><p>&nbsp;</p>","ConditionName":"Hepatitis B","OpenGraphTitle":"Hepatitis B","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"<p>Hepatitis B is preventable with a vaccine.</p>","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"<p>Some people have acute illness with symptoms that last several weeks. The symptoms include:</p><ul><li>yellowing of the skin and eyes (jaundice)</li><li>dark urine</li><li>feeling very tired</li><li>nausea</li><li>vomiting</li><li>pain in the abdomen</li></ul><p>When severe, acute hepatitis can lead to liver failure, which can lead to death.</p><p>Although most people will recover from acute illness, some people with chronic hepatitis B will develop progressive liver disease and complications like cirrhosis and hepatocellular carcinoma (liver cancer). These diseases can be fatal.</p>","MetaTitle":"Hepatitis B","ConditionLongerOverview":"<p>Hepatitis B can cause a chronic infection and puts people at high risk of death from cirrhosis (severe scarring of the liver) and liver cancer.</p><p>It can spread through contact with infected body fluids like blood, saliva, vaginal fluids and semen. It can also be passed from a mother to her baby.</p><p>Hepatitis B can be prevented with a safe and effective vaccine. The vaccine is usually given soon after birth with boosters a few weeks later. It offers nearly 100% protection against the virus.</p>","Title":"Hepatitis B","PreventionLongerSummary":"<p>All babies should receive the hepatitis B vaccine as soon as possible after birth (within 24 hours). This is followed by two or three doses of hepatitis B vaccine at least four weeks apart. <br /></p><p>Booster vaccines are not usually required for people who have completed the three-dose vaccination series.<br /></p><p>The vaccine protects against hepatitis B for at least 20 years and probably for life.<br /></p><p>Hepatitis B can be passed from mother to child. This can be prevented by taking antiviral medicines to prevent transmission, in addition to the vaccine. <br /></p><p>To reduce the risk of getting or spreading hepatitis B:&nbsp;</p><ul data-list=\"0\" data-level=\"1\"><li>practice safe sex by using condoms and reducing the number of sexual partners</li><li>avoid sharing needles or any equipment used for injecting drugs, piercing, or tattooing</li><li>wash your hands thoroughly with soap and water after coming into contact with blood, body fluids, or contaminated surfaces</li><li>get a hepatitis B vaccine if working in a healthcare setting</li></ul><p></p>","SourceKey":"/entity/mediacentre/factsheets/fs204","PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"<p><a href=\"https://www.who.int/health-topics/hepatitis#tab=tab_1\">General information on hepatitis B</a></p><p><a href=\"https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/overview\">Technical information on hepatitis</a></p>","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. This fact sheet provides information about transmission, symptoms, diagnosis, treatment, prevention and WHO's work to support prevention and treatment. ","PublicationDateAndTime":"2026-07-28T15:55:59Z","ConditionBriefOverview":"<p>Hepatitis B is an infection of the liver caused by the hepatitis B virus. The infection can be acute (short and severe) or chronic (long term).</p>","MetaDescription":"Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. This fact sheet provides information about transmission, symptoms, diagnosis, treatment, prevention and WHO's work to support prevention and treatment. ","MedicalTreatmentLongerSummary":"<p>Care for acute hepatitis B should focus on making the person comfortable. They should eat a healthy diet and drink plenty of liquids to prevent dehydration from vomiting and diarrhoea.</p><p>Chronic hepatitis B infection can be treated with oral antiviral medicines, including tenofovir or entecavir.</p><p>Treatment can slow the advance of cirrhosis, reduce cases of liver cancer, and improve long term survival.</p><p>Most people who start hepatitis B treatment must continue it for life.</p>","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"<p>Most people do not experience any symptoms when newly infected.</p>","Highlight":"<p><a href=\"https://www.who.int/publications/i/item/9789240122383\">Global hepatitis report 2026</a></p><p><a href=\"https://www.who.int/publications/i/item/9789240090903\">Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection</a></p><p><a href=\"https://www.who.int/publications/i/item/9789240104082\">Priorities in planning person-centred hepatitis B and C testing services: operational guide</a></p><p><a href=\"https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/strategies/global-health-sector-strategies/developing-ghss-2022-2030\">Global health sector strategy on viral hepatitis</a>\r\n</p><p><a href=\"https://www.who.int/publications/i/item/9789241515191\">Consolidated strategic information guidelines for viral hepatitis</a></p><p><a href=\"https://www.who.int/publications/i/item/9789241509350\">Manual for the development and assessment of national viral hepatitis plans</a></p><p><a href=\"https://www.who.int/campaigns/world-hepatitis-day\">World Hepatitis Day</a></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/hepatitis-pakistan-doctors-office.tmb-768v.jpg?sfvrsn=398d7336_44","FormatedDate":"28 July 2026","TrimmedTitle":"Hepatitis B"},{"Id":"b0adeaca-0321-4859-ac7a-82f4f9fcd6d9","LastModified":"2024-10-01T14:03:16Z","PublicationDate":"2018-06-02T02:28:11Z","DateCreated":"2018-06-02T02:28:09Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"mpox","ItemDefaultUrl":"/mpox","NewsNumberOfAdditionalItems":1,"MedicalTreatmentBriefSummary":"The goal of treating mpox is to take care of the rash, manage pain and prevent complications. Early and supportive care is important to help manage symptoms and avoid further problems.","Content":"<h2>Key facts &nbsp;</h2><ul><li>Mpox, previously known as monkeypox, is a viral illness caused by the monkeypox virus, a species of the genus <em>Orthopoxvirus</em>. There are two distinct clades of the virus: clade I (with subclades Ia and Ib) and clade II (with subclades IIa and IIb). In 2022&ndash;2023 a global outbreak of mpox was caused by the clade IIb strain.&nbsp;</li><li>Mpox continues to be a threat today, and an upsurge of cases in the Democratic Republic of the Congo and other countries caused by clades Ia and Ib has raised concern. </li><li>There are vaccines for mpox. Vaccination should be considered along with other public health interventions.&nbsp; </li><li>Common symptoms of mpox are a skin rash or mucosal lesions which can last 2&ndash;4 weeks accompanied by fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.&nbsp;</li><li>Mpox can be transmitted through close contact with someone who has mpox, with contaminated materials, or with infected animals.&nbsp;During pregnancy, the virus may be passed to the fetus, or to the newborn during or after birth.</li><li>Mpox is treated with supportive care for symptoms such as pain and fever, with close attention to nutrition, hydration, skin care, prevention of secondary infections and treatment of co-infections, including HIV where present.</li></ul><hr /><h2>Overview</h2><p>Mpox is an infectious disease that can cause a painful rash, enlarged lymph nodes, fever, headache, muscle ache, back pain and low energy. Most people fully recover, but some get very sick.&nbsp;</p><p>Mpox is caused by the monkeypox virus (MPXV). It is an enveloped double-stranded DNA virus of the&nbsp;<em>Orthopoxvirus</em>&nbsp;genus in the&nbsp;<em>Poxviridae</em>&nbsp;family, which includes variola, cowpox, vaccinia and other viruses. There are two distinct clades of the virus: clade I (with subclades Ia and Ib) and clade II (with subclades IIa and IIb).</p><p>A global outbreak of clade IIb began in 2022 and continues to this day, including in some African countries. There are also growing outbreaks of clades Ia and Ib affecting the Democratic Republic of the Congo and other countries in Africa. As of August 2024, clade Ib has also been detected beyond Africa.</p><p>The natural reservoir of the virus is unknown, but various small mammals such as squirrels and monkeys are susceptible.&nbsp;</p><h2>Transmission&nbsp;</h2><p>Mpox spreads from person to person mainly through close contact with someone who has mpox, including members of a household. Close contact includes skin-to-skin (such as touching or sex) and mouth-to-mouth or mouth-to-skin contact (such as kissing), and it can also include being face-to-face with someone who has mpox (such as talking or breathing close to one another, which can generate infectious respiratory particles).</p><p>People with multiple sexual partners are at higher risk of acquiring mpox.&nbsp;</p><p>People can also contract mpox from contaminated objects such as clothing or linen, through needle injuries in health care, or in community settings such as tattoo parlours.&nbsp;</p><p>During pregnancy or birth, the virus may be passed to the baby.&nbsp;Contracting mpox during pregnancy can be dangerous for the fetus or newborn infant and can lead to loss of the pregnancy, stillbirth, death of the newborn, or complications for the parent. </p><p>&nbsp;Animal-to-human transmission of mpox occurs from infected animals to humans from bites or scratches, or during activities such as hunting, skinning, trapping, cooking, playing with carcasses or eating animals<em>.&nbsp;</em>The animal reservoir of the monkeypox virus remains unknown and further studies are underway.&nbsp;</p><p>More research is needed on how mpox spreads during outbreaks in different settings and under different conditions.</p><h2>Signs and symptoms&nbsp;</h2><p>Mpox causes signs and symptoms which usually begin within a week but can start 1&ndash;21 days after exposure. Symptoms typically last 2&ndash;4 weeks but may last longer in someone with a weakened immune system.&nbsp;</p><p>Common symptoms of mpox are:&nbsp;</p><ul><li>rash&nbsp;</li><li>fever&nbsp;</li><li>sore throat&nbsp;</li><li>headache&nbsp;</li><li>muscle aches&nbsp;</li><li>back pain&nbsp;</li><li>low energy&nbsp;</li><li>swollen lymph nodes.&nbsp;&nbsp;</li></ul><p>For some people, the first symptom of mpox is a rash, while others may have fever, muscle aches or sore throat first.&nbsp;&nbsp;</p><p>The mpox rash often begins on the face and spreads over the body, extending to the palms of the hands and soles of the feet. It can also start on other parts of the body where contact was made, such as the genitals. It starts as a flat sore, which develops into a blister filled with liquid that may be itchy or painful. As the rash heals, the lesions dry up, crust over and fall off.&nbsp;</p><p>Some people may have one or a few skin lesions and others have hundreds or more. These can appear anywhere on the body including:&nbsp;</p><ul><li>palms of hands and soles of feet&nbsp;</li><li>face, mouth and throat&nbsp;</li><li>groin and genital areas&nbsp;</li><li>anus.</li></ul><p>Some people also have painful swelling of their rectum (proctitis) or pain and difficulty when peeing (dysuria) or when swallowing.&nbsp;</p><p>People with mpox can pass the disease on to others until all sores have healed and a new layer of skin has formed. Some people can be infected without developing any symptoms. Although getting mpox from someone who is asymptomatic (not showing symptoms) has been reported, information is still limited on how common it is.&nbsp;&nbsp; </p><p>Children, pregnant people and people with weak immune systems, including people living with HIV that is not well controlled, are at higher risk for serious illness and death due to complications from mpox.&nbsp;</p><p>Some people with mpox become very sick. For example, the skin can become infected with bacteria, leading to abscesses or serious skin damage. Other complications include pneumonia; corneal infection with loss of vision; pain or difficulty swallowing; vomiting and diarrhoea causing dehydration or malnutrition; and infections of the blood (sepsis), brain (encephalitis), heart (myocarditis), rectum (proctitis), genital organs (balanitis) or urinary passages (urethritis). Mpox can be fatal in some cases. &nbsp;</p><h2>Diagnosis&nbsp;</h2><p>Identifying mpox can be difficult because other infections and conditions can look similar. It is important to distinguish mpox from chickenpox, measles, bacterial skin infections, scabies, herpes, syphilis, other sexually transmitted infections, and medication-associated allergies. Someone with mpox may also have another sexually transmitted infection at the same time, such as syphilis or herpes. Alternatively, a child with suspected mpox may also have chickenpox. For these reasons, testing is key for people to get care as early as possible and prevent severe illness and further spread.</p><p>The preferred laboratory test for mpox is detection of viral DNA by polymerase chain reaction (PCR). The best diagnostic specimens are taken directly from the rash &ndash; skin, fluid or crusts &ndash; collected by vigorous swabbing. In the absence of skin lesions, testing can be done using swabs of the throat or anus. Testing blood is not recommended. Antibody detection methods may not be useful as they do not distinguish between different orthopoxviruses.&nbsp;</p><p>HIV testing should be offered to adults with mpox, and children as appropriate. Diagnostic tests for other conditions should be considered where feasible, for example, varicella zoster virus (VZV), syphilis and herpes.</p><h2>Treatment and vaccination&nbsp;</h2><p>The goal of treating mpox is to take care of the rash, manage pain and prevent complications. Early and supportive care is important to help manage symptoms and avoid further problems.&nbsp;</p><p>Getting an mpox vaccine can help prevent infection (pre-exposure prophylaxis). It is recommended for people at high-risk of getting mpox, especially during an outbreak. </p><p>Groups that may be at high risk of mpox include:&nbsp;</p><ul><li>health and care workers at risk of exposure;&nbsp;</li><li>people in the same household or close community as someone who has mpox, including children;</li><li>people who have multiple sex partners, including men who have sex with men; and </li><li>sex workers of any gender and their clients.</li></ul><p>The vaccine can also be administered after a person has been in contact with someone who has mpox (post-exposure prophylaxis). In these cases, the vaccine should be given less than 4 days after contact with someone who has mpox. The vaccine can be given for up to 14 days if the person has not developed symptoms.</p><p>Some antivirals have received emergency use authorization in some countries and are being evaluated in clinical trials. To date, there is no proven effective antiviral treatment for mpox. It is a priority to continue evaluation of therapeutics in robust clinical trials and to focus on optimizing supportive care for patients.</p><p>Individuals with HIV and mpox should continue taking their antiretroviral therapy (ART). ART should be initiated within 7 days of diagnosis of HIV.</p><h2>Self-care and prevention</h2><p>Most people with mpox will recover within 2&ndash;4 weeks. Things to do to help the symptoms and prevent transmitting mpox to others:&nbsp;</p><p>Do&nbsp;</p><ul><li>contact your health care provider for advice;</li><li>stay at home and in your own, well-ventilated room if possible;&nbsp;</li><li>wash hands often with soap and water or hand sanitizer, especially before or after touching sores;&nbsp;</li><li>wear a mask and cover lesions when around other people until your rash heals;&nbsp;</li><li>keep skin dry and uncovered (unless in a room with someone else);&nbsp;</li><li>avoid touching items in shared spaces and disinfect shared spaces frequently;&nbsp;&nbsp;</li><li>use saltwater rinses for sores in the mouth;&nbsp;</li><li>take warm baths with baking soda or Epsom salts for body sores; and&nbsp;</li><li>take over-the-counter medications for pain like paracetamol (acetaminophen) or ibuprofen.&nbsp;</li></ul><p>Do not&nbsp;</p><ul><li>pop blisters or scratch sores, which can slow healing, spread the rash to other parts of the body, and cause sores to become infected; or&nbsp;</li><li>shave areas with sores until scabs have healed and you have new skin underneath (this can spread the rash to other parts of the body).&nbsp;</li></ul><p>To prevent spread of mpox to others, people with mpox should isolate at home following guidance from their health care provider, or in hospital if needed, for the duration of the infectious period (from onset of symptoms until lesions have healed and scabs fall off). Covering lesions and wearing a well-fitting mask when in the presence of others may help prevent spread. Using condoms during sex will help reduce the risk of getting mpox but will not prevent spread from skin-to-skin or mouth-to-skin contact.&nbsp;If having sex, use condoms as a precaution for 12 weeks (about 3 months) after you have recovered.</p><p>Taking a break from sexual activity with new partners during periods of increased transmission can reduce the risk of getting mpox. Those who have had contact with someone with mpox should monitor for signs and symptoms for 21 days (3 weeks) and take precautions such as avoiding sexual activity during this period.</p><p>Health workers should follow infection prevention and control measures to protect themselves while caring for patients with mpox by wearing appropriate personal protective equipment (PPE) (i.e. gloves, gown, eye protection and respirator) and adhering to protocol for safely swabbing lesions for diagnostic testing and handling sharp objects such as needles.</p><h2>Outbreaks</h2><p>The monkeypox virus was discovered in Denmark (1958) in monkeys kept for research. The first reported human case of mpox was a nine-month-old boy in the Democratic Republic of the Congo (1970). Following the eradication of smallpox in 1980 and the end of smallpox vaccination worldwide, mpox steadily emerged in central, east and west Africa. Since then, mpox has been reported sporadically in central and east Africa (clade I) and west Africa (clade II). In 2003, an outbreak in the United States of America was linked to imported wild animals (clade II). Since 2005, thousands of cases are reported in the Democratic Republic of the Congo every year. In 2017, mpox re-emerged in Nigeria and continues to spread between people across the country and in travellers to other destinations. </p><p>Data on suspected and confirmed cases reported up to 2021 are available&nbsp;<a href=\"https://apps.who.int/iris/bitstream/handle/10665/365630/WER9803-29-36.pdf?sequence=1&amp;isAllowed=y\" target=\"_blank\">here</a> and data on laboratory confirmed cases from 2022 until today are available <a href=\"https://worldhealthorg.shinyapps.io/mpx_global/\">here</a>.</p><p>In May 2022, an outbreak of mpox appeared suddenly and rapidly spread across Europe, the Americas and then all six WHO regions. The global outbreak has affected primarily (but not only) gay, bisexual, and other men who have sex with men and has spread person-to-person through sexual networks. More information on the global outbreak is available&nbsp;<a href=\"https://www.who.int/emergencies/situations/monkeypox-oubreak-2022\">here</a>, including information on <a href=\"https://www.who.int/publications/i/item/9789240077287\">community responses</a> to control the outbreak.</p><p>In 2022, outbreaks of mpox due to clade I occurred in refugee camps in the Republic of the Sudan. </p><p>Since 2022, there has also been an upsurge in mpox cases and deaths in the Democratic Republic of the Congo. In some areas of the country, a new offshoot of clade I, called clade Ib, has been spreading person-to-person. As of mid-2024, the clade has also been reported in other countries. </p><p>Over 120 countries have reported mpox between Jan 2022 &ndash; Aug 2024, with over 100&nbsp;000 laboratory-confirmed cases reported and over 220 deaths among confirmed cases.</p><h2>Stigma and discrimination</h2><p>Stigma and discrimination for any disease are never acceptable. Stigma linked to mpox can undermine public health efforts or prolong a disease outbreak, as people may be more reluctant to come forward and seek care and treatment. For mpox, stigma, discrimination and racism have been particularly directed against communities initially most affected by the disease, namely men who have sex with men, trans people and gender diverse communities.</p><h2>WHO response&nbsp;</h2><p>WHO works with Member States and partners to prevent and respond to outbreaks of mpox. This includes coordinating research on vaccines and treatments, strengthening country health systems, and working to facilitate equitable access to vaccines, therapeutics, diagnostics and other tools.</p><p>WHO Director-General Dr Tedros Adhanom Ghebreyesus has declared mpox a public health emergency of international concern (PHEIC) twice, the first time in May 2022 and the second time in August 2024.</p>","ConditionName":"Mpox","OpenGraphTitle":"Mpox","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"<div>Most people with mpox will recover within 2&ndash;4 weeks. Things to do to help the symptoms and prevent infecting others:</div><div><br /></div><div>Do</div><ul><li>Stay home and in your own room if possible&nbsp;</li><li>Wash hands often with soap and water or hand sanitizer, especially before or after touching sores</li><li>Wear a mask and cover lesions when around other people until your rash heals</li><li>Keep skin dry and uncovered (unless in a room with someone else)</li><li>Avoid touching items in shared spaces and disinfect shared spaces frequently&nbsp;</li><li>Use saltwater rinses for sores in the mouth</li><li>Take sitz baths or warm baths with baking soda or Epsom salts for body sores</li><li>Take over-the-counter medications for pain like paracetamol (acetaminophen) or ibuprofen</li></ul><div><br /></div><div>Do not</div><ul><li>Pop blisters or scratch sores, which can slow healing, spread the rash to other parts of the body, and cause sores to become infected&nbsp;</li><li>Shave areas with sores until scabs have healed and you have new skin underneath (this can spread the rash to other parts of the body)&nbsp;</li></ul><div><br /></div><p>&nbsp;</p>","EventNumberOfAdditionalItems":0,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"<div>Common symptoms of mpox are:</div><ul><li>rash</li><li>fever</li><li>sore throat</li><li>headache</li><li>muscle aches</li><li>back pain</li><li>low energy</li><li>swollen lymph nodes&nbsp;</li></ul><div><br /></div><div>For some people, the first symptom of mpox is a rash, while others may have different symptoms first.&nbsp;</div><div>The rash begins as a flat sore which develops into a blister filled with liquid and may be itchy or painful. As the rash heals, the lesions dry up, crust over and fall off.&nbsp;</div><div><br /></div><div>Some people may have one or a few skin lesions and others have hundreds or more. These can appear&nbsp; anywhere on the body such as the:</div><ul><li>palms of hands and soles of feet</li><li>face, mouth and throat</li><li>groin and genital areas</li><li>anus</li></ul><div><br /></div><div>Some people also have painful swelling of their rectum or pain and difficulty when peeing.</div><div><br /></div><div>People with mpox are infectious and can pass the disease on to others until all sores have healed and a new layer of skin has formed.&nbsp;</div><div><br /></div><div>Children, pregnant people and people with weak immune systems are at risk for complications from mpox.&nbsp;</div>","MetaTitle":"Mpox","ConditionLongerOverview":"<p>Anyone can get mpox. It spreads from contact with infected:</p><ul><li>persons, through touch, kissing, or sex</li><li>animals, when hunting, skinning, or cooking them</li><li>materials, such as contaminated sheets, clothes or needles&nbsp;</li><li>pregnant persons, who may pass the virus on to their unborn baby</li></ul><p>If you have mpox:</p><ul><li>Tell anyone you have been close to recently&nbsp;</li><li>Stay at home until all scabs fall off and a new layer of skin forms&nbsp;</li><li>Cover lesions and wear a well-fitting mask when around other people</li><li>Avoid physical contact</li></ul>","Title":"Mpox","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs161","PhotoStoryNumberOfAdditionalItems":0,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":0,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":0,"OtherRelated":"<p><a href=\"https://www.who.int/multi-media/details/recovering-from-monkeypox-at-home\">Recovering from mpox at home (infographic)</a></p><div><p><a href=\"https://www.who.int/publications/m/item/how-to-use-a-bifurcated-needle-to-perform-multiple-puncture-vaccination-technique\">How to use a bifurcated needle to perform multiple puncture vaccination technique</a></p></div>","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"WHO fact sheet on mpox: includes key facts, definition, outbreaks, transmission, symptoms, diagnosis, treatment, prevention, WHO response.","PublicationDateAndTime":"2024-08-26T11:01:26Z","ConditionBriefOverview":"<p>Mpox is an infectious disease caused by the monkeypox virus. It can cause a painful rash, enlarged lymph nodes and fever. Most people fully recover, but some get very sick.</p><p>&nbsp;</p><p></p>","MetaDescription":"WHO fact sheet on mpox: includes key facts, definition, outbreaks, transmission, symptoms, diagnosis, treatment, prevention, WHO response.","MedicalTreatmentLongerSummary":"<p>Getting an mpox vaccine can help prevent infection. The vaccine should be given within 4 days of contact with someone who has mpox (or within up to 14 days if there are no symptoms).</p><p>It is recommended for people at high risk to get vaccinated to prevent infection with mpox, especially during an outbreak. This includes:</p><ul><li>health workers at risk of exposure</li><li>men who have sex with men</li><li>people with multiple sex partners</li><li>sex workers</li></ul><p>Persons who have mpox should be cared for away from other people.</p>","CommentaryNumberOfAdditionalItems":0,"SymptomsBriefSummary":"<p>Mpox causes signs and symptoms which usually begin within a week but can start 1&ndash;21 days after exposure. Symptoms typically last 2&ndash;4 weeks but may last longer in someone with a weakened immune system.<p>&nbsp;</p></p>","Highlight":"<p><a href=\"https://www.who.int/health-topics/mpox\">WHO's work on mpox</a></p><p><a href=\"https://www.who.int/news-room/questions-and-answers/item/mpox\">Questions and answers on mpox</a>\r\n</p><p><a href=\"https://www.who.int/podcasts/episode/science-in-5/episode--124---mpox--what-you-need-to-know\">Science in 5: Mpox, what you need to know</a></p><p><a href=\"https://www.who.int/emergencies/situations/monkeypox-oubreak-2022\">Mpox outbreak 2022</a></p><p><a href=\"https://www.who.int/teams/blueprint/monkeypox\">R&amp;D Blueprint and mpox</a></p><p><a href=\"https://www.who.int/news-room/public-advice\">Public advice</a></p><p><a href=\"https://www.who.int/emergencies/outbreak-toolkit/disease-outbreak-toolboxes/mpox-outbreak-toolbox\">Mpox Outbreak Toolbox (who.int)</a></p>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/health-topics/monkeypox/12763.tmb-768v.jpg?sfvrsn=cd044fbd_39","FormatedDate":"26 August 2024","TrimmedTitle":"Mpox"},{"Id":"4d0ff53d-9f65-4316-a6f7-5a5c06ab2d6f","LastModified":"2024-10-24T14:34:22Z","PublicationDate":"2018-06-02T02:28:13Z","DateCreated":"2018-06-02T02:28:11Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"japanese-encephalitis","ItemDefaultUrl":"/japanese-encephalitis","NewsNumberOfAdditionalItems":2,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>Japanese encephalitis virus (JEV) is a flavivirus related to dengue, yellow fever and West Nile viruses, and is spread by mosquitoes (especially <em>Culex</em> <em>tritaeniorhynchus</em>).</li><li>JEV is the main cause of viral encephalitis in many countries of Asia with an estimated 100 000 clinical cases every year <em>(1)</em>. </li><li>Although symptomatic Japanese encephalitis (JE) is rare, the case-fatality rate among those with encephalitis can be as high as 30%. Permanent neurologic, cognitive and behavioural sequelae occur in 30&ndash;50% of those with encephalitis. </li><li>The majority of cases occur in children below 15 years of age.</li><li>Twenty-four countries in the WHO South-East Asia and Western Pacific Regions have endemic JEV transmission, exposing more than 3 billion people to risks of infection. </li><li>There is no cure for the disease. Treatment is focused on relieving severe clinical signs and supporting the patient to overcome the infection. </li><li>Safe and effective vaccines are available to prevent JE. WHO recommends that JE vaccination be integrated into national immunization schedules in all areas where JE disease is recognized as a public health issue.</li></ul><h2>Overview</h2><p>Japanese encephalitis virus (JEV) is an important cause of viral encephalitis in Asia. It is a mosquito-borne flavivirus and belongs to the same genus as dengue, Zika, yellow fever and West Nile viruses. The first case of Japanese encephalitis viral disease (JE) was documented in 1871 in Japan. The annual incidence of clinical disease varies both across and within endemic countries, ranging from 10 per 100 000 population or higher during outbreaks. A literature review and modelling study estimates about 100 000 clinical cases (95% CI: 61 720&ndash;157 522) of JE globally each year, with approximately 25 000 deaths (95% CI: 14 550&ndash;46 031). JE primarily affects children. Most adults in endemic countries have natural immunity after childhood infection, but individuals of any age may be affected.<br /></p><h2>Signs and symptoms</h2><p>Most JEV infections are mild (fever and headache) or without apparent symptoms, but approximately 1 in 250 infections results in severe clinical illness. The incubation period is 4&ndash;14 days. In children, gastrointestinal pain and vomiting may be the dominant initial symptoms. Severe disease is characterized by rapid onset of high fever, headache, neck stiffness, disorientation, coma, seizures, spastic paralysis and ultimately death. The case fatality rate can be as high as 30% among those with disease symptoms. Of those who survive, 20&ndash;30% suffer permanent cognitive, behavioural or neurological sequelae such as seizures, &nbsp;hearing or vision loss, speech, language, memory, and communication problems or weakness of the limbs. <br /></p><h2>Transmission</h2><p>Twenty-four countries in the WHO South-East Asia and Western Pacific Regions have JEV transmission risk, which includes more than 3 billion people. JEV is transmitted to humans through bites from infected mosquitoes of the <em>Culex</em> species (mainly <em>Culex tritaeniorhynchus</em>). Humans, once infected, do not develop sufficient viraemia to infect feeding mosquitoes. The virus exists in a transmission cycle between mosquitoes, pigs and/or water birds (enzootic cycle). The disease is predominantly found in rural and periurban settings, where humans live in closer proximity to these vertebrate hosts, in particular domestic pigs. In most temperate areas of Asia, JEV is transmitted mainly during the warm season, when large epidemics can occur. In the tropics and subtropics, transmission can occur year-round but often intensifies during the rainy season and pre-harvest period in rice-cultivating regions.<br /></p><h2>Diagnosis</h2><p>Individuals who live in or have travelled to a JE-endemic area and experience encephalitis are considered a suspected JE case. Initial diagnosis of JE can be made by clinical examination followed by a lumbar puncture. A laboratory test is required to confirm JEV infection and to rule out other causes of encephalitis. WHO recommends testing for JEV-specific IgM antibody in a single sample of cerebrospinal fluid (CSF) or serum, using an IgM-capture ELISA. If tested negative, a convalescent sample may be tested. Testing of CSF sample is preferred to reduce false-positivity rates from previous infection or vaccination.</p><p>Surveillance of the disease is mostly syndromic for acute encephalitis syndrome. Confirmatory laboratory testing is often conducted in dedicated sentinel sites, and efforts are undertaken to expand laboratory-based surveillance. Case-based surveillance is established in countries that effectively control JE through vaccination.<br /></p><h2>Treatment</h2><p>Encephalitis is a medical emergency and requires urgent medical attention. There is no antiviral treatment for patients with JE. Treatment is supportive and includes stabilization and relief of &nbsp;symptoms. &nbsp;</p><p>Those who have lived through encephalitis<strong>&nbsp;</strong>often have health-care needs requiring long-term treatment and care including rehabilitation. The ongoing psychosocial impacts of disability from encephalitis can have medical, educational, social and human rights-based implications. Despite the high burden of sequelae on people with encephalitis, their families and the community, access to both services and support for these conditions is often insufficient, especially in low- and middle-income countries. Individuals and families with members disabled by encephalitis should be encouraged to seek services and guidance from local and national Organizations of Disabled People (ODPs) and other disability focused organizations, which can&nbsp;provide vital advice about legal rights, economic opportunities and social engagement to ensure people disabled by encephalitis are able to live full and rewarding lives.<br /></p><h2>Prevention and control</h2><p>Progress has been made in Asia with the implementation of JE vaccination programmes, with most endemic countries having country-wide or targeted programmes in place.&nbsp; A decline in incidence of the disease has been reported in recent years, which is likely due in part to vaccination. Gavi supports JE catch-up campaigns and co-finances the vaccine for routine immunization in eligible countries.</p><p>Safe and effective JE vaccines are available to prevent disease. WHO recommends having strong JE prevention and control activities, including JE immunization in all regions where the disease is a recognized public health priority, along with strengthening surveillance and reporting mechanisms. Even if the number of JE-confirmed cases is low, vaccination should be considered where there is a suitable environment for JE virus transmission. Introduction of the vaccine should be done in conjunction with a one-time catch-up campaign.</p><p>There are three main types of JE vaccines currently in use: several inactivated Vero cell-derived vaccines, a live attenuated vaccine, and a live recombinant (chimeric) vaccine. One inactivated vaccine and the two live vaccines are WHO prequalified.</p><p>The risk to travellers to Japanese encephalitis-endemic areas is normally low, but travellers should take precautions to avoid mosquito bites. Personal preventive measures include the use of mosquito repellents, long-sleeved clothes, coils and vaporizers. Travellers spending extensive time in JE endemic areas are recommended to get vaccinated before travel.</p><p>In endemic areas, there is little evidence to support a reduction in JE disease burden from interventions other than the vaccination of humans. Thus, vaccination of humans should be prioritized over vaccination of pigs and mosquito control measures. However, the spread of JEV in new areas has been correlated with agricultural development and intensive rice cultivation supported by irrigation programmes.<strong><br /></strong></p><h2>WHO response</h2><p></p><p>WHO responds to Japanese encephalitis in the following way:</p><ul><li>supports countries in the confirmation of outbreaks through its collaborating network of laboratories;</li><li>develops surveillance standards and case definitions for reporting;</li><li>provides guidance on clinical management of disease and long-term care;</li><li>supports vector control efforts in conjunction with the Global Vector Control Response;</li><li>develops guidance on the optimal use of vaccines through the publication of <a href=\"https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers\">vaccine position papers</a>;</li><li>prequalifies vaccines as a service to UNICEF and Gavi.</li><li>WHO is implementing the&nbsp;<a href=\"https://www.who.int/news/item/28-04-2022-draft-intersectoral-global-action-plan-on-epilepsy-and-other-neurological-disorders-2022-2031\">Intersectoral global action plan on epilepsy and other neurological disorders&nbsp;</a>in consultation with Member States to address many challenges and gaps in providing care and services for people with epilepsy and other neurological disorders such as JE that exist worldwide.</li></ul> <p>&nbsp;</p><p><strong>References</strong></p><p>1. Quan et al., <a href=\"https://elifesciences.org/articles/51027\">https://elifesciences.org/articles/51027</a></p>","ConditionName":"","OpenGraphTitle":"Japanese encephalitis","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Japanese encephalitis","ConditionLongerOverview":"","Title":"Japanese encephalitis","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs386","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":3,"OtherRelated":"<h3>Map: Japanese encephalitis</h3>\r\n<a href=\"https://cdn.who.int/media/images/default-source/imported/map-japanese-encephalitis.png?sfvrsn=91d0f0c5_2\"><img src=\"https://cdn.who.int/media/images/default-source/imported/map-japanese-encephalitis.tmb-340v.png?sfvrsn=91d0f0c5_4\" data-displaymode=\"Thumbnail\" alt=\"map japanese encephalitis\" title=\"map japanese encephalitis\" data-openoriginalimageonclick=\"true\" /></a><br />\r\n<strong>Click to enlarge</strong>","FactSheetNumberOfAdditionalItems":0,"OpenGraphDescription":"Japanese encephalitis (JE) is the most important cause of viral encephalitis in Asia. It is a mosquito-borne flavivirus, meaning it is related to dengue, yellow fever and West Nile viruses. WHO recommends having strong prevention and control activities, including JE immunization in all regions where the disease is a recognized public health problem.","PublicationDateAndTime":"2024-08-06T15:23:00Z","ConditionBriefOverview":"","MetaDescription":"Japanese encephalitis (JE) is the most important cause of viral encephalitis in Asia. It is a mosquito-borne flavivirus, meaning it is related to dengue, yellow fever and West Nile viruses. WHO recommends having strong prevention and control activities, including JE immunization in all regions where the disease is a recognized public health problem.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<ul><li><a href=\"https://apps.who.int/iris/handle/10665/242325\">Japanese encephalitis vaccines: WHO position paper - February 2015</a></li><li><a href=\"https://apps.who.int/iris/handle/10665/271003\">Estimated global incidence of Japanese encephalitis: a systematic review</a><br />Bulletin of WHO</li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/departments/ntd-library/japanese-encephalitis/18767880-4400671563do.tmb-768v.jpg?Culture=en&sfvrsn=5839d0da_6","FormatedDate":"6 August 2024","TrimmedTitle":"Japanese encephalitis"},{"Id":"87138707-e067-444e-a903-58587d67c89e","LastModified":"2026-10-06T15:33:36Z","PublicationDate":"2025-04-04T15:02:49Z","DateCreated":"2025-04-04T15:02:49Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"pre-eclampsia","ItemDefaultUrl":"/pre-eclampsia","NewsNumberOfAdditionalItems":null,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key Facts</h2><ul><li>Pre-eclampsia is a hypertensive disorder that affects 3-8% of women who give birth worldwide <em>(1)</em>.</li><li>Pre-eclampsia can progress to eclampsia which involves seizures and can be life-threatening.</li><li>Pre-eclampsia and eclampsia contribute significantly to maternal and perinatal morbidity and mortality.</li><li>Hypertensive disorders are responsible for around 16% of maternal deaths globally, in 2023 this was the equivalent to around 42&nbsp;000 deaths <em>(2, 3)</em>.</li><li>In women with pre-eclampsia magnesium sulfate injections can be given to reduce the risk of eclampsia by more than half. Despite the availability of magnesium sulfate, its use is still limited in many low-resource settings.<br />&nbsp;</li></ul><hr /><br /><h2>Overview</h2><p>Pre-eclampsia is a high blood pressure disorder that typically develops after 20 weeks into pregnancy. It can present serious risks to both mother and baby. Early detection and management are crucial to prevent progression to eclampsia, which involves seizures. Both conditions can be life-threatening.</p><h2>Diagnosis </h2><p>Pre-eclampsia is diagnosed based on the onset of hypertension (blood pressure &ge;140/90 mm Hg) proteinuria (protein in the urine) (&ge;0.3 g/24 hours) after 20 weeks of gestation. Severe pre-eclampsia may include symptoms such as severe headaches, visual disturbances and upper abdominal pain.</p><h2>Risk factors</h2><p>Several factors can increase the risk of developing pre-eclampsia during pregnancy. Understanding these risk factors is essential for proactive monitoring and management. Having a risk factor doesn't always mean pre-eclampsia will occur, but closer medical supervision beyond routine screening is recommended.</p><p>Several factors can increase the risk of developing pre-eclampsia, including:</p><ul><li>first-time pregnancies</li><li>multiple pregnancies (twins, triplets, etc.)</li><li>obesity</li><li>pre-existing conditions such as hypertension, diabetes, or kidney disease</li><li>family history of pre-eclampsia.</li></ul><h2>Symptoms</h2><p>Symptoms of pre-eclampsia can vary significantly among individuals. While some may experience a range of noticeable symptoms, others may remain asymptomatic. It is important to be aware of potential indicators and seek medical attention if any concerns arise during pregnancy or after childbirth.</p><p>Common symptoms of pre-eclampsia include:</p><ul><li>persistent high blood pressure</li><li>proteinuria</li><li>severe headaches</li><li>visual disturbances (e.g., blurred vision, seeing spots)</li><li>upper abdominal pain</li><li>nausea and vomiting (after the first trimester)</li><li>swelling in the hands and face.</li></ul><h2>Complications</h2><p>Pre-eclampsia, if left untreated, can lead to serious complications for both mother and baby. These complications can range from short-term issues to long-term health problems. Prompt medical intervention is crucial to minimize these risks.</p><p>Complications can be severe and include:</p><ul><li>eclampsia (seizures)</li><li>HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count)</li><li>organ damage (kidneys, liver, brain)</li><li>placental abruption</li><li>preterm birth</li><li>fetal growth restriction</li><li>maternal and fetal death.</li></ul><h2>Treatment and management </h2><p>The primary treatment for pre-eclampsia is the administration of magnesium sulfate to prevent seizures.</p><p>The treatment and management of pre-eclampsia depend on the severity of the condition and the gestational age of the pregnancy. The goal is to prevent complications.</p><p>Other management strategies include:</p><ul><li>antihypertensive medications to control blood pressure</li><li>corticosteroids to accelerate fetal lung maturity if preterm delivery is anticipated</li><li>close monitoring of maternal and fetal health.</li></ul><h2>Prevention </h2><p>While there's no guaranteed way to prevent pre-eclampsia, certain strategies can help lower the risk. Early and consistent prenatal care is essential for monitoring and managing potential risk factors.</p><p>Preventive measures focus on regular prenatal care to monitor for early signs of pre-eclampsia. Recommendations include:</p><ul><li>regular blood pressure checks</li><li>urine tests for protein</li><li>monitoring for symptoms such as headaches and visual disturbances</li><li>lifestyle considerations, such as maintaining a healthy weight and activity (when permitted)</li><li>managing pre-existing conditions, especially pre-existing high blood pressure.</li></ul><p>Additional prevention measures include:</p><ul><li>low dose of aspirin by 20 weeks or when antenatal care begins</li><li>calcium supplementation during pregnancy in settings with low dietary intake</li><li>treatment of pre-existing high blood pressure with antihypertensive medications.</li></ul><h2>WHO response</h2><p>The World Health Organization (WHO) has developed guidelines to improve health during pregnancy. This includes prevention and treatment of pre-eclampsia and eclampsia and continuously reviewing evidence to see if revisions in the recommendations are needed so that improvements in care can be effected. These guidelines aim to reduce maternal and perinatal morbidity and mortality by promoting evidence-based clinical practices. Key WHO recommendations include:</p><ul><li>calcium supplementation during pregnancy in areas with low dietary calcium intake</li><li>low-dose aspirin during pregnancy for women at high risk of pre-eclampsia</li><li>use of magnesium sulfate for the prevention of eclampsia</li><li>training healthcare providers in the early detection and management of pre-eclampsia</li><li>strengthening health systems to ensure timely and effective care for pregnant women.</li></ul><p>By implementing these guidelines, WHO aims to address the profound inequities in maternal and perinatal health globally and achieve the health targets of the Sustainable Development Goals (SDGs).</p><p>&nbsp;</p><h3>References</h3><ol><li>Edgardo Abalos, Cristina Cuesta, Ana L. Grosso, Doris Chou, Lale Say. Global and regional estimates of preeclampsia and eclampsia: a systematic review. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology. 2013. Volume 170, pp 1-7.</li><li>Cresswell JA, et al. Global and regional causes of maternal deaths 2009&ndash;20: a WHO systematic analysis. Lancet Glob Health. 2025;13(4):e626&ndash;e634. doi:10.1016/S2214-109X(24)00560-6.</li><li>Trends in maternal mortality estimates 2000 to 2023: estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population Division. Geneva: World Health Organization; 2025.</li></ol><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Pre-eclampsia","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Pre-eclampsia","ConditionLongerOverview":"","Title":"Pre-eclampsia","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":null,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"WHO fact sheet on pre-eclampsia, including key facts, risk factors, symptoms, complications, treatment, prevention and WHO response.","PublicationDateAndTime":"2026-10-06T15:48:00Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on pre-eclampsia, including key facts, risk factors, symptoms, complications, treatment, prevention and WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<div class=\"arrowed-link\"><a href=\"https://www.who.int/health-topics/maternal-health\">WHO's work on maternal health</a></div><h2>WHO guidelines</h2><ul><li><a href=\"https://www.who.int/publications/i/item/9789241548335\">WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia</a>, 2011</li><li><a href=\"https://www.who.int/publications/i/item/9789240037540\">WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia</a>, 2021</li><li><a href=\"https://www.who.int/publications/i/item/9789240003118\">WHO recommendation: Calcium supplementation during pregnancy for the prevention of pre-eclampsia and its complications</a>, 2018</li><li><a href=\"https://www.who.int/publications/i/item/9789240008793\">WHO recommendations on drug treatment for non-severe hypertension in pregnancy</a>, 2020</li><li><a href=\"https://www.who.int/publications/i/item/9789241550437\">WHO recommendations: drug treatment for severe hypertension in pregnancy</a>, 2018</li><li><a href=\"https://www.who.int/publications/i/item/9789241549912\">WHO recommendations on antenatal care for a positive pregnancy experience</a>, 2016</li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/topics/womens-childrens-and-adolescent-health/maternal-health/pregnancy-examination.tmb-768v.jpg?sfvrsn=2be6af5a_6","FormatedDate":"6 October 2026","TrimmedTitle":"Pre-eclampsia"},{"Id":"6e669a6c-b8c7-446d-9d67-6fefce989c68","LastModified":"2025-02-20T17:37:12Z","PublicationDate":"2018-06-02T02:28:15Z","DateCreated":"2018-06-02T02:28:14Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"crimean-congo-haemorrhagic-fever","ItemDefaultUrl":"/crimean-congo-haemorrhagic-fever","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":"","Content":"<div><h2><span>Overview</span></h2><p><span>Crimean-Congo haemorrhagic fever (CCHF) is a widespread disease caused by a tick-borne virus (<em>Nairovirus</em>) of the <em>Bunyaviridae</em> family. The CCHF virus causes severe viral haemorrhagic fever outbreaks, with a case fatality rate of 10&ndash;40%. </span></p></div><p><span>CCHF is endemic in Africa, the Balkans, the Middle East and Asian countries south of the 50th parallel north &ndash; the geographical limit of the principal tick vector. </span></p><h2 class=\"section_head1\">The Crimean-Congo haemorrhagic fever virus in animals and ticks</h2><p><span>The hosts of the CCHF virus include a wide range of wild and domestic animals such as cattle, sheep and goats. Many birds are resistant to infection, but ostriches are susceptible and may show a high prevalence of infection in endemic areas, where they have been at the origin of human cases. For example, a former outbreak occurred at an ostrich abattoir in South Africa. There is no apparent disease in these animals.</span></p><p><span>Animals become infected by the bite of infected ticks and the virus remains in their bloodstream for about one week after infection, allowing the tick-animal-tick cycle to continue when another tick bites. Although a number of tick genera are capable of becoming infected with CCHF virus, ticks of the genus <em>Hyalomma</em> are the principal vector.</span></p><h2 class=\"section_head1\">Transmission </h2><p><span>The CCHF virus is transmitted to people either by tick bites or through contact with infected animal blood or tissues during and immediately after slaughter. The majority of cases have occurred in people involved in the livestock industry, such as agricultural workers, slaughterhouse workers and veterinarians.</span></p><p><span>Human-to-human transmission can occur resulting from close contact with the blood, secretions, organs or other bodily fluids of infected persons. Hospital-acquired infections can also occur due to improper sterilization of medical equipment, reuse of needles and contamination of medical supplies.</span></p><h2 class=\"section_head1\">Signs and symptoms</h2><p><span>The length of the incubation period depends on the mode of acquisition of the virus. Following infection by a tick bite, the incubation period is usually one to three days, with a maximum of nine days. The incubation period following contact with infected blood or tissues is usually five to six days, with a documented maximum of 13 days. </span></p><p><span>Onset of symptoms is sudden, with fever, myalgia, (muscle ache), dizziness, neck pain and stiffness, backache, headache, sore eyes and photophobia (sensitivity to light). There may be nausea, vomiting, diarrhoea, abdominal pain and sore throat early on, followed by sharp mood swings and confusion. After two to four days, the agitation may be replaced by sleepiness, depression and lassitude, and the abdominal pain may localize to the upper right quadrant, with detectable hepatomegaly (liver enlargement). </span></p><p><span>Other clinical signs include tachycardia (fast heart rate), lymphadenopathy (enlarged lymph nodes), and a petechial rash (a rash caused by bleeding into the skin) on internal mucosal surfaces, such as in the mouth and throat, and on the skin. The petechiae may give way to larger rashes called ecchymoses, and other haemorrhagic phenomena. There is usually evidence of hepatitis, and severely ill patients may experience rapid kidney deterioration, sudden liver failure or pulmonary failure after the fifth day of illness. </span></p><p><span>The mortality rate from CCHF is approximately 30%, with death occurring in the second week of illness. In patients who recover, improvement generally begins on the ninth or tenth day after the onset of illness. </span></p><h2 class=\"section_head1\">Diagnosis </h2><p><span>CCHF virus infection can be diagnosed by several different laboratory tests:</span></p><ul><li>enzyme-linked immunosorbent assay (ELISA) ;</li><li>antigen detection;</li><li>serum neutralization;</li><li>reverse transcriptase polymerase chain reaction (RT-PCR) assay; and</li><li>virus isolation by cell culture.</li></ul><p><span>Patients with fatal disease, as well as in patients in the first few days of illness, do not usually develop a measurable antibody response and so diagnosis in these individuals is achieved by virus or RNA detection in blood or tissue samples. </span></p><p><span>Tests on patient samples present an extreme biohazard risk and should only be conducted under maximum biological containment conditions. However, if samples have been inactivated (e.g. with virucides, gamma rays, formaldehyde, heat, etc.), they can be manipulated in a basic biosafety environment. </span></p><h2 class=\"section_head1\">Treatment<span></span></h2><p>Early intensive supportive care including fluid management and treatment of specific symptoms, can improve survival chance.<br /></p><p>There is currently no specific treatment approved for Crimean-Congo haemorrhagic fever. The antiviral drug ribavirin has been given off label as treatment; however, there is currently considerable uncertainties about its efficacy on the outcome of patients with CCHF given the lack of clinical evidence, as well as on its optimal dosing regimens. Whenever possible, if the decision is to use ribavirin to treat patients, they must be enrolled into a randomized clinical trial with ribavirin or other investigational therapeutics to assess clinical outcomes and safety.</p><p><span>&nbsp;</span></p><h2 class=\"section_head1\">Prevention and control </h2><h3 class=\"section_head3\">Controlling CCHF in animals and ticks</h3><p><img src=\"https://cdn.who.int/media/images/default-source/health-topics/crimean-congo-haemorrhagic-fever/crimean-congo-310px.jpg?sfvrsn=b0f46f51_6\" alt=\"Crimean-Congo-310px\" sf-size=\"94774\" /></p><p><em>Ticks of the genus Hyalomma are the principal vector of Crimean-Congo haemorrhagic fever. Photo:&nbsp;</em><span style=\"background-color:initial;font-family:inherit;font-size:inherit;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\"><em>Robert Swanepoel/NICD South Africa</em></span></p><p>It is difficult&nbsp;<span>to prevent or control CCHF infection in animals and ticks as the tick-animal-tick cycle usually goes unnoticed and the infection in domestic animals is usually not apparent. Furthermore, the tick vectors are numerous and widespread, so tick control with acaricides (chemicals intended to kill ticks) is only a realistic option for well-managed livestock production facilities. </span></p><p><span>For example, following an outbreak at an ostrich abattoir in South Africa (noted above), measures were taken to ensure that ostriches remained tick free for 14 days in a quarantine station before slaughter. This decreased the risk for the animal to be infected during its slaughtering and prevented human infection for those in contact with the livestock.</span></p><p><span>There are no vaccines available for use in animals.</span></p><h3 class=\"section_head3\">Reducing the risk of infection in people </h3><p><span>Although an inactivated, mouse brain-derived vaccine against CCHF has been developed and used on a small scale in eastern Europe, there is currently no safe and effective vaccine widely available for human use.</span></p><p><span>In the absence of a vaccine, the only way to reduce infection in people is by raising awareness of the risk factors and educating people about the measures they can take to reduce exposure to the virus.</span></p><p><span>Public health advice should focus on several aspects.</span></p><ul><li>Reducing the risk of tick-to-human transmission: </li><ul class=\"disc\"><li>wear protective clothing (long sleeves, long trousers);</li><li>wear light coloured clothing to allow easy detection of ticks on the clothes;</li><li>use approved acaricides (chemicals intended to kill ticks) on clothing;</li><li>use approved repellent on the skin and clothing;</li><li>regularly examine clothing and skin for ticks; if found, remove them safely;</li><li>seek to eliminate or control tick infestations on animals or in stables and barns; and</li><li>avoid areas where ticks are abundant and seasons when they are most active. </li></ul><li>Reducing the risk of animal-to-human transmission: </li><ul class=\"disc\"><li>wear gloves and other protective clothing while handling animals or their tissues in endemic areas, notably during slaughtering, butchering and culling procedures in slaughterhouses or at home;</li><li>quarantine animals before they enter slaughterhouses or routinely treat animals with pesticides two weeks prior to slaughter.</li></ul><li>Reducing the risk of human-to-human transmission in the community: </li><ul class=\"disc\"><li>avoid close physical contact with CCHF-infected people;</li><li>wear gloves and protective equipment when taking care of ill people;</li><li>wash hands regularly after caring for or visiting ill people.</li></ul></ul><h3 class=\"section_head3\">Controlling infection in health-care settings</h3><p><span>Health-care workers caring for patients with suspected or confirmed CCHF, or handling specimens from them, should implement standard infection control precautions. These include basic hand hygiene, use of personal protective equipment, safe injection practices and safe burial practices. </span></p><p><span>As a precautionary measure, health-care workers caring for patients immediately outside the CCHF outbreak area should also implement standard infection control precautions. </span></p><p><span>Samples taken from people with suspected CCHF should be handled by trained staff working in suitably equipped laboratories.</span></p><p><span>Recommendations for infection control while providing care to patients with suspected or confirmed Crimean-Congo haemorrhagic fever should follow those developed by WHO for Ebola and Marburg haemorrhagic fever.</span></p><h2 class=\"section_head1\">WHO response</h2><p><span>WHO is working with partners to support CCHF surveillance, diagnostic capacity and outbreak response activities in Europe, the Middle East, Asia and Africa.</span></p><p><span>WHO also provides documentation to help disease investigation and control, and has created an aide&ndash;memoire on standard precautions in health care, which is intended to reduce the risk of transmission of bloodborne and other pathogens. </span></p><div>&nbsp;</div>","ConditionName":"","OpenGraphTitle":"Crimean-Congo haemorrhagic fever","DocumentNumberOfAdditionalItems":1,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":2,"SymptomsLongerSummary":"","MetaTitle":"Crimean-Congo haemorrhagic fever","ConditionLongerOverview":"","Title":"Crimean-Congo haemorrhagic fever","PreventionLongerSummary":"","SourceKey":"/entity/mediacentre/factsheets/fs208","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":3,"OtherRelated":"","FactSheetNumberOfAdditionalItems":1,"OpenGraphDescription":"WHO fact sheet on Crimean-Congo haemorrhagic fever: includes key facts, definition, signs and symptoms, transmission, diagnosis, treatment, prevention and control, WHO response.","PublicationDateAndTime":"2025-02-20T15:57:00Z","ConditionBriefOverview":"","MetaDescription":"WHO fact sheet on Crimean-Congo haemorrhagic fever: includes key facts, definition, signs and symptoms, transmission, diagnosis, treatment, prevention and control, WHO response.","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":"","Highlight":"<p><strong>Related links</strong></p><ul><li><a href=\"https://www.who.int/health-topics/crimean-congo-haemorrhagic-fever/#tab=tab_1\"><a href=\"https://www.who.int/health-topics/crimean-congo-haemorrhagic-fever/#tab=tab_1\">More information on Crimean-Congo haemorrhagic fever</a></a></li><li><a href=\"https://www.who.int/publications/i/item/WHO-HIS-SDS-2014.4-Rev.1\">Interim infection control recommendations for patients with suspected or confirmed Filovirus (Ebola, Marburg) haemorrhagic fever</a></li><li><a href=\"https://www.who.int/publications/m/item/standard-precautions-in-health-care\">Aide-memoire: standard precautions in health care</a></li><li><a href=\"http://www.emro.who.int/health-topics/haemorrhagic-fevers-viral/index.html\">More information on haemorrhagic fevers</a></li></ul>","Provider":"OpenAccessProvider","ThumbnailUrl":"/images/default-source/fallback/icons/factsheet.tmb-768v.jpg?Culture=en&sfvrsn=ff4e4ba1_24","FormatedDate":"20 February 2025","TrimmedTitle":"Crimean-Congo haemorrhagic fever"},{"Id":"ae60a79e-2915-4691-b7c8-c196ba122de2","LastModified":"2026-04-08T13:45:10Z","PublicationDate":"2022-05-02T08:54:09Z","DateCreated":"2022-05-02T08:54:09Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"refugee-and-migrant-health","ItemDefaultUrl":"/refugee-and-migrant-health","NewsNumberOfAdditionalItems":2,"MedicalTreatmentBriefSummary":"","Content":"<h2>Key facts</h2><ul><li>About 1 in 8 people (or more than a billion) are on the move globally.</li><li>Of this total, an estimated 304&nbsp;million are international migrants (2024), double the number in 1990 (154&nbsp;million). This includes approximately 170&nbsp;million migrant workers and 7&nbsp;million international students.</li><li>It is estimated that 117.3&nbsp;million people are forcibly displaced, including 73.5&nbsp;million internally displaced persons (IDPs), 36.4&nbsp;million refugees, and 8.4&nbsp;million asylum seekers. Among them, 49&nbsp;million are children, and 2.3&nbsp;million were born into refugee life.</li><li>Human mobility is expected to continue growing, driven by poverty, insecurity, limited access to basic services, conflict, environmental degradation and disasters. Health systems must be equipped to respond to these evolving needs.</li><li>Displacement and migration can have both positive and negative health impacts. Refugees and migrants' social and economic contributions, such as remittances, can improve access to services in countries of origin, while restrictive environments in transit and destination countries may pose health risks.</li><li>Refugees and migrants often experience poorer health outcomes due to language and cultural barriers, institutional discrimination and restrictive policies that limit access to or use of health services.<br />&nbsp;</li></ul><hr /><br /><h2>Overview</h2><p>More people are on the move now than ever before, and displacement and migration continue to rise. Yet many refugees and migrants face poorer health outcomes than the host populations. Many face constraints in accessing health care. Addressing their health needs is, therefore, a global health priority and integral to the principle of the right to health for all. Refugees and migrants have specific physical and mental health needs that are influenced by their experiences in their country of origin, conditions during their journeys, and the policies and environments in destination countries.</p><p>Climate change, in addition to conflicts and disasters, is transforming patterns of displacement and migration and amplifying risks to health and well-being. Displaced and migrant populations are often among those most affected, yet they often remain excluded from national health and climate adaptation strategies.</p><h2>Definitions and data</h2><p>There is no universally accepted definition of a migrant, however, the United Nations Department of Economic and Social Affairs defines an international migrant as &ldquo;any person who changes his or her country of usual residence,&rdquo; regardless of legal status, duration of stay or reasons for moving(1, 2).</p><p>Under international law and the UNHCR's mandate, refugees are people outside their country of origin who need international protection because they fear persecution or a serious threat to their life, physical integrity or freedom in their country of origin as a result of persecution, armed conflict, violence or serious public disorder(3).</p><p>Asylum seekers are individuals who seek international protection. In countries where asylum cases are judged on a case-by-case basis using specific eligibility criteria, asylum seekers are people whose claim has not been finally decided on by the country in which they have submitted it. Not every asylum seeker will ultimately be recognized as a refugee, but every recognized refugee is initially an asylum seeker(3).</p><p>Migrants may face limitations in accessing health care due to their migratory status, but international law recognizes the right to the highest attainable standard of health, consistent with the 2030 Agenda for Sustainable Development, particularly SDG 3 (Ensure healthy lives and promote well-being for all at all ages)(4<em>)</em>. Although governed by different legal frameworks, refugees and migrants share the same universal human rights and fundamental freedoms as everyone else(4).</p><p>Overall, over 1&nbsp;billion people (1 in 8) are on the move worldwide.</p><p>As of 2024, there were an estimated 304&nbsp;million international migrants worldwide; this is almost double the number of international migrants in 1990 (154&nbsp;million)(5). In 2022 there were an estimated 167.7&nbsp;million migrant workers, including many essential health workers, and 6.9&nbsp;million international students(6).</p><p>As of mid-2025, the number of forcibly displaced people reached 117&nbsp;million, up from 83&nbsp;million in 2020. This includes 36.8&nbsp;million refugees, with 8.4&nbsp;million asylum seekers; notably, low- and middle-income countries host 71% of the world&rsquo;s refugees and others in need of international protection(7).</p><p>Migration and displacement also occur within country borders. Latest available estimates &ndash; from 2005 &ndash; estimated the number of internal migrants at 763&nbsp;million(8)<em>.</em> In 2024, there were approximately 83.4&nbsp;million internally displaced persons (IDPs) worldwide(9)<em>.</em></p><p>Data on displacement and migration remains constrained due to divergent definitions, varying methodologies and the exclusion of irregular migrants and those working in informal sectors from official statistics.</p><h2>Common health issues</h2><p>Refugees and migrants have specific health needs that reflect their experiences before, during and after displacement and migration. These needs may not always align with the services available in host communities, underscoring the importance of inclusive, equitable and people-centred health systems.</p><p>Many people leave their homes as a result of conflict, environmental degradation, disasters or economic hardship. Their health needs are shaped by conditions during all phases of their journey. Evidence presented in the first&nbsp;<a href=\"https://www.who.int/publications/i/item/9789240054462\">World report on the health of refugees and migrants</a> shows that refugees and migrants do not increase the risk of communicable disease transmission in host countries; instead, health risks arise from conditions experienced during displacement, including limited access to clean water, sanitation, food, shelter and essential health services. These structural and environmental factors drive vulnerability to illness and disease.</p><p>These conditions can increase risks of infectious diseases (e.g. measles, food- and waterborne illnesses), accidental injuries, hypothermia, burns, and other health consequences linked to hazardous travel and unmet basic needs. Refugees and migrants may also face heightened exposure to gender-based violence, with serious physical and mental health impacts.</p><p>Refugees and migrants may experience problems commonly associated with extreme stress, such as anxiety, sleep disturbances, fatigue, or irritability. Some individuals may develop depression, anxiety disorders or post-traumatic stress disorder (PTSD), linked to their experiences of conflict, loss, violence, or prolonged uncertainty.</p><p>Although refugees and migrants share many health determinants with host populations, displacement and migration introduce additional structural and environmental barriers. Strengthening equitable access to health services and addressing social, economic and environmental determinants of health are essential to building sustainable, inclusive and effective support for refugee and migrant communities, while fostering the overall resilience of host societies.</p><h2>Barriers to access to health services</h2><p>Many refugees and migrants, especially those in vulnerable or irregular situations, experience poorer health outcomes due to substandard living conditions and unfavorable social, economic and environmental determinants.</p><p>They may face xenophobia, discrimination, and obstacles in accessing health and social services. Migrants in irregular situations may be excluded from national programmes for health promotion, disease prevention, treatment, and care, including financial protection schemes. This results in high out-of-pocket costs, language barriers, and inadequate cultural or linguistic support.</p><p>Women and girls may face challenges accessing gender-based violence prevention and response services. Unaccompanied and separated children are at heightened risk of exploitation, abuse and neglect. People with disabilities may encounter additional accessibility and attitudinal barriers. Ensuring inclusive, accessible, and participatory approaches is essential to upholding their rights, health, and safety.</p><p>In humanitarian settings, insecurity, infrastructure damage and disruptions to supply chains create further obstacles to accessing health care. These challenges affect both displaced populations and host communities.</p><h2>WHO response</h2><p>WHO affirms that all people, including refugees and migrants, have the right to health and should be able to access people-centred, high-quality services without financial hardship. This requires integrating refugee and migrant health into national and local policies, financing, planning, implementation, monitoring and evaluation.</p><p>While parallel health structures may sometimes be necessary in emergencies, these must remain temporary. WHO supports sustainable inclusion of refugees and migrants within national systems and services.</p><p>Guided by the <a href=\"https://www.who.int/publications/i/item/9789240093928\">WHO global action plan on promoting the health of refugees and migrants, 2019&ndash;2030</a>, WHO, through its Special Initiative on Health and Migration, works with Member States, and partners to advance health equity and the protection of health-related rights for refugees and migrants. WHO leads global advocacy, sets evidence-based norms and standards, strengthens data and research, and promotes coordinated, multisectoral approaches that address the specific health needs of refugees and migrants.</p><p>WHO also supports multilateral collaboration through active engagement in the United Nations Network on Migration, working with UN agencies and international stakeholders to improve policy coherence and collective action. At country level, WHO works to strengthen health systems to deliver integrated, culturally-sensitive and high-quality services for host communities, refugees and migrants alike.</p><p>Ensuring refugees and migrants have timely, affordable and dignified access to health care is essential to achieving health for all.<br />&nbsp;</p><h3>References</h3><ol><li>Glossary on migration. Geneva: International Organization for Migration; 2019 (<a href=\"https://publications.iom.int/system/files/pdf/iml_34_glossary.pdf\" target=\"_blank\">https://publications.iom.int/system/files/pdf/iml_34_glossary.pdf</a>). Licence: CC BY-NC-ND 3.0 IGO.</li><li>UNHCR master glossary of terms [online database]. Geneva: United Nations High Commissioner for Refugees; 2021 (<a href=\"https://www.unhcr.org/glossary/\" target=\"_blank\">https://www.unhcr.org/glossary/</a>).</li><li>2016 UNGA Summit for Refugees and Migrants (NY Declaration). In: Seventy-first General Assembly, 19 September 2016: resolution 71/1: New York declaration for refugees and migrants. New York, NY: United Nations; 2016 (<a href=\"https://docs.un.org/en/a/res/71/1\" target=\"_blank\">https://docs.un.org/en/a/res/71/1</a>). Licence: CC BY-4.0.</li><li>International migrant stock 2024: key facts and figures. New York, NY: United Nations Department of Economic and Social Affairs; 2024 (UNDESA/POP/2024/DC/NO.13;  <a href=\"https://www.un.org/development/desa/pd/content/international-migrant-stock\" target=\"_blank\">https://www.un.org/development/desa/pd/content/international-migrant-stock</a>). Licence: CC BY-4.0.</li><li>ILO global estimates on international migrant workers, fourth edition. Geneva: International Labour Organization; 2024 (ILO global estimates on international migrants in the labour force | International Labour Organization <a href=\"https://www.ilo.org/publications/major-publications/ilo-global-estimates-international-migrants-labour-force\" target=\"_blank\">https://www.ilo.org/publications/major-publications/ilo-global-estimates-international-migrants-labour-force</a>).</li><li>A quick look at global mobility trends [infographic]. Project Atlas; 2024 (<a href=\"https://www.iie.org/wp-content/uploads/2024/11/Project-Atlas_Infographic_2024-1.pdf\" target=\"_blank\">https://www.iie.org/wp-content/uploads/2024/11/Project-Atlas_Infographic_2024-1.pdf</a>).</li><li>Mid-year trends [website]. United Nations High Commissioner for Refugees; 2026 (<a href=\"https://www.unhcr.org/uk/publications/mid-year-trends\" target=\"_blank\">https://www.unhcr.org/uk/publications/mid-year-trends</a>). Licence: CC BY-4.0.</li><li>Human Development Report 2009: overcoming barriers: human mobility and development. New York, NY: United Nations Development Programme; 2009 (<a href=\"https://hdr.undp.org/content/human-development-report-2009\" target=\"_blank\">https://hdr.undp.org/content/human-development-report-2009</a>). Licence: CC BY-4.0.</li><li>2025 Global Report on Internal Displacement (GRID). Geneva: Internal Displacement Monitoring Centre; 2025 (<a href=\"https://www.internal-displacement.org/global-report/grid2025/\" target=\"_blank\">https://www.internal-displacement.org/global-report/grid2025/</a>).</li></ol><p>&nbsp;</p>","ConditionName":"","OpenGraphTitle":"Refugee and migrant health","DocumentNumberOfAdditionalItems":null,"PreventionBriefSummary":"","SelfCareLongerSummary":"","EventNumberOfAdditionalItems":null,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":"","MetaTitle":"Refugee and migrant health","ConditionLongerOverview":"","Title":"Refugee and migrant health","PreventionLongerSummary":"","SourceKey":null,"PhotoStoryNumberOfAdditionalItems":null,"SelfCareBriefSummary":"","FactFileNumberOfAdditionalItems":null,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":1,"OtherRelated":"","FactSheetNumberOfAdditionalItems":null,"OpenGraphDescription":"More people are on the move now than ever before, and displacement and migration continue to rise. Yet many refugees and migrants face poorer health outcomes than the host populations. Many face constraints in accessing health care. ","PublicationDateAndTime":"2026-03-25T15:03:41Z","ConditionBriefOverview":"","MetaDescription":"More people are on the move now than ever before, and displacement and migration continue to rise. Yet many refugees and migrants face poorer health outcomes than the host populations. Many face constraints in accessing health care. ","MedicalTreatmentLongerSummary":"","CommentaryNumberOfAdditionalItems":null,"SymptomsBriefSummary":"","Highlight":"<div class=\"arrowed-link\"><a href=\"https://www.who.int/news-room/questions-and-answers/item/refugee-and-migrant-health\">Questions and answers: Refugee and migrant health</a></div><div class=\"arrowed-link\"><a href=\"https://www.who.int/health-topics/refugee-and-migrant-health\">WHO's work on refugee and migrant health</a></div><div class=\"arrowed-link\"><a href=\"https://www.who.int/teams/health-and-migration-programme/overview\">Health and Migration Programme</a></div>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/topics/populations-demographics-human-behaviour-and-injuries/refugee-and-migrants/170542-(2).tmb-768v.jpg?sfvrsn=f40ac934_6","FormatedDate":"25 March 2026","TrimmedTitle":"Refugee and migrant health"},{"Id":"d326b79a-eb89-4cdf-9f50-5552aca20dba","LastModified":"2026-08-27T03:01:23Z","PublicationDate":"2018-06-02T02:28:17Z","DateCreated":"2018-06-02T02:28:16Z","IncludeInSitemap":true,"SystemSourceKey":null,"UrlName":"echinococcosis","ItemDefaultUrl":"/echinococcosis","NewsNumberOfAdditionalItems":3,"MedicalTreatmentBriefSummary":null,"Content":"<p>Human echinococcosis is a zoonotic disease (a disease that is transmitted to humans from animals) that is caused by parasites, namely tapeworms of the genus <em>Echinococcus</em>. Echinococcosis occurs in 4 forms:</p><ul><li><p>cystic echinococcosis, also known as hydatid disease or hydatidosis, caused by infection with a species complex centred on&nbsp;<em>Echinococcus granulosus</em>;</p></li><li><p>alveolar echinococcosis, caused by infection with <em>E. multilocularis</em>;</p></li><li><p>two forms of neotropical echinococcosis: polycystic caused by infection with <em>E. vogeli</em>; and</p></li><li><p>unicystic caused by <em>E. oligarthrus</em>.</p></li></ul><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\">The two most important forms, which are of medical and public health relevance in humans, are cystic echinococcosis (CE) and alveolar echinococcosis (AE).</span></p><p><span style=\"background-color:transparent;text-align:inherit;text-transform:inherit;white-space:inherit;word-spacing:normal;caret-color:auto;\">&nbsp;</span></p><h2 class=\"section_head1\">Transmission</h2><p>A number of herbivorous and omnivorous animals act as intermediate hosts of <em>Echinococcus</em>. They become infected by ingesting the parasite eggs in contaminated food and water, and the parasite then develops into larval stages in the viscera.</p><p>Carnivores act as definitive hosts for the parasite, and harbour the mature tapeworm in their intestine. The definitive hosts are infected through the consumption of viscera of intermediate hosts that contain the parasite larvae.</p><p>Humans act as so-called accidental intermediate hosts in the sense that they acquire infection in the same way as other intermediate hosts, but are not involved in transmitting the infection to the definitive host.</p><p>Several distinct genotypes of <em>E. granulosus</em> are recognised, some having distinct intermediate host preferences. Some genotypes are considered species distinct from <em>E. granulosus</em>. Not all genotypes cause infections in humans. The genotype\r\n    causing the great majority of cystic echinococcosis infections in humans is principally maintained in a dog&ndash;sheep&ndash;dog cycle, yet several other domestic animals may also be involved, including goats, swine, cattle, camels and yaks.</p><p>Alveolar echinococcosis usually occurs in a wildlife cycle between foxes or other carnivores&nbsp; with small mammals (mostly rodents) acting as intermediate hosts. Domesticated dogs and cats can also act as definitive hosts.</p><p>&nbsp;</p><h2 class=\"section_head2\">Signs and symptoms</h2><h3 class=\"section_head3\">Cystic echinococcosis / hydatid disease</h3><p>Human infection with <em>E. granulosus</em> leads to the development of one or more hydatid cysts located most often in the liver and lungs, and less frequently in the bones, kidneys, spleen, muscles and central nervous system.</p><p>The asymptomatic incubation period of the disease can last many years until hydatid cysts grow to an extent that triggers clinical signs, however approximately half of all patients that receive medical treatment for infection do so within a few years\r\n    of their initial infection with the parasite.</p><p>Abdominal pain, nausea and vomiting are commonly seen when hydatids occur in the liver. If the lung is affected, clinical signs include chronic cough, chest pain and shortness of breath. Other signs depend on the location of the hydatid cysts and the\r\n    pressure exerted on the surrounding tissues. Non-specific signs include anorexia, weight loss and weakness.</p><h3 class=\"section_head3\">Alveolar echinococcosis</h3><p>Alveolar echinococcosis is characterized by an asymptomatic incubation period of 5&ndash;15 years and the slow development of a primary tumour-like lesion which is usually located in the liver. Clinical signs include weight loss, abdominal pain, general\r\n    malaise and signs of hepatic failure.</p><p>Larval metastases may spread either to organs adjacent to the liver (for example, the spleen) or distant locations (such as the lungs, or the brain) following dissemination of the parasite via the blood and lymphatic system. If left untreated, alveolar\r\n    echinococcosis is progressive and fatal.</p><p>&nbsp;</p><h2 class=\"section_head1\">Distribution</h2><p>Cystic echinococcosis is globally distributed and found in every continent except Antarctica. Alveolar echinococcosis is confined to the northern hemisphere, in particular to regions of China, the Russian Federation and countries in continental Europe\r\n    and North America.</p><p>In endemic regions, human incidence rates for cystic echinococcosis can reach more than 50 per 100 000 person-years, and prevalence levels as high as 5%&ndash;10% may occur in parts of Argentina, Peru, East Africa, Central Asia and China. In livestock,\r\n    the prevalence of cystic echinococcosis found in slaughterhouses in hyperendemic areas of South America varies from 20%&ndash;95% of slaughtered animals.</p><p>The highest prevalence is found in rural areas where older animals are slaughtered. Depending on the infected species involved, livestock production losses attributable to cystic echinococcosis result from liver condemnation and may also involve reduction\r\n    in carcass weight, decrease in hide value, decrease of milk production, and reduced fertility.</p><p>&nbsp;</p><h2 class=\"section_head1\">Diagnosis</h2><p>Ultrasonography imaging is the technique of choice for the diagnosis of both cystic echinococcosis and alveolar echinococcosis in humans. This technique is usually complemented or validated by computed tomography (CT) and/or magnetic resonance imaging\r\n    (MRI) scans.</p><p>Cysts can be incidentally discovered by radiography. Specific antibodies are detected by different serological tests and can support the diagnosis.<br />Early detection of <em>E. granulosus</em> and <em>E. multilocularis</em> infections, especially in\r\n    low-resource settings, is still needed to aid in the selection of clinical treatment options.</p><p>&nbsp;</p><h2 class=\"section_head1\">Treatment</h2><p>Both cystic echinococcosis and alveolar echinococcosis are often expensive and complicated to treat, sometimes requiring extensive surgery and/or prolonged drug therapy. There are 4 options for the treatment of cystic echinococcosis:</p><ul><li>percutaneous treatment of the hydatid cysts with the PAIR (Puncture, Aspiration, Injection, Re-aspiration) technique;</li><li>surgery</li><li>anti-infective drug treatment</li><li>&ldquo;watch and wait&rdquo;. </li></ul><p>The choice must primarily be based on the ultrasound images of the cyst, following a stage-specific approach, and also on the medical infrastructure and human resources available.</p><p>For alveolar echinococcosis, early diagnosis and radical (tumour-like) surgery followed by anti-infective prophylaxis with albendazole remain the key elements. If the lesion is confined, radical surgery can be curative. Unfortunately in many patients\r\n    the disease is diagnosed at an advanced stage. As a result, if palliative surgery is carried out without complete and effective anti-infective treatment, frequent relapses will occur.</p><p>&nbsp;</p><h2 class=\"section_head1\">Health and economic burden</h2><p>Both cystic echinococcosis and alveolar echinococcosis represent a substantial disease burden. Worldwide, there may be in excess of 1 million people living with these diseases at any one time. Many of these people will be experiencing severe clinical\r\n    syndromes which are life-threatening if left untreated. Even with treatment, people often face reduced quality of life.</p><p>For cystic echinococcosis, there is an average of 2.2% post-operative death rate for surgical patients and about 6.5% of cases relapse after an intervention, thereby requiring prolonged recovery time.</p><p>The 2015 WHO Foodborne Disease Burden Epidemiology Reference Group (FERG) estimated echinococcosis to be the cause of 19 300 deaths and around 871 000 disability-adjusted life-years (DALYs) <em>(1)</em> globally each year.</p><p>Annual costs associated with cystic echinococcosis are estimated to be US$ 3 billion for treating cases and losses to the livestock industry.</p><p>&nbsp;</p><h2 class=\"section_head1\">Surveillance, prevention and control</h2><p>Robust surveillance data is fundamental in order to show burden of disease and to evaluate progress and success of control programmes. However, as for other neglected diseases which are focused in underserved populations and remote areas, data is especially\r\n    scarce and will need more attention if control programmes are to be implemented and measured.</p><h3 class=\"section_head3\">Cystic echinococcosis / hydatid disease</h3><p>Surveillance for cystic echinococcosis in animals is difficult because the infection is asymptomatic in livestock and dogs. Surveillance is also not recognized or prioritized by communities or local veterinary services.</p><p>Cystic echinococcosis is a preventable disease as it involves domestic animal species as definitive and intermediate hosts. Periodic deworming of dogs with praziquantel (at least 4 times per year), improved hygiene in the slaughtering of livestock (including\r\n    the proper destruction of infected offal), and public education campaigns have been found to lower and, in high-income countries, prevent transmission and alleviate the burden of human disease.</p><p>Vaccination of sheep with an <em>E. granulosus</em> recombinant antigen (EG95) offers encouraging prospects for prevention and control. The vaccine is currently being produced commercially and is registered in China and Argentina. Trials in Argentina\r\n    demonstrated the added value of vaccinating sheep, and in China the vaccine is being used extensively.</p><p>A programme combining vaccination of lambs, deworming of dogs and culling of older sheep could lead to elimination of cystic echinococcosis disease in humans in less than 10 years.</p><h3 class=\"section_head3\">Alveolar echinococcosis</h3><p>Prevention and control of alveolar echinococcosis is more complex as the cycle involves wild animal species as both definitive and intermediate hosts. Regular deworming of domestic carnivores that have access to wild rodents should help to reduce the\r\n    risk of infection in humans.</p><p>Deworming of wild and stray definitive hosts with anthelminthic baits resulted in significant reductions in alveolar echinococcosis prevalence in European and Japanese studies. Culling of foxes and unowned free-roaming dogs appears to be highly inefficient.\r\n    The sustainability and cost&ndash;benefit effectiveness of such campaigns are controversial.</p><p>&nbsp;</p><h2 class=\"section_head2\">WHO and country response</h2><h3>Strengthening&nbsp;echinococcosis prevention and control</h3><p>Informal Working Groups on Echinococcosis were founded in 1985 under the auspices of the WHO. For 10 years, under the leadership of Professor J. Eckert (University of Zurich, Switzerland), the groups organised meetings of specialists and promoted international\r\n    scientific exchange and co-operation in the field of echinococcosis research. In 1995, the WHO modified the structure of the groups and transformed them into a single group, the WHO Informal Working Group on Echinococcosis (WHO-IWGE). The mission\r\n    of the WHO-IWGE is to strengthen prevention and control of echinococcosis through effective collaboration with strategic partners and relevant sectors. The current Chair of the WHO-IWGE is Professor Thomas Junghanss (Heidelberg University, Germany),\r\n    and Co-Chair is Professor Okan Akhan (Hacettepe University, Turkey).&nbsp; </p><p>The WHO-IWGE developed in 1995 a standardized classification of cystic echinococcosis (CE) that could be applied in all settings.&nbsp; In 2009, the consensus for diagnosis and treatment of CE and alveolar echinococcosis (AE) reached by the WHO-IWGE was\r\n    published (Brunetti et al., 2010), providing updated guidelines for diagnosis and treatment. </p><p>The WHO-IWGE is in the process of reviewing the diagnosis and associated clinical management of echinococcosis and elaborating technical manuals with practical applicability.&nbsp; Several workings groups have been created to cover the different aspects\r\n    of the diseases and are working on creating those documents. The group is also working to promote the collection and mapping of epidemiological data.&nbsp;&nbsp;</p><h3>Building capacity to enhance early diagnosis and clinical management of CE</h3><p>WHO has been asked by the endemic countries to provide support on early diagnosis and clinical management of cystic echinococcosis.&nbsp; WHO supports capacity building through training courses targeting medical and paramedical personnel, focused on the\r\n    clinical management of cystic echinococcosis in rural areas of affected countries. This is an integral component to support universal health coverage.</p><p>Morocco undertook a project aimed at decentralizing diagnostic and therapeutic techniques and promoting the PAIR (puncture, aspiration, injection, re-aspiration) strategy in rural and hyperendemic areas. </p><p>Mongolia has recognized the importance of echinococcosis as a public-health problem and, at the request of the Ministry of Health, WHO in 2013 conducted an initial situation analysis. The analysis focused on implementing early diagnosis and building a\r\n    basic surveillance system covering humans and animals to understand the actual burden of the disease. </p><p>A cross-sectional study conducted in Bulgaria, Romania and Turkey in 2014-2015, found that the true burden of CE is poorly understood and that many cases remain asymptomatic, with no appropriate medical diagnosis and treatment. The study assessed the\r\n    prevalence of the disease among rural populations in the three countries. </p><p>In the Americas, a cystic echinococcosis control manual was produced by the Pan American Health Organization / WHO Regional Office for the Americas (OPS) and Panaftosa in 2017. It has been published in Spanish.</p><h3>Working with veterinary and food safety authorities to support the development of echinococcosis control programmes</h3><p>The transmission cycle of cystic echinococcosis (CE) involves dogs, and intermediate hosts, commonly sheep. In order to break the transmission cycle, control measures need to consider those animals. Control measures in dogs and sheep, as part of a One-Health\r\n    approach include the deworming of dogs with praziquantel at least 4 times per year and the vaccination of lambs with EG95 vaccine.</p><p>Under the umbrella of One Health, WHO and its partner, the World Organization for Animal Health (OIE) are supporting the development of echinococcosis control programs including animal interventions.&nbsp; Joint meetings are being held regularly and technical\r\n    support is provided to promote control, for example in the Central Asia and South Caucasus countries.</p><p>WHO assists countries to develop and implement pilot projects leading to the validation of effective cystic echinococcosis control strategies. Working with the veterinary and food safety authorities as well as with other sectors is essential to attain\r\n    the long-term outcomes of reducing the burden of disease and safeguarding the food value chain. </p><p>WHO is supporting individual countries to develop their CE control program such as in Mongolia. In 2018, a multidisciplinary stakeholder meeting was convened in Ulaanbaatar to start developing the National Action Plan for control of echinococcosis. No\r\n    significant investment for echinococcosis has been made, and therefore programmatic steps have been progressing slowly but WHO continues to bring the stakeholders together and further actions have been agreed in 2019. WHO has also facilitated the\r\n    validation of diagnostic tests used for echinococcosis in dogs that is important for surveillance, and create a baseline in Bayankhongor province of Mongolia. </p><p>China is integrating echinococcosis prevention, control and treatment in their economic and development plans to raise attention to the vast problem in the country, especially the Tibetan plateau, as well as in the Central Asian Republics.</p><p>WHO is promoting One-Health approaches, such as the one developed by Dr Larrieu in the Argentinian Patagonia which involves community health workers, dog deworming and sheep vaccination.&nbsp;</p><h3>Improving data on CE</h3><p>Surveillance data is key to understand the disease epidemiological situation and taking action in the risk areas, and for setting up priorities. Data is also necessary to monitor the progress of interventions and evaluate the outcomes of control actions. </p><p>Indicators are specific variables that assist with the data analysis and provide tools for health authorities and people involved in disease control. &nbsp;WHO has defined a new set of indicators at country and global level for CE and is developing reporting systems to guide and assist the countries on data collection and reporting. </p><p>At global level, the indicators are 1- Number of endemic countries for CE, and 2- Number of countries with intensified control in hyper endemic areas. A hyperendemic area has been defined as an area with an annual incidence of 5 human cases/100,000 people.</p><p>At country level there are epidemiological indicators and control progress indicators.&nbsp; The epidemiological indicators include a combination of passive and active surveillance.&nbsp; The control indicators include impact and outcome indicators.&nbsp;&nbsp;\r\n    <br /></p><hr /><p><em>(1)</em> One DALY (disability-adjusted life year) can be thought of as one lost year of &ldquo;healthy&rdquo; life. The sum of these DALYs across the population, or the burden of disease, can be thought of as a measurement of the gap between current\r\n        health status and an ideal health situation where the entire population lives to an advanced age free of disease and disability.</p><div>&nbsp;</div>","ConditionName":null,"OpenGraphTitle":"Echinococcosis","DocumentNumberOfAdditionalItems":0,"PreventionBriefSummary":null,"SelfCareLongerSummary":null,"EventNumberOfAdditionalItems":1,"MultimediaNumberOfAdditionalItems":null,"SymptomsLongerSummary":null,"MetaTitle":"Echinococcosis","ConditionLongerOverview":null,"Title":"Echinococcosis","PreventionLongerSummary":null,"SourceKey":"/entity/mediacentre/factsheets/fs377","PhotoStoryNumberOfAdditionalItems":1,"SelfCareBriefSummary":null,"FactFileNumberOfAdditionalItems":1,"SortTitle":"","LocalPublicationDate":"","Summary":"","FeatureStoryNumberOfAdditionalItems":3,"OtherRelated":"","FactSheetNumberOfAdditionalItems":6,"OpenGraphDescription":"Echinoccosis is caused by larval stages of tapeworms transmitted through ingestion of eggs, shed in faeces of dogs and wild animals. More than 1 million people are affected at any one time. #BeatNTDs","PublicationDateAndTime":"2021-05-17T21:36:00Z","ConditionBriefOverview":null,"MetaDescription":"Fact sheet on echinococcus providing key facts, definition, information on transmission, signs and symptoms, distribution, diagnosis, treatment, health and economic burden, prevention and control and WHO response.","MedicalTreatmentLongerSummary":null,"CommentaryNumberOfAdditionalItems":1,"SymptomsBriefSummary":null,"Highlight":"<div class=\"arrowed-link\"><a href=\"https://www.who.int/health-topics/echinococcosis\">WHO's work on echinococcosis</a></div><div class=\"arrowed-link\"><a href=\"https://www.who.int/teams/control-of-neglected-tropical-diseases/overview\">More about Neglected Tropical Diseases</a></div>","Provider":"OpenAccessProvider","ThumbnailUrl":"https://cdn.who.int/media/images/default-source/imported/echinoccosis-jpg.tmb-768v.jpg?sfvrsn=55549f89_44","FormatedDate":"17 May 2021","TrimmedTitle":"Echinococcosis"}],"@odata.nextLink":"http://www.who.int/api/hubs/factsheets?$skip=50"}